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 Abstract 
 
Molecular characterization of porcine genes encoding complement components of the 
terminal lytic pathway and their association with hemolytic complement activity 
 
Activation of the complement system from three different pathways (classical, alterna-
tive and lectin pathway) results in the generation of the C3-convertase enzyme, which 
plays a key role in formation of the membrane attack complex (C5b-C9) causing the 
death of target cells. The porcine C3 and C5 complement components were character-
ized and studied for association with hemolytic complement activity (Kumar et al. 2004, 
Wimmers et al. 2003). In order to gain understanding for the membrane attack complex 
action in the innate immune mechanism, in this study it was focussed on the terminal 
complement components C6, C7, C8, and C9 to characterize their molecular structure, 
to detect single nucleotide polymorphisms (SNPs), to establish their location on chro-
mosome, and to associate their genetic variation with hemolytic complement activity in 
both classical and alternative pathway in the pig.  
 
The entire length of cDNA sequence of the candidate genes C6, C7, C8A, C8B, C8G 
and C9 were identified with 3306, 3561, 2146, 2461, 840 and 2536 bp encoding 935, 
843, 589, 611, 202 and 543 amino acids, respectively. The porcine deduced protein se-
quence of the candidate genes showed 67-83% identities with human analogue. Respec-
tively, screening the coding region revealed five, six, seven, nine, and two SNPs in the 
porcine C6, C7, C8A, C8B, and C9 but non in C8G by polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP). Most of the SNPs belong to the 
functional protein domains such as TSP1, LDLa, MACPF, CCP and FIMAC. Genotyp-
ing for several SNP sites in three porcine breeds German Landrace (LR), Pietrain (PIE) 
and Muong Khuong (MK) showed that European breeds (LR and PIE) had higher allelic 
variation than the Asian breed (MK). All genotypic frequencies fit to Hardy-Weinberg 
equilibrium rule. 
 
Using the INRA-Minnesota porcine Radiation Hybrid mapping panel, the porcine C6, 
C7, and C9 were assigned to the q-arm of chromosome 16 (q1.4) whereas the porcine 
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C8A, and C8B were mapped to chromosome 6 (q3.1-q3.5). Particularly the porcine 
C8G was located on chromosome 1 (q2.13).  
 
Genetic association with hemolytic complement activity in both classical (CH50) and 
alternative pathway (AH50) was carried out in 417 animals of a F2 DUMI resource 
population derived from cross between Duroc and Berlin Miniature Pig. Therefore, the 
F2 DUMI animals were immunized with Mycoplasma hyopneumoniae (Mh), Aujeszky 
(ADV) and porcine reproductive and respiratory syndrome (PRRSV) vaccine. Sera were 
isolated from blood samples taken prior and post vaccinations and measurement for 
CH50 and AH50 was conducted thereafter. For each gene except the porcine C8G, the 
SNP site with amino acid substitution 862AÆG for C6, 881AÆG for C7, 1544CÆT 
for C8A, 222CÆT for C8B, and 407CÆG for C9, segregating in the DUMI, were used 
for genotyping the F2 animals using PCR-RFLP with the restriction enzymes TaqI, 
MboII, Hin6I, FnuDII, and HpyCH4III, respectively. The association results illustrated 
that significant difference in hemolysis among genotypes was found in CH50 for C7 
(p=0.0080), and C9 (p=0.0488). However, this was close to significance for C6 
(p=0.0853) and C8A (p=0.0650) in CH50. Therefore between homozygous genotypes 
CC and TT for C8A hemolytic activity showed significant difference (p=0.0522). There 
was no association of any of the candidate gene with hemolytic complement activity in 
the alternative pathway. Analyzing the interaction between genotypes and eight differ-
ent immunization time points in AH50 revealed significant differences for C8A 
(p=0.0027), C8B (p=0.0231), and C9 (p=0.0340) whereas in CH50 this interaction was 
found significant for C8B (p=0.0048). Hemolytic complement activity showed the 
highest values at the fourth day after immunization with ADV vaccine for CH50 
whereas linear increment during the experiment was performed for AH50. Along the 
vaccination program after each of complement stimulation by different vaccines, a short 
termed increment of complement activity was found, especially with ADV vaccine. 
Also male animals always performed higher hemolysis than females in both pathways. 
These results show that hemolytic complement activity depends on the genetic varia-
tion, sex, age, kind of vaccine, and interaction of complement components. 
 
In summary, the obtained results provide the means for further understanding the role of 
C6, C7, C8, and C9 in natural immune response of the host against pathogens. It also 
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promotes the porcine C6, C7, C8, and C9 as candidate genes in efforts to genetically 
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Infectious diseases in farm animals and their control by therapeutic, prophylactic and 
metaphylactic treatments and veterinary management schemes cause immense costs, 
animal welfare concerns and increasingly burden man and environment with chemot-
herapeutics. Disease infections are a main problem in animal production systems caus-
ing customer ´s demands that the use of medicals and vaccines should be reduced. In 
pig production, producers are using antibiotics to treat illness, to prevent the spread of 
disease and to improve the nutritional efficiency of animals. The use of antibiotics in 
farm animals affects the treatment of human diseases due to bacterial resistance. The 
question is how to reduce antibiotics in pork? Stopping the use of antibiotics for animal 
growth is one of the best ways done in recent years but not at all. Particularly, My-
coplasma hyopneumoniae (Mh) infection causes the disease Porcine Enzootic 
Pneumonia, a highly contagious and chronic disease affecting pigs and a significant 
reduction in the growing performance of pigs with estimated economic losses of $0.2-1 
billion per year in the United States (Clark et al. 1991). Mh is spread worldwide and 
present in almost pig herd (Minion 2002). Antibiotics are less effect in disease treatment 
because they do not completely remove the infection. Vaccines have been found to 
reduce the severity of the disease but do not prevent the disease from occurring in 
infected pigs (Haesebrouck et al. 2004). Sadly, the immune response in presence of Mh 
in pigs is slow and ineffective (Minion 2002). In the case of Porcine Reproductive and 
Respiratory Syndrome Virus (PRRSV) infection, during outbreak periods the farrowing 
rate declined by 10.92 points. The number of pigs weaned per litter declined by 1.5 pigs 
per litter. Mortality level of nursery pigs increased by 10.65% points. Mortality level in 
grow-finish pigs increased by 6.05% points. Feed efficiency and average daily gain for 
nursery and grow-finish pigs were also impacted. Average daily gain declined by 0.21 
pounds per day (25% decline) for the nursery pigs and 0.20 pounds per day (12% de-
cline) for the grow-finish pigs…The total economic impact on production costs to pig 
producers in the United States is projected to be $560.32 million annually (Kliebenstein 
2004). Another question is what are better livestock management techniques to improve 
the health status in both animal and human? Immunologically and genetically improved 
health and natural disease resistance leads to higher product quality, reduced danger of 
transmission of infectious agents or traces of antibiotics and has positive impact on pro-
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duction efficiency and animal welfare. Disease reduction by genetic means has certain 
advantages through cumulative and permanent effects. The use of powerful methodolo-
gies in molecular biology, biochemistry, and physiology in the last two decades has led 
to impressive progress in our understanding of the mechanisms of complement activa-
tion and its role in immune responses for preventing pathogen in human and some dif-
ferent animal species (Makrides 1998). Direct selection for disease incidence requires, 
besides a unique pig identification and disease registration system, challenge routines 
that are inconvenient in intensive pig production. Indirect selection for the expression of 
immune capacity may be an alternative but requires detailed knowledge of the different 
components of the immune system. Complement is an important humoral innate im-
mune defence system against invading microorganisms. The activation of the comple-
ment cascade allows the direct killing of microbes, the disposal of immune complexes, 
and the regulation of other immune processes. In pig, the complement components C7 
and C8A have been completely characterized at the molecular level (Agah et al. 2000, 
Nakajima et al. 1998). Agah et al (2000) could show that addition of purified porcine 
C7 restored the hemolytic activity of C7-depleted human sera in a dose-dependent man-
ner. Genetic polymorphism of the sixth complement component was also detected in 
several different breeds of pig (Shibata et al. 1993). Furthermore, the porcine C8A gene 
was physically assigned to chromosome 6q3.3-q3.5 by in situ hybridization using por-
cine bacterial artificial chromosome (BAC) clone as a hybridization probe (Nakajima et 
al. 1998) and the porcine C9 gene has been mapped to chromosome 16q1.4 by fluores-
cence in situ hybridization (Thomsen et al. 1998).  
 
In order to gain more knowledge about regulation of pig complement system as well as 
to contribute to the improvement of farm animal health status, an investigation on the 
complete cDNA molecular structure of the porcine terminal complement components 
C6, C7, C8 and C9 genes was conducted to detect single nucleotide polymorphisms 
within the candidate genes and to study their association with hemolytic complement 
activity in the classical and alternative pathway in the F2 DUMI resource population and 
to assign them to porcine chromosomes by radiation hybrid and linkage mapping. 
  
2 Literature review 
 
2.1 Innate immunity and adaptive immune response 
 
The two primary immune responses to microorganisms and their antigens are generated 
by the innate and acquired or adaptive immune systems. The innate immune system is 
considered the first line of defense in protecting the host from invading organisms 
(Thacker 2003). This means that the cells of the innate system recognize, and respond 
to, pathogens in a generic way in a non-specific manner and not confer long-lasting or 
protective immunity to the host. Only if the organism escapes and survives the innate 
immune response an adaptive or acquired immune response occur, resulting in the gen-
eration of a specific immune response that will target that particular organism or anti-
gen. The response increases with each exposure to the antigen (Thacker 2003).   
 
Figure 1 Response to invading microorganisms by innate and adaptive im-
mune systems (Thacker 2003) 
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The major component of the natural immunity consists of the natural killer (NK) cells, 
phagocytes, dendritic cells, and the complement system (Heyworth 2001, Medzhitov 
2001). Lymphocytes (B and T cells) superimposed on innate immunity to improve host 
defense against microbes are the primary cell type of the adaptive immune response 
(Thacker 2003). The adaptive immune response is distinguished from innate immune 
mechanisms by a higher degree of specific reactivity for the including agent and recall 
memory (Doenhoff 2000). Its function is mediated by specific antibody or humoral im-
munity and a specific cellular immune response or cell mediated immunity (Corbeil 
1991). This study only refers to the activity of the complement system.  
 
2.2 Complement system 
 
The complement system, an effector mechanisms of humoral immunity as well as an 
important mediator of the innate immune system (Thacker 2003), is a highly regulated 
and complex set of interacting proteins in blood plasma and on the cell surfaces that can 
recognize, bind to and kill or remove invading microbes. Normally, these proteins are 
inactive until they are cleaved by a protease, which, in turn, converts them into another 
protease. On the other hand, some components of the system serve as the substrate of a 
prior component and then as an enzyme to activate a subsequent component. There are 
three pathways of complement activation classical pathway, lectin pathway and alterna-
tive pathway leading to the formation of the membrane attack complex (MAC). Assem-
bly of the MAC on target cells results in the formation of transmembrane pores that can 
lead to cell killing (Müller-Eberhard 1986).  
 
2.2.1 The classical pathway 
 
The classical pathway of complement activation is a sequentially acting, multistep cas-
cade in which the complement component C1, C4, C2, and C3 are involved (Loos et al. 
1998). The component C1 circulates in blood serum as a molecular complex containing 
6 molecules of C1q, 2 molecules of C1r and 2 molecules of C1s. The activation of the 
complement system, through the classical pathway is initiated by interaction of the C1q 
component with the Fc regions of antigen-antibody complexes (Wimmers et al. 2003, 
Reid et al. 1981). Once the globular ‘heads’ of subcomponent C1q are bound by anti-
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body, the `stalks´ bind and activate C1r and C1s to generate an enzyme (Haeney, 1998) 
that cleaves two serum proteins (1) C4 to release C4a and C4b, which binds covalently 
to sugar residues on cell-surface glycoproteins and (2) C2 to release C2b and the glyco-
protein C2a, which binds noncovalently to a site on C4b to give the C4b2a complex, 
`the C3 convertase´ (Loos et al. 1998). The C3-convertase enzyme catalyzes the cleav-
age of C3 into C3a and C3b, which binds covalently to glycoproteins scattered across 
the cell surface. Macrophages and neutrophils have receptors for C3b and can bind the 
C3b-coated cell or particle preparatory to phagocytosis. This effect qualifies C3b as an 
opsonin. C3a is a small fragment, which can bind to receptors on basophils and mast 
cells triggering them to release their vasoactive contents (e.g., histamine). Because of 
the role of these materials in anaphylaxis, C3a is called an anaphylatoxin. Some of the 
C3b binds C4b2a to form the C4b2a3b enzymatic molecule (C5 convertase of classical 
pathway) for initiation of the lytic pathway (Sunyer and Lambris 2001) 
 
2.2.2 The lectin pathway 
 
The lectin pathway is mainly driven by manose-binding lectin (MBL) (Thiel et al. 
1997), one of the most important constituents of the innate immune system (Fraser et al 
1998). Activation of the lectin pathway is similar to the classical pathway, with binding 
of the MBL serum protein, which is homologous to C1q of classical pathway, to man-
nose-containing carbohydrates on bacteria or viruses that activates the complement cas-
cade (Thacker 2003). The binding results in the association of two serine proteases, 
MASP1 and MASP2 (MBL-associated serine proteases), which are respectively ho-
mologous with C1r and C1s in the classical pathway, to form a complex molecule in the 
presence of a calcium. The MASP2 enzyme subsequently cleaves C4 into C4a and C4b 
as well as C2 into C2a and C2b to form the C4b2a complex playing a role as a C3 
convertase in classical pathway activation (Fujita 2002). The C3 convertase then 
cleaves C3 into C3a and C3b, which binds to the membrane in association with C4b and 
C2a to form C4b2a3b (C5 convertase of lectin pathway) for lytic pathway activation. 
By contrast, MASP1 is able to cleave C3 directly which results in activation of the al-
ternative pathway (Fujita 2002). 
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2.2.3 The alternative pathway 
 
The alternative pathway represents an important part of the innate immunological sys-
tem containing plasma proteins C3, factor B (a single-polypeptide chain glycoprotein), 
factor P (properdin) and factor D (adipsin). The alternative complement pathway is di-
rectly activated via binding of spontaneously activated C3b to the surface of a pathogen 
(Thacker 2003, Reid et al. 1981). It is initiated by the spontaneous hydrolysis of C3, 
which is abundant in the plasma activated by a H2O molecule and reacting with factor B 
in the presence of Mg2+ ions to form the C3(H2O)B molecule. Factor D then splits the 
bound Factor B into Bb and Ba, to form the C3(H2O)Bb enzymatic molecule (Haeney 
1998). The C3(H2O)Bb enzyme is at low level in plasma but it can directly cleave the 
other C3 molecules to release C3a from the C3b molecule which reacts repeatedly with 
factor B and D to form the C3bBb enzymatic molecule. The C3bBb binds a serum pro-
tein called properdin to form the C3bBbP stable enzymatic molecule complex (C3 con-
vertase), which in return can split molecules of C3 into C3a and C3b. Factor P binding 
to C3bBb extends the half-life of the complex (Fearon et al. 1975). The C3b subse-
quently binds with C3bBb to form a C3bBb3b molecule (C5 convertase of alternative 
pathway), which initiates the lytic pathway (Parish 2001, Zipfel 2001).  
 
2.2.4 Membrane attack complex (MAC) 
 
 
Figure 2  Assembly of the MAC. Activation of complement leads to the formation of 
C5b-9, the cytolytic membrane attack complex of complement, or MAC 
(Schreck et al. 2000) 
 
Activation of the three pathways of the complement system generates the C5 convertase 
as a source of inspiration in formation of the membrane attack complex (MAC) on tar-
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get-cell membranes. This complex is a multiprotein set assembled by sequential addi-
tion of complement components C5b, C6, C7, C8, and C9 (DiScipio et al. 1984, Podack 
et al. 1982). In human the formation of MAC begins with specific cleavage of compo-
nent C5 between residues 74 and 75 into C5a and C5b by C5 convertases: C4b2a3b 
from classical pathway, C4b2a3b from lectin pathway or C3bBb3b from alternative 
pathway (Hofsteenge et al. 1999, Makrides 1998, Müller-Eberhard 1988). The C5a is a 
potent anaphylatoxin and mediates various inflammatory events while the ability of C5b 
to bind C6 decays rapidly in a C5b-6 metastable bimolecular complex (Wuerzner 2003, 
DiScipio 1992, 1988, Podack et al. 1979, 1976). Then C7 associates mainly with the C6 
subunit of the C5b-6 complex (DiScipio et al. 1988, Müller-Eberhard 1988) forming 
C5b-7. Upon binding of C7 to C5b-6, the trimolecular C5b-7 complex undergoes a con-
formational transition and allows insertion of this complex into lipid membranes (DiS-
cipio 1992, 1988, Podack et al. 1979, 1976). Both C5b-6 and C7 are soluble proteins, 
whereas the C5b-7 complex is amphiphilic and capable of tightly binding phospholipid 
membranes (DiScipio et al. 1988). Then C8B binds to C5b-7 complex by a specific rec-
ognition site on C5b (Stewart et al. 1987). Self-polymerization of C9 is initiated by 
binding C5b-8 to C9 via C8A to form C5b-C9 complex of the terminal complement 
components (Stewart et al. 1987, Podack et al. 1982) and constitutes a supramolecular 
organization (Tschopp et al. 1986). The C5b-9 complex can contain one molecule of 
each of component C5b, C6, C7, C8 and 6-18 molecules of C9 that polymerize into 
barrel-like structures and can vary dramatically in size (Esser 1994, Tschopp 1984). Of 
these, components C6 to C9 are related plasma proteins, which differ in size and com-
plexity (Hofsteenge et al. 1999, Müller-Eberhard 1986). Insertion of further C9 mole-
cules into the target membrane causes local distortion of the phospholipid bilayer per-
meability resulting in `leaky patches´ (Esser 1991) or forming a hydrophilic channel 
through the membrane (Bhakdi et al. 1991). It ultimately results in cellular activation, 
cell lysis or cell death (Morgan 1989, Esser 1987, Discipio et al. 1984). However, depo-
sition of small amounts of the MAC on cell membranes of nucleated cells may mediate 
a range of cellular processes without causing cell death (Nicholson-Weller et al. 1993, 
Morgan 1992). Gram-positive organisms are already protected against complement lysis 
by the presence of their peptidoglycan cell walls. MAC inhibition may not be the sole 
function of streptococcal inhibitor of complement (Fernie-King et al. 2001). The cyto-
lytic activities of the membrane attack complex (MAC) are inhibited through the bind-
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ing of CD59 antigen to C8 and C9 (Meri et al. 1990). The MAC has an approximate Mr 
of 1.7 x 106 (Tschopp et al. 1986) 
 




Figure 3 Structural organization of the MAC protein family. Shown are maps based on 
sequences of the mature human proteins and the module boundaries listed in 
the SWISS-PROT Protein Sequence Data Bank. Abbreviations correspond to 
thrombospondin type I (TSP1), low-density lipoprotein receptor class A 
(LDLa), epidermal growth factor (EGF), complement control protein (CCP) 
and Factor I membrane attack complex (FIMAC) modules. The membrane at-
tack complex/perforin segment is designated MACPF. Numbers correspond to 
the first residue in each module. Dots above each map indicate the approxi-
mate location of Cys residues, which are highly conserved. All are involved in 
intrachain disulfide bonds except Cys164 in C8A, which is linked to C8G. The 
shaded region fanking Cys164 corresponds to a 17-residue insertion that is 
unique to C8A. Hexagonal symbols designate Asn residues that are potential 
N-glycosylation sites (Schreck et al. 2000) 
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The four terminal components of the complement system (C6, C7, C8 and C9) are gly-
coproteins (Witzel-Schloemp et al. 1998, Dewald et al. 1996, Hobart et al. 1995, Chak-
ravarti et al. 1988, Müller-Eberhard et al. 1986) and C-mannosylated on multiple tryp-
tophan residues. From the 113 Trp residues in the complete membrane attack complex, 
50 were found to undergo C-mannosylation (Hofsteenge et al. 1999). 
 
2.3.1 The sixth complement component (C6) 
 
Complement C6 is one of five plasma proteins that are incorporated into the lytic termi-
nal complement complex on lipid membranes upon activation of the complement cas-
cade (Haefliger et al. 1989). Human C6 is a single-chain glycoprotein with an estimated 
Mr of 95-128 kDa and a carbohydrate content of 3.8-11.3% (DiScipio et al. 1982, Kolb 
et al. 1982, Podack et al. 1979, 1976). C6 is larger than C7, C8A, C8B, and C9 (Chak-
ravarti et al. 1989). The structure of human C6 sequence is encoded with 18 exons 
(Hobart et al. 1993). The complete polypeptide structure of mature C6 deduced from the 
cDNA sequence consists of 913 amino acid residues (DiScipio et al. 1989, Haefliger et 
al. 1989) preceded by a typical 21-residue signal peptide. The protein is homologous 
with the other terminal components of complement, C7-C9 (DiScipio et al. 1989) and 
most similar in structure to complement C7, sharing 33.5% identical residues with C7 
including all 56 cysteine residues (Haefliger et al. 1989). It is noteworthy that cysteine 
is clearly the most conserved of all the amino acids because 55 of the 56 cysteines 
found in C7 match those in C6 (DiScipio et al. 1989). Human C6 contains a large num-
ber of cysteine residues, 64 in total in a sequence of two domains, an amino-terminal 
region, C6a (a.a 22-631) that is related to C8 and C9, and a carboxyl-terminal region, 
C6b (a.a 632-934) that has partial homology to the complement regulatory proteins fac-
tor H and factor I (DiScipio et al. 1989, Haefliger et al. 1989). The absence of any free 
sulfhydryl groups in the C6 protein inplies that all of the 64 cysteines are linked in 32 
disulfide bonds. Disulfide linkages may exert a stabilizing influence on C6 structure 
because the activity of this molecule is partially resistant to treatment with chaotrophs 
(DiScipio et al. 1989).  
 
The amino-terminal fragment of C6 has 30, 26, 22, and 18% residues identical with 
those of C7, C8A, C8B, and C9, respectively, while the carboxyl-terminal polypeptide 
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has 27% of its amino acids identical to those from the corresponding region of C7. The 
sequence of 490 first amino-terminal half of the C6 protein has 47-52% similarity with 
C7, C8A, C8B, and C9, as well as 31-38% similarity with thrombospondin (TSP1), epi-
dermal growth factor (EGF), and low density lipoprotein receptor (LDLa). It is there-
fore a member of the channel-forming complement proteins (Chakravarti et al. 1989). 
Most of the predicted C6 alpha-helical structure resides in a portion of the polypeptide 
chain that is free of cysteine and which shares homology with C9 and perforin (DiS-
cipio et al. 1989). A site of asparaginyl glycosylation of C6 contained in the sequence 
Asn-Phe-Thr was located at position 324 (Chakravarti et al. 1989). C6 deficiency can 
not form the membrane attack complex (MAC) (Mead et al. 2002) 
 
2.3.2 The seventh complement component (C7) 
 
Complement C7 is one of the components of membrane attack complex (MAC) gener-
ated by the terminal complement cascade. The derived human C7 protein sequence con-
sists of 821 amino acids, and in addition, the precursor protein contains a 22-residue 
hydrophobic leader peptide. The C7 is highly gene homologous to C6, C8A, C8B, and 
C9 (Hobart et al. 1995, DiScipio et al. 1988). The human seventh component of com-
plement is a single chain plasma glycoprotein of Mr 97.3 kDa, encoded by 18 exons 
whose sizes vary from 56 to 244 bp (Hobart et al. 1995, DiScipio et al. 1988). The hu-
man C7 single polypeptide chain is glycosylated at two sites and has 56 cysteines pre-
sumed to form 28 disulfide bonds. Disulfide bonds are important for stabilizing the 
structure of this protein. Virtually all the cysteines are found in small units of 35-77 
amino acids that exhibit homology with those of various proteins including the low-
density lipoprotein receptor, epidermal growth factor precursor and thrombospondin. 
The carboxyl-terminal segment of C7 is between amino acids 575-843 (DiScipio et al. 
1988). Human C7 plays a major role in bringing about the hydrophilic- amphiphilic 
transition during the formation of the membrane attack complex, and it serves as a 
membrane anchor for the C5b-7 complex (DiScipio et al. 1988). 
 
The porcine C7 was a single glycoprotein with an approximate molecular mass of 90-
100 kDa. Similar to human C7, the predicted amino acid sequence of precursor porcine 
C7 also consists of 843 amino acid residues. Human (GenBank acc. no. NM 000587) 
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and porcine C7 share an overall identity of 80% at the protein level. The two potential 
asparaginyl-linked glycosylation sites (Asn-X-Ser/Thr) at positions 202 and 754 in hu-
man C7 are also conserved in porcine C7. Both human and porcine C7 have 56 cysteine 
residues, the majority of which are located either at the amino or carboxyl terminus of 
the protein, giving rise to cysteine-rich domains (Agah et al. 2000). Although the func-
tion of these cysteine-rich motifs remains unclear, one speculation is that they play a 
role in the stabilization of β-turns that are presumably involved in protein-protein inter-
actions (DiScipio et al. 1988).  
 
Although liver has been demonstrated to be the major site for the synthesis of C6 and 
C8, the major site of C7 synthesis has not yet been elucidated. Human cDNA was ob-
tained from liver, but C7 is not detected in the human hepatoma-derived cell line 
HepG2, thus suggesting that human hepatocytes do not primarily synthesize C7 (DiS-
cipio et al. 1998, Wuerzner et al. 1994). Interestingly, circulating C7 initially switches 
to 50% of the transplanted allotype following allogeneic liver transplantation, but com-
pletely reverts to the original allotype by 6 weeks (Wuerzner et al. 1994). These data 
suggest that mature mononuclear white blood cells (i.e. Kupffer cells in the liver) may 
be a major source of C7 production (Agah et al. 2000) 
 
2.3.3 The eight complement component (C8) 
 
Human C8 oligomeric protein, is one of five components of the membrane attack com-
plex of complement (MAC) which consists of three different polypeptides C8A (alpha 
chain, Mr = 64 kDa), C8B (beta chain, Mr = 64 kDa) and C8G (gamma chain, Mr = 22 
kDa) (Plumb et al. 1999, Steckel et al. 1980). It is arranged asymmetrically as a disul-
fide-linked C8alpha-gamma heterodimer that is a noncovalently associated with beta 
chain (Haefliger et al. 1987, Howard et al. 1987, Rao et al. 1987).  
 
The entire human C8A cDNA length was determined to be 2443 base pairs which, when 
translated, yields an apparent leader sequence of 30 amino acids. This sequence con-
tains an apparent initiation methionine, signal peptide, and propeptide which ends with 
an arginine-rich sequence that is characteristic of proteolytic precessing sites found in 
the pro form of protein precursor (Rao et al. 1987). Cysteine-rich repeat sequence found 
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in low-density lipoprotein receptor and to the cysteine-rich epidermal growth factor type 
sequence found in a number of proteins. There are 1 or 2 asparagine-linked in C8A gene 
(Rao et al. 1987). Both proteins C8A and C9 contain nearly the same number of amino 
acids and cysteine-rich amino- and carboxyl-terminal domains (Rao et al. 1987). The 
complete amino acid sequence of pig C8A was determined by characterizing the full-
length cDNA clone isolated from a porcine liver cDNA library. The 2145 bp sequence 
(GenBank acc. no. AB008156) of this clone have a 558 amino acid open reading frame 
and a 31 amino acid leader sequence. Porcine C8A was found to be similar to human 
and rabbit C8A in length, leader sequence, conserved cysteine residues (29 cysteines), 
cysteine-rich modules (TSP1, LDLa, EGF) (Nakajima et al. 1998). The location of these 
modules is very similar among pig, rabbit, and human. Differences in the amino acid 
sequence among the three species were detected in the proposed candidate site for 
CD59 recognition (amino acids 382-419) (Nakajima et al. 1998). During MAC forma-
tion, C8A mediates binding and self-polymerization of C9 to form a pore-like structure 
on the membrane of target cells (Slade et al. 2006, Scibek et al. 2002). 
 
Figure 4  Functional sites in C8. (Left panel) Schematic representation of sites of 
interaction (hatched) in each subunit of C8. Sites are arbitrarily located 
within each subunit but are depicted as distinct and nonoverlapping be-
cause they function simultaneously within the MAC. Membrane interac-
tion sites are designated `m´. (Right panel) Relative location of the C8 
subunits within membrane-bound C5b-8 and the MAC (Plumb et al. 
1998). C9 is depicted as a polymer composed of an arbitrary number of 
monomeric units (Schreck et al. 2000). 
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Human C8B-cDNA-positive clones were partially sequenced to characterize the 12 ex-
ons of the gene with sizes from 69 to 347 bp (Kaufmann et al. 2004). In serum, the beta-
subunit is non-covalently bound to the disulfide-linked alpha-gamma subunit (Kauf-
mann et al. 1993). Amino-linked carbohydrate on C8 beta is not necessary for associa-
tion with C8 alpha-gamma or for C8 activity (Letson et al. 1996). Analysis of the de-
rived amino acid sequence revealed several membrane surface seeking-segments that 
may facilitate C8B interaction with target membranes during complement-mediated 
cytolysis. Determination of the carbohydrate composition indicated 1 or 2 asparagine-
linked but no O-linked oligosaccharide chains (Howard et al. 1987). Comparison with 
the amino acid sequence of C9 shows an overall homology with few deletions and 
insertions. In particular, the cysteine-rich domains and membrane-inserting regions of 
C9 are well conserved. These findings are discussed in relation to a possible mechanism 
of membrane attack complex formation (Haefliger et al. 1987). Analysis of the C8B 
sequence reveals several segments with the potential to form amphipathic C8B-
structures that are capable of interacting with membrane surfaces. These segments may 
serve two functions. One is that they may assist in stabilizing interactions of C8 with 
C5b-7 by direct association with the membrane surface. Second, these segments may 
contribute directly to the lytic activity of C5b-8 and C5b-9 through membrane 
perturbation (Howard et al. 1987). 
 
For human C8A and C8B, the overall homology is 33% on the basis of identity and 
53% when conserved substitutions are allowed. For C8B and C9, the values are 26% 
and 47%, respectively (Howard et al. 1987). For C8A and C9, they are 24% and 46%, 
respectively (Rao et al. 1987). The human C8A and C8B are homologous to C6, C7, 
and C9 and form the MAC family of proteins (Plumb et al. 1998, Hobart et al. 1995). 
C8A and C8B have correspondingly similar roles in MAC-mediated lysis of erythro-
cytes and bacterial killing. C8G is not required for complement-mediated killing of 
Gram-negative bacteria (Parker et al. 2002). 
 
The gamma chain whose functional role remains undefined is not related to any other 
complement protein but is a member of the lipocalins, a family of proteins that bind 
small hydrophobic ligands (Dewald et al. 1996). C8G is structural homology to protein 
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HC (alpha-1-microglobulin/bikunin precursor) (Hunt et al. 1987). Human C8 gamma is 
a 22 kDa subunit of complement component C8 (Schreck et al. 2000). C8G has one 
internal disulfide bridge between Cys76 and Cys168 within the carboxy-terminal 12 kDa 
fragment, whereas the remaining cysteine residue 40 forms the disulfide bridge with C8 
alpha (Haefliger et al. 1987). C8G may act as a retinol transporting protein in plasma 
(Haefliger et al. 1991) and plays a role for binding an as yet unidentified ligand (De-
wald et al. 1996, Kaufman et al. 1994, Ng et al. 1987). 
 
2.3.4 The ninth complement component (C9) 
 
Human C9 is the most abundant component of the membrane attack complex of the 
complement system of immune defense. It is the last protein that binds to the assem-
bling membrane attack complex (MAC) of complement, completing the sequence of 
events that leads to the destruction of target membranes. The single chain serum protein 
is encoded by a gene composed of 11 exons and located on chromosome 5p13 (Witzel-
Schloemp et al. 2001). The nucleotide sequence of the ninth component of human com-
plement coding 537 amino acids in a single polypeptide chain was determined (Discipio 
et al. 1984).   
 
There are the presence of surface-binding domains in the amino terminal half and chan-
nel-forming domains in the carboxyl terminal portion of native, monomeric C9 (Shiverg 
et al. 1986). Human monomeric native C9 (Mr = 66 kDa) can be cleaved by α-thrombin 
into two single-chain polypeptide fragments: C9a (Mr = 28 kDa) and C9b (Mr = 38 
kDa), which are the amino and carboxyl-terminal segments of the protein, respectively 
(DiScipio et al. 1985). The carboxyl terminal fragment (C9b) enters lipid bilayer mem-
branes and form single channels of defined but heterogeneous sizes and lyses erythro-
cytes in the absence of a fully assembled C5b-8 complex. The C9a fragment contains 
several regions of possible amphipathic β-structures. It is conceivable that such areas in 
C9a serve to bind the peptide sufficiently strongly to the membrane surface to cause 
leakiness (Shiverg et al. 1986). Human C9 water-soluble glycoprotein will insert 
quickly into lipid bilayers after binding to the membrane bound C5b-8 complex (Steckel 
et al. 1983, Hu et al. 1981, Podack et al. 1981). The principal binding site for C9 lies 
within the MACPF domain of C8alpha (Slade et al. 2006). The molecular weight calcu-
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lated from the sequence for the nonglycosylated C9 protein is 60,700 (DiScipio et al. 
1984).  
 
2.4 Functional protein domains in candidate genes 
 
The membrane attack complex (MAC) is an assembly of terminal complement compo-
nent C5b-9 in lytic pathway of complement system (NCBI homepage). The membrane 
attack is important for mammalian immune defense against invading microorganisms 
and infected host cells. Proteins of the complement MAC and the protein perforin share 
a common MACPF domain that is responsible for membrane insertion and pore forma-
tion (Hadders et al. 2007). C8A is the first complement protein to insert into the mem-
brane. The size of the MACPF domain of C8A is consistent with known C9 pore sizes 
(Hadders et al. 2007). Therefore, the principal binding site for C9 lies within the 
MACPF domain of C8A (Slade et al. 2006) 
 
Perforin is a protein found in cytolytic T-cell and killer cells. In the presence of calcium, 
perforin polymerises into transmembrane tubules and is capable of lysing, non-
specifically, a variety of target cells. There are a number of regions of similarity in the 
sequences of complement components C6, C7, C8A, C8B, C9 and perforin (NCBI 
homepage).  
 
The complement control protein (CCP) modules are defined by a consensus sequence 
within a stretch of about 60 amino acid residues. These modules have been identified 
more than 140 times in over 20 proteins, including 12 proteins of the complement sys-
tem (Norman et al. 1991). Typically, two to four modules contribute to a binding site, 
implying that the orientation of the modules to each other is critical for function (NCBI 
homepage). The CCP modules mediate specific protein-protein and protein-
carbohydrate interactions that are key to the biological function of the regulators of 
complement activation and, paradoxically, provide binding sites for numerous patho-
gens (O'Leary et al. 2004). The carboxyl-terminal domains of C6 and C7, which have 
cysteine-rich modules homologous to those found in factors H and I, have the capacity 
to link specifically with C5.  
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The factor I membrane attack complex (FIMAC) domain is found in the terminal com-
plement component proteins (Figure 3), complement component factor I and agrin. Fac-
tor I is responsible for cleaving alpha chains of C4b and C3b in the presence of the co-
factors, C4-binding protein and factor H, respectively. Agrin is a component of the 
basal lamina that causes the aggregation of acetylcholine receptors and acetylcholine-
esterase on the surface of muscle fibres of the neuromuscular junction 
(http://www.ebi.ac.uk/interpro). The FIMACs in C7 mediate reversible binding to C5 
(Thai 2004). The C5b-binding domain of C6 was located in the 34 kDa carboxyl termi-
nal fragment consisting of two short consensus repeats and two factor I modules (Hae-
fliger et al. 1989). Although the FIMACs are not required absolutely for C6 activity, 
these modules promote interaction of C6 with C5 enabling a more efficient bimolecular 
coupling ultimately leading to the formation of the C5b-6 complex (DiScipio and Berlin 
1999). 
 
Both TSP1 and TSP2 are induced in response to injury (Bornstein 2001). Antisense 
treatment reduced the number of TSP1-positive macrophages by 50% or more (DiPietro 
et al. 1996).  
 
In human C6, most of the cysteines are located in short (34-77 amino acids) discrete 
segments that exhibit homology with a wide variety of other proteins such as TSP1, 
LDLa at the carboxyl terminus (DiScipio et al. 1989, Haefliger et al. 1989), EGF, and 
CCP and FIMAC (DiScipio et al. 1989). In contrast to C7 and other terminal comple-
ment proteins, the TSP1 module at the amino terminus occurs as a tandem repeat in C6. 
The last tandem repeat at the carboxyl terminus of C6 and C7 has been identified as a 
new distinct module (FIMAC module), which is closely related to a segment in the 
heavy chain of complement control factor I (Chakravarti et al. 1989).  
 
Both human C8A and C8B subunits contain a pair of amino-terminal modules (TSP1 
and LDLa), a pair of C-terminal modules (EGF+TSP1) and an extended central segment 
referred to as the membrane attack/perforin (MACPF) domain (Musingarimi et al. 2002, 
Plumb et al. 1998, Hobart et al. 1995). Binding to C8A-G is dependent on the TSP1 + 
LDLa + MACPF segment of C8B. Within this segment, the TSP1 module and MACPF 
domain are principally involved and act cooperatively to mediate binding. Residues 
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within this segment also mediate binding and incorporation of C8 into the MAC (Mus-
ingarimi et al. 2002).  
 
Human C9 is a typical mosaic protein with thrombospondin (TSP1) and low density 
lipoprotein receptor (LDLa) domains at its amino-terminus and an epidermal growth 
factor-like (EGF) domain at its carboxyl-terminus (Smith et al. 1992).  
 
2.5 Polymorphisms and deficiency of candidate complement components 
 
2.5.1 The sixth complement component (C6) 
 
Genetic polymorphisms of the complement component C6 have been reported in human 
(Fernie et al. 1995, Wuerzner et al. 1995, Dewald et al. 1993, Hobart et al. 1975), par-
ticularly, in a Japanese population (Soejuma et al. 2005, Nishimukai et al. 2003, 1986, 
Nakamura et al. 1984, Tokunaga et al. 1983), in 203 Chinese Han people in Liaoning 
Province of northeast China (Tsunenari et al. 1992), among Russian rural inhabitants of 
the Tomsk region (Kucher et al. 1993), in a group of Africans (Fernie et al. 1996), in the 
Senegal population (Corbo et al. 1994), in Korean living in Seoul (Park et al. 1988), in 
individuals of African descent living in the United States or Europe (Parham et al. 
2007), in 167 unrelated Norwegian Lapps (Olving et al. 1980), in the German popula-
tion (Schwarzenholz et al. 2000, Kühnl et al. 1980, Kunstmann et al. 1980), in a African 
ethnic group (Fernie et al. 1996). Genetic variation was not only found in exon but also 
in intron fragments of human C6 (Parham et al. 2007, Nishimukai et al. 2003, Fernie et 
al. 1997, 1995, Wuerzner et al. 1995). In other species, polymorphisms were also de-
tected, in the rhesus monkey (Hall 1977), in the chimpanzee (Raum et al. 1980), in the 
rabbit (Goldman et al. 1982, Kunstmann et al. 1980), in the common marmoset (White-
house 1984), in the dog (Shibata et al. 1995, Anderson et al. 1983, Eldridge et al. 1983), 
in the Manx shearwater (Whitehouse 1982), in the rat (Granados et al. 1884), in the 
mouse (Hayakawa et al. 1984, Orren et al. 1989), in the pig (Shibata et al. 1993). The 
porcine C6 locus was found highly polymorphic (Shitaba et al. 1993). 
 
Deficiency of the sixth component of complement is frequently associated with recur-
rent neisserial infections, especially meningitis caused by Neisseria meningitidis (Par-
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ham et al. 2007, Nishizaka et al. 1996) or candidiasis and toxoplasmosis (Morgan et al. 
1989). Various kinds of polymorphisms were found in different species: Neisseria 
infections in human can be caused by a `silent´ alleles at the C6 loci (Alvarez et al. 
1995) or a compound heterozygote for two C6 gene mutations resulting in premature 
termination codons and C6 null alleles in a 16 year-old African-American male (Zhu et 
al. 1998) or three frameshift mutations in African-Americans and in two Dutch C6-
deficient kindreds (Hobart et al. 1998) or a homozygous single-base deletion in one 
African American and a heterozygous single base deletion in one Japanese resulting in 
frame shifts and premature termination of the C6 polypeptide (Nishizaka et al. 1996). 
C6 deficiency caused by unstable mRNA or a point mutation in the C6 gene resulting in 
an aberrant transcription of the C6 gene was also studied in the rat (Van Dixhoorn et al. 
1997). In addition, point mutations observed in the Peru-Coppock mouse strain C6 gene 
may result in C6 deficiency (Bhole et al. 2004). C6 deficiency due to a blank allele for 
C6 was detected in the chimpanzee (Raum et al. 1980) and C6 deficiency involved in 
atherosclerotic lesion progression in rabbit (Schmiedt et al. 1998). Furthermore, C6 de-
ficiency in two of 241 individuals in six breeds of pig (Landrace, Large White, Duroc, 
Berkshire, Meishan, Jinhua) and cross breeds tested was found, which suggested the 
presence of a null allele in pig populations. Marked breed differences among the gene 
frequencies and heterozygosities at C6 locus were observed (Shitaba et al. 1993). 
 
2.5.2 The seventh complement component (C7) 
 
Genetic polymorphisms of the seventh component of complement (C7) were found in 
human (Fernie et al. 1999, Horiuchi et al. 1999, Fernie et al. 1997, Fernie et a. 1995), 
especially in Caucasian population (Dewald 1988), in Asian populations (Horiuchi et al. 
2002), in a Japanese population (Nishimukai et al. 2003, Wuerzner et al. 1991, Komatsu 
et al. 1989, Nishimukai et al. 1986, Washio et al. 1986, Nakamura et al. 1984), among 
Russian rural inhabitants of the Tomsk region (Kucher et al. 1993), in group of Africans 
(Fernie et al. 1997, 1996), in two Korean families (Kang et al. 2006), in Korean living 
in Seoul (Park et al. 1988), in 203 Chinese Han population in Liaoning Province of 
northeast China (Tsunenari et al. 1992), in Senegal population (Corbo et al. 1994), in 
the Cayapa Indians living in north-western Ecuador (Soelder et al. 1996). Different ge-
netic mutations have also been described in intron segments of human complement 
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component C7 (Nishimukai et al. 2003, Fernie et al. 1999, 1996, 1995, Nishizaka et al. 
1996), in the domestic dog (Eldridge et al. 1983), in the common marmoset (White-
house 1984).  
 
The complement C7 deficiency was found in human diseases such as candidiasis and 
toxoplasmosis (Morgan et al. 1989). In the case of meningococcal meningitis a number 
of C7 polymorphisms were found including a large deletion mutation in exon in an Ko-
rean 11 year-old girl (Ki et al. 2005) or a 11-base pair deletion of nucleotides leading to 
the generation of a downstream stop codon causing the premature truncation of the C7 
protein product in a Bolivian and Czech origin patient and a two-base pair deletion of 
nucleotides leading again to the generation of a downstream stop codon that provokes 
the truncation of the C7 protein in Spanish family (Barroso et al. 2006). Neisseria recur-
rent infections due to single base deletion of nucleotide and a missense mutation result-
ing in a change of amino acid were found in individuals of Moroccan Sephardic Jewish 
ancestry, a Spanish family (Barroso et al. 2004) as well as among a highly inbred Arab 
population living in the lower Galilee region of Israel (Behar et al. 2002) or a two base-
pair deletion of nucleotides leading to the generation of a downstream stop codon caus-
ing the truncation of the C7 protein product in another Spanish family (Barroso et al. 
2004) or appearance of a silent allele in three C7-deficient families (Alvarez et al. 1995) 
or a homozygous GÆT transversion leading to a stop codon in a Spanish family 
(Horiuchi et al. 1999) or a homozygous AÆT transversion leading to a stop codon TGA 
and a homozygous 2-bp deletion caused a frameshift, generating a premature termina-
tion codon 4-6 nucleotides downstream in two unrelated Japanese males (Nishizaka et 
al. 1996). Other case reports describe ankylosing spondylitis conducting on the serum of 
a 44 year-old woman of French-Canadian descent (Delâge et al. 1977), systemic lupus 
erythematosus due to a single base mutation leading to a stop codon that causes the 
premature truncation of the C7 protein in Spanish family additionally a AÆC transver-
sion resulting in an amino acid change (Barroso et al. 2006).  
 
2.5.3 The alpha and gamma chain of the eighth complement component (C8A-G) 
 
The alpha-gamma chain extensive genetic polymorphisms were found in human (Zhang 
et al. 1995, Nakamura et al. 1986, Rogde et al. 1985, Rittner et al. 1984), in 203 Chinese 
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Han population in Liaoning Province of Northeast China (Tsunenari et al. 1992). Par-
ticularly, Dewald et al. (1996) described the first known polymorphisms in the human 
C8G gene, namely a polymorphic site in exon and two more ones in intron segments. In 
pig, an allele variation GÆA (amino acid substitution ArgÆHis, codon 
485CGCÆCAC) was found in several different breeds Landrace, Large White, Duroc, 
Berkshire, Jinhua, Crown Miniature Pig, wild boar, and Meishan. (Nakajima et al. 
1998). 
 
Two kinds of inherited C8 deficiency have been reported in man. Type I, in which no 
C8 antigen is detected, was thought to represent deficiency of the whole molecule, 
whereas in type II, antigenically deficient C8, which apparently lacks only the beta 
chain, is found (http://www.genome.ad.jp/dbget-bin/www_bget?omim+120950). Asso-
ciation between the hereditary deficiency of the eighth component of complement and 
inflammatory disease like systemic lupus erythematosus disease in human (Jasin 1977) 
was reported. In addition, C8 deficiency in the serum of a 23-yr-old woman resulting in 
gonococcal infection syndrome (Petersen et al. 1976), inherited deficiency of C8 in a 
patient with recurrent meningococcal infections (Densen et al. 1983) or in a family with 
xeroderma pigmentosum (Giraldo et al. 1977) was identified. Genetic deficiency of the 
alpha-gamma-subunit of the eighth complement component was found in a strain of the 
New Zealand White rabbit leading to the following physiologic characteristic changes 
such as the body weight at the first week of life, mature weight, litter size, survival rates 
(Komatsu et al. 1985).  
 
2.5.4 The beta chain of the eighth complement component (C8B) 
 
Detection of C8B different genetic mutations was described in human (Dewald et al. 
1994, Kaufmann et al. 1993, Herrmann et al. 1989, Rogde et al. 1985, Alper et al. 
1983).  
 
The mutated allele was also found in intron of the C8B gene (Barba et al. 1994). C8 
beta deficiency is usually detected in individuals who survive meningococcal disease 
(Wulffraat et al. 1994). Association between C8B deficiency and juvenile chronic ar-
thritis in a 13-year-old boy (Wulffraat et al. 1994) or recurrent neisserial infections re-
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sulting an allele substitution leading to a codon stop in C8B human sequence (Kauf-
mann et al. 1993) was reported. The common CÆT mutation in the C8B genes is the 
genetic basis of C8 beta-chain deficiency in two members of this Bosnian family (Kot-
nik et al. 1997). Causes for C8B deficiency can be due to presence of mutated null al-
leles in a healthy Italian population (Bellavia et al. 1996), in 34 unrelated families from 
the United States and the former Soviet Union (Saucedo et al. 1995) or a nucleotide 
exchange creating a stop codon (Rao et al. 2004, Barba et al. 1994, Kaufmann et al. 
1993) or not a major allele deletion in Norwegian meningococcal disease patients 
(Rogde et al. 1990).  
 
2.5.5 The ninth complement component (C9) 
 
Different single nucleotide polymorphisms have been reported in human (Witzel-
Schloemp et al. 2001, Coto et al. 1991, Rogne et al. 1991, Coto et al. 1990). Deficiency 
of the ninth component of human complement is the most common complement defi-
ciency in Japan but is rare in other countries (Kira et al. 1998). C9 deficiency can lead 
to meningococcal meningitis due to creating a point mutation leading to termination 
codon in four Japanese C9-deficient patients (Kira et al. 1998), dermatomyositis due to 
the low titre of serum hemolytic complement (CH50) and a non-sense mutation in a 28 
year-old Japanese woman (Ichikawa et al. 2001), recurrent neisseria infections associat-
ing two different point mutations, both generating TGA stop codons in the coding se-
quence in Swiss family with inherited C9 deficiency (Witzel-Schloemp et al. 1997) or a 
`silent´ allele (Alvarez et al. 1995) and the long-surviving mismatched kidney allografts 
in an Caucasian group due to absence of C9 (Hobart et al. 1997). Absence of C9 can 
also happen in a person with good health (Inai et al. 1979) or in serum of a 47 year-old 
woman with paroxysmal nocturnal haemoglobinuria. 
 
Human C9 contains a motif (48WSEWS52) common to a family of cytokine receptors 
that is similar to a tryptophan-rich motif (WEWWR) of the membrane pore formers, 
thiol-activated cytolysins. Mutation of this motif in C9 resulted in polymerized protein, 
consistent with this site keeping the N-terminus in a protected conformation and pre-
venting premature self-polymerization (Taylor et al. 1997).  
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2.6 Position of candidate genes on chromosome 
 
RH panels consist of rodent cell lines that contain fragments of porcine foreign DNA, 
produced by X-Ray breakage. DNA fragment size is inversely proportional to the radia-
tion dose and breakage is largely sequence independent as is the retention frequency of 
fragments (Alexander et al. 1999). Since the 118 clones/7000Rad INRA-Minnesota 
porcine radiation hybrid (IMpRH) panel has been constructed by Yerle et al (1998) it 
rapidly becomes the wonderful physical mapping tool for assigning candidate markers 
on chromosomes and for linking cytogenetic maps further. Considering the porcine 
map, it appears necessary to have a more accurate tool to determine the position and 
order of genes and markers. The IMpRH method based on the presence or absence of 
specific porcine/hamster DNA sequences in RHs is mainly determined by PCR. Order 
and distance between markers is calculated using a statistical algorithm that estimates 
the frequency of breakage between markers.  
Figure 5  Locations of published human C6, C7 or C9 mutations leading to deficien-
cies in relation to the modules (indicated in the box). Boundary mutations, 
generating nonsense intron sequence till a stop codon is reached (#), and 
amino acid substitutions (A111B) are indicated. In addition, mutations lead-
ing to subtotal deficiency are boxed (Wuerzner 2003) 
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The assignment for human complement component C9 to chromosome 5 was confirmed 
by in situ hybridization to human metaphase chromosomes, giving a regional localiza-
tion of 5p13 (Abbott et al. 1989) which is the same regional chromosomal position of 
human C6 and C7 (Hobart et al. 1993). The gene encoding the human C8A and C8B are 
physically linked on chromosome 1p32 (Platteborze et al. 1996, Michelotti et al. 1995, 
Theriault et al. 1992, Rogde et al. 1986) whereas the human C8G is closely linked to a 
series of marker loci located in the most telomeric region of chromosome 9q34.3. Re-
markably, this chromosomal region contains at least four other lipocalin genes (Dewald 
et al. 1996). In pig, the C8A gene was physically mapped to chromosome 6q3.3-q3.5 by 
in situ hybridization using the porcine bacterial artificial chromosome (BAC) clone as a 
hybridization probe (Nakajima et al. 1998) whereas the C9 was mapped to 16q1.4 by 
fluorescence in situ hybridisation (Thomsen et al. 1998). 
 
2.7 Hemolytic complement activity 
 
The previous studies for hemolytic complement activity were conducted on many dif-
ferent animal species. Schwab et al. (1966) reported the effect of temperature on the 
hemolytic activity of lizard and toad sera was similar to the effect on bactericidal activ-
ity, but with pig serum hemolytic activity was at a maximum between 35 and 40oC . 
This has been suggested that fetal pigs are unable to produce antibodies, and, hence, 
their serum does not kill smooth strains of gram-negative bacteria (Sterzl et al. 1962). 
Classical pathway hemolytic complement activity was assayed in camel trypanosomosis 
infected with Trypanosoma evansi (Ouma et al. 1997) 
 
The hemolytic complement activity of pig C6 gene was conducted to test the lysis of 
plasma ability with sensitised sheep erythrocytes. No lysis occurred in C6-deficient 
samples, but lysis was observed in normal plasma. Shitaba et al (1993) summarized that 
the presence of a null allele in pig population was found in other animals including man. 
Inheritance of C6 deficiency has not been tested yet.  
 
A high degree of biochemical and structural similarity between porcine and human C7 
protein was observed by Agah et al. (2000). Hemolytic assays were performed to test 
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whether porcine C7 could functionally replace human C7 in C7-deficient human sera. 
The experiment was conducted by addition of purified porcine C7 that restored the 
hemolytic activity of C7-depleted human sera in a dose-dependent manner. A function-
ally inhibitory mAb (Monoclonal antibody) against porcine C7 attenuated the hemolytic 
activity of human, rabbit, or rat sera, suggesting an important conserved C7 epitope 
among species. The results demonstrated that porcine and human C7 are highly con-
served, sharing structural and functional characteristics (Agah et al. 2000). Additionally, 
CH50 titer was used to analyze hemolytic complement activity in human having anky-
losing spondylitis due to C7 component deficiency (Delâge et al. 1977). 
 
Absence of the eighth complement component and a disease compatible with systemic 
lupus erythematosus was found in a 56 year-old black woman. After the addition of 
functionally pure C8 hemolytic activity could be restored. C8 deficiency may be associ-
ated with a subtle defect in the defense mechanisms to viral infection leading to viral 
persistance and perhaps to diseases such as systemic lupus erythematosus where chronic 
viral infections have been implicated (Jasin 1977). Total hemolytic complement activity 
(CH50) was tested for the purpose of developing hereditary deficiency of complement 
component of C8 alpha-gamma and C6 in a colony of New Zealand White rabbits (Ko-
matsu 1985). 
 
Association between C9 deficiency with CH50 titer and diseases such as meningococcal 
meningitis (Zoppi et al. 1990), systemic lupus erythematosus (Takeda et al. 1994, 
Kawai et al. 1989), long-surviving mismatched kidney allografts (Hobart et al. 1997) 
were found. Almost all the ninth complement components (C9) deficiency in Japan 
shows Arg95 stop mutation of C9 gene but not in patients with systemic lupus erythema-
tosus susceptibility (Kanemitsu et al. 2000). C9 deficiency is also described in serum 
complement levels (CH50) of a 29 year-old woman in good health (Inai et al. 1979). 
Supplement of complement component C9 in neonatal serum can enhance the capacity 
of Escherichia coli killing shown by a radiobinding assay and immunogold electron 
microscopy using a monoclonal anti-C9 antibody (Lassiter et al. 1994). Using purified 
components demonstrated that C5b-9 exerts a regulatory effect on the formation of the 
classical and alternative pathway C3 convertases and on the utilization of C5 by cell-
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bound C5 convertase. C5b-9 complex was unable to inhibit the lysis of cells bearing 
C5b-7 by C8 and C9 (Bhakdi et al. 1988). 
 
In recent years people are much more concerned about the sustainable animal produc-
tion system including quality control of food for human and animal, animal welfare and 
health status, effects of animal production on the environment, the influences of new 
technology application in animal and plant production, future animal production sites 
and global trading strategy (http://www.agriculture.de/acms1/conf6/pdf/sumsum.pdf). 
With the economic development the income of many people is increasing quickly not 
only in developing countries but also in poor countries. The demand for both quantity 
and quality of food in the daily meal is more and higher. Thus in animal breeding pro-
grams people address to produce animals with less fat, much muscle, less water in meat, 
less toxin or antibiotic, etc. Development in biotechnology and farm animal breeding 
genetic technology contributes a great potential for this. It will bring producer and cus-
tomer much more benefit because of decreasing in production cost and price of product. 
Since the complement system was known as a natural disease resistance mechanism of 
host body and can support to solve several problems as described above, many studies 
on the complement components have been conducted in various animal species. In pig 
some porcine genes encoding complement components have already been identified or 
even analyzed as candidate genes for disease resistance. Sofar, one by one, the porcine 
C1 composed of three subcomponents C1q (alpha chain (GenBank acc. no. AY349424) 
and beta chain (GenBank acc. no. AY349420)), C1r (GenBank acc. no. AY349421) and 
C1s (GenBank acc. no. AY349426) were sequenced (Trakooljul et al. 2004). The por-
cine C2 nucleotide (2574 bp) and deduced protein (752 amino acids) sequences were 
found in GenBank (acc. no. NM_001101815, NCBI homepage) derived from the pig 
DNA sequence of clone PigI-707F1 (GenBank acc. no. AL773527) (Sehra 2007). The 
porcine C3 cDNA sequences including 5´ and 3´ flanking regions (GenBank acc. no. 
AF154933) were determined and polymorphisms were detected to carry out an associa-
tion analysis between C3 and complement activity traits (Mekchay et al. 2003, Wim-
mers et al. 2003). Moreover, Firth et al. (2007) showed the porcine C3d sequence 
(GenBank acc. no. EU257630) with 999 bp coding 333 amino acid whereas the porcine 
C4 (GenBank acc. no. AY349423) consists of 1656 bp encoding 517 amino acids (Tra-
kooljul et al. 2004). In a total of 5422 bp of cDNA sequence coding the 1677 amino 
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acid precursor, the porcine complete C5 cDNA (GenBank acc. no. AY332748) was se-
quenced, screened for single nucleotide polymorphisms, and an association analysis 
with various immunological parameters was conducted (Kumar et al. 2004). In addition, 
Yi and Kang (2007) also separated porcine C5a cDNA sequence with 723 bp coding 
226 amino acids (GenBank acc. no. EF210575) from C5. Several polymorphisms were 
detected within porcine C6 gene (Shibata et al. 1996) while the porcine C7 (GenBank 
acc. no. AF162274) was isolated and characterized (Agah et al. 2000). The complete 
C8A cDNA (2145 bp) as well as deduced protein (589 amino acid) sequence (GenBank 
acc. no. ADB13968) was determined and mapped to porcine chromosome 6q3.3-q3.5 
(Nakajima et al. 1998) whereas the porcine C9 was assigned to chromosome 16q14 
(Thomsen et al. 1998). In this work, focus was on the characterization of the genes en-
coding the terminal pathway of the complement system. Their variation and association 
with hemolytic complement activity in the classical and alternative pathway were stud-
ied in a F2 DUMI resource population immunized with Mycoplasma, Aujeszky and 
PRRS vaccination, and the genes were assigned to porcine chromosome.  
 
  
3 Materials and methods 
 
Hereafter a general schema, which allows following the experiment up easily, is dis-
played (Figure 6). 
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Figure 6 General schema of experimental approach 
 28Materials and methods 
3.1 Materials 
 
3.1.1 Materials on station 
 
3.1.1.1 Experimental animals, tissue and data collection 
 
In this study, one animal of each of the pig breeds Hampshire (HS), German Landrace 
(LR), Duroc (DR), Pietrain (PIE), Berlin Mininature Pig (BMP) and Muong Khuong 
(MK) (Vietnamese potbelly pig) was used to determine the entire sequence of the cond-
ing region (cds) of the candidate genes and to screen for polymorphisms. In addition, 
unrelated LR (n=30), PIE (n=30) and MK (n=25) animals as well as animals of the F2 
DUMI resource population were used for genotyping to determine allele frequencies 
and to perform linkage mapping and association analysis with hemolytic complement 
activity. 
 
The Muong Khuong breed is a large resource population of pig reared by H´Mong 
householders who are living in the Northwest mountain area, mainly in Lao Cai prov-
ince of Vietnam. These pigs are often kept at small-scale level (one-several animals per 
householder). The animals are allowed moving freely around the house/ garden and 
foraging for feed. They can enjoy anything they like in nature and in soil such as vege-
tables, worms, minerals, etc. They are also fed available simple feed resources or farm 
by-products such as rice bran, ground-yellow corn, vegetable, etc. The Muong Khuong 
pigs are divided in three different phenotypes (Figure 7). Birth weight can reach 
0.60±0.04 kg and weight at 12 months of age can weigh up to 92.44±2.13 kg (average 
gain 4-6 kg per month). The adult weight at around 18 months can be up to 120 kg. The 
Muong Khuong pig, one of Vietnamese potbelly pig breeds, known as a breed, which 
can resist diseases and endoparasites and which is able to adapt well to harsh environ-
mental conditions (temperature, humidity, nutrition, management) but not scientifically 
verified, represents a naturally selected population. In a recent report Thuy et al. (2006) 
indicated that the Vietnamese autochthonous breeds including Muong Khuong breed 
show higher degree of polymorphism, allelic diversity, and heterozygosity than several 
European pig breeds (German Landrace, Pietrain and Large White). Vietnamese local 
breeds are a source for promising alleles of unpredictable economic value (Lemke et al. 
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2005). Genetic distances show large differences among European-based, Chinese, and 
Vietnamese indigenous breeds and reflect the geographical distribution of breeds. In 
comparison with the European breeds, the Vietnamese indigenous pig breeds harbour a 
considerable amount of genetic diversity and therefore they will be of significance for 
livestock bioconservation (Thuy et al. 2006). 
X Z Y
 
Figure 7   Three different phenotypes in Muong Khuong pig breed: X_black colour 
with 6 white points (one in the middle of head, four in legs and one in the 
bottom of tail), Y_brown colour, and Z_dark black colour 
 
Six adult Muong Khuong animals (three males and three females) selected at an average 
live weight of about 65 kg were bought for experimental sampling in Muong Khuong 
district of Lao Cai province. The fresh tissue specimens were submerged in RNAlater 
solution and stored at – 20oC according to Ambion´s manufacture instruction (Figure 8). 
Total mRNA was isolated from the liver tissue and reverse transcribed to cDNA 
whereas DNA was extracted from tail/ ear samples of 25 Muong Khuong animals. 
 
Liver tissue and ear/tail tissue samples from 30 unrelated individuals of each commer-
cial breed LR and PIE raised at the Research and Performance Test Station, Franken-
forst, University of Bonn, Germany were collected for RNA isolation and for DNA iso-
lation, respectively.  
 
The F2 DUMI resource population was derived from a reciprocal cross of Duroc and 
Berlin Miniature Pig (Hardge et al. 1999). The Berlin Miniature Pig was bred from 
Vietnamese potbelly pig, Saddleback Pigs and German Landrace (Hardge et al. 1999). 
Five sows of Berlin Miniature Pigs were crossed with a Duroc boar and four Duroc 
sows were crossed with a Berlin Miniature boar to produce F1 animals (parental genera-
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tion). In total 47 F1 animals were used to produce the F2 animals (n=902) called the F2 




Carcass of Muong Khuong pig 




























Figure 8    Sampling in Muong Khuong animals on farm in Lao Cai province, Vietnam  
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About half of them (n=485) were reared at the Research Station of the Humboldt Uni-
versity, Berlin (F2 Berlin DUMI) while the other F2 animals (n=417) were reared and 
tested performance at the Research Farm of Frankenforst, Institute of Animal Breeding 
Science, University of Bonn (F2 Bonn DUMI). The F2 Bonn DUMI animals used in this 
study originated from 11 sows and three boars of the F1 generation and they have been 
phenotyped regarding the complement activity and immune responsiveness as described 
below (Figure 9). 
F0: 1♂Du x 2♀Mi  
      1♂Mi x 2♀Du 
F2: 21fullsib  
      families,   
      417 
      animals 
F1: 3♂Dumi  




Figure 9 The structure of F2 DUMI resource population based on reciprocal crossing 
of Duroc and Berlin Miniature Pig 
 
3.1.1.2 Phenotyping of the immune responsiveness: sampling design  
 
In order to investigate immune competence traits the following experiment was con-
ducted. The experiment carried out at the Frankenforst Research Station of University 
of Bonn consisted of two trials: (1) The control group with 36 F2 DUMI animals was 
unvaccinated. (2) The trial group containing the 381 remaining animals was immunized 
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with Mycoplasma hyopneumoniae vaccine (Mh) (Stellamune, Mycoplasma, Pfizer, 
Karlsruhe, Germany), Aujeszky virus vaccine (ADV) (Porcilis, Begonia Diluvac, In-
tervet, Tönisvorst, Germany) and Porcine Reproductive and Respiratory Syndrome Vi-
rus vaccine (PRRSV) (Ingelvac PRRS MLV, Boehringer Ingelheim, Germany) at six, 
14 and 20 weeks of age for measuring immunological parameters and analysing 
association between the candidate genes and hemolytic complement activity in both the 
classical and alternative pathway. EDTA anticoagulated blood samples were collected 
from each animal before (day 0) and after Mh and ADV vaccination (day 4 and 10) but 
only at day 10 after PRRSV vaccination (eight sampling time points) and were then 
cooled immediately in ice. Sera and plasma isolations were obtained within 2 hours af-
ter blood taking by centrifugation at 4oC at a maximum speed of 14.000 rpm for 10 min 









Vacinating Mh ADV PRRSV 
Week of age 6 14 20 
Blood sampling day 0, 4, 10 0, 4, 10 0, 10
Figure 10  Vaccination program and time of blood sampling before and after immu-
nization in F2 DUMI population 
 
3.1.2 Materials for laboratory analysis 
 
3.1.2.1 Chemicals, biological materials, kits and others 
 
Applied Biosystems (Darmstadt) : RNAlater®-ICE 
Biomol (Hamburg) : Phenol 
Fermentas (Leon-Rot) : Glycogen, Restriction enzymes (AluI, 
BbvI, BseDI, BsrDI, Eco91I, FnuDII, 
Hin6I, HpaII, PstI,) 
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Invitrogen (Karlsruhe) : SuperScripTMIII reverse transcriptase 
Macherey-Nagel (Düren) : NucleoSpin® Extract II 
New England Biolabs® Inc. (Frank-
furt am Main)  
: Restriction enzymes (AciI, BsrI, DdeI, 
HpyCH4III) 
Promega (Mannheim) : Dithiothreitol (DTT), Rnasin Ribonuclease 
inhibitor, RQ1 RNAse-free, DNAse I and 
10 x buffer, oligo (dT)13 VN primer, ran-
dom hexamer primer 
Roth (Karlsruhe) : Formaldehyde, Proteinase K, Sodium 
chloride, Sodium hydroxide, Tris, Acetic 
acid, Chloroform, dNTP, Ethylenediami-
netetraacetic acid (EDTA), Ethanol, 
Ethidium bromide, Formaldehyde, Sodium 
dodecylsulphate (SDS), Sodium chloride 
Sigma (Genosys, Steinheim) : Oligonucleotide primers, Agarose 
Sigma-Aldrich (Taufkirchen) : Isopropanol, TRI-Reagent, Taq poly-
merase 
 
3.1.2.2 Buffers and reagents 
 
 
Digestion buffer : Tris HCl, pH 8.0 0.05 M
  EDTA  0.1 M
  SDS  0.5%
  Water added up to 1000 ml
SDS solution  : Sodium dodecylsulphate 10%
Sodium acetate  : Sodium acetate trihydrat (>99.5%, 
D~1.42, M 136.08)  
3 M
  Acetic acid to adjust pH 5.2 
  Water added up to 1000 ml
1 x TE buffer : Tris  10 mM
  EDTA  1 mM
  Water added up to 1000 ml
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50 x TAE buffer  : Tris 2 M
  Acetic acid  57% (v/v)
  EDTA, pH 8.0 0.05 M
  Water added up to 1000 ml
 
3.1.2.3 Used softwares 
 




ClustalW2: DNA/ protein alignment  
(http://www.ebi.ac.uk/clustalw/) 
Conserved Domains Search: Functional protein domain analysis 
(http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) 
DiANNA 1.1 web server: Cysteine state and disulfide bond partner prediction 
(http://clavius.bc.edu/%7Eclotelab/DiANNA/) 
INRA-UMN porcine Radiation Hybrid (IMpRH) panel: RH mapping 
(http://www2.toulouse.inra.fr/lgc/pig/RH/IMpRH.htm) 
MEGA3: Phylogenetic analysis  
(http://www.megasoftware.net/) 
MultAlin : Multiple sequence alignment  
(http://bioinfo.genopole-toulouse.prd.fr/multalin/multalin.html) 




NCBI/Map Viewer  
(http://www.ncbi.nlm.nih.gov/mapview/) 
NCBI/Trace archive: retrieving genomic DNA sequence  
(http://www.ncbi.nlm.nih.gov/Traces/trace.cgi?) 
NEBcutter V2.0: Restriction digestion analysis  
(http://tools.neb.com/NEBcutter2/index.php) 
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NetCGlyc 1.0 Server: C-Manosylation site prediction 
(http://www.cbs.dtu.dk/services/NetCGlyc/) 
NetNGlyc 1.0 Server: N-Glycosylation site prediction 
(http://www.cbs.dtu.dk/services/NetNGlyc/) 
ORF Finder: deduced amino acid sequence  
(http://www.ncbi.nlm.nih.gov/gorf/gorf.html) 
P O L Y V I E W - 3D: 3D Protein structures  
(http://polyview.cchmc.org/polyview3d.html) 
Primer 3: Primer design  
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) 
SAS version 9.3.1, SAS Institute Inc., Cary, NC: Statistical analysis 
(http://support.sas.com/documentation/onlinedoc/91pdf/)  
SignalP 3.0: Signal peptide analysis  
(http://www.cbs.dtu.dk/services/SignalP/) 
SMART mode: Functional protein domain analysis  
(http://smart.embl-heidelberg.de/) 
Webcutter: Restriction digestion analysis  
(http://www.firstmarket.com/cutter/cut2.html) 






ABI 310 Genetic Analyzer (Applied Biosystems, Darmstadt)  
MegaBACE 1000 (GE Healthcare, München) 
PCR thermocycler (Biometra, Göttingen) 
Power supply BIO-RAD Model 200/2.0 (Electrophoresis for agarose gel, Groton) 
Spectrophotometer Nanodrop ND-1000 (Peqlab, Erlangen) 
UV transilluminator (High performance 302 – 365 nm, Cambridge) 
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3.2 Methods 
 
3.2.1 Immunological methods: complement activity measurement  
 
Data of complement activity were obtained previously by the following procedure: for 
determining complement activity in the classical and alternative complement pathway 
hemolytic assays were applied according to the methods of Liu and Young (1988) and 
Demey et al. (1993). Hemolytic complement activity was expressed as the amount of 
serum that caused a 50% hemolysis of antibody sensitised sheep red blood cells 
(SRBCs) in the reaction mixture. Calculation was based on the change in light-
scattering properties of erythrocytes upon lysis. The test conditions were evaluated and 
standardised for the assay of pig complement. SRBCs sensitised with hemolysin (anti-
sheep red blood cell stroma from rabbit, Sigma, Taufkirchen, Germany) were collected 
from healthy animals, submerged into Alsever´s solution and stored at 4oC until analy-
sis. SRBCs were diluted 1:75 in GVBSS and used as a 2% cell-suspension. Serial dilu-
tions of test sera (50 μl) were made in duplicate in flat-bottomed 96-well microtitre 
plates (1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256). Fifty microlitter of sensitised 
SRBCs suspension were added to each serum dilution, respectively. The plates were 
incubated for 90 min at 37oC. The results were recorded through absorbance level of a 
microplate reader (ThermoMax ELISA reader and Soft Max Pro software, Molecular 
Devices, USA) at 650 nm. The readings were transformed by the method of von Krogh 
according to Mayer (1961) and the hemolytic titer was expressed as the titre that lysed 
50% of the erythrocytes (CH50, U/ml) (Wimmers et al. 2003). 
 
Rabbit erythrocytes (RRBCs) were used as foreign surfaces for testing alternative com-
plement pathway activity in pig sera. Twenty-five microlitres of diluted sera (1:2, 1:3, 
1:4 and 1:6) with GVBS-Mg-EGTA buffer and 25 μl of 0.5% (v/v) rabbit erythrocytes 
were incubated at 37°C for 90 min in duplicate wells of flatted bottom 96-well mi-
croplates (Roth). A 150 μl GVBSS-Mg-EGTA buffer was added in each well and the 
absorbance values at 650 nm were read. The activity was expressed in term of serum 
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3.2.2 Molecular genetic methods 
 
3.2.2.1 DNA extraction  
 
Preparation of genomic DNA from tail or ear samples was performed by standard pro-
cedures involving Proteinase K digestion followed by phenol-chloroform extraction and 
ethanol precipitation. Tail or ear tissues were cut into small pieces of 2-3 mm and 
weighed about 0.1 g. The sample was placed in 2 ml tube containing 700 μl of digestion 
buffer. To lyse the cells and digest proteins, 35 μl of Proteinase K solution (20 mg/ml) 
was added and the samples were then incubated at 55oC overnight with mixing. An 
equal volume of phenol-chloroform (1:1 v/v, 700 μl for each) was added. The two 
phases were mixed until they formed a homogenous emulsion. The two phases were 
separated by centrifugation at 5000 rpm for 3 min at 4oC. The aqueous phase was col-
lected in fresh tubes. Phenol-chloroform extraction was repeated and was followed by a 
chloroform extraction. One-tenths volume of sodium acetate (3 M, pH 6.0) and an equal 
volume of isopropanol (700 μl) were added. The samples were shaken gently until pre-
cipitation of DNA. The DNA pellet was washed three times with 1 ml ethanol (70%) 
and dried at room temperature. Finally the DNA was resuspended in 1× TE buffer and 
stored at 4oC for analysis. 
 
3.2.2.2 RNA isolation  
 
Total RNA was isolated from liver tissue of six different breeds (HS, DR, LR, PIE, 
BMP and MK). About 100 mg of liver was ground into fine powder with a set of porce-
lain mortar and pestle, submerged with 1 ml TRI Reagent in 2 ml tubes, mixed well, 
homogenized by passing several times through 0,9 mm needle attached to a syringe, and 
incubated at room temperature for 5 min for complete cell lysis. The sample was centri-
fuged for 15 min at 4oC at 12,000 x g. The aquesous phase was transferred to a fresh 
tube and 500 μl of isopropanol were added and gently mixed by inversion. After incu-
bation at room temperature for 10 min the RNA was pelleted by centrifugation at 4oC 
for 10 min at 12,000 x g. The supernatant was discarded while the white RNA pellet at 
the bottom of the tube was kept and washed with 1 ml of chilled 70% ethanol by gentle 
vortexing lightly and centrifuging at 12,000 x g for 5 min at 4oC. The ethanol was re-
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moved by pipetting and the RNA pellet was air dried at room temperature. The RNA 
pellet was resuspended in 30 μl of RNAse-free water. DNAseI was used to remove 
traces of genomic DNA. The DNAseI digestion was performed in 50 μl solution, con-
taining 30 μl RNA solution, 5 μl of 10 x buffer, 5 μl DDT (0.1 M), 1 μl RNAse-free 
water and was then incubated for 1 hour at 37oC. For subsequent RNA clean-up the 
NucleoSpin® Extract II Kit was used according to manufacturer instructions. The final 
RNA concentration was measured by using Nanodrop spectrophotometer. The integrity 
was checked on 1% agarose gel/TAE containing formaldehyde and ethidiumbromide. 
 
3.2.2.3 Complementary DNA (cDNA) synthesis 
 
First-strand cDNA was synthesis from 1 μg of total RNA using 500 ng of oligo (dT)13 
VN primer and 500 ng random hexamer primers. For denaturing the RNA was mixed 
with the primers, brought to a final volume of 11 μl and subsequently heated for 5 min 
at 68oC and immediately chilled on ice for at least 2 min. After addition of a reaction 
mix containing 4 μl of 5x First Strand Buffer, 1 μl of 0.1M dithiothreitol (DTT), 1 μl of 
rRNAsin (Rnase Inhibitor 40 U/μl), 25 μM dNTPs and 1 μl of Super ScriptTMIII Rnase 
H- and RNAse free water to a final volume of 20 μl, the cDNA synthesis reaction pro-
ceeded by incubation of the reaction mixture at 25oC for 5 min (Hexamer annealing), 
followed by 50oC for 1 hour (reverse transcription), 70oC for 15 min (reverse transcrip-
tion inhibition) in a thermal cycler. The cDNA solution was diluted 1:5 and stored at –
20oC for the subsequent PCR reaction. To confirm the complete removal of genomic 
DNA and successful cDNA synthesis, RNA and cDNA were used as template in a PCR 
reaction using intron spanning primers amplifying a part of β-actin gene. 
 
3.2.2.4 Amplicon and primer design  
  
In order to obtain whole cDNA sequence of the candidate genes, screening known hu-
man and murine sequences in public databases was conducted and the nucleotide-
nucleotide BLAST tool (blastn) was used to retrieve available porcine orthologs (ex-
pressed sequence tags, ESTs) of the candidate genes. The retrieved porcine sequences 
from previous sequence information (GenBank acc. no. BP444694.1, BP444335.1, 
BP454270.1, BP445832.1, BP451787.1 for C6, BI336392, CF176130, AF162274 for 
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C7, BP448099.1, BP 449671.1, BX920949.1 for C8A, BP447190.1, BP446376.1, 
BX918195.1 for C8B, BP139629.1, BP443148.1 for C8G, BP139003.1, CJ007506.1, 
BX920671, CF363669 for C9) were assembled into contigs and the exon structure. Pos-
sible gaps were determined and their approximate sizes were estimated using the 
orthologous human and mouse sequences. For the porcine C7 gene the whole cds was 
already cloned by Agah et al. (2000, GenBank acc. no. AF162274). In order to bridge 
existing gaps and to amplify overlapping fragments of the whole cds, comparative se-
quencing primers amplifying amplicons suitable for direct sequencing were designed 
using Primer3 tool. The primer sequences, their position in the cDNA sequence and the 
lengths of corresponding amplicons are given in table 1. 
 
3.2.2.5 Polymerase chain reaction (PCR) 
 
A standard PCR mixture for sequencing and genotyping contained 50 ng of liver cDNA 
or 100 ng of genomic DNA, 0.2 mM of each primer (forward and reverse primer), 50 
μM of each dNTP, 0.5 U of Taq polymerase and 1xPCR buffer containing 1.5 mM of 
MgCl2 in a final volume of 20 μl. Standard PCR thermal cycling program was set up 
with an initial denaturation step of 94oC for 4 min, followed by 40 cycles at 94oC for 30 
sec, annealing at 60oC for 30 sec, elongation at 72oC for 1 min and a final extension at 
72oC for 5 min. Individually, due to the combination condition the thermal program for 
primers C9.5 and C9.8.8a were conducted under the annealing temperature 50 and 55oC 
for 45 sec, respectively, followed by elongation step at 72oC for 75 sec. Additionally, 
for some primer pairs touchdown PCR profiles turned out to be optimal with conditions: 
initial denaturation at 94°C for 4 min, followed by eight cycles at 94°C for 30 sec, from 
58-54oC for primers C6.1, C7.1 and C7.2, from 64-60oC for primers C7.3a and C7.4 or 
68-64oC for primer C7.5 for 30 sec, at 72°C for 1 min (annealing temperature was step-
downs 0.5°C for each cycle repeated two times), then followed by 35-40 cycles of 94°C 
for 30 sec, at 54, 60 or 64°C for 30 sec, at 72°C for 1 min, and ending with an extension 
step at 72oC for 5 min. Thermal cycling conditions are summarized in table 1. Three to 
3-5 μl of PCR products were analyzed on 1% agarose gel stained with ethidium bromide 
in 1 x TAE buffer and electrophoresed to evaluate specifity and efficiency of the ampli-
fication and the remainder was retained for sequencing or genotyping.  
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3.2.2.6 PCR product purification 
 
The PCR products were purified by ethanol precipitation as follow: 42.5 μl of 100% 
ethanol, 1.7 μl of sodium acetate (pH 5.2, 3 M) and 1 μl of glycogen (1 µg/µl) were 
added into 17 μl of the PCR product and the mixture was incubated overnight at –20oC. 
The PCR products were pelleted by centrifugation at 14000 rpm at 4oC for 50 min, sub-
sequently air dried and dissolved in 10 μl of PCR-grade water. Alternatively the PCR-
products were purified using the NucleoSpin® Extract II Kit according to manufacturer 
instructions. The concentration and purity of the purified PCR products was evaluated 
on the Nanodrop spectrophotometer. 
 
3.2.2.7 Sequencing 
In order to identify cDNA/ DNA sequences and polymorphisms of the candidate genes, 
the PCR products after purification were used for sequencing based on the Sanger dide-
oxy nucleotide triphosphate (ddNTP) terminator method. According to the protocol, a 
total of 10 µl reaction mixture was prepared containing 5 ng of the purified PCR prod-
ucts for each 100 bp of the DNA fragment length, 5 pm (0.5 µl) primer either up or 
down, 1.5 µl BigDyeR Terminator Ready Reaction Premix and water. The cycle se-
quencing reaction was done with an initial denaturation step of 96oC for 1 min followed 
by 25 cycles at 96oC for 10 sec, from 50-65oC (according to the annealing temperature 
of each primer as given in table 1 and 4) for 5 sec, 60oC for 4 min and cooled down to 
6oC. The products were purified using the Princeton Seperations Centri Sep Spin Col-
umn Kit. An aliquot of 4 µl of PCR products was analyzed on the MegaBACE 1000 or 
the ABI 310 Genetic Analyzer capillary sequencer. Each sequence chromatogram was 
manually inspected using Chromas and when need trimmed of poor-quality sequence. 
 
3.2.2.8 Screening for single nucleotide polymorphisms (SNPs) 
 
For SNP identification the processed individual sequences of each of the six breeds 
were aligned and compared together using the web-based program `MultAlin´. The SNP 
sites are confirmed by either using polymerase chain reaction-restriction fragment 
length polymorphism (PCR-RFLP), which can discriminate between the alleles, or by 
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resequencing. Individual sequence traces were inspected using Chromas software. Veri-
fication of SNP was performed using cDNA as template. The typical restriction diges-
tion reaction mixture was performed in a total volume of 20 μl containing 15 μl aliquot 
of PCR product, 10 U of the appropriate restriction enzyme and 2 μl supplied reaction 
buffer. Incubation was done overnight to ensure complete digestion and was finished by 
heat inactivation for 20 min according to Fermentas or New England Biolabs manufac-
turer´ s instruction. The enzymes and conditions used for RFLP analysis are summa-
rized in table 3. Fragment length polymorphisms were analyzed on a 3-5% agarose gel 
stained with ethidium bromide for evaluation and documentation. 
  
3.2.2.9 SNP genotyping  
 
Once the general mutation picture was established, some of the SNP sites in each gene 
were selected for genotyping in unrelated healthy animals of breeds LR (n=30), PIE 
(n=30) and MK (n=25) and 417 animals of F2 DUMI population by using PCR-RFLP 
analysis or by resequencing. Amplifications as well as methods for the restriction diges-
tion reaction are described above. All of the PCR products were separated on 3-5% aga-
rose gel for discriminated allele identification. For genotyping, genomic DNA samples 
were used. The exon structure of the individual genes, derived from pig-human and/or 
pig-mouse comparison, was considered when designing amplicons. Intron sequences 
were either determined by amplification of genomic DNA using suitable primer pairs 
and sequencing or the sequences were retrieved from public databases as described in 
paragraph 3.2.2.4. Therefore one of two primers located on one exon segment whereas 
another primer was designed in the neighbouring exon or intron sequence. A summary 
of PCR conditions, amplicon designs and primers used for genotyping is given in table 4. 
 
3.2.2.10 Assignment of candidate genes to chromosomes  
 
In order to perform physical mapping of the candidate genes the INRA-University of 
Minnesota porcine 7000Rad Radiation Hybrid panel (IMpRH) containing 118 pig/ ham-
ster DNA hybrid clones (Hawken et al. 1999, Yerle et al. 1998) was employed. Based 
on accession number sequence DQ333199, NM_214282, 5´flanking region of clone 
XX-1C1, DQ333201, DQ333202 and DQ333198, specific primer pairs, which allowed 
amplifying DNA fragments of 159 to 707 bp for mapping C6, C7, C8A, C8B, C8G and 
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C9 were derived. Amplicon design, primer sequences and PCR conditions are summa-
rized in table 2. Prior to mapping, PCR conditions were optimized so that specific am-
plification of porcine DNA but not DNA of the hamster parental lines or amplification 
of fragments unambiguosly distinguishable between the two species was achieved. The 
expected porcine DNA fragments were then sequenced to verify their identity. PCR 
reaction was performed in a total 15 μl reaction mixture containing 25 ng of hybrid 
DNA, 100 μM of each dNTP, 0.1 μM of each primer, 1×supplied PCR buffer contain-
ing 1.5 mM MgCl2 and 1 U Taq polymerase. PCR reactions were prepared for 118 
DNA templates of the IMpRH panel (positive), a hamster DNA template (negative con-
trol), a blank-template without DNA (negative control) and a porcine genomic DNA 
(positive control). The PCR products were amplified using standardized thermal profile 
as follows: 4 min of initial denaturation at 94oC, 40 cycles at 94oC for 30 sec, at the 
annealing temperature 58oC or 60oC (depending on the specific primer pairs shown in 
table 2) for 30 sec, at 72oC for 1 min and a final extension at 72oC for 5 min. For map-
ping of the C7 gene a modified, touch-down thermal profile was employed: 94oC for 4 
min, followed by 9 cycles at 94oC for 30 sec, annealing temperature from 60-51°C (-
1°C per cycle) for 30 sec, 72oC for 1 min, followed by 40 cycles of 94oC for 30 sec with 
annealing temperature at 50oC for 30 sec, at 72oC for 1 min, ending with an extension 
step at 72oC for 5 min. The entire PCR reactions were separated on 3% agarose gel 
stained with ethidium bromide and amplification products were independently scored as 
present (1), absent (0), or ambiguous (?). The results translated into vector format for 
submitting to IMpRH mapping tool. The PCR-screening of the IMpRH panel was per-
formed twice. For ambiguous data, the PCR was repeated to minimize genotyping er-
rors and the remaining discrepancies scored as ambiguous. Two-point linkage analysis 
was done using the IMpRH mapping tool available at the IMpRH Web Server. 
 
Linkage mapping of candidate genes was performed using CRIMAP version 2.4 (Green 
et al. 1990). Therefore genotype information of the respective complement genes and of 
microsatellite markers previously obtained of the DUMI resource population was used 
(Wimmers et al. 2002). 
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3.2.2.11 Phylogenetic analysis 
 
In order to estimate evolutionary distances for amino acid sequences of the candidate 
genes among various species that are believed to have a common ancestor in interrela-
tionships unrooted phylogenetic trees were constructed by using the neighbour-joining 
distance-matrix method with 500 bootstrap replicates on the reliabitity of internal 
branches. Amino acid sequences were extracted from reports in GenBank. In this study 
the computational phylogenetics program MEGA 3 (Kumar et al. 2004), which calcu-
lates genetic distance from multiple sequence alignments, was used for analysis.  
 
3.2.2.12 Statistical analysis 
 
In this study, the SAS´s PROC MIXED procedure combined with REPEATED state-
ment (The SAS software package, release 9.1) was used for analyzing the variance of 
experimental dataset to estimate the effect of genotypes of candidate genes on comple-
ment activity at eight different time points of vaccination. The analysis model address 
valid standard errors of the fixed effect factor estimates in order to identify other sig-
nificant environmental and genetic effects apart from the factor of genotypes and its 
interaction by stepwise elimination of non-significant effects. The SAS mixed linear 
model was as given below: 
 
yijklmno =  μ + sirei + damj + parityk + treatmentl + genotypem + timen + sexo +  
ANIMALijklmno + (genotype x time)mn + εijklmno 
Where: 
yijklmno : hemolytic complement activity in classical pathway 
μ : overall mean 
sirei : fixed effect of sire; i=1-3 
damj : fixed effect of dam; j=1-11 
parityk : fixed effect of parity; k=1-5 
treatmentl  
: fixed effect of treatment-vaccinated trial/unvaccinated 
  control; l=1-2 
genotypem  : fixed effect of genotype; m=1-3 
timen
: fixed effect of time point of measurement prior and    
  after vaccinations; m=1-8 
sexo : fixed effect of sex; 0=1-2 
ANIMALijklmno : random effect of animal 
(genotype x time)mn : interaction between genotype and time point 
εijklmno : residual error 
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Table 1 Oligonucleotide primer pairs used for determination of the coding sequence 










C6 gene  GenBank acc.no. DQ333199   
- C6.1  up (5´-3´): ttacaagaagatggaaaggagga (nt. 55-77, 5´UTR) 




- C6.6 up (5´-3´): cagcaagttggaatgcaatg (nt. 603-622, exon 5) 
down (3´-5´): gacgtcagaaagctgcaaatc (nt. 1135-1155, exon 8) 
60 553 
- C6.7 up (5´-3´): tcccacaaaaaggattccag (nt. 1060-1079, exon 7&8) 
down (3´-5´): aatttggctgcgtattctcg (nt. 1678-1697, exon 11) 
60 638 
- C6.10 up (5´-3´): ctttggcatgggagaaagg (nt. 1505-1523, exon 10) 
down (3´-5´): ctggcattccacatctcctc (nt. 2225-2244, exon 14) 
60 740 
- C6.8 up (5´-3´): catcggtgatgatgaggaca (nt. 2013-2032, exon 13) 
down (3´-5´): tggagtctgtatcaagcacaca (nt. 2546-2566, exon 17) 
60 554 
- C6.9 up (5´-3´): ttaaagggccattgtcaacc (nt. 2449-2468, exon 16) 
down (3´-5´): aactcctggatgtggcagtc (nt. 3018-3037, 3´ UTR) 
60 589 
C7 gene GenBank acc.no. AF162274   
- C7.1 up (5´-3´): ttctgccctgaatgttttcc (nt. 96-115, 5´UTR) (**)




- C7.2 up (5´-3´): ttttgcaacttgctgagtcat (nt. 806-826, exon 8) 




- C7.3a up (5´-3´): gccctggaggagtatctgg (nt. 1330-1348, exon 11) 




- C7.4 up (5´-3´): agaattctgtccatcacctcct (nt. 1704-1725, exon 13) 




- C7.5 up (5´-3´): ccctatgaatgcggatcttc (nt. 2152-2171, exon 16&17) 




-C7pro2DNA up (5´-3´): catggaaaatgaggctctgg (nt. 410-429, ti: 784743778; 
name: dpcxa0_039446.z1; mate:784159587, 5´UTR) 
down (3´-5´): gctgggactgtttggaaatg (nt. 111-130 in reverse com-
plement,ti: 848892623; name: rdpaxb0_005371.y1; mate: 
854561309), 5´UTR) 
58 531 
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Table 1 (continued)   
Gene name/ 






    
-C7pro3DNA up (5´-3´): gaggcttatcccttgccttac (nt. 603-623, ti: 860292528; 
name: bye_78346.z1; mate:768266164, 5´UTR)  
down (3´-5´): tgtttgggaaaacattcagg (nt.387-406 in reverse com-
plement, ti: 808296981; name: rdpcxb0_216535.y1; mate: 
785838286, 5´UTR) 
58 403 
C8A gene GenBank acc.no. DQ333200   
- C8A.1 up (5´-3´): ggtcctggtctgtagacacctc (nt. 5-26, 5´UTR) 
down (3´-5´): gatcctgacatcttcacagtcatc (nt. 485-505, exon 4) 
60 501 
- C8A.3 up (5´-3´): gagtgtctgaggcaagcaca (nt. 365-384, exon 3) 
down (3´-5´): ttgctgtaaatgggctacctg (nt. 870-890, exon 6) 
60 526 
- C8A.4 up (5´-3´): aagccctggcagacagtaaa (nt. 753-772, exon 6) 
down (3´-5´): gtggccacctccaagtttt (nt. 1306-1324, exon 8) 
60 572 
- C8A.5 up (5´-3´): catcatgctttggagggtct (nt. 1218-1237, exon 8) 
down (3´-5´): ccttggctccctctgactt (nt. 1700-1718, exon 10-11) 
60 501 
- C8A.7.8 up (5´-3´): tacgagatactgcgccacac (nt. 1499-1517, exon 10) 
down (3´-5´): agctggcaggacagagaaaa (nt. 1969-1988, 3´UTR) 
60 490 
C8B gene  GenBank acc.no. DQ333201   
- C8B.1 up (5´-3´): atgaagacctctgggacgtg (nt. 65-84, exon 1) 
down (3´-5´): tccatttcctgctgacacttt (nt. 544-564, exon 4) 
60 500 
- C8B.2 up (5´-3´): atcagtcggatgaggcaaac (nt. 507-526, exon 4) 
down (3´-5´): tgaccctctgaaggaactcg (nt. 1009-1028, exon 7) 
60 522 
- C8B.3 up (5´-3´): agcgcgttacaagctgaaat (nt. 967-986, exon7) 
down (3´-5´): cggctgtcaccagttcatag (nt. 1474-1493, exon 10) 
60 527 
- C8B.4 up (5´-3´): gcagtgcagtacaacccaga (nt. 1427-1446, exon 9) 
down (3´-5´): gtggaagctggtgtggagat (nt. 1922-1941, 3´ UTR) 
60 515 
C8G gene  GenBank acc.no. DQ333202   
- C8G.1 up (5´-3´): tcgtcctgctctctgtctcc (nt. 2-21, 5´UTR) 
down (3´-5´): gcgtacagcttcaccgacag (nt. 487-506, exon 4) 
60 505 
- C8G.4 up (5´-3´): accttccgaaagctggatg (nt. 313-331, exon 2-3) 
down (3´-5´): ttgagaccgacagtgtttaatga (nt. 790-812, 3´UTR) 
60 500 
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Table 1 (continued)   
Gene name/ 






C9 gene GenBank acc.no. DQ333198   
- C9.1 up (5´-3´): cctttgcagtatgcattttaga (nt. 112-133, exon 1) 
down (3´-5´): ttctgaaatttttgtcaactttgg (nt. 706-729, exon 5) 
60 618 
- C9.3.1 up (5´-3´): aaagaggcgccttctgtgta (nt. 428-447, exon 4) 
down (3´-5´): tgggttccataggtttccaa (nt. 1116-1135, exon 7) 
62 708 
- C9.5 up (5´-3´): tattcctgcatgtcaaaggag (nt. 979-999, exon 7) 
down (3´-5´): ccaagttttgtttctttaggtgtg (nt. 1561-1584, exon 10 ) 
50  606 
- C9.8.8a up (5´-3´): atgctccggtgctcataaat (nt. 1492-1511, exon 9) 
down (3´-5´): ccgcatatttgactgctgac (nt. 1998-2017, exon 11) 
55  526 
(*)_The primer sequences followed by TI number, name and mate information collected from the pig 
genome sequencing project accessible via the Trace Archive tool (NCBI homepage) 
(**)_according to GenBank acc. no. BI336392 
(***)_according to GenBank acc. no. CF176130 
 
 
Table 2  Oligonucleotide primers used for radiation hybrid mapping 




    
C6.4DNA up 5´-3´: ttcctttttgcaaggatcaga (nt. 1437-1457, exon 10) 
down 3´-5´: tcaatcacagcaggattttcc (nt. 1575-1595, exon 10) 
58 159 
C7.4.1DNA up 5´-3´: agttatcagttgttggttgttca (nt. 739-761, exon 8) 
down 3´-5´: ctcctcctaaggacccagac (nt. 915-931, exon 8) 
50 (*) 196 
C8Apro2DNA up 5´-3´: tgcttctggaggtgttcattt (clone xx-1c1) 
down 3´-5´: cggttcaccttctcctgtatg (clone xx-1c1) 
60 707 
C8B6DNA up 5´-3´: gaaacaagagaagcagcatgg (nt. 1302-1322, exon 9) 
down 3´-5´: ttaattttgatgatgtctgggttg (nt. 1438-1461, exon 9) 
60 160 
C8G1DNA up 5´-3´: cctcttgacgctgctcct (nt. 75-92, exon 1) 
down 3´-5´: gagccacgtgcagtgaagt (nt. 268-286, exon2) 
58 295 
C9.2DNA up 5´-3´: ggagcattgagacctttgga (nt. 283-302, exon 3) 
down 3´-5´: gccagctcagactcttccac (nt. 528-547, exon 4) 
60 511 
(*) A touch down PCR program was used to amplified a fragment of 196 bp under following thermal cy-
cling conditions: 94oC for 4 min, followed by 9 cycles at 94oC for 30 sec, annealing temperature step-
downs every 1 cycle of 1oC (from 60-51oC) for 30 sec, at 72oC for 1 min, then followed by 40 cycles of 
94°C for 30 sec, at 50°C for 30 sec, at 72°C for 1 min, and ending with an extension step at 72oC for 5 
min. 
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Table 3 List of restriction enzyme used for PCR-RFLP 
 
Enzyme name Specificity (1) (2) (3) Source 
      
AciI  5´-C^CGC-3´ 
3´-GGC^G-5´ 




37 65 TangoTM Arthrobacter luteus (Fermentas)
BbvI (BseXI) 5´-GCAGC(N)8^-3´ 
3´-CGTCG(N)12^-5´
65 80 BseXI Bacillus stearothermophilus Ra 3-
212 (Fermentas)
 
BseDI  5´-C^CNNGG-3´ 
3´-GGNNC^C-5´  





55 80 R Bacillus stearothermophilus Isl 15-
111 (Fermentas)
FnuDII (Bsh1236I) 5´-CG^CG-3´ 
3´-GC^GC-5´  
37 65 R Bacillus sphaericus RFL1236 
(Fermentas)
 
BsrI  5´-ACTGGN^-3´ 
3´-TGAC^CN -5´ 




37 65 NEBuffer 3 A E. coli strain that carries the DdeI 
gene from Desulfovibrio desulfuri-
cans (NCIB 83120) (Biolabs) 
Eco91I  5´-G^GTNACC-3´ 
3´-CCANTG^G-5´ 
37 65 O+ Escherichia coli RFL91(Fermentas)
Hin6I  5´-G^CGC-3´ 
3´-CGC^G-5´ 
37 65 TangoTM Haemophilus influenzae RFL6 
(Fermentas) 
 
HpaII  5´-C^CGG-3´ 
3´-GGC^C-5´ 




37 80 NEBuffer 4 A E. coli strain that carries the 
HpyCH4III gene from Helicobacter 
pylori CH4 (S.A. Thompson) (Bio-
labs) 
KpnI 5´-GGTAC^C-3´  
3´-C^CATGG-5´ 
37 80 KnpI Klebsiella pneumoniae OK8 
(Fermentas) 
as) 
MaeII (TaiI) 5´-ACGT^-3´ 
3´-^TGCA-5´  








37 80 O Providencia stuarti (Fermentas) 
TaqI 5´-T^CGA-3´ 
3´-AGC^T-5´ 
65 80 TaqI Thermus aquaticus YT-1 (Fermen-
tas) 
 
(1)_Incubation temperature (oC), (2)_Thermal inactivation in 20 min (oC), (3)_Recommended buffer 
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Table 4      Oligonucleotide primers used to discriminate alleles for genotyping 
 
Primer name Primer sequence (genome localization) (*)
Gene: position 
of SNP in acc. 
no. as indi-








C6.2DNAmk   up 5´-3´: ggagagcccagaggagaagt (nt. 748-767, exon 6) 
down 3´-5´: cgagcctataatcagcattgg (nt. 566-586, ti: 
1373546263; name: rplun0101_g6.y1) 
C6: 862AÆG 58 177 
C6.6DNAmk up 5´-3´: tcctttttgcaaggatcagag (nt. 1438-1458, exon 10) 
down 3´-5´: aacagcataaacaatggaggtg (nt. 754-775, ti: 
1420506448; name:SS_WGS-957p20.p1k; 
mate:1420506449) 
C6: 1557CÆG 56 352 
C7.1.BsrDI up 5´-3´: acaactgggtctctgggttc (ti: 848149583; 
name:bd_52849.z1; mate:863305860) 
down 3´-5´: aacatctgaaacgctctccac (nt. 254-274, exon 4)  
C7: 154AÆG 56 301 
C7.9DNAmk up 5´-3´: gagttatcagttgttggttgttcag (nt. 738-762, exon 8) 




C7.4.1DNA up 5´-3´: agttatcagttgttggttgttca (nt. 859-881, exon 8) 
down 3´-5´: ctcctcctaaggacccagac (nt. 915-934, exon 8) 
C7: 881AÆG 51 196 
C8A.5.TfiI up 5´-3´: cacctcgtgtgtaacggaga (nt. 434-453, exon 4) 




C8A4DNAmk up 5´-3´: aagcccatttacgagatactgc (nt.1490-1511, exon 10) 




C8A.19.KnpI up 5´-3´: agcacagaggtcttggttgg  (clone xx-1c1) 




C8B1DNA up 5´-3´: tgagaggccacactctcttg (nt. 160-179, exon 2) 
down 3´-5´: cttctgacagggatcacacg (nt. 288-307, exon 2) 
C8B: 222CÆT 54 (**) 148 
C8B13DNAmk up 5´-3´: caagagcacctgcttccaa (nt. 481-499, ti: 775597740; 
name: rbyc_22121.y1; mate:813000763) 




C8B.14.MaeII up 5´-3´: ttcttatcatcgggctggtc (clone XX-1E1) 
down 3´-5´: ctgccttgtccttgcttctt (clone XX-1E1) 
C8B: 1244AÆG 56 528 
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Table 4 (continued)    
Primer name Primer sequence (genome localization) (*)
Gene: position 
of SNP in acc. 
no. as indi-








     
C9.2DNA up 5´-3´: ggagcattgagacctttgga (nt. 283-302, exon 3) 




C9.2bDNA up 5´-3´: gagccttgcgaagaccttg (nt. 363-381, exon 3) 
down 3´-5´: atagatggcccccttttcac (intron detected) 
C9: 407CÆG 60 292 
(*)_The primer sequences followed by TI numbers, name and mate information were collected form vari-
ous large-scale sequencing projects of pig using the Trace Archive tool (NCBI homepage) 
(**)_A touch down PCR program was used with initial denaturation 94oC for 4 min, followed by 8 cycles 
at 94oC for 30 sec, annealing temperature 58-54oC (step-downs of 0.5oC for each cycle), then followed by 
30 cycles of 94°C for 30 sec, 54°C for 30 sec, 72°C for 1 min, and ending with an extension step at 72oC 




Information in this chapter is given in the following order: molecular characterization of 
the candidate genes and identification of polymorphisms, detection of genotypes and 
location of the candidate genes on the porcine chromosomes as well as genetic associa-
tion of the genes to hemolytic complement activity in both the classical and alternative 
pathways. 
 
4.1 Molecular characterization and detection of polymorphisms 
 
4.1.1 The sixth component of the porcine complement system (C6) 
 
4.1.1.1 Complementary DNA and predicted protein sequence  
 
The porcine C6 gene was sequenced using six exon-primers as described in table 1. 
Full-length cDNA nucleotide sequence consists of 3306 bp including 144 and 354 nu-
cleotides of 5´and 3´ untranslated region, respectively (GenBank acc. no. DQ333199). 
Examination of the cDNA sequence revealed a single large open reading frame encod-
ing 935 amino acids (GenBank acc. no. ABD13967), which commenced at the second 
available ATG codon. The porcine C6 protein sequence contains 64 cysteines. An 
analysis using the SignalP 3.0 tool has revealed a putative cleavage site after the signal 
peptide sequence between positions 21 and 22. The porcine C6 sequence has 18 exons 
predicted due to comparison with human intron-exon structure using the Map Viewer or 
alternatively, by collecting DNA genomic porcine sequences using the Trace Archive 
tool. The length and position of C6 exons are shown in table 22. Further detailed char-
acterization of C6 molecule is in annex (Figure 40). The complete porcine C6 sequence 
shows higher homology (≥82%) to B. taurus, C. familiaris, H. sapiens, P. troglodytes 
than to other species at both DNA and protein levels (Table 5 and Figure 11). By using 
the SMART analysis tool it is possible to identify and delineate ten distinct structural 
units in the porcine C6 protein, which have the characteristic features of the modules 
TSP1, LDLa, MACPF, EGF, CCP and FIMAC. Hence, the C6 modules are expected to 




to be potentially encoded by a single exon (Haefliger et al. 1989). Location of the mod-





























Figure 11   The phylogenic tree of C6 proteins. An unrooted tree was constructed by the 
neighbor-joining method based on the alignment of amino acid sequences. It 
shows the phylogenetic relationship of C6 proteins among species. Bootstrap 
indices were used to verify the reliability of the branches. The numbers on 
interior branches refer to the bootstrap values with 500 replications; only 
values >50% are indicated. The numbers indicate the `relative phylogenetic 
distance´ between two branches of the tree. The relevant amino acid se-
quences were identified as GenBank accession numbers in table 5. The phy-
logenetic tree for evaluating evolutionary distances was computed using the 




Figure 12 Location of protein domains in the porcine C6 sequence 
 
 
Table 5   Percent nucleotide sequence and amino acid sequence identities of the por-
cine C6 with different species analysed by using ClustalW2 multiple se-
quence alignment 
 
 Complementary DNA Amino acids 
C6 GenBank acc. no bp % GenBank acc. no a.a %
S. scrofa DQ333199 3306 100 ABD13967 935 100
C. familiaris AB126594 2805 85 XP_536488 936 83
H. sapiens AB126593 2805 85 CAA50994 934 82
B. taurus NM_001045979 3295 83 AAI14015 932 84
X. tropicalis XM_536488 3166 82 AAH76972 934 53
P. troglodytes NM_000065 3551 81 BAD02322 934 82
P. pygmaeus NM_176074 3038 74 BAD02323 934 82
R. norvegicus XM_001371501 2802 71 NP_788263 934 76
M. musculus XM_429140 2808 65 AAH11251 769 74
O. mykiss BC011251 2844 64 CAF22026 941 43
M. domestica BC076972 3286 52 XP_001371538 933 65
B. belcheri BC057429 3075 49 BAB47147 921 27
G. gallus AJ622903 3216 39 XP_429140 935 58




4.1.1.2 Single nucleotide polymorphisms 
 
By sequencing an animal of each breed (HS, DR, LR, PIE, BMP, and MK), five single 
nucleotide polymorphisms (SNPs) were found in the coding region of the porcine C6 
gene, respectively. The SNPs were determined by PCR-RFLP method using the restric-
tion enzymes AciI, TaqI, PstI, BsrI and DdeI. Both the nucleotide variations at nt. 
1138CÆT and 1557CÆG belong to the MACPF domain. Two SNPs at nt. 862AÆG 
and 1557CÆG have amino acid substitutions asparaginesÆasparagine acid and aspar-
agine acidÆglutamine acid, respectively. The fifth appears within the FIMAC module 
of amino acid sequence. Point mutations at position 843 and 1557, respectively, are 
transversion AÆC and CÆG while the others are transitions (Table 6).   
 
Table 6  Characterization of SNPs in the porcine C6 candidate gene 
 
Variation, bp  Variation, a.a Codon Exon  Enzyme Module 
843AÆC - 233CCAÆCCC 6 AciI -
862AÆG Asn ÆAsp  240AACÆGAC 6 TaqI -
1138CÆT - 332CTGÆTTG 8 PstI MACPF
1557CÆG AspÆGlu  471GACÆGAG 10 BsrI MACPF
2604CÆT - 820GCCÆGCT 17 DdeI FIMAC
 
 
4.1.2 The seventh component of the porcine complement system (C7) 
 
 
4.1.2.1 Complementary DNA and predicted protein sequence  
 
 
The 2532 bp full-length porcine C7 cDNA sequence (GenBank acc. no. AF162274) and 
an open reading frame encoding 843 amino acid residues (GenBank acc. no. 
NP_999447) have been reported by Agah et al. (2000). The protein C7 precursor con-
tains 56 cysteine residues. Here we report 807 (nt. –806Æ0) and 122 (nt. 2533-2654) 
nucleotides of new sequences in the 5´ and 3´ flanking region without any putative 
polyadenylation signal, respectively. The transcriptional initiation site was assigned to 
position -110 bp upstream of the start codon predicted by the DRAGON 
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GC+PROMOTER FINDER version 1.0 (http://sdmc.lit.org.sg/ERE-V2/index) (Figure 
41). The first 28 amino acids represent the signal peptide as predicted using the SignalP 
3.0 tool. The signal peptide predictions from both the SMART and the SignalP 3.0 tool 
are identical. This means that the residues numbered from 29 to 843 encode the mature 
porcine C7. Eighteen exons of the pig C7 gene were identified due to blasting the por-
cine and human genomic C7 sequence by using the Trace Archive and the Map Viewer 
tool , respectively. According to figure 41, the length and position of exon fragments are 
displayed in table 23. The porcine C7 sequence shows higher homology (≥83%) to B. 
taurus and H. sapiens than other species concerning nucleotide and protein sequences 
(Table 7 and Figure 13). In porcine C7 gene five classes of the modules TSP1, LDLa, 














Figure 13 The phylogenic tree of C7 proteins. An unrooted tree was constructed by the 
neighbor-joining method based on the alignment of amino acid sequences. It 
shows the phylogenetic relationship of C7 proteins among species. Bootstrap 
indices were used to verify the reliability of the branches. The numbers on 
interior branches refer to the bootstrap values with 500 replications; only 
values >50% were indicated. The numbers indicate the `relative phyloge-
netic distance´ between two branches of the tree. The relevant amino acid 
sequences were identified as GenBank accession numbers in table 7. The 
phylogenetic tree for evaluating evolutionary distances was computed using 




Figure 14  Location of protein domains in the porcine C7 sequence   
 
Table 7 Percent nucleotide sequence and amino acid sequence identities of the por-
cine C7 with different species analyzed by using ClustalW2 multiple se-
quence alignment  
 
 Complementary DNA Amino acids 
C7 GenBank acc. no bp % GenBank acc. no a.a %
S. scrofa  AF162274 2532 100 AAD45918 843 100
B. taurus BC114076 3709 87 AAI14077 843 83
H. sapiens BC063851 4015 86 AAH63851 843 83
R. norvegicus XM_001054007 4727 80 XP_001054007 844 78
M. mulatta XM_001085533 1659 79 XP_001085533 552 76
M. musculus XM_973486 2547 77 XP_978580 848 72
O. mykiss AJ622902 2777 54 CAF22025 845 43
P. olivaceus AB020964 2618 39 BAA88899 805 43
D. rerio XM_685854 2532 54 XP_690946 849 41
 
4.1.2.2 Single nucleotide polymorphisms 
 
Five primer pairs were designed along the body of the porcine C7 cDNA sequence to 
screen polymorphisms. Using PCR-RFLP method with digestion of specific restriction 
enzymes, which separate DNA fragments at the sites with different alleles, six poly-
morphic sites were detected. All they are transitions. The polymorphisms at nt 546, 870 
and 1764 are silent mutations whereas the other remainders have amino acid substitu-
tions. Five of six polymorphisms belong to the functional protein domains such as 
TSP1, MACPF and CCP (Table 8). 
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Table 8  Characterization of SNPs in the porcine C7 candidate gene 
 
Variation, bp  Variation, a.a Codon Exon  Enzyme Module 
154AÆG IleÆVal 52ATTÆGTT 4 BsrDI TSP1
200CÆT ThrÆMet 67ACGÆATG 4 MaeII TSP1
546CÆT - 182AACÆAAT 6 MaeII -
870CÆT - 290AGCÆAGT 8 Hin6I MACPF
881AÆG LysÆArg 294AAAÆAGA 8 MboII MACPF
1764AÆG - 588ACAÆACG 17 MaeII CCP
 
 
4.1.3 The alpha chain of the eighth component of the porcine complement system (C8A) 
 
4.1.3.1 Complementary DNA and predicted protein sequence  
 
The nucleotide sequence coding for the alpha-eighth component of porcine complement 
factors (C8A) has been determined by sequencing PCR products from five primer pairs, 
which amplified overlapping fragments of 490 to 572 nucleotides in length (Table 1). 
The full-length cDNA sequence consists of 2146 nucleotides (GenBank acc. no. 
DQ333200) encoding 589 amino acids in a single polypeptide chain (GenBank acc. no. 
ABD13968). Nakajima et al. (1998) reported the leader peptide sequence formed by the 
first 31 amino acids in the porcine C8A protein sequence. Validation in length and posi-
tion of 11 porcine C8A exons was conducted by comparing with porcine and human 
genomic sequences using the Trace Archive and the Map Viewer tool, respectively (Ta-
ble 21). A part of the first exon belongs to the 5´ flanking region while the ending seg-
ment of the last exon is a part of the 3´ flanking region. Further characterization of C8A 
sequence is found in figure 42. The porcine C8A sequence shows more homology with 
B. taurus, C. familiaris, M. mulatta, H. sapiens, P. troglodytes than with other species at 
both nucleotide and protein levels (≥77%) (Table 9 and Figure 16). The polypeptide 
chain of the gene encoding the porcine C8A complement component contains 31 cys-
teines. Small cysteine-rich modules in the porcine C8A protein are highly homologue 
with TSP1, LDLa, and MACPF modules using the SMART analysis tool (Figure 15). 
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4.1.3.2 Single nucleotide polymorphisms  
 
The same primer pairs were used to identify porcine C8A cDNA sequence as well as to 
screen polymorphisms, which were confirmed via restriction digestion by specific en-
zymes (Table 1). Results showed that seven SNPs were detected in the porcine C8A 
gene. Most SNPs were silent mutations except two of them at sites 1544CÆT and 
1674AÆG leading to amino acid exchanges. The protein domains containing polymor-
phisms were TSP1 (358CÆT, 1768CÆT), and MACPF (1207CÆT, 1510AÆG, 
1544CÆT). At the nucleotide position 1545, variation of alleles GÆA leading to amino 
acid substitution ArgÆHis at the second position of codon 485 (CGCÆCAC) was con-
firmed by restriction digestion with HhaI enzyme (Nakajima et al. 1998). Further char-
acterization of point mutations is given in table 10. 
 
Table 9   Percent nucleotide sequence and amino acid sequence identities of the por-
cine C8A with different species analyzed by using ClustalW2 multiple se-
quence alignment  
 
 Complementary DNA Amino acids 
C8A GenBank acc. no bp % GenBank acc. no a.a %
S. scrofa DQ333200 2146 100 ABD13968 589 100
H. sapiens BC132913 1915 83 AAI32914 584 78
C. familiaris XM_536695 1816 83 XP_536695 589 77
B. taurus BC112635 2316 82 AAI12636 589 80
P. troglodytes XM_513435 2392 81 XP_513435 584 78
M. mulatta XM_001114403 2393 80 XP_001114403 584 77
O. cuniculus NM_001082255 2070 72 NP_001075724 585 74
R. norvegicus XM_001064004 3133 66 XP_001064004 587 71
M. musculus BC027748 3665 65 CAM23655 587 72
X. tropicalis BC074554 1973 50 AAH74554 584 48
G. gallus XM_426667 2227 49 XP_426667 603 52



























Figure 16 The phylogenic tree of C8A proteins. An unrooted tree was constructed by 
the neighbor-joining method based on the alignment of amino acid se-
quences. It shows the phylogenetic relationship of C8A proteins among 
species. Bootstrap indexes were used to verify the reliability of the 
branches. The numbers on interior branches refer to the bootstrap values 
with 500 replications; only values >50% were indicated. The numbers in-
dicate the `relative phylogenetic distance´ between two branches of the 
tree. The relevant amino acid sequences were identified as GenBank ac-
cession numbers in table 9. The phylogenetic tree for evaluating evolun-




Table 10  Characterization of SNPs in the porcine C8A candidate gene 
 
Variation, bp  Variation, a.a Codon Exon  Enzyme Module 
     
358CÆT - 89AGCÆAGT 3 HpyCH4III TSP1
535AÆG - 148CCAÆCCG 4 TfiI -
1207CÆT - 372AGCÆAGT 8 BsrI MACPF
1510AÆG - 473CTAÆCTG 10 Hin6I MACPF
1544CÆT ArgÆCys 485CGCÆTGC 10 Hin6I MACPF
1674AÆG TyrÆCys 528TACÆTGC 10 Eco91I -
1768CÆT - 559GGCÆGGT 11 KnpI TSP1
 
 
4.1.4 The beta chain of the eighth component of the porcine complement system (C8B) 
 
 
4.1.4.1 Complementary DNA and predicted protein sequence  
 
The complete porcine C8B cDNA sequence spans 1987 nucleotides, including 28 and 
123 nucleotides of 5´ and 3´ untranslated region, respectively (GenBank acc. no 
DQ333201). The predicted protein sequence of the gene is 661 amino acids (GenBank 
acc. no. ABD13969), which contains ten amino acids more than human protein. A total 
of 27 cysteines were found in protein structure. Figure 43 shows further information for 
porcine C8B characterization. The signal peptide was identified between amino acids 
the first 44 and 45 using the SignalP 3.0 tool. Nucleotide (≥80%) and protein (≥75%) 
sequence show higher similarity with C. familiaris, H. sapiens, M. mulatta, O. cuniculus 
than with other species (Table 11 and Figure 17). Alignment of the porcine C8B cDNA 
sequence along with collected porcine and human DNAs using the Trace Archive and 
the Map Viewer tool, respectively, has revealed length and position of twelve exons in 
the porcine C8B (Table 24). Using the SMART analysis tool it is possible to identify 
and delineate four distinct structural units in the C8B protein sequence, which have the 






























Figure 17  The phylogenic tree of C8B proteins. An unrooted tree was constructed by 
the neighbor-joining method based on the alignment of amino acid se-
quences. It shows the phylogenetic relationship of C8B proteins among spe-
cies. Bootstrap indexes were used to verify the reliability of the branches. 
The numbers on interior branches refer to the bootstrap values with 500 rep-
lications. The numbers indicate the `relative phylogenetic distance´ between 
two branches of the tree. The relevant amino acid sequences were identified 
as GenBank accession numbers in table 11. The phylogenetic tree for evalu-
ating evolutionary distances was computed using the MEGA3 software 
(Kumar et al. 2004) 
 
4.1.4.2 Single nucleotide polymorphisms  
 
Here nine polymorphisms were detected in porcine C8B gene. Most of them were iden-
tified using PCR-RFLP analysis except the polymorphic site at nucleotide position 935 
with three different alleles using repeated comparative sequencing. The polymorphic 
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site at locus 935 with three different alleles was not only a transition but also a transver-
sion while all remainders were transitions. Eight of these nine contain one amino acid 
exchange. Five of nine SNPs belong to the MACPF protein domain (Table 12). 
 
Table 11   Percent nucleotide sequence and amino acid sequence identities of the por-
cine C8B with different species analysed by using ClustalW2 multiple se-
quence alignment  
 
 Complementary DNA Amino acids 
C8B GenBank acc. no bp % GenBank acc. no a.a %
S. scrofa DQ333201 1987 100 ABD13969 611 100
C. familiaris XM_536694 1773 87 XP_536694 590 79
H. sapiens NM_000066 2053 84 AAI30576 591 79
M. mulatta XM_001114456 2082 83 XP_001114456 591 78
O. cuniculus NM_001082668 2052 80 NP_001076137 590 75
B. taurus BC112600 1330 79 AAI12601 383 85
M. musculus AB077306 1586 79 BAC41371 523 71
R. norvegicus XM_001058539 2395 73 XP_001058539 589 73
G. gallus XM_422502 2165 59 XP_422502 584 57
D. rerio XM_001332783 1742 53 XP_001332819 562 44
O. mykiss AF418597 1855 51 AAL16647 587 43
P. olivaceus AB020962 1849 50 BAA86877 588 43
M. domestica XM_001381244 1896 44 XP_001381281 631 34
 
 




Table 12 Characterization of SNPs in the porcine C8B candidate gene 
 
Variation, bp  Variation, a.a Codon Exon  Enzyme Module 
99CÆT ProÆLeu 24CCGÆCTG 1 HpaII -
222CÆT ThrÆMet 65ACGÆATG 2 FnuDII -
935AÆGÆT ThrÆGlyÆSer 303ACAÆGCAÆTCA 7 (*) MACPF
1244AÆG IleÆVal 406ATCÆGTC 8 MaeII MACPF
1259CÆT ProÆSer 411CCGÆGCG 8 HpaII MACPF
1374CÆT AlaÆVal 449GCCÆGTC 9 BseDI MACPF
1494CÆT AlaÆVal 489GCGÆGTG 10 AciI MACPF
1797CÆT AlaÆVal 590GCAÆGTA 12 BbvI -
1801CÆT - 591GCCÆGTC 12 AluI -
(*)_detected by resequencing 
 
4.1.5 The gamma chain of the eighth component of the porcine complement system (C8G) 
 
4.1.5.1 Complementary DNA and predicted protein sequence  
 
The gene encoding the porcine C8G gene was sequenced and its structure was deter-
mined. The complete porcine C8G cDNA sequence (GenBank acc. no. DQ333202) con-
tains 840 bp including 51 and 180 bp of the 5´ and 3´ UTR regions, respectively. The 
entire coding region is composed of 609 bp corresponding to an open reading frame 
encoding 202 amino acids (GenBank acc. no. ABD13970). Both human and pig C8G 
proteins contains three cysteine residues. Seven exons of the porcine C8G were identi-
fied based on alignment along length of porcine AK233484 genomic DNA sequence in 
GenBank (clone: LVRM10157D04, Uenishi et al. 2004) according to intron-exon junc-
tion rule (start with GT – end with AG) and length of human C8G DNA genomic se-
quence using the Map Viewer sequence alignment tool (Table 25). Further information 
about porcine C8G sequence is found in figure 44. The SignalP 3.0 analysis revealed, 
that the first exon contains the 5´ UTR together with the signal peptide coding se-
quences between amino acids 20-21. The porcine C8G cDNA and polypeptide precur-
sor sequence show a high degree of ≥65% identity with M. musculus, O. cuniculus, C. 
familiaris and H. sapiens sequences (Table 13 and Figure 20). A sequence, which is 
  
 63Results 
similar to lipocalin module was found between amino acids 48-184 using Conserved 
Domains Search CDS/CCD protein domain analysis tool (Figure 19).  
  
4.1.5.2 Single nucleotide polymorphisms 
 
The porcine C8G was screened for polymorphisms by comparative sequencing but no 
polymorphism was found in its cDNA sequence. 
 
Figure 19 Location of protein domains in the porcine C8G sequence 
 
Table 13  Percent nucleotide sequence and amino acid sequence identities of the por-
cine C8G with different species analyzed by using ClustalW2 multiple se-
quence alignment  
 
 Complementary DNA Amino acids 
C8G GenBank acc. no bp % GenBank acc. no a.a %
S. scrofa DQ333202 840 100 ABD13970 202 100
M. musculus BC019967 1063 71 AAH19967 202 71
C. familiaris XM_537791 769 66 XP_537791 202 80
O. cuniculus L26979 751 66 AAA31193 202 74
H. sapiens M17999 857 65 AAI13627 202 82
G. gallus XM_001234026 684 59 XP_001234027 225 40
R. norvegicus XM_001073643 1212 55 XP_001073643 202 73
M. mulatta XM_001117839 417 53 XP_001117839 138 73
O. mykiss AJ622904 977 34 CAF22027 221 32





















Figure 20 The phylogenic tree of C8G proteins. An unrooted tree was constructed by 
the neighbor-joining method based on the alignment of amino acid se-
quences. It shows the phylogenetic relationship of C8G proteins among spe-
cies. Bootstrap indexes were used to verify the reliability of the branches. 
The numbers on interior branches refer to the bootstrap values with 500 rep-
lications. The numbers indicate the `relative phylogenetic distance´ between 
two branches of the tree. The relevant amino acid sequences were identified 
as GenBank accession numbers in table 13. The phylogenetic tree for evalu-
ating evolutionary distances were computed using the MEGA3 software 
(Kumar et al. 2004) 
 
4.1.6 The ninth component of the porcine complement system (C9) 
 
4.1.6.1 Complementary DNA and predicted protein sequence  
 
The cDNA length of the porcine C9 candidate gene was obtained due to amplifying and 
sequencing PCR product fragments derived from four primer pairs given in table 1. Se-
quencing results established a continuous cDNA sequence of 2536 bp in length (Gen-
Bank acc. no. DQ333198) including 1632 bp of coding sequence. The 5´ and 3´ UTR 
contain 89 and 815 bp, respectively. The 3´ UTR has a polyadenylation signal sequence 
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(ATTAAA) between nucleotides 2505-2510. Alignment to porcine and human C9 se-
quence using the Trace Archive and the Map Viewer tool, respectively, confirmed the 
length and position of 11 exon fragments in the porcine C9 as shown in table 26. Com-
puter prediction revealed the first 21 amino acids in C9 protein sequence as being a sig-
nal peptide sequence using the SignalP 3.0 tool. Examination of the cDNA sequence 
revealed a single large open reading frame of 543 amino acids with 19 cysteine resi-
dues. The open reading frame is terminated by a TAG stop codon after nucleotide posi-
tion 1718. The protein sequence of porcine C9 shows high similarity to that of E. cabal-
lus, B. taurus, M. mulatta, H. sapiens (≥67%) according to the ClustalW2 alignment 
(Table 14 and Figure 22). Using the SMART analysis tool we have detected porcine 
protein structure characterized by modules TSP1, LDLa and MACPF (Figure 21). Fur-
ther characterization for porcine C9 sequence is showed in figure 45. 
 
Figure 21 Location of protein domains in the porcine C9 sequence 
 
4.1.6.2 Single nucleotide polymorphisms 
 
Two segments of the porcine C9 gene encompassing the presumably polymorphic co-
dons from comparative sequencing were amplified using polymerase chain reaction. 
According to the restriction fragment patterns obtained after BsrDI and HpyCH4III 
digestion of the PCR products, two polymorphisms were detected at nucleotide 
350AÆG and 407CÆG corresponding to codon 87CAAÆCAG and 106CACÆCAG. 
The first SNP belongs to the TSP1 module and the second locates on the LDLa module. 
The second polymorphism is a nucleotide substitution CÆA in the third position of 
codon 106 causing an amino acid exchange HisÆGln, whereas the remainder is a silent 

































Figure 22  The phylogenic tree of C9 proteins. An unrooted tree was constructed by 
the neighbor-joining method based on the alignment of amino acid se-
quences. It shows the phylogenetic relationship of C9 proteins among spe-
cies. Bootstrap indexes were used to verify the reliability of the branches. 
The numbers on interior branches refer to the bootstrap values with 500 
replications. The numbers indicate the `relative phylogenetic distance´ be-
tween two branches of the tree. The relevant amino acid sequences were 
identified as GenBank accession numbers in table 14. The phylogenetic 
tree for evaluating evolutionary distances were computed using the 




Table 14   Percent nucleotide sequence and amino acid sequence identities of the por-
cine C9 with different species analysed by using ClustalW2 multiple se-
quence alignment  
 
 Complementary DNA Amino acids 
C9 GenBank acc. no bp % GenBank acc. no a.a %
S. scrofa DQ333198 2536 100 ABD13966 543 100
E. caballus NM_001081950 2661 79 NP_001075419 547 71
B. taurus BC105174 2697 78 AAI05175 548 70
H. sapiens BC020721 2094 78 AAH20721 559 67
O. cuniculus NM_001082346 2018 77 NP_001075815 557 66
M. mulatta XM_001084671 2774 73 XP_001084671 561 69
C. familiaris XM_536494 1840 72 XP_536494 589 65
R. norvegicus NM_057146 2083 66 NP_476487 567 61
M. domestica XM_001372031 1572 66 XP_001372068 523 52
M. musculus BC011137 1767 64 AAH11137 561 55
F. heteroclitus AY495671 1844 45 AAR87007 577 35
C. idella AY391781 2123 41 AAS76086 650 35
O. mykiss AM039888 2104 40 CAJ01692 601 33
P. olivaceus AB020963 2313 31 BAA86878 558 33
T. rubripes FRU87241 2854 5 AAC60288 586 32
 
 
4.2 Structural relationship analysis among the porcine homologous complement candi-
date sequences 
 
From above obtained results, it is very possible to recognize that there is a relationship 
of functional domains in the protein sequences of the porcine terminal complement 
components. The amino acid sequences of the candidate gene are closely related to each 
other with respect to the percentage of residue identities ranging from 22-30% as re-
vealed by ClustalW2 alignment tool (Figure 23). The porcine C8G protein with only 












Figure 23  Similarity among amino acid se-
quences of the candidate genes shown
by using ClustalW2 multiple se-











Figure 24  The phylogenic tree of homologous proteins of the terminal lytic pathway. 
An unrooted tree was constructed by the neighbor-joining method based on 
the alignment of amino acid sequences. It shows the phylogenetic relation-
ship among the terminal complement components. Bootstrap indexes were 
used to verify the reliability of the branches. The numbers on interior 
branches refer to the bootstrap values with 500 replications. The numbers 
indicate the `relative phylogenetic distance´ between two branches of the 
tree. The relevant amino acid sequences were identified as GenBank acces-
sion numbers ABD13967 (C6), NP_999447 (C7), ABD13968 (C8A), 
ABD13969 (C8B) and ABD13966 (C9). The phylogenetic tree for evaluat-
ing evolutionary distances were computed using the MEGA3 software 
(Kumar et al. 2004) 
 
Data in figure 24 re-emphasizes the great similarity between C6 and C7 while C9 has a 
structure more similar to C8A than to C8B. The protein sequences of the candidate 
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genes contain segments which are homologous to those of other proteins described as 
TSP1, LDLa, MACPF, EFG, CCP and FIMAC. Most of these modules are cysteine-rich 
sequences. The amino acid sequence of CCP module contains four cysteines in which 
two of them are at the first and last position of sequence. There are 58, 45, 17, 18, three, 
13 of 64, 56, 31, 27, three, 19 cysteines found in C6, C7, C8A, C8B, C8G and C9 that 
located in small functional protein domains, respectively (Table 15 and Figure 25).  
 
Type I protein segment (similar to TSP1 module) 
C8A (a.a 44-94)    LSNWAEWTEC-FPCQDKKYRYRSLLQPNKFG-GAICS--GNVWDQASCHSPTECL 51 
C8B (a.a 79-129)   LSSWSSWTTC-DPCQKKRYRHASLLRPSQFH-GEPCN--FSDKEVEDCVSNRPCR 51 
C6  (a.a 84-134)   LGDYGPWSDC-DPCVEKQFKVRSILRPNQFG-GQPCT--EPLMTFRPCIPSKLCK 51 
C9  (a.a 45-95)    MSPWGEWSRC-DPCLKQMFRSRSIETFGQFN-GQKCV--DAVGDRRQCVPTEPCE 51 
C7  (a.a 30-80)    WDSYAPWSEC-NGCTKTQTRRRPVAVYGQYG-GHPCV--GSTFETQSCEPTRGCP 51 
C6  (a.a 568-617)  WGCWSSWSTC-DATYKRSRTRECNNPAPRQG-GKPCD--GERRQEEHCTFSIMQ- 50 
C8A (a.a 547-586)  WSCWSSWSAC-RLG-TQERRRECNNPAPQNG-GASCS--GHKVQT---------- 40 
C7  (a.a 503-551)  WSCWSSWGPC-AQG-KKTRSRKCNNPPPSGG-GKSCI--GETSESRQCEDEDLE- 49 
C6  (a.a 26-79)    HYPWTQWSSCSKTCNSGTQTRQRQITINQYYLDNFCDRLCTKQETRECN-WQTCP 54 
 
 
Type II protein segment (similar to LDLa module) 
C6  (a.a 139-175)  DCKNKFRCD-SGRCIASKLECNGENDCG-DNSDERNCGR 37 
C8B (a.a 249-450)  RCEGFVCAQ-TGRCINRRLLCNGDNDCG-DQSDEANCKR 37 
C8A (a.a 98-135)   QCGQDFQCKETGRCLKRHLVCNGDRDCL-DGSDEDDCED 38 
C9  (a.a 133-169)  DCGSDFQCG-TGRCIKRRLLCNGDNDCG-DFSDEDDCDS 37 
C7  (a.a 100-136)  GCGERFRCF-SGQCISKSLVCNGDSDCEEDSADEDRCE- 37 
 
 
Type III protein segment (similar to EGF module) 
C6  (a.a 512-570)  CQCAPCPNNGRPVLSGTECLCVCQSGTYGDNCERRAPDYKSNAVDGN 47 
C8B (a.a 519-547)  ----PCQGNGVPVLKESRCDCICPAGFQGSACE-------------- 29 
 
Type IV protein segment (similar to CCP module) 
C6  (a.a 644-699)  CPQPVPPENGFIRNEKTLYSVGEDVEIVCLTGFKTVGYQYFRCLPDRTWR---RGDVEC 56 
C7  (a.a 571-626)  CPSPPALKDGFVQNEETTFPVGKNIVYSCNEGYSLVGDPVARCGEDLQWT---VGKMHC 56 
C7  (a.a 631-688)  CVLPTLMRGLQSHPQKPFYTVGEKVTFSCSSGMSLEGPSTFLCGSSLKWSP-EMKNVQC 58 
C6  (a.a 704-761)  CLLPVVPEVLKLSPFQRLYKIGDSIELSCPKGFVIAGPSRYTCSGD-SWTPPISSSLTC 58 
 
Type V protein segment (similar to FIMAC module) 
C7  (a.a 696-765)  AKKVPECQLWEK--LQNSKCVCKMP-YECGSS--LDVCARDERSKRILRLTVCKMHVLQC 55 
C7  (a.a 772-840)  --ACGACPLWEKCDAQSSKCVCRAA-SECEEAG-FRVCV--EVNGREQTMTECEAGVLRC 54 
C6  (a.a 861-934)  SCGYDTCYSWEKCSATTSKCICLLP-FQCLKGGYQHYCVKMGSSTTTRTMNICEVGAIRC 59 
C6  (a.a 767-839)  TRLKGHCQPGQK--QLGSECVCLSPEEDCSHHS-EDLCVLDTDSNHYFTSSACKFLAEKC 57 
 
C7  (a.a 696-765)  QG-RNYTLSVGETCTL 70 
C7  (a.a 772-840)  LG-LSITVTSIRPCAP 69 
C6  (a.a 861-934)  AL-RKMEILYPGRCRS 74 
C6  (a.a 767-839)  LNNQQLQFLHIGSCQD 73 
 
Figure 25  Multiple alignments of homologous protein domains in both the amino ter-
minus and carboxyl terminus of the candidate genes C6, C7, C8A, C8B and 




C6 (a.a 312-516)   SFIRIHKVIKVLNFTMKT-KDLQLSDVFLKALNHLPLEYNAALYSRIFDDFGTHYFTSGS 59 
C8A (a.a 291-497)  SFIRIFTKVQTASFMMRR-DNIMLDEVMLQSLMELPEQYNYGMYAKFIDDYGTHYITSGS 59 
C9 (a.a 297-507)   IFLHVKGVIHLGRFVMRK-RDVMLTKTFLDDVKYLPSTYEKGEYFAFLETYGTHYSSSGS 59 
C7 (a.a 249-450)   QLLVVQNTVEVAQFINNNPEFLQLAESFWKELSYLPPLYDYSAYRRLIDQYGTHYLQSGS 60 
C8B (a.a 303-510)  TFLHARSDLEVARYKLKS-RNLMLHYEFLQRVKQLPLEYSYGEYRDLFRDFGTHYITEAV 59 
 
C6 (a.a 312-516)   LGGVYDLLYQFSNEELKNSGLTQEEAKNCIRIETKKRYFIVTKTKVEHRCTTNRMSEKYE 119 
C8A (a.a 291-497)  MGGVYEYILVLNKENMTKSGVTSDDVTSCFGGSFGIDYDYTDNLQITG-SLSGKHCKKLG 118 
C9 (a.a 297-507)   LGGLYELIYVLDKATMTEKGIELRDVHRCLG--FNLDLSLNFGVEIKG-KIDSENCLKRG 116 
C7 (a.a 249-450)   LGGEYKVLFYVDSEKVAESDLGSEDKKKCASSHISFLFKS-----------SKHKCKAME 109 
C8B (a.a 303-510)  LGGVYEYTLIMNKEAMERADYSLKDVHACAQHGFKIGVAIEEVYVKLG--VPVHKCKDIL 117 
 
C6 (a.a 312-516)   GSFLQGSEKSISLVKGGRSEYAAALAWEKGSSGPG--------EKTYSDWLESVKENPAV 171 
C8A (a.a 291-497)  GGHREDEESNMAVEDIISRVRGGSSGWGGGLTQNGS-------IITYRAWGRSLKYNPAV 171 
C9 (a.a 297-507)   DGKTENIMNDDFIDDVISFIRGGTRKYATELKEKLLKGAKMINVTDFVNWASSLNDAPVL 176 
C7 (a.a 249-450)   EALKSASGTQSNVLRGVPFVRGGRPGFVSGLSYLELDNPDG-NKQRYSSWAGSVTDLPQV 168 
C8B (a.a 303-510)  NEIKDRNKRSSMVNDLVVLVRGGASEHITALAYKDLP-----TADLMQEWGDAVQYNPDI 172 
 
C6 (a.a 312-516)   IDFELAPITDLVR--NIPCAVTRRNNLRRAFREYAA 205 
C8A (a.a 291-497)  IDFEMKPIYEILRHTNLGPLEAKRQNLRRALDQYLM 207 
C9 (a.a 297-507)   INQKLSPIYDLIP-VKLNDAHLKRQNLERAIEDYIN 211 
C7 (a.a 249-450)   IKQKLTPLYELVK--EVPCASVKRLYLKRALEEYLD 202 
C8B (a.a 303-510)  IKIKAEPLYELVTAADFAYSSTVKQNMKRALEEFEK 208 
 
 Figure 25   (continued) The alignment was created using ClustalW2 program. Cys-
teines are shaded in grey. Amino acids are enumerated on the right hand 
margin. The TSP1, LDLa, EGF, CCP, FIMAC and MACPF domains con-
tain 40-54, 37-38, 29-47, 56-58, 69-74 and 202-211 amino acids, respec-
tively. The TSP1 region is repeated three, two, two times in C6, C7 and 
C8A protein sequence, respectively. Similarity among TSP1s, LDLas, 
EGFs, CCPs, FIMACs or MACPFs in the candidate genes is found in a 
range of 5-55%, 32-70%, 48%, 14-35%, 13-36% or 26-34%, respectively. 
 
Table 15  Number of cysteine residues in each functional protein domain of the can-
didate genes. Each value in the same cell reflects an individual domain of 
the same type, i.e. C6 has three TSP1 domains  
 
Gene TSP1 LDLa MACPF EGF CCP FIMAC Lipocalin
   
C6 6, 5 and 5 6 3 7 4 and 4 8 and 10 -
C7 5 and 5 6 3 - 4 and 4 8 and 10 -
C8A 5 and 4 6 2 - - - -
C8B 5 6 2 5 - - -
C8G - - - - - - 3
C9 5 6 2 - - - -
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4.3. Detection of genotypes and assignment of candidate genes to pig chromosome 
 
4.3.1. Genotype analysis 
 
Table 16  Genotypic frequencies of the candidate genes in different breeds. (Up to 
down) the SNPs were detected by restriction digestion enzyme TaqI, PstI, 
BsrDI, Hin6I, MboII, TfiI, Hin6I, KnpI, FnuDII, by repeated comparative 
sequencing, MaeII, BsrDI and HpyCH4III 
 
Gene: SNP LR % PIE % MK % 
C6: 862AÆG (n) 30  30  25  
AA 14 0.47 1 0.03 0 0.00 
AG 13 0.43 11 0.37 0 0.00 
GG 3 0.10 18 0.60 25 1.00 
C6: 1557CÆG (n) 30  30  25  
CC 2 0.07 0 0.00 0 0.00 
CG 5 0.17 0 0.00 0 0.00 
GG 23 0.77 30 1.00 25 1.00 
C7: 154AÆG (n) 30  30  25  
AA 3 0.10 0 0.00 0 0.00 
AG 12 0.40 5 0.17 0 0.00 
GG 15 0.50 25 0.83 25 1.00 
C7: 870CÆT (n) 30  30  25  
CC 0 0.00 0 0.00 7 0.28 
CT 13 0.43 12 0.40 16 0.64 
TT 17 0.57 18 0.60 2 0.08 
C7: 881AÆG (n) 30  30  25  
AA 0 0.00 0 0.00 7 0.28 
AG 13 0.43 12 0.40 16 0.64 
GG 17 0.57 18 0.60 2 0.08 
C8A: 535AÆG (n) 30  30  25  
AA 2 0.07 9 0.30 0 0.00 
AG 10 0.33 15 0.50 5 0.20 
GG 18 0.60 6 0.20 20 0.80 
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Table 16 (continued) 
       
Gene: SNP LR % PIE % MK % 
       
C8A: 1544CÆT (n) 30  30  25  
CC 10 0.33 14 0.47 23 0.92 
CT 12 0.40 12 0.40 2 0.08 
TT 8 0.27 4 0.13 0 0.00 
C8A: 1768CÆT (n) 30  29  25  
CC 23 0.77 25 0.86 18 0.72 
CT 7 0.23 4 0.14 7 0.28 
TT 0 0.00 0 0.00 0 0.00 
C8B: 222CÆT (n) 30  30  25  
CC 30 1.00 30 1.00 18 0.72 
CT 0 0.00 0 0.00 7 0.28 
TT 0 0.00 0 0.00 0 0.00 
C8B: 935AÆGÆT (n) 30  30  25  
AA 7 0.23 0 0.00 0 0.00 
AG 6 0.20 0 0.00 0 0.00 
AT 13 0.43 9 0.30 2 0.08 
GT 2 0.07 4 0.13 7 0.28 
TT 2 0.07 17 0.57 16 0.64 
C8B: 1244AÆG (n) 30  29  25  
AA 7 0.23 6 0.21 0 0.00 
AG 19 0.63 17 0.58 4 0.16 
GG 4 0.13 6 0.21 21 0.84 
C9: 350AÆG (n) 30  30  25  
AA 2 0.07 2 0.07 0 0.00 
AG 18 0.60 8 0.27 0 0.00 
GG 10 0.33 20 0.67 25 1.00 
C9: 407CÆG (n) (*) 30  30  25  
CC 0 0.00 0 0.00 0 0.00 
CG 0 0.00 0 0.00 0 0.00 
GG 30 1.00 30 1.00 25 1.00 
       




Table 17 Allelic frequencies at several SNPs in different breeds of pig 
 
Gene: SNP LR % PIE % MK % 
       
C6: 862AÆG       
A 41 0.68 13 0.22 0 0.00 
G 19 0.32 47 0.78 50 1.00 
C6: 1557CÆG       
C 9 0.15 0 0.00 0 0.00 
G 51 0.85 60 1.00 50 1.00 
C7: 154AÆG       
A 18 0.30 5 0.08 0 0.00 
G 42 0.70 55 0.92 50 1.00 
C7: 870CÆT       
C 13 0.22 12 0.20 30 0.60 
T 47 0.78 48 0.80 20 0.40 
C7: 881AÆG       
A 13 0.22 12 0.20 30 0.60 
G 47 0.78 48 0.80 20 0.40 
C8A: 535AÆG       
A 14 0.23 33 0.55 5 0.10 
G 46 0.77 27 0.45 45 0.90 
C8A: 1544CÆT       
C 32 0.53 40 0.67 48 0.96 
T 28 0.47 20 0.33 2 0.04 
C8A: 1768CÆT       
C 53 0.88 54 0.93 43 0.86 
T 7 0.12 4 0.07 7 0.14 
C8B: 222CÆT       
C 60 1.00 60 1.00 43 0.86 
T 0 0.00 0 0.00 7 0.14 
C8B: 935AÆGÆT       
A 33 0.50 9 0.15 2 0.04 
G 14 0.21 4 0.07 7 0.14 
T 19 0.29 47 0.78 41 0.82 
C8B: 1244AÆG       
A 33 0.55 29 0.50 4 0.08 
G 27 0.45 29 0.50 46 0.92 
C9: 350AÆG       
A 22 0.37 12 0.20 0 0.00 
G 38 0.63 48 0.80 50 1.00 
C9: 408CÆG       
C 0 0.00 0 0.00 0 0.00 





Once mutations were established, genomic DNA from unrelated animals of Landrace 
(n=30), Pietrain (n=30), Muong Khuong (n=25) and F2 DUMI population (n=417) were 
amplified using the primer pairs in table 1 and table 4 in order to examine genetic vari-
ability in the candidate genes by using PCR-RFLP or repeated comparative sequencing. 
Differences of allelic frequencies were observed among Vietnamese and European 
commercial breeds. The frequency of heterozygous animals in the European breeds is 
higher than in the Vietnamese breed Muong Khuong pig for C6, C8A and C9 candidate 
genes. However for C7 and C8B it is reverse. Especially, all genotypes of C8B at locus 
935 with three different alleles were found in the Landrace breed but in Pietrain and 














Figure 27  Representative patterns of detection of SNP using PCR-RFLP at postions 
X_862AÆG, homologous AA (177 bp), GG (113 bp + 64 bp) and het-
erologous AG (113 bp + 64 bp + 177 bp) Y_881AÆG, homologous AA 
(196 bp), GG (144 + 52 bp) and heterologous AG (144 bp + 52 bp + 196 
bp) Z_1544CÆT, homologous CC (33 bp), TT (163 bp) and heterologous 
CT (33 bp + 163 bp) [_222CÆT, homologous CC (64 bp + 84 bp), 
TT(148 bp) and heterologous CT (64 bp + 84 bp + 148 bp) \_407CÆG, 
homologous GG (139 bp) and heterologous CG (121 bp + 139 bp) in por-
cine C6, C7, C8A, C8B and C9 cadidate genes, respectively. PCR products 
were digested with TaqI, MboII, Hin6I, FnuDII and HpyCH4III. 
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No significant differences between the observed and the expected numbers of genotypes 
were found in genotyped SNPs in Landrace, Pietrain and Muong Khuong populations in 
the candidate genes. It means that all genotypic patterns were found to be in Hardy-
Weinberg equilibrium in commercial breeds. The restriction enzymes TaqI, MboII, 
Hin6I, FnuDII and HpyCH4III were used for detecting the variation of the nucleotides 
862AÆG, 881AÆG, 1544CÆT, 222CÆT and 407CÆG in C6, C7, C8A, C8B and C9 
genes, respectively, which were segregating in the F2 DUMI resource population. They 
were used to evaluate association between genotypes and hemolytic complement activ-
ity in both the classical and alternative pathway as well as for linkage mapping using the 
CRIMAP tool. Representative patterns for SNP genotyping using repeated comparative 
sequencing and PCR-RFLP are shown in figure 26 and figure 27, respectively. 
 
4.3.2 Location of the candidate genes on porcine chromosome 
 
Genetic linkage and chromosomal localization studies previously established that C8A 
and C9 are located on chromosome 6q3.1-q3.3 (Nakajima et al. 1998) and 16q1.4 
(Thomsen et al. 1998) using in situ hybridization, respectively. In this study, to deter-
mine the location and order of certain candidate genes, we used the IMpRH panel, 
which allows assigning unambiguously the six loci to porcine chromosomes from 
pig/hamster genomic DNA amplification products converted into vector sequences. 
Two-point RH analyses were used for the identification of linkage groups using LOD 
score threshold of 5.0. With all information for markers, including vectors summarized 
in table 18, it was demonstrated that both porcine C8A and C8B loci were physically 
assigned to the same chromosome 6q3.1-q3.5 whereas the porcine C6, C7 and C9 genes 
were closely linked on the same q-arm of chromosome 16 (16q1.4). The assignment of 
C9 agrees with previously obtained results of Thomson et al. (1998). C8G was assigned 
to chromosomes 1q2.13. Moreover, the porcine C6, C7, C8A, C8B, C8G and C9 sig-
nificantly linked to markers S0077, SW1069, SW322, SSC10D08 and SW403, respec-
tively (Figure 29). All LOD scores are greater than 6.  
 
Genetic linkages using two-point analysis from CIRMAP 2.4 (Green et al. 1990) were 
confirmed between C7 and C6 with rec. fracs. = 0.02, LOD = 50.45, between C9 and 
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C6 with rec. fracs = 0.06, LOD = 31.50, between C9 and C7 with rec. fracs = 0.06, 










Figure 28  A representative pattern for PCR result of 118 DNA clones of the IMpRH. 
The symbols (0), (?), and (1) used for absent, ambigous and present results, 
respectively. The letters a, b, c, and d show a hamster sample (nagative con-
trol), a blank sample without DNA (negative control), a pig DNA (positive 


















Figure 29  Position of the candidate genes on porcine chromosomes. Linkage is 















































Table 18 Summary of RH mapping results of the candidate genes 
 
 Result in vector 1 2 3 4






























14.45 27 31 16q1.4
      
(1)_ LOD score, (2)_ Distance in cR, (3)_ Retention fraction (%), (4)_Chromosome 
 
4.4. Association of candidate genes with hemolytic complement activity 
 
Genotype analysis results were applied to associate with hemolytic complement activity 
in both classical and alternative pathway in the F2 DUMI resource population. 
 
4.4.1. The classical lytic pathway  
 
The effect of different genotypes on hemolytic complement activity in the classical 
pathway was analyzed using repeated measures mixed models of analysis of variance. 
Genotypes of the porcine C7 (p=0.0080), and C9 genes (p=0.0488) revealed significant 
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effects on CH50 whereas the genotypes of C6 (p=0.0853) and C8B (p=0.4410) did not. 
The effect of C8A was close to significance (p=0.0650). For the genotypes CC and TT 
of C8A least squares means were obtained differing at p=0.0522 (Figure 30 and Table 
19). Additionally, although there was no difference between C8B genotypes in CH50 
(p=0.4410) the interaction of genotypes and eight different time points before and after 
immunizations with Mycoplasma, Ausjezky and PRRSV was highly significant differ-
ence (p=0.0048) (Table 31 and Figure 32). In general, CH50 activities were increased 
after each of complement activation by vaccination. The highest least squares means 
were observed at the fourth day after ADV vaccination in all candidate genes.  
 
Table 19  Least squares means of hemolytic activity in both the classical (CH50) and 
alternative (AH50) complement pathways for different genotypes (LSM±SE) 
(U/ml) 
 
 CH50 AH50 CH50 AH50
   
Porcine C6 Porcine C7 
AA 59.72±7.65 66.94±5.87 AA 70.27±3.62 61.11±2.70
AG 64.98±3.39 61.75±2.57 AG 67.72±3.60 61.42±2.72
GG 70.42±3.32 61.41±2.49 GG 44.13±8.55 59.69±7.22
p-value 0.0853 0.6581 p-value 0.0080 0.8319




CC 59.45±4.07 61.94±3.13 CC 65.58±3.11 60.96±2.33
CT 65.08±3.49 60.64±2.66 CT 62.07±3.47 60.30±2.61




   
Porcine C9  
GG 69.49±3.17 62.73±2.82  
CG 63.59±3.65 61.52±2.39  



















































Figure 30  Histogram of least squares
means of hemolytic com-
plement activity in the
classical pathway depend-
ing on genotypes of the













































Figure 31 Histogram of least squares
means of hemolytic com-
plement activity in the al-
ternative pathway depend-





























































































































































Genotype x time p=0.3136
CG GG
 
Figure 32   Histogram of least squares
means of hemolytic com-
plement activity in the clas-
sical pathway along vacci-
nation for the interaction of
genotypes of each candidate

























































































































































Genotype x time p=0.0340
CG GG
 
Figure 33 Histogram of least squares
means of hemolytic com-
plement activity in the alter-
native pathway along vacci-
nation  for the interaction of
genotypes of each candidate




4.4.2 The alternative pathway 
 
Studying the effect of genetic variation on hemolytic complement activity in the alterna-
tive pathway was conducted for all candidate genes except C8G because of no poly-
morphism was found within its sequence. AH50 values were used to evaluate lysis level 
of different genotypes in each gene. As a result, no difference of genotypes in AH50 test 
was found in all porcine candidate genes C6, C7, C8A, C8B and C9 (Figure 31 and Ta-
ble 19). However, there was statistically significant interaction of genotypes and time 
points of immunization on AH50 for C8A (p=0.0027), C8B (p=0.0231) and C9 
(p=0.0340) (Figure 33). Homozygous genotypes AA, CC and TT in candidate genes C6, 
C8A and C8B, respectively, showed higher complement activity in the alternative 
pathway. AH50 increment of these genotypes was unlinear after vaccinations. Hemo-




5.1 Structure of candidate genes 
 
5.1.1 Characteristic of the porcine C6 and C7 complement genes 
 
Complement C6 is a glycosylated plasma protein (DiScipio et al. 1989). The porcine C6 
protein sequence (GenBank acc. no. ABD13967) showed >80% identity to the human 
orthologue. With an atomic composition formula of C4565H7108N1288O1429S74 the porcine 
C6 molecular weight (Mr) was predicted about 105.27 kDa; i.e. similar to human C6 
(Mr =105 kDa) (Schreck et al. 2000) by using the ProtParam tool 
(http://au.expasy.org/tools/protparam.html). Both pig and human sequences for C6 con-
tain 64 cysteines forming 32 disulfide bonds, which are important to stabilize the pro-
tein structure and to maintain its activity (DiScipio et al. 1989). The bonds could be 
formed between Cys1-Cys11, Cys2-Cys16, Cys3-Cys20, Cys4-Cys31, Cys5-Cys10, Cys6-
Cys30, Cys7-Cys36, Cys8-Cys9, Cys12-Cys39, Cys13-Cys17, Cys14-Cys38, Cys15-Cys60, 
Cys18-Cys26, Cys19-Cys33, Cys21-Cys48, Cys22-Cys24, Cys23-Cys45, Cys25-Cys62, Cys27-
Cys52, Cys28-Cys32, Cys29-Cys50, Cys34-Cys44, Cys35-Cys40, Cys37-Cys42, Cys41-Cys53, 
Cys43-Cys58, Cys46-Cys56, Cys47-Cys64, Cys49-Cys51, Cys54-Cys61, Cys55-Cys63, and 
Cys57-Cys59 as predicted using the DiANNA 1.1 software (Ferre and Clote 2005). Ac-
cording to von Heijne's theory (1986), the signal peptide sequence is most likely 
cleaved after the alanine residue. Consequently, the first 21 residues of the open reading 
frame of human C6 show the typical features of a signal peptide, as one would expect 
for a secreted protein (Haefliger et al. 1989). In silico prediction for porcine C6 indi-
cates existence of a complementary signal peptide. After removing signal peptide se-
quence, the biological active polypeptide chain is composed of 913 residues in human 
sequence (DiScipio et al. 1989) and 914 residues in pig sequence. The porcine amino 
terminal C6a fragment (a.a 22-631) starts just after the signal peptide followed by the 
carboxyl terminal C6b segment (a.a 632-934) (Haefliger et al. 1989, DiScipio et al. 
1989, Ripoche et al. 1988, Goldberger et al. 1987, Kristensen et al. 1986). The whole 
porcine C6 protein sequence was most closely homologous to the porcine complement 
C7 with 29% identity. However, analysis of C6a revealed high similarity to C8A, C8B 
and C9. The C6b fragment only shows considerable similarity to C7. Corresponding 
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results were found in human (DiScipio et al. 1989, Haefliger et al. 1987, Rao et al. 
1987, Stanley et al. 1985, DiScipio et al. 1984). Similarly to the human C6 (Ripoche et 
al. 1988, Goldberger et al. 1987, Kristensen et al. 1986) the porcine C6b had partial 
homology to the complement regulatory proteins, CCP and FIMAC. Consequently a 
number of predicted and/or experimentally proven functions and properties of particular 
human amino acid sequence motifs can be expected in the porcine protein too. Human 
C6 has two possible sites for N-glycosylation (Asn-X-Ser/Thr), one at the amino (a.a 
324) and one at the carboxyl terminus (a.a 855) (DiScipio et al. 1989, Clamp et al. 
1975). The first is conserved in the pig whereas at the second site at position 855 there 
is a Ser instead of Asn. Using the NetNGlyc 1.0 Server tool one more N-glycosylation 
site was found at a.a 860 in the carboxyl terminus of the porcine C6 (Figure 46). In the 
C6 amino-terminus there are three cysteine-rich segments, a pair of TSP1 domains fol-
lowed by a LDLa domain, containing 11 disulfide bonds. This region has a predomi-
nance of β-sheet and β-turns (DiSipio et al. 1989). Further, several hydrophobic peaks 
are seen in the middle segment of C6 protein containing a MACPF module, analogous 
to C9. The membrane-binding region may reside here (DiSipio et al. 1989). The region 
consists of type EGF and TSP1 units containing seven disulfide bridges with a pre-
dominance of β-sheet and β-turns. In the putative carboxyl domain, each CCP and each 
FIMAC has two and nine disulfide bonds, respectively. The model for the CCP motif 
envisions two pairs of overlapping disulfide bonds with distorted β-sheet interspaced by 
turns (DiSipio et al. 1989). The third TSP1 of C6 contributes to the C5 binding site of 
C6 and involved in terminal complement complex assembly (Wuerzner et al. 1995) 
 
Porcine and human C7 are highly conserved, sharing structural and functional charac-
teristics (Agah et al. 2000). The porcine C7 molecular weight (C4043H6287N1123O1268S67) 
was 93.06 kDa, similar to human C7 (Mr = 92 kDa) (Schreck et al. 2000). Similar to 
human C7, the predicted amino acid sequence of the precursor porcine C7 (GenBank 
acc. no. AAD45918) consists of 843 amino acid residues. The pig precursor protein 
contains a 28-residue hydrophobic signal peptide identified in the pig using the SMART 
and the SignalP analysis tools while it is 22 residues in human (DiScipio et al. 1998). 
Both pig and human C7 have 56 cysteines (6.8% of the total amino acid composition) 
giving rise to cysteine-rich domains (Agah et al. 2000) and share an overall identity of 
83% at the protein level. The cysteine residues are presumed to form 28 disulfide bonds, 
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which are important for stabilizing the structure of this protein (DiScipio et al. 1988). 
Via calculation with the DiANNA 1.1 software the possible disulfide bonds in the por-
cine C7 protein were predicted at: Cys1-Cys6, Cys2-Cys32, Cys3-Cys22, Cys4-Cys23, 
Cys5-Cys18, Cys7-Cys36, Cys8-Cys55, Cys9-Cys50, Cys10-Cys14, Cys11-Cys16, Cys12-Cys45, 
Cys13-Cys34, Cys15-Cys56, Cys17-Cys54, Cys19-Cys43, Cys20-Cys21, Cys24-Cys25, Cys26-
Cys40, Cys27-Cys28, Cys29-Cys31, Cys30-Cys39, Cys33-Cys44, Cys35-Cys38, Cys37-Cys46, 
Cys41-Cys42, Cys47-Cys49, Cys48-Cys52, and Cys51-Cys53. Most of cysteine residues are 
found in small modules like TSP1, LDLa, CCP or FIMAC. Mature human C7 consists 
of two protein domains at the amino (a.a 23-575) and carboxyl terminus (a.a 576-843) 
(Haefliger et al. 1989, DiScipio et al. 1988). Both human and porcine C7 have two N-
glycosylation sites, one at amino acid 202 of amino terminus and another at amino acid 
754 of carboxyl terminus (Agah et al. 2000, DiScipio et al. 1988) (Figure 47). The 
amino terminal area of human C7 (a.a 22-347) is hydrophilic, but the carboxyl-terminal 
polypeptide (a.a 348-843) contains several intermittent zones of hydrophobicity, with 
the region between positions 629 to 807 having a particularly strong hydrophobic ten-
dency (DiScipio et al. 1988). 
 
5.1.2 Characteristic of the porcine C8 complement gene 
 
The eighth component of the terminal complement lytic pathway is a serum protein 
consisting of three amino acid chains, encoded by C8A, C8B, and C8G (Kaufmann et 
al. 1993). Human C8A and C8G are covalently linked while C8B is noncovalently asso-
ciated with the C8A-G (Tschopp et al. 1981). The C8B is responsible for binding of C8 
to C5b-7 (Monahan et al. 1980) whereas the C8A interacts with C9 (Stewart et al. 1985) 
to form the membrane attack complex (C5b-9) which can polymerize to form trans-
membrane pores and causes osmotic cell lysis. The C8G may act as a retinol transport-
ing protein in plasma (Haefliger et al. 1991) and bind to yet unidentified ligands (De-
wald et al. 1996, Kaufman et al. 1994, Ng et al. 1987). The C8G is not involved in the 
lytic mechanism and its function is still unknown (Brickner et al. 1984). 
 
The pig C8A cDNA sequence (GenBank acc. no. DQ333200) contains 2146 nucleotides 
encoding 589 amino acids (GenBank acc. no. ABD13968). This is in agreement with 
558 amino acids and a 31 amino acid leader sequence (signal peptide) in porcine C8A 
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protein sequence previously reported by Nakajima et al. (1998). However, the authors 
published a cDNA sequence (GenBank acc. no AB008156) with 2145 nucleotides. With 
an adenine missing at position 825 this would lead to a frameshift with a stop codon 
causing a deficient C8A protein. In addition, using the SignalP 3.0 tool analysing hu-
man and porcine signal peptides revealed that their putative cleavage site is situated 
between a.a 19 and 20 whereas Nakajima et al. (1998) reported the first 31 residues be-
longing to the signal peptide corresponding to predictions in the human C8A (Rao et al. 
1987). Moreover, compared with the protein sequence reported by Nakajima et al. 
(1998) we have found three different amino acids at positions 244 (KÆX), 419 (MÆL) 
and 483 (AÆV). These could be polymorphic sites with amino acid substitutions be-
tween porcine breeds analysed. Porcine C8A has a molecular weight of approximately 
66 kDa calculated from the atomic composition formula C2856H4406N808O906S45 using the 
ProtParam tool while it was 64 kDa in human C8A (Steckel et al. 1980). The whole 
porcine C8A protein sequence, which is similar to human and rabbit C8A in length 
(Nakajima et al. 1998), contains 31 cysteines. Possibly, the disulfide bonds are formed 
between Cys1-Cys7, Cys2-Cys26, Cys3-Cys5, Cys4-Cys20, Cys6-Cys23, Cys8-Cys25, Cys9-
Cys19, Cys10-Cys14, Cys11-Cys15, Cys12-Cys18, Cys13-Cys21, Cys16-Cys27, Cys22-Cys31, 
Cys24-Cys28, and Cys29-Cys30. Cysteine-rich modules like TSP1 (one in amino terminus 
(a.a 43-95) and one in carboxyl terminus (a.a 542-598)), LDLa (a.a 111-133), and EGF 
(a.a 522-533) were found in porcine C8A protein (Nakajima et al. 1998). The content of 
these modules is similar to the computer prediction result here using SMART analysis 
tool although they showed some different nucleotide positions. There are one or two N-
glycosylation sites in human C8A (Rao et al. 1987). These correspond to sequences 
Asn-Trp-Ala (a.a 46-48) and Asn-Gly-Ser (a.a 442-444) in the porcine C8A protein 
sequence. Examination of the porcine C8A revealed one more N-glycosylation site at 
a.a 364-366 (Asn-Met-Thr) using the NetNGlyc 1.0 Server tool (Figure 48). Nakajima 
et al. (1998) proposed candidate site for CD59 recognition between a.a 382-419. The 
CD59 is known as a 18-20 kDa GPI-anchored membrane protein that functions as a key 
regulator of the terminal step of the complement activation cascade. It restricts binding 
of C9 to the C5b-8 complex, thereby preventing the formation of the MAC (Qian et al. 
2000). During biosynthetic process, C8A contains a unique insertion (residues 189-
205), which includes Cys194 that forms the disulfide bond to human C8G. With a small 
exchange from Thr193 in human to Ala196 in pig, both these segments are highly con-
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served. Therefore C8G must contain a complementary binding site for the C8A (Plumb 
and Sodetz 2000). The C8A-G disulfide bond has a key role in binding to C8B through 
a site located on C8A (Plumb et al. 1999). Plumb et al. (1999) illustrated that the bind-
ing site for C8B and C8G reside within the MACPF region of C8A. C8A mediates bind-
ing and self-polymerization of C9 to form a pore-like structure on the membrane of tar-
get cells (Slade et al. 2006, Scibek et al. 2002). The amino-terminal modules in C8A are 
important for C9 binding and/or expression of C8 activity (Plumb et al. 1999). 
 
The porcine C8B cDNA sequence (GenBank acc. no DQ333201) shows 99% identity to 
a 2455 bp region (GenBank acc. no AK232952) separated from clone LVRM10055B03 
(Uenishi et al. 2004). The difference is due to (1) lack of one nucleotide at the first posi-
tion in 5´UTR flanking region (2) abundance of one nucleotide after position 1910 in 3´ 
UTR flanking region (3) deletion of two nucleotides at positions 1728 and 1737 in cod-
ing region of GenBank acc. no AK232952. The deletions would lead to deficiency of 
C8B protein due to the formation of a stop codon. As compared to the 2563 bp nucleo-
tide sequence of GenBank acc. no AK233291 (Uenishi H et al. 2004) we added 474 bp 
of 3´UTR flanking region of porcine C8B cDNA sequence including a polyadenylation 
signal (AATAAA) (nt. 2408-2413). Therefore, full-length porcine C8B sequence as 
shown in figure 43 is 2461 bp. The signal peptide sequence is 54 residues in human 
(Howard et al. 1987) while it is only 44 amino acids in the pig according to the SignalP 
3.0 analysis. Three asparagines as candidates for potential N-glycosylation sites are at 
sequences Asn-Phe-Ser (a.a 101-103), Asn-Val-Thr (a.a 243-245) and Asn-Trp-Ser (a.a 
553-555) in human C8B (Howard et al. 1987) corresponding to sequences Asn-Phe-Ser 
(a.a 113-115), Asn-Val-Thr (a.a 255-257) and Asp-Trp-Phe (a.a 565-567) in the pig, 
respectively. Probably the porcine C8B has three N-glycosylation sites, which two of 
them are conserved with human C8B and one extra site at a.a 56-58 (Asn-Glu-Ser) in 
the amino terminus (Figure 49). One of three possible sites of human C8B contains the 
same Ser-Asn-Trp-Ser sequence found at the proposed glycosylation site in human 
C8A. Probably, the porcine C8B only contains two possible sites because the first 
amino acid in the third sequence is an asparagine acid (Asp) instead of an asparagine 
(Asn). Using the ProtParam tool the molecular weight of porcine C8B 
(C3040H4735N855O915S39) was predicted to be 69.15 kDa while that of human C8B was 64 
kDa (Steckel et al. 1980). With a total 27 cysteines found in the C8B protein structure 
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disulfide bonds could be formed between Cys1-Cys15, Cys2-Cys9, Cys3-Cys26, Cys4-
Cys24, Cys5-Cys13, Cys6-Cys7, Cys8-Cys27, Cys10-Cys12, Cys11-Cys23, Cys14-Cys16, 
Cys17-Cys22, Cys18-Cys21, Cys20-Cys25. Analysis of the derived amino acid sequence 
revealed several membrane surface seeking segments that may facilitate C8B interac-
tion with target membranes during complement-mediated cytolysis (Howard et al. 
1987). The soluble terminal complement complex can be formed in C8B-deficient sera 
that contain little or no C8B (Hogasen et al. 1998). The homology between the porcine 
C8B and C8A protein is 28% on the basis of amino acid identities. 
 
 
The primary sequence of porcine the C8G (GenBank acc. no. DQ333202) has been elu-
cidated with 840 bp encoding 202 deduced amino acid residues (GenBank acc. no. 
ABD13970). The first 20 residues of the open reading frame of the human C8G show 
the typical features of a signal peptide using signalP analysis tool. The length of the 
human and porcine C8G protein sequence is the same and both share 82% identity. Us-
ing the ProtParam tool for the C8G molecule (C999H1582N288O281S5) 22.29 kDa molecu-
lar weight was predicted, similar to human C8G with 22 kDa (Steckel et al., 1980). Por-
cine C8G gene was not homologous to the other candidate genes in the terminal lytic 
complement pathway because it only contains a lipocalin domain (aa 48-184), which 
binds small hydrophobic ligands (Ortlund et al. 2002, Schreck et al. 2000). Both the 
human and porcine C8G have three cysteine residues at a.a 60, 96 and 188. The position 
of these cysteines is conserved in pig and human. The DiANNA 1.1 computer predic-
tion (Ferre and Clote 2005, Ortlund et al. 2002) revealed a disulfide bond between Cys1-
Cys3. According to Haefliger et al. (1987) the first cysteine (the 60th amino acid) in C8G 
protein sequence forms the disulfide bridge with C8A whereas another internal disulfide 
bridge exists between the second (the 96th a.a) and the third cysteine residues (the 188th 
a.a). The possible N-glycosylation site is at a.a 173 (Asn-Leu-Thr) using the NetNGlyc 
1.0 Server tool (Figure 50). 
 
5.1.3 Characteristic of the porcine C9 complement gene 
 
Complement component C9 binds to C5b-8 sites on target cells and polymerizes to form 
the membrane attack complex (Taylor et al. 1997). In this study, the deduced porcine 
C9 protein sequence contains 543 amino acids (GenBank acc. no. ABD13966) showing 
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67% identity to human C9 (559 a.a). The first 21 amino acids may represent the signal 
peptide according to the SignalP 3.0 computer prediction tool. The domain within the 
first 16 amino acids at the amino-terminus of C9 is crucial in preventing the self-
polymerization of the globular protein (Taylor et al. 1997). Porcine C9 
(C2748H4301N753O836S30) has a weight of 62.23 kDa using the ProtParam tool whereas 
human C9 is Mr = 72 kDa (Schreck et al. 2000). The porcine C9 has 19 cysteine resi-
dues corresponding to disulfide bonds Cys1- Cys11, Cys2- Cys14, Cys3- Cys19, Cys4- 
Cys5, Cys6- Cys15, Cys7- Cys9, Cys8- Cys13, Cys10- Cys18, and Cys12- Cys16 as predicted 
with the DiANNA 1.1 analysis tool. The C9 protein has a carbohydrate content of 7.8% 
(Biesecker et al. 1982, 1980). Carbohydrate is usually attached to plasma proteins 
through an asparaginyl side chain within the characteristic sequence Asn-X-Ser/Thr 
(Clamp et al. 1975). Examination of the sequence of human C9 reveals only one se-
quence Asn-Glu-Thr (a.a 277-279) with an asparaginyl residue at position 277 likely to 
be a carbohydrate attachment site (DiScipio et al. 1984). This N-glycosylation site was 
not found in the porcine C9 protein. However by using the NetNGlyc 1.0 Server tool it 
showed that the porcine C9 has two N-Glycosylation sites at a.a 35-37 (Asn-Gly-Thr) in 
the amino terminus and (Asn-Val-Thr) in the carboxyl terminus (Figure 51). C9 water-
soluble glycoprotein will insert quickly into lipid bilayers after binding to the membrane 
bound C5b-8 complex (Steckel et al. 1983, Hu et al. 1981, Podack et al. 1981). The 
C8A, C8B and C9 are members of a family of structurally related proteins that are ca-
pable of interacting to produce a hydrophilic to amphiphilic transition and membrane 
association (Howard et al. 1987). The principal binding site for C9 lies within the 
MACPF domain of C8A (Slade et al. 2006). The C9 polypeptide chain assumes a `U´ 
shape, in which the TSP1 and LDLa modules are located on the upper rim. The EGF 
module is located on the lower edge of the upper rim, and midsection of the polypeptide 
chain constructs the barrel of the tubule. TSP1 and LDLa modules do not participate 
directly in polymerization but cover the hydrophobic central region of the polypeptide 
chain in the monomer (DiScipio and Berlin 1999). In vertebrates, C9 and perforin form 










































Figure 34  3D-structure of C6 (a.a 180-515), C7 (a.a 128-411), C8A (136-497), C8B 
(a.a 168-508) and C9 (122-506) homologous protein fragments built based 
on knowledge of structure features of homologues peptides and proteins with 










































Figure 34 (continued) Position of amino acids at point mutations within 3D-protein re-




















Figure 34 (continued) 
C9 
 
5.1.4 Common and specific structural and functional features of components of the ter-
minal lytic complement pathway 
 
It is really crucial to study the characteristic of the last complement proteins C6, C7, C8, 
C9 that act in concert to form the transmembrane pore at molecular level. The architec-
ture of porcine C6, C7, C8A, C8G and C9 genes was identified and analyzed. Com-
pared to human protein sequences the porcine C6, C8A, and C8B are one, five, and 20 
amino acids longer, respectively, the porcine C9 is 16 amino acids shorter, whereas por-
cine C7 or C8G are of the same length as the human proteins. Actually, homology (22-
31%) was found between amino terminus of C6 and C7 with whole mature C8A, C8B 
and C9 proteins (Figure 35 and Figure 36). The porcine C6, C7, C8A, C8B and C9 are 
mosaic proteins constructed from small cysteine-rich segments like TSP1, LDLa, EGF, 
CCP, FIMAC and MACPF whereas C8G individually composes of a lipocalin domain. 
The ubiquity of several types of cysteine-rich homology segments suggests that they 
have some utility in protein function (DiScipio et al. 1988). Respectively, 58, 45, 17, 18, 
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three, 13 of total 64, 56, 31, 27, three, 19 cysteines found in C6, C7, C8A, C8B, C8G 
and C9 are located in these functional protein domains. Each CCP (56-58 amino acids) 
contains four cysteines whereas six cysteines were found in each LDLa segment (37-38 
amino acids). Within each CCP unit the two disulfide bonds are formed (1) between the 
first and the third cysteines, and (2) between the second and the fourth cysteines. Each 
short consensus unit is stabilized by small irregular groups of anti-parallel β-sheet inter-
spaced by four or five tight turns (DiScipio et al. 1989). The FIMAC units are some-
what knotted by disulfide bonds but contain elements of conventional secondary struc-
ture (DiScipio et al. 1989). In both human and pig, the amino terminus of C6 has a tan-
dem repeat of TSP1 whereas the carboxyl termini of C6 and C7 have a tandem of CCP 
and FIMAC. Each of five terminal complement mosaic proteins (C6, C7, C8A, C8B and 
C9) has a MACPF motif. Proteins containing MACPF domains play important roles in 
vertebrate immunity, embryonic development, and neural-cell migration (Rosado et al. 
2007). The MACPF domain structure is similar with poreforming cholesterol-dependent 
cytolysins (CDCs) from gram-positive bacteria. These lytic MACPF proteins may use a 
CDC-like mechanism to form pores and disrupt cell membranes (Rosado et al. 2007). 
The CCP and FIMAC domains in C6 and C7 have the capacity to link specifically with 
C5 (DiScipio 1992, Haefliger et al. 1989, Ripoche et al. 1988, Catterall et al. 1987). 
Although the FIMAC is not required absolutely for C6 activity, this module promotes 
interaction of C6 with C5 enabling a more efficient bimolecular coupling ultimately 
leading to the formation of the C5b-6 complex (DiScipio et al. 1999, Haefliger et al. 
1989). Binding of the FIMAC in C7 to the C345C domain in C5 is essential for incorpo-
ration of C7 into C5b-6 and hence for successful MAC assembly (Thai and Ogata 2005, 
2004). The CCP modules mediate specific protein-protein and protein-carbohydrate 
interactions that are key to the biological function of the regulators of complement acti-
vation and, paradoxically, provide binding sites for numerous pathogens (O'Leary et al. 
2004). The TSP1 conserved sequence motif has been suggested to play a key role in 
mechanisms by which malaria parasites avoid host defenses mediated by complement 
(Goundis et al. 1988). Both amino-terminal modules TSP1 and LDLa in C8A have a 
role in forming the principal binding site for C9 and that binding may be dependent on a 
cooperative interaction between these modules and the C8A MACPF domain (Scibek et 
al. 2002). However, Slade et al. (2006) indicated that principal binding site for C9 lies 
within the MACPF domain of C8A. The binding specificity between C8B and C8A-G 
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subunits is determined by a cooperative interaction of the asparaginyl-terminal TSP1 
module and MACPF (Musingarimi et al. 2002). Site-specific antibodies directed to the 
LDLa homology unit in C9 cross-reacted with C6 and C7 (Tschopp et al. 1986). The 
porcine C8G is a lipocalin protein. According to King et al. (1994) some of the lipocalin 
proteins are allergens. Allergies are hypersensitivity reactions of the immune system to 
specific substances called allergens (such as pollen, stings, drugs, or food) that, in most 
people, result in no symptoms.  
 
Based on obtained results it can be summarized that the complex of the porcine terminal 
complement components (C6-9) comprises of typical related mosaic proteins of high 
complexity and different size. These proteins contain modules being similar to segments 
of other proteins in the complex. The MAC can be regarded as a protein macromolecule 
from many smaller polypeptide sequences (C5b-9), which merge to each other due to 
interaction among their cysteine-rich homologous modules to form the membrane asso-
ciation. Homologous molecules of the terminal pathway (C6-9) originate from an ances-
tral gene. The porcine C6 is the largest protein in the terminal lytic pathway and most 
similar in structure to complement C7. Distance between porcine C8A and C9 is close 
on the phylogenetic tree. The C8A and C8B genes have correspondingly similar roles in 
MAC-mediated lysis of erythrocytes and bacterial killing and C8G is not required for 
expression of C8 activity (Schreck et al. 1998) and for complement-mediated killing of 
gram-negative bacteria (Parker et al. 2002). Presence of the MACPF module in all pro-
teins C6 to C9 may have an important role in their combination to form in the stable 
complement complex as well as in lysis activity. The components of the MAC are 
physically formed in an associated arrangement C5b-C6-C7-C8B-C8A.G-C9. The char-
acteristic pore-like appearance of the MAC is attributed to the association of as many as 
12-18 C9 molecules that self-polymerize to form a circular structure in the membrane 
(Tschopp 1984). The individual components are hydrophilic proteins; however, when 
combined they form an amphipathic complex that is capable of binding to and disrupt-
ing local membrane organization (McCloskey et al. 1989). The increase in membrane 
permeability leads to osmotic lysis of simple cells such as erythrocytes or initiation of a 
variety of intracellular signaling events in the case of nucleated cells (Mold 1998). In 
bacteria, the MAC disrupts the outer membrane thereby increasing permeability and 
inducing lethal changes in the inner membrane (Esser 1994). Regulation of the mem-
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brane attack pathway is essential to protect host cells from damage at sites of comple-
ment activation (Morgan 1999). In most tissues, ubiquitously expressed complement 
regulatory proteins prevent autologous destruction, protecting host cells from the pow-
erful cytolytic activity of activated complement (Scolding et al. 1998).  
Figure 36  Comparison of the porcine
C6 (a.a 632-935) and C7
(a.a 576-843) carboxyl-
termini with whole mature
porcine C8A, C8B and C9
proteins using Clustal W
alignment tool. 
Figure 35  Comparison of the porcine
C6 (a.a 22-631) and C7 (a.a
23-575) amino-termini with
whole mature porcine C8A,
C8B and C9 proteins using
Clustal W alignment tool.  
 
5.2 Polymorphisms, genotyping and assignment of candidate genes to chromosome 
 
Screening of the porcine C6, C7, C8A, C8B and C9, respectively, detected five, six, 
seven, nine, two single nucleotide polymorphisms (SNPs) in the coding regions, 
whereas there is no polymorphism within the porcine C8G when using one animal of 
each porcine breed (HS, DR, LR, PIE, BMP and MK). Most of the polymorphisms lie 
in cysteine-rich functional protein domains such as TSP1, LDLa, MACPF, CCP or FI-
MAC. Especially, eight of nine SNP within C8B have amino acid substitutions includ-
ing the SNP at nt 935 with three different segregating alleles (AÆGÆT). In the porcine 
C9 gene, the polymorphic site at nucleotide 407CÆG corresponding to codon 
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106CACÆCAG (HisÆGln) shows two different genotypes GG and CG in F2 DUMI 
resource population but not in LR, PIE or MK. Allele `C´ maybe derived from Saddle-
back Pigs, one of the breeds used to breed Berlin Miniature Pigs. These genetic varia-
tions may play an important role in the structural formation and function of the protein 
domains and therefore may affect the activity of the complement components in cell lysis.  
In order to evaluate genetic variation between Asian and European porcine breeds sev-
eral SNP sites were selected for genotyping animals of porcine breeds LR, PIE, and 
MK. As a result, allele variety was found higher in LR and PIE (European breeds) than 
in MK (Asian breed) with different frequencies. Calculation and evaluation of all geno-
typic and allelic frequencies fit to Hardy-Weinberg equilibrium by Chi-square test. Ge-
netic variations with amino acid substitution at loci that affect disease resistance traits 
found between European and Asian breed have great significance in breeding to im-
prove pig health. Genetic variation in pigs has been shown in response to pathogens or 
immune system challenges (Henryon et al. 2002, Wilkie and Mallard 1999, Mallard et 
al. 1998) and in responses of pigs to infections with PRRSV (Petry et al. 2005).  
 
In human the genes encoding the proteins of the membrane attack complex of the ter-
minal lytic pathway (C5b-9) are required for complement bactericidal activity (Esser 
1994, Schreiber et al. 1979). Genetic variations in C6 to C9 proteins associate with 
Neisseria infections (Ki et al. 2005, Witzel-Schloemp et al. 1997, Alvarez et al. 1995, 
Kaufmann et al. 1993, Figueroa et al. 1991). The polymorphic sites found in pig candi-
date genes are not conserved to ones associated with Neisseria infections in human. 
 
Radiation hybrid mapping is known as a powerful tool for comparative gene mapping 
because gene assignments are made without the detection of genetic polymorphism as 
needed for linkage mapping. The assignment of genes using radiation hybrid (RH) pan-
els is an efficient way to map genes and markers as well as to integrate the linkage and 
cytogenetic maps of a species (Hawken et al. 1999, Yerle et al. 1998). Application of 
the IMpRH panel allowed to unambiguously assigning the six loci to porcine chromo-
somes. The analysis revealed four new assignments and confirmed previous results. RH 
mapping result showed that C8A was assigned to 6q3.1-q3.5. This is also in agreement 
with previous result of Nakajima et al. (1998). The authors reported that the porcine 
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C8A gene physically maps to chromosome 6q3.3-3.5 according to in situ hybridization 
using the porcine bacterial artificial chromosome (BAC) clone as a hybridization probe. 
 
The porcine C9 has been mapped to 16q1.4 by fluorescence in situ hybridization 
(Thomsen et al. 1998), which is confirmed by our results. Genetic mapping correspond-
ingly revealed linkage of C6 and C7 to C9 and AGXT2 that have previously been as-
signed to the q arm of Ssc16 (Ponsuksili et al. 2001, Thomsen et al. 1998, Wintero et al. 
1998) while on chromosome 6q3.1-q3.5 C8B links closed to C1q and C8A that have 
been reported by Jorgensen et al. (1997) and Nakajima et al. (1998), respectively. This 






Figure 37 Correspondences between human and pig chromosomal segments. Location 
of the porcine C6, C7 and C9 gene on the q-arm of chromosome 16 
































Figure 38 Correspondences between human and pig chromosomal segments. Loca-
tion of the porcine C8G gene on the q-arm of chromosome 1 (Ssc1q2.13) 







Figure 39 Correspondences between human and pig chromosomal segments. Location 
of the porcine C8A and C8B gene on the q-arm of chromosome 6 (Ssc 
6q3.1-q3.5) adapted from http://www2.toulouse.inra.fr/lgc/pig/compare/ 
SSCHTML/SSC1B.HTM 
 
The mapping results also fit the current pig-mouse and pig-rat comparative maps as 
accessible via the MGI webpage 
(http://www.informatics.jax.org/searches/homology_form.shtml). Further, the location 
of distinct C8 loci on chromosomes supports genetic evidence that C8 contains three 




Looking on the genetic maps of other species the sixth and seventh complement com-
ponents are mapped to the same chromosome. Also C8A and C8B components are al-
ways found on the same chromosome. Additionally C9 complement component could 
be mapped to the same chromosome carrying C6 and C7 in all species addressed here 
except in B. taurus and D. rerio. The C8G gene is always located in a different chromo-
some (Table 20) 
 
Table 20 Chromosomal assignments of the genes in difference species 
 

















C6 20 21 - 5p13 6 15A1 2q16 5
C7 20 21 Z 5p13 - 15A1 2q16 5
C8A 3 - - 1p32 1 4C6 5q34 1
C8B 3 - 8 1p32 1 4C6 5q34 1
C8G - 24 - 9q34.3 - 2A3 3p13 -
C9 1 5 - 5p14-p12 6 15A1 2q16 -
 
 
5.3 Association analysis with hemolytic complement activity 
 
5.3.1 Hemolytic complement activity depending on genotypes of the candidate genes 
 
In human, deficiencies of candidate genes C6, C7, C8 and C9 have been studied and 
associated with meningitis infection in many different populations (Takata et al. 1989, 
Cooke et al. 1987, Keller et al. 1987, Moolenaar et al. 1987, Vogler et al. 1979). The 
studies have provided important information about the role of complement in the de-
fense against pathogens, agents of infectious diseases, especially meningococcal dis-
ease. Here we refer to the association and linkage of mutation points of the terminal 
complement components C6, C7, C8 and C9 with immune response of two kinds of 
pathogen, bacteria (Mycoplasma) and virus (Aujeszky and Porcine Reproductive and 
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Respiratory Syndrome) before and after vaccinations for hemolytic complement activity 
in both classical and alternative pathway in pigs.  
 
In the porcine C6 candidate gene, studying genetic association with hemolytic comple-
ment activity was carried out for the SNP 862AÆG, causing the 240AsnÆAsp amino 
acid substitution. Difference of genotypes in CH50 test was close to significance 
(p=0.0853) although along the vaccination program homozygous genotype GG always 
shows higher lysis levels. The allelic frequency of `G´ was found to be higher in MK 
than in other breeds. No evidence was found for significant association with hemolytic 
performance between the C6 genotypes and AH50. Comparing effects of different al-
leles on hemolytic complement activity in both pathways, one might tend to regard the 
`G´ allele as favorable and thus carriers of the allele or breed with high `G´ allele fre-
quency as valuable genetic resources.  
 
In porcine C7 gene, the SNP site at position 881AÆG (294LysÆArg) was genotyped 
and associated with hemolytic complement activity in the F2 DUMI resource popula-
tion. It showed that lysis activity reached maximum level at the day 4 post-ADV vacci-
nation in CH50 and at day 10 after PRRSV immunization in AH50. There is highly sig-
nificant difference between genotypes in CH50 with the allele `A´ being favorable in 
terms of complement activity (p=0.0080) while there was no difference in AH50. It in-
dicated that the time course of hemolytic complement activity in the classical pathway 
depends on the C7 genotypes. In the DUMI resource population the allele `A´ originates 
from the Berlin Miniature Pig grandparents. Berlin Miniature Pigs were bred from Viet-
namese potbelly pig, Saddleback Pig and German Landrace with the first being the 
likely source of the `A´ allele. Interestingly this allele is more frequent in the Muong 
Khuong compared to German Landrace and Pietrain. According to Clapperton et al. 
(2005) levels of innate immune traits were shown to differ between different pig breeds 
although it is unknown whether this effect would lead to breed differences for resistance 
to infectious diseases.  
 
In the porcine C8A gene, association of C8A genotypes at SNP site 1544CÆT 
(485ArgÆCys) with hemolytic complement activity was studied. As a result, the asso-
ciation of C8A with CH50 was close to significance (p=0.0650), however the difference 
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between the two homozygous genotypes CC and TT was significant at p=0.0522. Ani-
mals with genotype TT show strong lysis ability at the early time point before Mh vac-
cination and this hemolytic activity showed a linear increment during experiment. At 
later time points the performance of heterozygous animals is similar to animals of the 
TT genotype, whereas at the early time points the hemolytic complement activity of 
heterozygous animals was as low as for the CC genotype. This might indicate domi-
nance effects of the allele `T´ that are different in their direction depending on the vac-
cination. Additionally, interaction between genotypes and time points caused significant 
difference in AH50 test (p=0.0027). This showed that hemolytic complement activity in 
alternative pathway depends on C8A during the time course of vaccination. 
 
In the porcine C8B gene, analysis of CH50 hemolytic complement activity depending 
on C8B genotypes at SNP 222 (65ThrÆMet) in animals of the DUMI population along 
the vaccination program demonstrated that at the beginning of the vaccination program, 
before and after Mycoplasma vaccination, the hemolytic complement activity in animals 
with genotype CT (42.8±3.4) was the lowest compared to CC (51.5±3.4) or TT 
(52.5±5.7). At time points around ADV vaccination differences depending on C8B 
genotypes were not obvious whereas at PRRSV vaccination genotype CT (71.2±4.4) vs 
CC (68.8±3.9) or TT (62.3±7.2) revealed highest value, i.e. `T´ allele really exposes its 
own maximal hemolytic ability in the heterozygous pattern at this point time. Also the 
allele `T´ performs its own optimum lysis ability compared with remainders at day 10 
after Mh or ADV immunization in the alternative complement pathway. However, the 
difference for CH50 and AH50 activity among genotypes at particular time points was 
not statistically significant. The `T´ allele at nucleotide 222 in the DUMI populations 
originates from the Berlin Miniature Pig grandparents. Berlin Miniature Pigs were bred 
from Vietnamese potbelly pig, Saddleback Pig and German Landrace (Hardge et al. 
1999) with the first being the likely source of the `T´ allele. The time course of hemo-
lytic complement activity depends on the C8B genotypes. Different effects of C8B 
genotypes on hemolytic complement activity associated with particular vaccinations 
against bacterial and viral pathogens could be due to host-pathogen-interaction. Viet-
namese local breeds are a source of promising alleles of unpredictable economic value 
(Lemke et al. 2005). In this case it can suggest that allele `T´ presenting in Muong 
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Khuong population is a valuable genetic resource, which provides new perspectives to 
improve innate immune response in pigs.  
 
Screening the full-length cDNA sequence of the porcine C9 (GenBank acc. no. 
DQ333198) revealed two SNP sites: 350AÆG (codon 87CAAÆCAG) and 407CÆG 
(106CACÆCAG). The second SNP has an amino acid substitution HisÆGln whereas 
the first is a silent mutation. Therefore, the second was investigated to associate with 
hemolytic complement activity in both classical and alternative pathway. For the por-
cine C9, significant difference in hemolysis was found between two genotypes GG 
(69.49±3.17) and CG (63.59±3.65) for the classical (p=0.0488) but not for the alterna-
tive pathway (62.73±2.82 vs 61.52±2.39, respectively). However, statistically signifi-
cant difference was found in the interaction of genotypes and immunization point times 
(p=0.0340) in the alternative pathway. Appearance of allele `C´ in heterozygous CG, 
probably from Saddleback Pigs, has made decreasing lysis activity whereas homozy-
gous GG always shows hemolysis at a higher level during experiment in the classical 
pathway. CH50 tests showed the highest lysis value at the fourth day after ADV vacci-
nation in both homozygous GG genotype (83.09±3.85) and heterozygous CG 
(78.12±4.72), whereas AH50 can be seen as a linear increasing line during the experi-
ment. The genotype GG shows high variation in the level and reactivity of the comple-
ment cascade along the experiment. It could come up to the highest value (83.09±3.85) 
at the fourth day post ADV immunization in CH50 and go down to one of the lowest 
values (47.81±3.10) at the fourth day post Mh immunization in AH50. Due to their dif-
ferent impact on the classical and alternative pathway the C9 genotypes are of high in-
terest for further studies. 
 
5.3.2 Other factors on hemolytic complement activity in both pathways 
 
The complement system comprises over 30 distinguished proteins and is known as a 
biochemical cascade for lysis invading external pathogens. These proteins are primarily 
formed in the liver and circulate under inactive form in blood plasma. When there is, 
however, presence of attacking pathogens these proteins will become active. As an acti-
vated enzyme, prior protein bind to subsequent protein to form the membrane attack 
complex (C5b-9). Of course, concentration of MAC will be higher in blood plasma and 
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on membrane of target cell at that time. Then the complex inserts into the cell mem-
brane, punches a hole, increases leakage of water and ions through the cell membrane, 
initiates osmotic cytolysis and kills target cells. In turn, C5b-9 complex exerts a regula-
tory effect on the formation of C3 convertases of the classical and alternative pathway 
and on the utilization of C5 by cell-bound C5 convertases. Feedback inhibition by C5b-
9 represents a biologically relevant mechanism through which complement may auto-
regulate its effector functions (Bhakdi et al. 1988). 
 
Due to the important role of the complement system in natural immune regulation 
mechanism of host body against pathogens, many studies for the complement compo-
nents have been carried out; for example in bacterial meningitis infections in which the 
C5-9 complex attacks the gram-negative bacteria (Vázquez-Bermúdez et al. 2003, Zhu 
et al. 2000, Eng 1980, Haeney et al. 1980). The morbidity of meningococcal infections 
may be attenuated in the presence of reduced levels of the membrane attack complex 
(Ross and Densen 1984). Deficiencies of complement components of the terminal 
pathway predispose to both autoimmune disease and infections were also reported. 
Causes of deficiency can be inherited (Toshiro et al. 1999, Inai et al. 1989, Fukumori 
and Horiuchi 1998) or acquired and complete or partial.  Moreover, deficiency of mem-
brane attack complex proteins of the complement system often appears common in 
countries where bacterial diseases are highly prevalent (Zimran et al. 1987, Orren et al. 
1987).  Most of deficiencies are associated to polymorphisms present in the molecular 
structure of at least one complement component. Vissher et al. (2002) also provided 
evidence for substantial genetic variation between pigs and concluded that there is the 
possibility for genetic improvement of the immune capacity and response to pathogens. 
 
Since the complement system plays an important role in natural defense system of pigs, 
genetic variation of C3, C5 as well as mannose-lectin genes (MBL1 and MBL2) were 
associated with hemolytic complement activity (Phatsara et al. 2007, Kumar et al. 2004, 
Mekchay et al. 2003, Wimmers et al. 2003). On the same experimental materials, here it 
was focused on the porcine C6, C7, C8A, C8B, and C9 genes. Not as other complement 
components with dependently specific functions, the C6-9 assembly has the same func-
tion of cell lysis because all they are members of the MAC macromolecule. This means 
that reciprocal influence among the terminal complement components on hemolytic 
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complement activity is indispensable. Catalytic activity of previous components could 
affect not only the subsequent others but also the activity of whole MAC complex. The 
study showed significant differences between genotypes of several genes and hemolytic 
complement activity in the classical pathway but not in the alternative pathway for all 
candidate genes. Performance of genetic variation of the terminal complement compo-
nents C6-9 on hemolytic complement activity in the classical and alternative pathway is 
complicated. It is really indirect to use CH50 and AH50 for evaluating genetic effect of 
the terminal candidate genes on hemolytic complement activity because direct products 
at the end of the complement activation from three pathways (classical, lectin, and al-
ternative) are C5-convertases, the essential enzyme to split C5 into two smaller frag-
ments C5a as a potent anaphylatoxin and C5b as an event center for binding to C6 fol-
lowed by C7-9. However measurement of CH50 and AH50 is the best screening test for 
deficiency of the complement components of classical, alternative or terminal pathway. 
Beside the genotypes of candidate genes, a number of other factors that affect comple-
ment activity were evident along the experiment. These factors have been taken into 
account in the analysis using adequate statistical models. Some of these factors may 
contributed to the fact that the association of the candidate genes of the terminal lytic 
pathway of the complement cascade, that is common to the classical and alternative 
pathway of complement activation, was shown for CH50 but not for AH50 for all genes 
except C8G. Factors such as gender and age of the animals, the used vaccines, and in-
teraction of genotypes and vaccinations, interaction among complement genes them-
selves and also other immune genes that are discussed here may increase the power to 
detect effects on hemolytic complement activity measured in the classical pathways but 
mimic these effects in the alternative pathway. 
 
5.3.2.1 Effect of gender 
 
Higher hemolytic activity was found in male animals as compared to in the female ani-
mals in both pathways. Analysis of variance also indicated significant differences be-
tween genders. According to Olaho-Mukani et al. (1995) sex has an effect on comple-




5.3.2.2 Effect of age 
 
The complement system is immature at birth. Repeated antigenic stimulation leads to 
the complete maturation of immunity during the first few years of life (Durandy 2003). 
Clearly, hemolysis showed low hemolytic values before primary immunization with Mh 
and reach higher ones after the following vaccinations with ADV and PRRSV.  In hu-
man (Yonemasu et al. 1978) and in pigs (Olaho-Mukani et al. 1995, Tyler et al. 1988) 
age has an effect on complement component concentration, i.e. observation on serum 
concentration of C3 in healthy Japanese Yonemasu et al. (1978) reported that the con-
centration reaches the lowest value at 24 hours after birth (680.0±45.7 μg/ml) and co-
mes up the highest at one year old (1385± 65.3 μg/ml). The age of the patient affects 
interpretation of complement levels in various diseases (Yonemasu et al. 1978). Short 
term elevation of complement activity after immunizations is an (sub-)acute phase re-
sponse of the immune system and the long term increase between vaccinations may be 
due to aging (Wimmers et al. 2003). Pig breed and age are important factors influencing 
the response to various stressors or infectious challenges (Sutherland et al. 2005) 
 
5.3.2.3 Interaction of complement components 
 
Due to aging as well as accumulation after various vaccinations the complement system 
is increasingly activated and responsive. Activities of the terminal complement compo-
nents C6 to C9 depend on the activity of other components acting on higher levels of 
the cascade. Especially the formation of the C3 convertase and subsequently the C5 
convertase are key to the final overall hemolytic complement activity. The release of 
C5b from C5 that binds to C6-9 to form the membrane attack complex   is cause of in-
teraction of different protein sequences in the three pathways of complement activation. 
The hemolytic complement activity in the alternative pathway partly depends on C3b 
formed after the complement activation of the classical pathway. The C3b plays an im-
portant role for accelerating complement activation in the alternative pathway. Hemoly-
sis in subsequent time points was higher than the previous along the experiment for 
AH50 due to both antigen-specific and antigen-nonspecific immune responses and re-
sponsiveness that accumulated after each vaccination. Clearly, generation of C3-
convertase has directly strong effect on the formation of the MAC (C5b-9). Of course, 
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complement activation also depends on other signals of the immune system like inter-
leukins. Vaccinations are known to effect acute phase response through cytokines like 
IL1, IL6 and TGFB1 that are released during immune response and in particular trigger 
the expression of C3 (Gonzalez-Ramon et al. 2000, Mackiewicz et al. 1990, Castell et 
al. 1989).  
 
CRP known as an acute-phase serum protein and a mediator of innate immunity binds 
to microbial polysaccharides and to ligands exposed on damaged cells. Surface bound 
CRP reduces deposition of and generation of C5b-9 by the alternative pathway and 
deposition of C3b (Mold et al. 1999). CRP is most efficient at early classical pathway 
activation and reacts with Fc γ receptors (Marnell et al. 1995, Crowell et al. 1991, Ber-
man et al. 1986). CRP binding to C1q differs from IgG binding in being localized to 
collagen-like regions rather than the globular head groups of C1q (Jiang et al. 1991) 
 
5.3.2.4  Effect of vaccination 
 
It was shown that vaccination leads to an acute phase response measurable by an in-
creased serum level of haptoglobin in pigs (Rekitt et al. 2001, Asai et al. 1999). Incre-
ment of the C3c serum concentration, as observed in this experiment, is part of the acute 
phase response (Volanakis et al. 1995, Kusher et al 1982). At the same time it reflects in 
vivo complement activation, while hemolytic complement activity describes the in vitro 
capacity of the complement system (Storm et al. 1992). Also hemolytic complement 
activity is elevated after immunizations. Various structures of lipopolysaccharides 
(LPS) of gram-negative enterobacteria, influence the complement activation. The rough 
LPS of Coxiella burnetii variant activated complement via the alternative pathway, 
whereas the intermediate LPS variant activated the classical pathway (Vishwanath and 
Hackstadt 1988). LPS of various Mycoplasma species have been shown to interact with 
C1 and induce an antibody-independent activation of the complement system via the 
classical pathway (Rosendal et al. 1994, Bredt et al. 1977). A previous study showed 
that Brucella abortus do not activate the bovine alternative pathway (Hoffmann and 
Houle 1983). The rough (O-antigen deficient) Brucella abortus will bind C1 and be 
killed by the classical pathway (Eisenschenk et al. 1999) whereas the alternative path-
way does not kill Brucella abortus (Eisenschenk et al. 1995). For Salmonella minne-
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sota, it was shown that the bacteria avoided killing by complement because membrane 
attack complexes were rapidly sloughed off. Although C3b as well as the stable com-
plexes C5b-7 on the surface of Salmonella minnesota was formed (Joiner et al. 1982a), 
subsequent additions of C8-9 caused release of C5b-7 complexes (Joiner et al. 1982b). 
Furthermore, the lipid A region of the LPS is responsible for classical pathway activa-
tion not to depend upon antibody to the lipid A whereas alternative pathway activation 
proceeds by a lipid A-independent mechanism (Morrison and Kline 1977). Lipid A of 
gram-negative bacteria binds and activates Cl to initiate the classical pathway (Betz et 
al. 1981). In the absence of anticapsular antibody, complement-mediated killing oc-
curred but not by the alternative pathway (Steele et al. 1984). In reverse way, an encap-
sulated strain of Escherichia coli was shown to be killed primarily by antibody-
dependent activation of the classical pathway (Taylor et al. 1983) whereas an unencap-
sulated rough strain of Escherichia coli activated the classical pathway independently of 
antibody (Betz et al. 1981). There also is evidence that killing of bacteria by the classi-
cal pathway system did not require specific antilipopolysaccharide antibodies and the 
chemical compositions of both the capsular polysaccharide and the O-antigen determine 
the degree of complement activation (Pluschke and Achtman 1984). O-antigen pre-
vented both complement component C3 deposition on the surface and complement-
mediated killing of Bordetella parapertussis. In addition, O-antigen was required for 
Bordetella parapertussis to systemically spread in complement-sufficient mice, but not 
complement-deficient mice (Goebel et al. 2008). This can cause deficiency of C3 for the 
alternative pathway activation. In other studies it is reported that porin protein of bacte-
ria binds to C1q (Alberti et al. 1996, Loos and Clas 1987). The association of LPS and 
porins in the absence of specific antibodies is a prerequisite for the activation of the 
classical pathway of complement leading to the killing of serum-sensitive bacteria 
(Loos and Clas 1987). Clearly the mechanisms of complement activation by bacteria are 
quite different depending on characteristics of the bacterial surface such as lipopolysac-
charides, lipid A, O-antigen of LPS, porin, ect. However, also viruses were shown to 
activate the complement cascade independent from existing antibodies via both the clas-
sical and the alternative pathway. Alphaherpesviridae, in particular Epstein-Barr-
Viruses, is an example for complement activation in both pathways (Mold et al. 1988, 




Furthermore, the glycoprotein C (gC) of HSV-1 and -2, bovine herpesvirus type 1, por-
cine herpesvirus 1 (ADV), and equine herpesvirus types 1 and 4 interact with C3b 
(Friedman et al. 2000). Glycoprotein C known as a receptor for C3bBb impedes decay-
accelerating activity for the alternative pathway C3 convertase and could block the 
effects of complement on the infected cells in the absence of antibody (Fries et al. 1986, 
McNearney et al. 1987). The complement activity differs between animal species 
infected by HSV. It is due to the difference in affinity between the gC of HSV and 
either the complement component or glycoprotein structure (i.e. a difference in 
glycosylation level) in each animal (Hidaka et al. 1991). Thus the increment of 
complement activity in blood samples obtained after vaccinations might be at least 
partly due to specific interaction between the bacterial and viral vaccination strains and 
complement components. It may be conducted that activation of either the alternative or 
the classical pathway in the experiment differentially depends on the vaccinations. 
Moreover, the immunization with Mycoplasma is a booster vaccination with the first 
application-taking place in the first week of life. For ADV it has been shown that 
maternal antibodies are present until week 14 and 15 of age (Pensaert and Kluge 1989, 
Wittmann 1984).  ADV immunization was done when maternal antibodies may still be 
present. Those mean that at the time point of Mh and ADV vaccination an immediate 
activation of the complement system via the classical pathway might have happened 
due to the formation of specific antigen-antibody complexes.  
 
All factors discussed above push hemolytic complement activity in the classical path-
way significantly stronger than in the alternative pathway. Consequently, the experi-
ment may have more power to elucidate effects on the hemolytic complement activity in 
the classical pathway than in the alternative pathway. 
 
In summary, in the present study the porcine genes encoding the terminal components 
of the complement cascade C6, C7, C8A, C8B, C8G, and C9 were characterized. The 
cDNA molecular structure was sequenced, polymorphisms detected, assignment to the 
porcine chromosome done, and association between SNPs and hemolytic complement 
activity evaluated. Genetic variations between European and Vietnamese porcine breeds 
are valuable. In the present study, Muong Khuong pig is also owner of genotypes which 
performed strong hemolytic complement activity. Therefore these genotypes can be 
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considered as the candidates to enhance natural resistance in pig in future. These geno-
types might be selected through many generations of Muong Khuong pig raised in bad 
conditions (no vaccination, insufficience of feed and nutrient unbalance ration, bad hy-
giene). Also these are result of natural selection of host against infectious environmental 
condition. Interestingly, variations of complement activities in Meishan breed were 
higher than in European breeds (Duroc, Landrace and Large White) (Komatsu et al. 
1998). Moreover, high similarity in molecular structure of the candidate genes among 
other species may open a new way to treat animals and humans with deficiency of com-
plement components even with newly designed proteins. The obtained results provide 
the means for further understanding the role of C6, C7, C8, and C9 in natural immune 
response of the host against pathogens. It also promotes the porcine C6, C7, C8, and C9 
as candidate genes in efforts to genetically improve general animal health, a goal of 
breeding programmes for food animals. The results also enrich evidence for genetic 
variation in host responses to vaccinations. The age-old principle should be regarded in 




This study aimed to characterize the porcine genes encoding the terminal components of 
the complement cascade C6, C7, C8A, C8B, C8G, and C9. Therefore the entire cDNA 
sequences were identified; SNPs were detected within candidate genes; genetic linkage 
and radiation hybrid mapping was performed; and association between SNPs and hemo-
lytic complement activity was analyzed.  
 
The cDNA sequences of the candidate genes C6, C7, C8A, C8B, C8G and C9 was iden-
tified with 3306, 3561, 2146, 2461, 840, and 2536 bp, including 144, 807, 91, 28, 51, 
and 89 bp of 5´ UTR and 354, 122, 285, 597, 180 and 815 bp of 3´ UTR region, respec-
tively. Alignment of cDNA sequences with human and porcine genomic sequences al-
lowed deducing 18, 18, 11, 12, seven, and 11 exons of the porcine candidate genes C6, 
C7, C8A, C8B, C8G and C9 encoding 935, 843, 589, 611, 202 and 543 amino acids, 
respectively. The porcine cDNA and deduced protein sequences of the candidate genes 
showed high (65-86% and 67-83%, respectively) identities with human analogues. A 
number of functional domains such as TSP1, LDLa, MACPF, EGF, CCP or FIMAC 
holding different roles in the formation of membrane attack complex (MAC) and cell 
lysis were detected.  
 
Screening the cDNA sequences using comparative sequencing revealed five, six, seven, 
nine and two single nucleotide polymorphisms (SNPs) within the candidate genes C6, 
C7, C8A, C8B and C9, respectively. These SNPs were confirmed using either PCR-
RFLP or resequencing method. There are two (240Asn ÆAsp, 471AspÆGlu), three 
(52IleÆVal, 67ThrÆMet, 294LysÆArg), two (485ArgÆCys, 528TyrÆCys), eight 
(24ProÆLeu, 65ThrÆMet, 303ThrÆGlyÆSer, 406IleÆVal, 411ProÆSer, 
449AlaÆVal, 489AlaÆVal, 590AlaÆVal), and one (106HisÆGln) SNPs with amino 
acid substitution in the porcine C6, C7, C8A, C8B and C9, respectively. No SNP was 
found in C8G among the breeds Hampshire (HS), Duroc (DR), German Landrace (LR), 
Pietrain (PIE), Berlin Miniature Pig (BMP) and Muong Khuong (MK). Most of the 
polymorphisms lie in cysteine-rich functional protein domains such as TSP1, LDLa, 
MACPF, CCP or FIMAC. These genetic variations may play an important role in the 
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structural formation and function of the protein domains and therefore may affect the 
activity of the complement components in cell lysis. 
 
The polymorphic sites 862AÆG (240Asn ÆAsp, TaqI) and 1557CÆG (471AspÆGlu, 
PstI) for C6, 154AÆG (52IleÆVal, BsrDI), 870CÆT (Hin6I) and 881AÆG 
(294LysÆArg, MboII) for C7, 535AÆG (TfiI), 1544CÆT (485ArgÆCys, Hin6I), and 
1768CÆT (524TyrÆCys, KnpI) for C8A, 222CÆT (65ThrÆMet, FnuDII), 
935AÆGÆT (303ThrÆGlyÆSer, resequencing), and 1244AÆG (406IleÆVal, MaeII) 
for C8B, 350AÆG (BsrDI) and 407CÆG (106HisÆGln, HpyCH4III) for C9 were 
genotyped using PCR-RFLP or resequencing in unrelated animals of the breeds German 
Landrace (n=30), Pietrain (n=30), and Muong Khuong (n=25). In the porcine C9 gene, 
the SNP 407CÆG shows two different genotypes GG and CG in F2 DUMI resource 
population but not in LR, PIE or MK animals. Allele `C´ maybe derived from Saddle-
back Pigs, one of the breeds used to breed Berlin Miniature Pigs. Genetic and allelic 
frequencies fit to Hardy-Weinberg equilibrium as revealed by using Chi-square test.  
 
Using 118 DNA clones of the INRA-Minnesota RH mapping panel the porcine C8A 
(LOD=7.00, 56 cR, linked close to marker SW1069), and C8B (LOD=8.18, 50 cR, 
linked close to marker SW322) were assigned to the same chromosome 6 (q3.1-q3.5), 
whereas the porcine C6 (LOD=18.13, 21 cR) and C7 (LOD=16.65, 23 cR) were linked 
to marker S0077 and C9 (LOD=14.45, 27 cR) linked to marker SW403 on the q-arm of 
chromosome 16 (q1.4). C8G (LOD=8.26, 44 cR, linked close to marker SSC10D08) 
was assigned to chromosome 1 (q2.13). Genetic mapping was performed in the DUMI 
F2 resource population using a set of previously genotyped markers. Genetic linkage 
using two-point analysis from CRIMAP 2.4 (Green et al. 1990) was confirmed between 
C7 and C6 (rec. fracs. = 0.02, LOD = 50.45), C9 and C6 (rec. fracs = 0.06, LOD = 
31.50), C9 and C7 (rec. fracs = 0.06, LOD = 35.84) on Ssc16, C8B and C8A (rec. fracs 
= 0.05, LOD = 65.72) on Ssc6.  
 
Furthermore, once the polymorphisms were established, one SNP for each candidate 
gene C6 (862AÆG), C7 (881AÆG), C8A (1544CÆT), C8B (222CÆT), and C9 
(407CÆT), was used for genotyping 417 animals of F2 DUMI resource population im-
munized with Mycoplasma (Mh), Aujeszky (ADV) and porcine reproductive and respi-
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ratory syndrome (PRRSV) vaccine. These genetic variations were used to evaluate as-
sociation with hemolytic complement activity in both the classical (CH50) and alterna-
tive pathway (AH50) for identifying potential effects on immune response ability of the 
candidate genes. Changes of CH50 and AH50 concentrations depending on genotypes 
of the candidate genes were observed prior (day 0) and after vaccinations (day 4 and 10 
for Mh and ADV but only day 10 for PRRSV vaccination). (1) For the hemolytic com-
plement activity in the classical pathway, statistically significant difference in CH50 
hemolysis was found between genotypes of the porcine C7 (p=0.0080) and C9 
(p=0.0488). Simultaneously, CH50 performance was close to significant difference be-
tween genotypes of the porcine C6 (p=0.0853) and C8A (p=0.0650). Along the vaccina-
tion program, the interaction between C8B genotypes and different immunization time 
points was found highly significant for the CH50 (p=0.0048). (2) For the hemolytic 
complement activity in the alternative pathway, although no significant differences were 
found between genotypes of the porcine candidate genes, the interactions of genotypes 
and time points in the AH50 activity were significant for C8A (p=0.0027), C8B 
(p=0.0231), and C9 (p=0.0340). (3) Also male animals always performed higher hemo-
lysis than females in both pathways. Analysis of variance also indicated significant dif-
ferences between genders. In summary, the CH50 shows the highest hemolysis value at 
the fourth day after ADV vaccination whereas the AH50 tends to increase linear during 
the experiment. Immune response in the short phases after each vaccinating was found 
in both pathways.  
 
Genetics, sex, age, kind of vaccine, interaction of complement components are major 
factors modulating to complement activation, therefore causing the lysis of target cells. 
These obtained results promote C6, C7, C8 and C9 as candidate genes in efforts to im-
prove the animal health in future. 
  
7  Zusammenfassung 
 
 
Diese Studie hatte das Ziel, porcine Gene zu charakterisieren, welche die terminalen 
Komponenten der Komplementkaskade, C6, C7, C8A, C8B, C8G und C9, kodieren. 
Dafür wurden die gesamten cDNA-Sequenzen identifiziert, SNPs wurden innerhalb von 
Kandidatengenen gesucht, `genetic linkage mapping´ und `radiation hybrid mapping´ 
wurden durchgeführt und Assoziationen zwischen den SNPs und der hämolytischen 
Komplementaktivität wurden analysiert.  
 
Die cDNA-Sequenzen der Kandidatengene C6, C7, C8A, C8B, C8G und C9 wurde i-
dentifiziert, mit 3306, 3561, 2146, 2461, 840, bzw. 2536 bp Länge, einschließlich 144, 
807, 91, 28, 51, und 89 bp Länge von der 5´ untranslatierte Region (UTR) und 354, 122, 
285, 597, 180 und 815 bp Länge der 3´ UTR. Der Vergleich der porcinen cDNA-
Sequenzen mit humanen genomischen Sequenzen erlaubte auf 18, 18, 11, 12, 7, und 11 
Exons der porcinen Kandidatengene C6, C7, C8A, C8B, C8G und C9 zu schließen, wel-
che für 935, 843, 589, 611, 202 bzw. 543 Aminosäuren kodieren. Die porcinen cDNAs 
und die abgeleiteten Proteinsequenzen der Kandidatengene zeigten hohe Homologie 
(65-86% bzw. 67-83%) mit den menschlichen Orthologen. Eine Reihe von Abschnitten 
mit Homologie zu funktionellen Domänen wie TSP1, LDLa, MACPF, EGF, CCP oder 
FIMAC wurden identifiziert, mit verschiedenen Rollen bei der Bildung von Membran-
Angriffs-Komplexen (MAC) und Zellysis.  
 
Untersuchung der cDNA-Sequenzen mit vergleichender Sequenzierung ergab, fünf, 
sechs, sieben, neun bzw. zwei Einzel-Nukleotid-Polymorphismen (SNPs) in den Kandi-
datengenen C6, C7, C8A, C8B bzw. C9. Diese SNPs wurden entweder mit Restriktions-
Fragment-Längen-Polymorphismus (PCR-RFLP) Methoden oder mit anschließender 
Resequenzierung bestätigt. Es gibt zwei (240AsnÆAsp, 471AspÆGlu), drei 
(52IleÆVal, 67ThrÆMet, 294LysÆArg), zwei (485ArgÆCys, 528TyrÆCys), acht 
(24ProÆLeu, 65ThrÆMet, 303ThrÆGlyÆSer, 406IleÆVal, 411ProÆSer, 
449AlaÆVal, 489AlaÆVal, 590AlaÆVal), oder ein (106HisÆGln) SNPs mit Amino-
säurenaustausch in den porcinen Genen C6, C7, C8A, C8B bzw. C9. Kein SNP wurde 
in C8G beim Vergleich von Individuen der Rassen Hampshire (HS), Duroc (DR), Deut-
sche Landrasse (LR), Pietrain (PIE), Berliner Miniaturschwein (BMP) und Muong 
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Khuong (MK) entdeckt. Die meisten der Polymorphismen liegen in der cysteinreichen 
funktionellen Proteindomäne wie z.B. TSP1, LDLa, MACPF, CCP oder FIMAC. Diese 
Variationen können eine wichtige Rolle für die Struktur und Funktion der Proteindomä-
nen spielen und könnten daher die Aktivität der Komplementkomponenten in der Zelly-
se beeinflussen.  
 
Die SNPs 862AÆG (240AsnÆAsp, TaqI) und 1557CÆG (471AspÆGlu, PstI) für C6, 
154AÆG (52IleÆVal, BsrDI), 870CÆT (Hin6I) und 881AÆG (294LysÆArg, MboII) 
für C7, 535AÆG (TfiI), 1544CÆT (485ArgÆCys, Hin6I), und 1768CÆT 
(524TyrÆCys, KnpI) für C8A, 222CÆT (65ThrÆMet, FnuDII), 935AÆGÆT 
(303ThrÆGlyÆSer, Resequenzierung) und 1244AÆG (406IleÆVal, MaeII) für C8B, 
350AÆG (BsrDI) und 407CÆG (106HisÆGln, HpyCH4III) für C9 wurden mittels 
PCR-RFLP oder Resequenzierung genotypisiert, in nicht verwandten Tieren der Rassen 
Deutsche Landrasse (n = 30), Pietrain (n = 30), und Muong Khuong (n = 25) und die 
Allel- und Genotyp-Frequenzen wurden geschätzt. In dem porcinen C9 segregierte der 
SNP 407CÆG mit zwei Genotypen GG und CG in der F2-Generation der DUMI-
Ressourcenpopulation, aber nicht bei LR, MK oder PIE Tieren. Das Allel `C´ könnte 
aus Sattelschweinen stammen, eine der Rassen, welche zur Züchtung der Berliner Mini-
aturschweine benutzt wurde. Die relativen Häufigkeiten der Allele und Genotypen pas-
sen zum Hardy-Weinberg-Gleichgewicht, wie mit Hilfe eines Chi-Quadrat-Tests ge-
zeigt wurde.  
 
Unter Benutzung von 118 DNA-Klonen des INRA-Minnesota RH-Mapping-Panel 
konnte das porcine C8A (LOD = 7,00, 56 cR, in der Nähe von Marker-SW1069), und 
C8B (LOD = 8,18, 50 cR, in der Nähe von Marker-SW322) auf dem Chromosom 6 
(q3.1-q3.5) lokalisisiert werden, während das porcine C6 (LOD = 18,13, 21 cR) und C7 
(LOD = 16,65, 23 cR) in der Nähe von Marker S0077 und C9 (LOD = 14,45, 27 cR) in 
der Nähe von Marker SW403 auf dem Q-Arm von Chromosom 16 (q1.4) lokalisiert 
werden konnte. C8G (LOD = 8,26, 44 cR, in der Nähe von Marker SSC10D08) wurde 
Chromosom 1 (q2.13) zugewiesen. Genetische Kartierung wurde in der DUMI F2 Res-
sourcenpopulation durchgeführt, unter Verwendung der zuvor genotypisieren Marker. 
Genkopplung konnte unter Verwendung der Zwei-Punkt-Analyse von CRIMAP 2.4 
(Green et al. 1990) zwischen C6 und C7 (rec. Fracs. = 0,02, LOD = 50,45), C6 und C9 
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(rec. Fracs = 0,06, LOD = 31,50) bzw. C9 und C7 (rec. Fracs = 0,06, LOD = 35,84) auf 
Ssc16 und C8B und C8A (rec. Fracs = 0,05, LOD = 65,72) auf Ssc6 bestätigt werden.  
 
Des Weiteren wurde, nachdem die Polymorphismen etabliert waren, ein SNP für jedes 
der Kandidatengene C6 (862AÆG), C7 (881AÆG), C8A (1544CÆT), C8B (222CÆT) 
bzw. C9 (407CÆT) für die Genotypisierung von 417 Tieren der F2 DUMI Ressourcen-
population benutzt, welche mit Mycoplasma- (Mh), Aujeszky- (ADV) und dem `Porci-
nen Reproduktiven und Respiratorischen Syndrom´- (PRRSV) -Impfstoff immunisiert 
worden waren. Um potenzielle Auswirkungen auf die Immunantwort durch die Kandi-
datengene zu identifizieren, wurde der Zusammenhang zwischen der hämolytischen 
Komplementaktivität mit dem klassischen Stoffwechselweg (CH50) als auch mit dem 
alternativen Stoffwechselweg (AH50) und der genetischen Variation an den Kandida-
tengenen untersucht. Änderungen der CH50 und AH50 in Abhängigkeit von Genotypen 
der Kandidatengene waren vor der Impfung (Tag 0) und nach der Impfung (Tag 4 und 
Tag 10 bei Mh und ADV, aber nur Tag 10 bei PRRSV) beobachtet worden. (1) Für die 
hämolytische Komplementaktivität im klassischen Reaktionsweg CH50 wurde ein sta-
tistisch signifikanter Unterschied zwischen Genotypen des porcinen C7 (p = 0,0080) 
und C9 (p = 0,0488) entdeckt. Effekte auf die CH50 waren statistisch nicht abzusichern 
für C6 (p = 0,0853) und C8A (p = 0,0650). Die Interaktion zwischen C8B-Genotypen 
und Messzeitpunkten für CH50 vor und nach Immunisierung war hochsignifikant (p = 
0,0048). (2) Für die hämolytische Komplementaktivität beim alternativen Reaktionsweg 
(AH50) waren die Wechselwirkungen von Genotypen und Zeitpunkten in der AH50-
Aktivität für C8A (p = 0,0027), C8B (p = 0,0231 ), bzw. C9 (p = 0,0340) signifikant. (3) 
Dazu zeigten männliche Tiere immer höhere Hämolyse im Vergleich zu weiblichen in 
beiden Stoffwechselwegen. Die Analyse der Varianz wies außerdem auf signifikante 
Unterschiede zwischen den Geschlechtern hin. Zusammenfassend lässt sich sagen, dass 
die CH50 Hämolyse den höchsten Wert am vierten Tage nach der ADV-Impfung zeigt, 
während der AH50 tendenziell zu einer linearen Zunahme während des Experimentes 
neigt. Immunreaktionen in der kurzen Phase nach jeder Impfung wurde in beide Stoff-
wechselwegen beobachtet.  
 
Die Genetik, das Geschlecht, die Art des Impfstoffs und die Interaktion der Komple-
mentkomponenten sind wichtige Faktoren, die das Komplementsystem modulieren, und 
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dadurch die Lyse von Zielzellen hervorrufen. Die erzielten Ergebnisse lassen darauf 
schließen, dass C6, C7, C8 und C9 Kandidatengene sind, um die Tiergesundheit in der 
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Hereafter, the primer sequences followed by TI number, name and mate information 
collected from the pig genome sequencing project accessible via the Trace Archive tool 
(NCBI homepage) are given in table 21, 22, 23, 24, 25, and 26. 
 
Table 21 Position and length of predicted porcine C8A exons 
 
Description Source  
  
Exon 1: nt. 5´UTR-171 Based on start of exon 2 
Exon 2: nt. 172-271 (100 bp) ti: 862132317; name:rdpaxb0_150586.y1; ma-
te:815435067 
Exon 3: nt. 272-416 (145 bp) ti: 863184494; name:rdpaxb0_077985.y1; ma-
te:854478286 
Exon 4: nt. 417-564 (148 bp) ti: 852982643; name:cpg0_164359.z1 
mate:815846657 
Exon 5: nt. 565-754 (190 bp) Based on end of exon 4 and start of exon 6 
Exon 6: nt. 755-955 (201 bp) ti: 1420494233; name:ss_WGS-24b13.p1k; 
mate:1420494234 
Exon 7: nt. 956-1196 (241 bp) ti: 1420494234; name:ss_WGS-24b13.q1k; 
mate:1420494233 
Exon 8: nt. 1197-1328 (132 bp) Based on end of exon 7 and start of exon 9 
Exon 9: nt. 1329-1486 (158 bp) ti: 1420545232; name:SS_WGS-667o09.q1k; 
mate:1420545231 
Exon 10: nt. 1487-1709 (223 bp) Based on end of exon 9 and start of exon 11 






Table 22  Position and length of predicted porcine C6 exons  
 
Description Source  
Exon 1: nt. 15 (5´UTR)-121 ti:1008570313; name:DurocWGS_20549_B01.b; 
mate:1008570314 
Exon 2: nt. 122-287 (166bp) ti: 812320666; name: rcpg0_152426.y1 ; 
mate: 858788103 
Exon 3: nt. 288-444 (157 bp) ti:1008617751; name:DurocWGS_20796_C15.b ; 
mate:1008617752 
Exon 4: nt. 445-589 (145 bp) ti: 815809106; name: byc_44258.z1;  
mate: 812837595 
Exon 5: nt. 590-731 (142 bp) ti: 808385472; name: dpcxb0_315815.z1;  
mate: 810707950 
Exon 6: nt. 732-870 (139 bp) ti: 1373546263; name: rplun0101_g6.y1 
Exon 7: nt. 871-1071 (201 bp) ti: 857624103; name: rbde_60509.y1; 
mate: 861251703 
Exon 8: nt. 1072-1312 (241 bp) ti: 1420614517; name: SS_WGS-857e09.p1k; 
mate:1420614518 
Exon 9: nt. 1313-1435 (123 bp) ti: 1420666160; name: SS_WGS-513i21.p1k  
mate:1420666161 
Exon 10: nt. 1438-1602 (167 bp) ti: 1420506449; name: SS_WGS-957p20.q1k; 
mate:1420506448 
Exon 11: nt. 1603-1828 (226 bp) ti: 1420506448 ; name: SS_WGS-957p20.p1k; 
mate:1420506449 
Exon 12: nt. 1829-2000 (172 bp) Based on end of exon 11 and start of exon 13 
Exon 13: nt. 2001-2112 (112 bp) ti: 821008954; name: rdpaxb0_030576.y1; 
mate:854483952 
Exon 14: nt. 2113-2245 (134 bp) ti: 847766479; name: rbdd_56378.y1; 
mate:768215414 
Exon 15: nt. 2246-2434 (188 bp) ti: 768215414; name: bdd_56378.z1; mate: 
847766479 
Exon 16: nt. 2435-2525 (91 bp) ti: 774040088; name: bdc_90777.z1; 
mate:823852002 
Exon 17: nt. 2526-2766 (242 bp) Based on human genomic C6 sequence 




Table 23 Position and length of predicted porcine C7 exons 
 
Description Source  
  
Exon 1: nt. -91 (5´UTR)-6 (96 bp) Based on human genomic C7 sequence and 
ti: 848892623; name:rdpaxb0_005371.y1; 
mate:854561309 
Exon 2: nt. 7-62 (56bp) ti: 774255673 name:rbda_68237.y1 
Exon 3: nt. 63-138 (76 bp) ti: 862200672; name:dpcxb0_048413.z1; ma-
te:808192830 
Exon 4: nt. 139-280 (142 bp) ti: 848149583 ; name:bd_52849.z1; 
mate:863305860 
Exon 5: nt. 281-428 (148 bp) ti: 862214178; name:dpcxb0_129835.z1; 
mate:808226750 
Exon 6: nt. 429-567 (139 bp) Based on end of exon 5 and start of exon 7 
Exon 7: nt. 568-738 (171 bp) ti: 1420727546; name:SS_WGS-599c18.p1k; 
mate:1420727547 
Exon 8: nt. 739-982 (244 bp) ti: 848447315; name:rbdb_77708.y1; 
mate:776645100 
Exon 9: nt. 983-1093 (111 bp) ti: 815376779 name:rdpaxb0_028437.y1 
mate:857329704 
Exon 10: nt. 1094-1260 (167 bp) ti: 1420836647 ; name:SS_WGS-971f04.q1k 
mate:1420836646 
Exon 11: nt. 1261-1489 (229 bp) ti: 842736254; name:rbdf_90630.y1; 
mate:769812863 
Exon 12: nt. 1490-1661 (172 bp) ti: 311627814; name:bE40H18T7; 
mate:311627813 
Exon 13: nt. 1662-1749 (88 bp) ti: 853061954; name:rbdg_17201.y1; 
mate:776550611 
Exon 14: nt. 1750-1882 (133 bp) ti: 1420455996; name:SS_WGS-658h03.p1k; 
mate:1420455997 
Exon 15: nt. 1883-2074 (192 bp) ti: 854810180; name:rdpaxb0_227330.y1 
Exon 16: nt. 2075-2165 (91 bp) ti: 1657934248; name: DurocWGS_30149_C10.b 
mate:1657934249 
Exon 17: nt. 2166-2350 (185 bp) ti: 863233311; name:rdpbxa0_029753.y1 
mate:808444829 





Table 24 Position and length of predicted porcine C8B exons 
 
Description Source  
Exon 1: nt. 5´UTR-156 Based on start of exon 2 
Exon 2: nt. 157-313 (157 bp) ti: 1420204053; name:SS_WGS-413k10.q1k; 
mate:1420204052 
Exon 3: nt. 314-455 (142 bp) ti: 823797500; name:bdf_14280.z1; 
mate:847963640 
Exon 4: nt. 456-597 (142 bp) Based on end of exon 3 and start of exon 5 
Exon 5: nt. 598-730 (133 bp) ti: 781569495; name:rbyb_35660.y1; 
mate:812924227 
Exon 6: nt. 731-928 (198 bp) Based on end of exon 5 and start of exon 7 
Exon 7: nt. 929-1169 (241 bp) ti: 857822592; name:rdpbxa0_158567.y1; 
mate:853343914 
Exon 8: nt. 1170-1298 (129 bp) Based on end of exon 7 and start of exon 9 
Exon 9: nt. 1299-1462 (164 bp) ti: 1420654355; name:SS_WGS-860j08.p1k; 
mate:1420654356 
Exon 10: nt. 1462-1616 (154 bp) ti: 860428303; name:rbye_44037.y1 
Exon 11: nt. 1617-1684 (68 bp) Based on human genomic C8B sequence 
Exon 12 : nt. 1685-3´ UTR Based on human genomic C8B sequence 
 
 
Table 25 Position and length of predicted porcine C8G exons 
 
Description Source  
Exon 1: nt. 50 (5´UTR)-189 (140bp) Based on human genomic C8G sequence 
and GenBank acc. no AK233484 
Exon 2: nt. 190-326 (137 bp) Based on GenBank acc. no AK233484 
Exon 3: nt. 327-397 (71 bp) Based on GenBank acc. no AK233484 
Exon 4: nt. 398-505 (108 bp) Based on GenBank acc. no AK233484 
Exon 5: nt. 506-607 (102 bp) Based on GenBank acc. no AK233484 
and human genomic C8G sequence 
Exon 6: nt. 608-646 (39 bp) Based on human genomic C8G sequence 




Table 26 Position and length of predicted porcine C9 exons 
 
Description Source  
Exon 1: 5´UTR-166 Based on human genomic C9 sequence 
Exon 2: nt. 167-272 (106 bp) Based on human genomic C9 sequence and start of 
exon 3 
Exon 3: nt. 273-417 (145 bp) ti: 1382154540; name:DurocWGS_21175_M13.g; 
mate:1382154539 
Exon 4: nt. 418-565 (148 bp) ti: 1382154540; name:DurocWGS_21175_M13.g; 
mate:1382154539 
Exon 5: nt. 566-704 (139 bp) ti: 311779440; name:bT60L15SP6; 
mate:311779441 
Exon 6: nt. 705-971 (267 bp) ti: 863194696; name:cpg0_070876.z1; 
mate:811045924 
 
Exon 7: nt. 972-1212 (241 bp) ti: 767686602; name:DurocWGS_20407_A01.g; 
mate:767686601 
Exon 8: nt. 1213-1338 (126 bp) ti: 784826320 name:dpcxb0_271689.z1;   
mate:766131427 
Exon 9: nt. 1339-1517 (179bp) ti: 767686601; name:DurocWGS_20407_A01.b; 
mate:767686602 
Exon 10: nt. 1518- 1747 
              (3´UTR) (230 bp) 
ti: 854554002; name:rdpcxb0_001135.y1; ma-
te:853317835 
Exon 11: nt. 1748-3´UTR Based on end of exon 10 
 
Table 27  Least squares means of the classical complement hemolytic activity for the 
interaction of different genotypes x time point in porcine C6 gene 
(LSM±SE) (U/ml) 
Vaccination Blood sampling AA  AG  GG  
Mycoplasma 1 45.87±9.32 48.44±3.87 53.57±3.78 
 2 42.99±10.03 56.03±3.99 61.52±3.87 
 3 51.46±11.02 53.92±4.15 62.28±3.99 
Aujeszky 4 62.43±11.63 68.50±4.20 76.68±4.04 
 5 83.05±12.00 79.24±4.29 82.21±4.12 
 6 76.70±12.63 67.72±4.40 75.51±4.16 
PRRSV 7 52.92±12.73 73.90±4.12 76.27±3.92 




Table 28  Least squares means of the classical complement hemolytic activity for the 
interaction of different genotypes x time point in porcine C7 gene 
(LSM±SE) (U/ml) 
Vaccination Blood sampling AA  AG  GG  
Mycoplasma 1 52.89±4.08 49.87±4.08 45.21±10.28 
 2 60.58±4.19 59.95±4.28 43.85±10.94 
 3 62.35±4.32 56.90±4.42 51.17±11.86 
Aujeszky 4 77.88±4.45 73.05±4.52 25.44±14.28 
 5 85.61±4.45 81.13±4.54 55.65±13.48 
 6 75.47±4.48 70.08±4.65 39.86±13.72 
PRRSV 7 74.46±4.25 75.80±4.36 51.32±13.49 
 8 72.93±4.42 74.99±4.55 40.56±13.53 
 
Table 29 Least squares means of the classical complement hemolytic activity for the 
interaction of different genotypes x time point in porcine C8A gene 
(LSM±SE) (U/ml) 
Vaccination Blood sampling CC  CT  TT  
Mycoplasma 1 49.51±4.67 45.41±4.01 52.96±3.72 
 2 50.95±5.14 52.89±4.10 62.38±3.89 
 3 50.39±5.34 51.94±5.26 62.59±4.02 
Aujeszky 4 62.06±5.49 71.76±4.30 71.94±4.15 
 5 70.59±5.67 81.61±4.37 80.35±4.17 
 6 63.46±6.13 69.25±4.49 71.91±4.23 
PRRSV 7 62.51±5.66 74.86±4.23 73.00±4.03 
 8 66.11±5.80 72.91±4.43 70.78±4.19 
 
Table 30 Least squares means of the classical complement hemolytic activity for the 
interaction of different genotypes x time point in porcine C8B gene 
(LSM±SE) (U/ml) 
Vaccination Blood sampling CC CT TT 
Mycoplasma 1 51.54±3.45 42.83±4.02 52.53±5.69 
 2 59.06±3.65 50.36±4.14 57.16±6.51 
 3 59.91±3.75 46.65±4.27 60.38±6.73 
Aujeszky 4 67.91±3.86 70.00±4.25 69.52±6.80 
 5 76.15±3.89 79.06±4.33 79.04±7.05 
 6 69.27±3.95 65.79±4.47 74.13±7.66 
PRRSV 7 71.98±3.73 70.64±4.20 59.09±6.77 




Table 31 Least squares means of the classical complement hemolytic activity for the 
interaction of different genotypes x time point in porcine C9 gene 
(LSM±SE) (U/ml) 
Vaccination Blood sampling CG  GG  
Mycoplasma 1 47.62±4.31 52.66±3.55 
 2 56.91±4.45 59.36±3.63 
 3 52.23±4.64 61.18±3.74 
Aujeszky 4 63.73±4.63 77.24±3.79 
 5 78.12±4.72 83.09±3.85 
 6 67.60±4.85 73.92±3.91 
PRRSV 7 71.48±4.53 74.96±3.70 
 8 71.03±4.82 73.51±3.87 
 
 
Table 32  Least squares means of the alternative complement hemolytic activity for the 
interaction of different genotypes x time point in porcine C6 gene 
(LSM±SE) (U/ml) 
Vaccination Blood sampling AA  AG  GG  
Mycoplasma 1 56.27±11.86 51.75±3.77 54.02±3.44 
 2 37.72±11.31 53.66±3.64 48.00±3.30 
 3 54.11±10.58 56.15±3.48 50.58±3.18 
Aujeszky 4 65.60±10.31 56.89±3.44 61.07±3.20 
 5 86.65±11.56 64.69±3.60 62.17±3.30 
 6 76.79±15.87 67.59±4.57 71.59±4.05 
PRRSV 7 81.87±12.75 71.72±4.07 72.94±3.67 
 8 76.54±12.91 71.59±4.06 70.88±3.67 
 
Table 33 Least squares means of the alternative complement hemolytic activity for the 
interaction of different genotypes x time point in porcine C7 gene 
(LSM±SE) (U/ml) 
Vaccination Blood sampling AA  AG  GG  
Mycoplasma 1 53.56±3.64 51.37±3.94 49.71±13.31 
 2 47.80±3.55 52.67±3.86 37.21±12.95 
 3 50.87±3.36 56.71±3.64 50.22±11.88 
Aujeszky 4 62.33±3.46 56.65±3.66 61.58±12.75 
 5 63.27±3.53 65.03±3.81 72.53±13.24 
 6 70.35±4.16 67.84±4.62 72.27±16.98 
PRRSV 7 69.51±3.64 70.55±3.99 58.73±13.99 




Table 34  Least squares means of the alternative complement hemolytic activity for the 
interaction of different genotypes x time point in porcine C8A gene 
(LSM±SE) (U/ml) 
Vaccination Blood sampling CC  CT  TT  
Mycoplasma 1 51.29±5.18 50.06±3.81 54.09±3.45 
 2 40.85±4.97 45.31±3.68 54.56±3.35 
 3 58.62±4.80 46.60±3.54 54.48±3.16 
Aujeszky 4 56.99±4.80 59.39±3.52 57.46±3.23 
 5 58.74±5.11 63.67±3.59 64.57±3.40 
 6 83.69±7.34 69.07±4.65 66.50±4.42 
PRRSV 7 79.50±6.04 76.56±4.15 66.02±3.81 
 8 65.87±5.90 74.42±4.06 69.50±3.74 
 
 
Table 35  Least squares means of the alternative complement hemolytic activity for the 
interaction of different genotypes x time point in porcine C8B gene 
(LSM±SE) (U/ml) 
Vaccination Blood sampling CC CT TT 
Mycoplasma 1 54.90±3.45 49.80±3.76 54.52±6.08 
 2 53.29±3.27 44.56±3.57 47.81±5.66 
 3 54.46±3.09 46.60±3.46 64.73±5.42 
Aujeszky 4 56.44±3.11 56.14±3.40 64.55±5.56 
 5 64.67±3.30 62.88±3.52 59.53±5.86 
 6 67.96±4.24 70.97±4.48 79.46±8.53 
PRRSV 7 66.59±3.71 78.58±4.03 73.83±7.01 
 8 69.37±3.66 72.82±3.96 67.47±6.95 
 
Table 36  Least squares means of the alternative complement hemolytic activity for the 
interaction of different genotypes x time point in porcine C9 gene 
(LSM±SE) (U/ml) 
Vaccination Blood sampling CG GG 
Mycoplasma 1 52.52±4.32 53.72±3.21 
 2 56.08±4.08 47.81±3.10 
 3 56.19±3.96 51.98±2.98 
Aujeszky 4 53.81±3.90 62.66±2.97 
 5 67.46±4.15 63.00±3.12 
 6 71.90±5.25 68.71±3.76 
PRRSV 7 72.70±4.63 71.66±3.46 





C6 seq                  agcttctgg    9 
C6 seq agcaggtacagaaggaaaaaataagaaataaaagattcaaaatat   54 
C6 seq ttacaagaagatggaaaggaggatcctacagttgggaacaaacta   99 
C6 seq gagaatcttctgaacctgccaggatctggagactctccaggcatg  144 
 
C6 seq atggacaaacactctgtcttgtattttatcttgctgagtggtctg  189 
C6 A.A M  D  K  H  S  V  L  Y  F  I  L  L  S  G  L     15 
C6 seq attgacaagagccaagcctgtttctgtgatcactacccatggact  234 
C6 A.A I  D  K  S  Q  A  C  F  C  D  H  Y  P  W  T     30 
C6 seq cagtggtccagctgctcaaaaacctgtaattctggaacccagacc  279 
C6 A.A Q  W  S  S  C  S  K  T  C  N  S  G  T  Q  T     45 
C6 seq agacagagacaaattactataaatcagtactatcttgacaacttt  324 
C6 A.A R  Q  R  Q  I  T  I  N  Q  Y  Y  L  D  N  F     60 
C6 seq tgtgaccggctttgcaccaagcaggagaccagagaatgtaactgg  369 
C6 A.A C  D  R  L  C  T  K  Q  E  T  R  E  C  N  W     75 
C6 seq caaacttgtcctatcaattgcctcctgggagattatggaccatgg  414 
C6 A.A Q  T  C  P  I  N  C  L  L  G  D  Y  G  P  W     90 
C6 seq tcagattgtgacccttgtgttgaaaaacagtttaaggttaggtcc  459 
C6 A.A S  D  C  D  P  C  V  E  K  Q  F  K  V  R  S    105 
C6 seq atcttgcgccccaatcagtttggaggacaaccatgtactgagcca  504 
C6 A.A I  L  R  P  N  Q  F  G  G  Q  P  C  T  E  P    120 
C6 seq ctcatgacctttcgaccatgtattccatctaaactctgcaaaatt  549 
C6 A.A L  M  T  F  R  P  C  I  P  S  K  L  C  K  I    135 
C6 seq gaagaggttgactgcaagaataaattccgctgtgacagtggtcgc  594 
C6 A.A E  E  V  D  C  K  N  K  F  R  C  D  S  G  R    150 
C6 seq tgcattgccagcaagttggaatgcaatggagaaaatgattgtgga  639 
C6 A.A C  I  A  S  K  L  E  C  N  G  E  N  D  C  G    165 
C6 seq gacaattcggatgagaggaattgtgggagaacaaaagcagtatgc  684 
C6 A.A D  N  S  D  E  R  N  C  G  R  T  K  A  V  C    180 
 
Figure 40  Nucleotide and predicted protein sequence of the porcine C6 gene. 
Nucleotide and amino acids are enumberated on the right side. The 
numbering of the nucleotide sequence starts with the first base of 
GenBank acc. no BP445061 and ends with the last base of Gen-
Bank acc. no BQ598214. The 5´flanking region contains 144 nu-
cleotides (nt.  1-144). The start codon (ATG) is in the first bold 
box (nt.  145-147). The porcine boundaries between exons are in 
bold and underline. Positions of polymorphism present in shade 
blocks with white bold font. Cysteine residues are in underline. 
The open reading frame is terminated by a TGA stop codon in the 
second bold box (nt.  2950-2952). The 3´UTR (nt.  2953-3306) 
contains the putative polyadenylation signal aataaa (nt.  3240-






 C6 seq tcacggaagtataatcccatccctagtgtacagttgatgggcgct  729 
C6 A.A S  R  K  Y  N  P  I  P  S  V  Q  L  M  G  A    195 
C6 seq gggtttcatattctggcaggagagcccagaggagaagtcctaggt  774 
C6 A.A G  F  H  I  L  A  G  E  P  R  G  E  V  L  G    210 
C6 seq aattctttcactggaggaatatgtaaaaccgtcaaaagcagtaaa  819 
C6 A.A N  S  F  T  G  G  I  C  K  T  V  K  S  S  K    225 
C6 seq gccagtaatccatttcgtgttccagccaatctagaaaacgtcaac  864 
C6 A.A A  S  N  P  F  R  V  P  A  N  L  E  N  V  N    240 
C6 seq tttgaggtacaaactaaagaagatgattttcaaacagatttctat  909 
C6 A.A F  E  V  Q  T  K  E  D  D  F  Q  T  D  F  Y    255 
C6 seq gaggatttaattcctcttgaaaatagtaaagatcaacaagccaca  954 
C6 A.A E  D  L  I  P  L  E  N  S  K  D  Q  Q  A  T    270 
C6 seq ggtttcggccaagagaagagctcttttcatgtaccaattttttat  999 
C6 A.A G  F  G  Q  E  K  S  S  F  H  V  P  I  F  Y    285 
C6 seq tcctcaaagaaaagccaaaccagcagccataattctgccttcaaa 1044 
C6 A.A S  S  K  K  S  Q  T  S  S  H  N  S  A  F  K    300 
C6 seq caagctattcaagcctcccacaaaaaggattccagttttattagg 1089 
C6 A.A Q  A  I  Q  A  S  H  K  K  D  S  S  F  I  R    315 
C6 seq atccataaagtgataaaagtcttaaacttcacaatgaaaactaaa 1134 
C6 A.A I  H  K  V  I  K  V  L  N  F  T  M  K  T  K    330 
C6 seq gatttgcagctttctgacgtctttttgaaagcacttaaccatctg 1179 
C6 A.A D  L  Q  L  S  D  V  F  L  K  A  L  N  H  L    345 
C6 seq cctctagaatacaacgctgctttgtacagccggatatttgatgat 1224 
C6 A.A P  L  E  Y  N  A  A  L  Y  S  R  I  F  D  D    360 
C6 seq tttgggactcactatttcacctctggctccctgggaggcgtgtac 1269 
C6 A.A F  G  T  H  Y  F  T  S  G  S  L  G  G  V  Y    375 
C6 seq gaccttctctatcagtttagcaatgaggaactgaagaactcaggt 1314 
C6 A.A D  L  L  Y  Q  F  S  N  E  E  L  K  N  S  G    390 
C6 seq ttaacacaggaagaagccaaaaactgtatccggattgaaacaaag 1359 
C6 A.A L  T  Q  E  E  A  K  N  C  I  R  I  E  T  K    405 
C6 seq aaacgttattttatagttacaaaaacaaaggtggaacaccggtgc 1404 
C6 A.A K  R  Y  F  I  V  T  K  T  K  V  E  H  R  C    420 
C6 seq accactaacaggatgtccgagaaatacgaaggttcctttttgcaa 1449 
C6 A.A T  T  N  R  M  S  E  K  Y  E  G  S  F  L  Q    435 
C6 seq ggatcagagaaatccatatccctggttaaaggtggaagaagtgag 1494 
C6 A.A G  S  E  K  S  I  S  L  V  K  G  G  R  S  E    450 
C6 seq tatgcagcggctttggcatgggagaaagggagttctggcccagga 1539 
C6 A.A Y  A  A  A  L  A  W  E  K  G  S  S  G  P  G    465 
C6 seq gagaagacatattctgactggttggaatcagtgaaggaaaatcct 1584 
C6 A.A E  K  T  Y  S  D  W  L  E  S  V  K  E  N  P    480 
C6 seq gctgtgattgactttgagcttgctcccatcacagacttggtaaga 1629 
C6 A.A A  V  I  D  F  E  L  A  P  I  T  D  L  V  R    495 
C6 seq aacatcccctgtgcggtgacaagacggaacaacctcaggagagct 1674 
C6 A.A N  I  P  C  A  V  T  R  R  N  N  L  R  R  A    510 
C6 seq ttccgagaatacgcagccaaatttgacccttgccagtgtgctccg 1719 
C6 A.A F  R  E  Y  A  A  K  F  D  P  C  Q  C  A  P    525 
C6 seq tgccccaacaacggccgccctgtgctctcagggaccgaatgtcta 1764 
C6 A.A C  P  N  N  G  R  P  V  L  S  G  T  E  C  L    540 
C6 seq tgtgtgtgccagagcggcacctacggtgacaactgtgagaggcgt 1809 
C6 A.A C  V  C  Q  S  G  T  Y  G  D  N  C  E  R  R    555 
 




C6 seq gccccggattacaaatctaatgccgtagatgggaactggggctgc 1854 
C6 A.A A  P  D  Y  K  S  N  A  V  D  G  N  W  G  C    570 
C6 seq tggtcttcctggagcacatgtgacgctacgtacaagagatcaagg 1899 
C6 A.A W  S  S  W  S  T  C  D  A  T  Y  K  R  S  R    585 
C6 seq acccgagaatgcaacaaccctgccccccggcaaggagggaaaccc 1944 
C6 A.A T  R  E  C  N  N  P  A  P  R  Q  G  G  K  P    600 
C6 seq tgcgacggggagaggcggcaggaggaacactgcacattctccata 1989 
C6 A.A C  D  G  E  R  R  Q  E  E  H  C  T  F  S  I    615 
C6 seq atgcagaacactggacagccatgcatcggtgatgatgaggacatg 2034 
C6 A.A M  Q  N  T  G  Q  P  C  I  G  D  D  E  D  M    630 
C6 seq aaagaaatagaccttcctgaaatagaatcagattcagggtgtcct 2079 
C6 A.A K  E  I  D  L  P  E  I  E  S  D  S  G  C  P    645 
C6 seq caaccagtccctccagaaaatggatttattcggaatgaaaagaca 2124 
C6 A.A Q  P  V  P  P  E  N  G  F  I  R  N  E  K  T    660 
C6 seq ctgtattcagttggggaagatgttgaaattgtatgccttactgga 2169 
C6 A.A L  Y  S  V  G  E  D  V  E  I  V  C  L  T  G    675 
C6 seq ttcaaaactgttggctaccagtacttcagatgcttacctgacaga 2214 
C6 A.A F  K  T  V  G  Y  Q  Y  F  R  C 
C6 seq acctggaggcgaggagatgtggaatgccag
 L  P  D  R    690 
cggactgactgcctc 2259 
C6 A.A T  W  R  R  G  D  V  E  C  Q  R  T  D  C  L    705 
C6 seq ttgccagtggtgccagaagtactgaaactgtcaccatttcagaga 2304 
C6 A.A L  P  V  V  P  E  V  L  K  L  S  P  F  Q  R    720 
C6 seq ttgtataaaattggtgactccattgagctaagctgtcccaaaggc 2349 
C6 A.A L  Y  K  I  G  D  S  I  E  L  S  C  P  K  G    735 
C6 seq tttgtcattgctgggccatcgaggtacacatgcagtggggattcc 2394 
C6 A.A F  V  I  A  G  P  S  R  Y  T  C  S  G  D  S    750 
C6 seq tggacaccacccatctcaagctcactcacctgtgaacaagatttt 2439 
C6 A.A W  T  P  P  I  S  S  S  L  T  C  E  Q  D  F    765 
C6 seq ctgacacgcttaaagggccattgtcaaccaggacaaaaacagttg 2484 
C6 A.A L  T  R  L  K  G  H  C  Q  P  G  Q  K  Q  L    780 
C6 seq ggatctgaatgtgtttgcctgtctccagaagaagactgcagccat 2529 
C6 A.A G  S  E  C  V  C  L  S  P  E  E  D  C  S  H    795 
C6 seq cattcagaagatctctgtgtgcttgatacagactccaatcattac 2574 
C6 A.A H  S  E  D  L  C  V  L  D  T  D  S  N  H  Y    810 
C6 seq tttacttcatccgcttgtaagtttttggctgagaaatgtttaaat 2619 
C6 A.A F  T  S  S  A  C  K  F  L  A  E  K  C  L  N    825 
C6 seq aatcagcaactccaatttctacatattggttcgtgccaagatggt 2664 
C6 A.A N  Q  Q  L  Q  F  L  H  I  G  S  C  Q  D  G    840 
C6 seq ccacagttggaatggggtcttgaaaggataaaactttcatccagt 2709 
C6 A.A P  Q  L  E  W  G  L  E  R  I  K  L  S  S  S    855 
C6 seq agcacaaagaatgaatcctgtggctatgatacctgctacagctgg 2754 
C6 A.A S  T  K  N  E  S  C  G  Y  D  T  C  Y  S  W    870 
C6 seq gaaaaatgttcagccaccacctccaagtgcatctgcctactgccc 2799 
C6 A.A E  K  C  S  A  T  T  S  K  C  I  C  L  L  P    885 
C6 seq ttccagtgtttgaagggtggataccaacactactgcgtcaaaatg 2844 
C6 A.A F  Q  C  L  K  G  G  Y  Q  H  Y  C  V  K  M    900 
C6 seq ggatcatcaacgaccacaagaaccatgaacatctgtgaagtagga 2889 
C6 A.A G  S  S  T  T  T  R  T  M  N  I  C  E  V  G    915 
C6 seq gccataagatgtgccctcaggaaaatggaaatactttatcctggg 2934 
C6 A.A A  I  R  C  A  L  R  K  M  E  I  L  Y  P  G    930 
C6 seq agatgtaggtctaactga 2952    
C6 A.A R  C  R  S  N  *    935 
 




C6 seq aatcttgataaacagatttactgtccaaaaataatccctacagag 2997 
C6 seq atgctcttgtataaacagcagactgccacatccaggagttactaa 3042 
C6 seq cataaattcttttgtgttagtttcatgtaattattctccctgcct 3087 
C6 seq cttgtgtcttctcctctatccaattctagtccacacccctaggta 3132 
C6 seq ataactttcacatcagtctagtaaattattctgttcatgtggcac 3177 
C6 seq taaaatgatggcacttctaatgaccttatgaagtacaaaaacctt 3222 
C6 seq aatttcttcaatgaatcaataaacatagaagtctcgaactgctta 3267 
C6 seq tcaaatacattcttgaaactgaaaaaaaaaaaaaaaaaa 3306 
 
Figure 40  (continued)  
 
 
     -
C7 seq aggaagagaaaatggacagggataatgactgtgacaagaacttcc -720 
806 catggaaaatgaggctctggcaaaaaaaagacaaggcaactg -765 
C7 seq caaaagagagatctgaatggcataggattaagggaagttcttggg -675  
C7 seq aaaattagtgatgcctttaaatatgtttgctaaaaatgatgctct -630 
C7 seq ttttgatcattctgtgaaagtccgacgtgaagggatgcttattat -585 
C7 seq gttgtgttaggctatctctgtatattctggggggattccactcca -540 
C7 seq gaatgttccacttacattttgggtaactgaactgcgtttgaattt -495 
C7 seq ttttcctccacaaagcgtttaatctcaaaggctgttgtataacac -450 
C7 seq ccatttagagaatcatgaaaacatccacttagtacagtagatcga -405 
C7 seq aggaggcttatcccttgccttacacagtctccttgggttgaaatc -360 
C7 seq acttaaacattgaagtgagaacatttgctgcctttcttgatttat -315 
C7 seq agatgtttttcttagaactacatttccaaacagtcccagctggct -270 
C7 seq gtagctaaggcctgtgtaaattgataagatgcatttggcttcaag -225  
C7 seq acacagactaagtacagggcagactcctggtgtccccagagaact -180 
C7 seq ccgttggggtagaagcagcatctcggaactgcttgctctatatat -135 
C7 seq gagtgccaagttaatccccagcagGgagggacaggcaaggaacag  -90 
C7 seq actgttgggctcttcctgctgctgaaaattcactgggcactggag  -45 
C7 seq gaggaaatctaccttcactcttctgccctgaatgttttcccaaac    0 
 
Figure 41  Nucleotide and predicted protein sequence of the porcine C7 gene. 
Nucleotide and amino acids are enumberated on the right side. The 
numbering of the nucleotide sequence starts with the first base of 
trace_name:dpcxa 0_039446.z1, ti: 784743778 and ends with the last 
base of GenBank acc. no CF176130.1. The start codon (ATG) is in 
the first bold box (nt.  1-3). The porcine boundaries between exons 
are in bold and underline. Positions of polymorphism present in 
shade blocks with white bold font. Cysteine residues are in underline. 
Transription start site (G) is in uppercase and bold at position –110. 
The open reading frame is terminated by a TAG stop codon in the 
second bold box (nt.  2530-2532). The downstream noncoding region 
contains further termination codons but does not include a polyade-




C7 seq atgaaggcaatgagtttagtcttcttggtgggacttataggagag   45 
C7 A.A M  K  A  M  S  L  V  F  L  V  G  L  I  G  E     15 
C7 seq ttccaagttttttcaagtgcctcctctcctgtcaattgtcagtgg   90 
C7 A.A F  Q  V  F  S  S  A  S  S  P  V  N  C  Q  W     30 
C7 seq gattcctatgctccttggtcagaatgcaatggttgtaccaagact  135  
C7 A.A D  S  Y  A  P  W  S  E  C  N  G  C  T  K  T     45 
C7 seq cagactcgcaggagacccgttgctgtttatgggcagtatggcggg  180 
C7 A.A Q  T  R  R  R  P  V  A  V  Y  G  Q  Y  G  G     60 
C7 seq catccctgtgtcggaagtacgtttgaaacacaatcatgtgaacct  225 
C7 A.A H  P  C  V  G  S  T  F  E  T  Q  S  C  E  P     75 
C7 seq acacgaggatgtccaacagaagaagggtgtggagagcgtttcaga  270 
C7 A.A T  R  G  C  P  T  E  E  G  C  G  E  R  F  R     90 
C7 seq tgtttttcaggtcagtgcatcagcaaatctttggtttgcaacggg  315 
C7 A.A C  F  S  G  Q  C  I  S  K  S  L  V  C  N  G    105 
C7 seq gattctgactgtgaagaagacagtgctgatgaagaccggtgtgag  360 
C7 A.A D  S  D  C  E  E  D  S  A  D  E  D  R  C  E    120 
C7 seq gactcagaaagcagaccttcctgtgacctcagtaaacctcctccc  405 
C7 A.A D  S  E  S  R  P  S  C  
C7 seq aacatagaacttactggaaatg
D  L  S  K  P  P  P    135 
gttacaatgcactcacgggccag  450 
C7 A.A N  I  E  L  T  G  N  G  Y  N  A  L  T  G  Q    150 
C7 seq tttaggaacagagtcctcaacactaaaagttttggtggtcaatgc  495 
C7 A.A F  R  N  R  V  L  N  T  K  S  F  G  G  Q  C    165 
C7 seq agaaaggtgtttagtggggatgggagagatttctacagactgagt  540 
C7 A.A R  K  V  F  S  G  D  G  R  D  F  Y  R  L  S    180 
C7 seq ggaaatgtcctctcctacacattccaggtgaaagtaaataatgat  585 
C7 A.A G  N  V  L  S  Y  T  F  Q  V  K  V  N  N  D    195 
C7 seq tttaattatgaattttacaatagtacctggtcttatgcaaaacat  630 
C7 A.A F  N  Y  E  F  Y  N  S  T  W  S  Y  A  K  H    210 
C7 seq acatctacagaacatacatcatccagtaaaggacgcgtcttcatt  675 
C7 A.A T  S  T  E  H  T  S  S  S  K  G  R  V  F  I    225 
C7 seq tttagttcttcctcttcttcctccagttattatgcaaaaacctat  720 
C7 A.A F  S  S  S  S  S  S  S  S  Y  Y  A  K  T  Y    240 
C7 seq gaaatccttaagaaaaagagttatcagttgttggttgttcagaac  765 
C7 A.A E  I  L  K  K  K  S  Y  Q  L  L  V  V  Q  N    255 
C7 seq actgttgaagtggctcaatttatcaataacaatccagaatttttg  810 
C7 A.A T  V  E  V  A  Q  F  I  N  N  N  P  E  F  L    270 
C7 seq caacttgctgagtcattctggaaggaactctcctaccttcctcct  855 
C7 A.A Q  L  A  E  S  F  W  K  E  L  S  Y  L  P  P    285 
C7 seq ctgtatgattacagtgcctaccgaagattaattgaccagtatggg  900 
C7 A.A L  Y  D  Y  S  A  Y  R  R  L  I  D  Q  Y  G    300 
C7 seq acacattatctgcagtctgggtccttaggaggagaatacaaagtt  945 
C7 A.A T  H  Y  L  Q  S  G  S  L  G  G  E  Y  K  V    315 
C7 seq ttattttatgtggactcagagaaagtcgcagaaagcgatcttggt  990 
C7 A.A L  F  Y  V  D  S  E  K  V  A  E  S  D  L  G    330 
C7 seq tcagaggataagaagaaatgtgcttcctcacatattagttttcta 1035 
C7 A.A S  E  D  K  K  K  C  A  S  S  H  I  S  F  L    345 
C7 seq tttaaatcatcaaagcacaaatgcaaggcgatggaagaggcctta 1080 
C7 A.A F  K  S  S  K  H  K  C  K  A  M  E  E  A  L    360 
C7 seq aaatcagcttcaggaactcagagcaatgtgttgcgaggggtcccg 1125 
C7 A.A K  S  A  S  G  T  Q  S  N  V  L  R  G  V  P    375 
C7 seq tttgtcagagggggacgtcctggctttgtgtctggccttagttac 1170 
C7 A.A F  V  R  G  G  R  P  G  F  V  S  G  L  S  Y    390 
 




C7 seq ctggagctggacaaccctgatggaaacaaacaacgatattcttcc 1215 
C7 A.A L  E  L  D  N  P  D  G  N  K  Q  R  Y  S  S    405 
C7 seq tgggcaggatctgtgactgatcttccccaagtcataaaacaaaag 1260  
C7 A.A W  A  G  S  V  T  D  L  P  Q  V  I  K  Q  K    420 
C7 seq ctgacacctttgtatgagctggtaaaggaagtaccctgtgcttct 1305 
C7 A.A L  T  P  L  Y  E  L  V  K  E  V  P  C  A  S    435 
C7 seq gtgaaaagactgtacttgaaacgggccctggaggagtatctggat 1350 
C7 A.A V  K  R  L  Y  L  K  R  A  L  E  E  Y  L  D    450 
C7 seq gaatttgactcctgccattgccaaccttgtcaaaacggtggcatg 1395 
C7 A.A E  F  D  S  C  H  C  Q  P  C  Q  N  G  G  M    465 
C7 seq gccagtgtcgaggggacccagtgtcagtgccattgcaaaccaaac 1440 
C7 A.A A  S  V  E  G  T  Q  C  Q  C  H  C  K  P  N    480 
C7 seq acatttggtgtggcgtgtgaacaaggagtcctcgtaggggatcat 1485 
C7 A.A T  F  G  V  A  C  E  Q  G  V  L  V  G  D  H    495 
C7 seq gcaggaggcattgatggagggtggagttgctggtcctcttggggc 1530 
C7 A.A A  G  G  I  D  G  G  W  S  C  W  S  S  W  G    510 
C7 seq ccctgtgcccaagggaagaaaacaaggagccgaaaatgcaataac 1575 
C7 A.A P  C  A  Q  G  K  K  T  R  S  R  K  C  N  N    525 
C7 seq ccaccccccagtgggggtgggaaatcctgtattggagaaacgtca 1620 
C7 A.A P  P  P  S  G  G  G  K  S  C  I  G  E  T  S    540 
C7 seq gaaagcaggcaatgcgaagatgaagatctggagcatcttcggttg 1665 
C7 A.A E  S  R  Q  C  E  D  E  D  L  E  H  L  R  L    555 
C7 seq cttgaaccacattgtttccctttgtctttggttccaacagaattc 1710 
C7 A.A L  E  P  H  C  F  P  L  S  L  V  P  T  E  F    570 
C7 seq tgtccatcacctcctgccttgaaagatggatttgttcaaaatgaa 1755 
C7 A.A C  P  S  P  P  A  L  K  D  G  F  V  Q  N  E    585 
C7 seq gagaccacgtttcctgttgggaaaaacatagtgtacagttgcaat 1800 
C7 A.A E  T  T  F  P  V  G  K  N  I  V  Y  S  C  N    600 
C7 seq gaaggatactctcttgttggagaccctgttgccagatgtggagaa 1845 
C7 A.A E  G  Y  S  L  V  G  D  P  V  A  R  C  G  E    615 
C7 seq gatttacagtggactgttgggaaaatgcattgtcagaaaattgcc 1890 
C7 A.A D  L  Q  W  T  V  G  K  M  H  C  Q  K  I  A    630 
C7 seq tgtgttctacctacactgatgcgtggcttacagagtcatccccag 1935 
C7 A.A C  V  L  P  T  L  M  R  G  L  Q  S  H  P  Q    645 
C7 seq aagcctttctacacagttggcgagaaggtgaccttttcctgttca 1980 
C7 A.A K  P  F  Y  T  V  G  E  K  V  T  F  S  C  S    660 
C7 seq agcggcatgtccttagaaggtccatcgacatttctctgtggatcc 2025 
C7 A.A S  G  M  S  L  E  G  P  S  T  F  L  C  G  S    675 
C7 seq agcctcaagtggagccctgagatgaaaaatgtccagtgtgtgcga 2070 
C7 A.A S  L  K  W  S  P  E  M  K  N  V  Q  C  V  R    690 
C7 seq aaagaggcccctttggcaaagaaagtgcctgaatgtcagctctgg 2115 
C7 A.A K  E  A  P  L  A  K  K  V  P  E  C  Q  L  W    705 
C7 seq gagaaactgcagaattcaaaatgtgtttgtaaaatgccctatgaa 2160 
C7 A.A E  K  L  Q  N  S  K  C  V  C  K  M  P  Y  E    720 
C7 seq tgcggatcttccttagacgtgtgcgctcgagatgagagaagcaaa 2205 
C7 A.A C  G  S  S  L  D  V  C  A  R  D  E  R  S  K    735 
C7 seq aggatcctgcgactgacagtttgcaagatgcatgttctccaatgt 2250 
C7 A.A R  I  L  R  L  T  V  C  K  M  H  V  L  Q  C    750 
C7 seq cagggtagaaattacactctttctgttggggagacctgtactctg 2295 
C7 A.A Q  G  R  N  Y  T  L  S  V  G  E  T  C  T  L    765 
C7 seq cctggctccgctgagaaagcttgcggtgcatgtccactctgggag 2340 
C7 A.A P  G  S  A  E  K  A  C  G  A  C  P  L  W  E    780 
 




C7 seq aaatgtgatgcccaaagcagcaaatgtgtctgcagagccgcctcg 2385 
C7 A.A K  C  D  A  Q  S  S  K  C  V  C  R  A  A  S    795 
C7 seq gagtgcgaggaagcggggttccgcgtctgcgtggaggtgaacggc 2430 
C7 A.A E  C  E  E  A  G  F  R  V  C  V  E  V  N  G    810 
C7 seq agggagcagacgatgaccgagtgtgaggccggcgtcctgagatgc 2475 
C7 A.A R  E  Q  T  M  T  E  C  E  A  G  V  L  R  C    825 
C7 seq ctaggactgagcatcactgtcaccagcatcaggccctgcgcgccc 2520 
C7 A.A L  G  L  S  I  T  V  T  S  I  R  P  C  A  P    840 
C7 seq gaagccccgtag 2532    
C7 A.A E  A  P  *    843 
 
C7 seq caatcccggcgcgcacaacctgccacgtaacagcttctcagcaca 2577 
C7 seq caggcctcttctttctcctcccactcatgtccacttctcccagtc 2622 
C7 seq ccctgcgtaaacgcaaacccctcgttctccca 2654 
 
Figure 41  (continued)  
 
C8A seq                                             c     1 
C8A seq  ggcacgagtggtctgtagacacctcttacttcaactccctaagta   46 
C8A seq  gttttagtccttctttgtaatatagggtagtggcttctggatgag   91 
 
C8A seq  atgttggctgttgcttttttcatcttgtctttgatgacttgtcag  136 
C8A A.A  M  L  A  V  A  F  F  I  L  S  L  M  T  C  Q     15 
C8A seq  cctggggtaaccataccggagaaggtgaaccggagagtcagtcgg  181 
C8A A.A  P  G  V  T  I  P  E  K  V  N  R  R  V  S  R     30 
C8A seq  gctgttctgagctccacccccacagccgtttcctgccagctaagc  226 
C8A A.A  A  V  L  S  S  T  P  T  A  V  S  C  Q  L  S     45 
C8A seq  aactgggcagagtggacagaatgcttcccatgccaggacaaaaag  271 
C8A A.A  N  W  A  E  W  T  E  C  F  P  C  Q  D  K  K     60 
C8A seq  tatagataccggagcctcctgcagccaaacaagtttgggggagcc  316 
C8A A.A  Y  R  Y  R  S  L  L  Q  P  N  K  F  G  G  A     75 
 
Figure 42  Nucleotide and predicted protein sequence of the porcine C8A gene. Nu-
cleotide and amino acids are enumberated on the right side. The number-
ing of the nucleotide sequence starts with the first base of GenBank acc. 
no AB008156 and ends with the last base of GenBank acc. no AB008156. 
The 5´flanking region contains 91 nucleotides (nt. 1-91). The start codon 
(ATG) is in the first bold box (nt.  92-94). The porcine boundaries be-
tween exons are in bold and underline. Positions of polymorphism present 
in shade blocks with white bold font. Cysteine residues are in underline. 
The open reading frame is terminated by a TGA stop codon in the second 
bold box (nt.  1859-1861). The 3´UTR (nt. 1862-2176) contains the puta-
tive polyadenylation signal attaaa (nt.  2110-2115) in bold and italic low-




C8A seq  atctgcagtgggaacgtctgggaccaagccagctgtcacagcccc  361 
C8A A.A  I  C  S  G  N  V  W  D  Q  A  S  C  H  S  P     90 
C8A seq  acagagtgtctgaggcaagcacagtgtggacaggatttccagtgt  406 
C8A A.A  T  E  C  L  R  Q  A  Q  C  G  Q  D  F  Q  C    105 
C8A seq  aaggagacagggcgctgcctgaaacgccacctcgtgtgtaacgga  451 
C8A A.A  K  E  T  G  R  C  L  K  R  H  L  V  C  N  G    120 
C8A seq  gacagggactgcttggatggctctgacgaggatgactgtgaagat  496 
C8A A.A  D  R  D  C  L  D  G  S  D  E  D  D  C  E  D    135 
C8A seq  gtcaggatcttcgaagatgactgcagccagtacgacccaattccg  541 
C8A A.A  V  R  I  F  E  D  D  C  S  Q  Y  D  P  I  P    150 
C8A seq  ggatcggagagggcgaccttggggtacaatattctgacccaggaa  586 
C8A A.A  G  S  E  R  A  T  L  G  Y  N  I  L  T  Q  E    165 
C8A seq  gaaacgcagagtgtgtatgatgccaggtattatgggggccagtgt  631 
C8A A.A  E  T  Q  S  V  Y  D  A  R  Y  Y  G  G  Q  C    180 
C8A seq  gagactgtctacaacggggagtggagggagcttcggtatgactct  676 
C8A A.A  E  T  V  Y  N  G  E  W  R  E  L  R  Y  D  S    195 
C8A seq  gcctgtgagcgtctctactatggagatgatgagaagtacttccgg  721 
C8A A.A  A  C  E  R  L  Y  Y  G  D  D  E  K  Y  F  R    210 
C8A seq  aacccttacaatttcctgaagtaccacttcgaagccctggcagac  766 
C8A A.A  N  P  Y  N  F  L  K  Y  H  F  E  A  L  A  D    225 
C8A seq  agtaaattttcctcagagtcatacgatgatgcaaatgaccttctt  811 
C8A A.A  S  K  F  S  S  E  S  Y  D  D  A  N  D  L  L    240 
C8A seq  aaaaaagtaaaaaatgagaagtctgtgtcagctggagtgaccgtt  856 
C8A A.A  K  K  V  K  N  E  K  S  V  S  A  G  V  T  V    255 
C8A seq  ggtataggccctacaggtagcccatttacagcaaatgtgggctta  901 
C8A A.A  G  I  G  P  T  G  S  P  F  T  A  N  V  G  L    270 
C8A seq  tcagggtcacgagagtctgcgttcttgaacaagctaagcacgtat  946 
C8A A.A  S  G  S  R  E  S  A  F  L  N  K  L  S  T  Y    285 
C8A seq  aacgagaagaaatacagcttcatcaggattttcacaaaggtacag  991 
C8A A.A  N  E  K  K  Y  S  F  I  R  I  F  T  K  V  Q    300 
C8A seq  actgctagttttatgatgaggagggacaatattatgctggatgaa 1036 
C8A A.A  T  A  S  F  M  M  R  R  D  N  I  M  L  D  E    315 
C8A seq  gttatgctgcagtcattaatggagcttccggagcagtacaattac 1081 
C8A A.A  V  M  L  Q  S  L  M  E  L  P  E  Q  Y  N  Y    330 
C8A seq  ggcatgtacgccaagttcattgatgactacggcacccattatatc 1126 
C8A A.A  G  M  Y  A  K  F  I  D  D  Y  G  T  H  Y  I    345 
C8A seq  acgtctggatcgatgggtggtgtttatgaatatatcctggtgctt 1171 
C8A A.A  T  S  G  S  M  G  G  V  Y  E  Y  I  L  V  L    360 
C8A seq  aacaaagaaaatatgacaaaatctggtgttaccagcgatgatgtc 1216 
C8A A.A  N  K  E  N  M  T  K  S  G  V  T  S  D  D  V    375 
C8A seq  acgtcatgctttggagggtcttttggcatcgactatgactataca 1261 
C8A A.A  T  S  C  F  G  G  S  F  G  I  D  Y  D  Y  T    390 
C8A seq  gataacttacaaattacaggaagtttatcaggaaaacattgtaaa 1306 
C8A A.A  D  N  L  Q  I  T  G  S  L  S  G  K  H  C  K    405 
C8A seq  aaacttggaggtggccacagagaagacgaagagagcaacatggct 1351 
C8A A.A  K  L  G  G  G  H  R  E  D  E  E  S  N  M  A    420 
C8A seq  gtggaagacatcatttctcgggtgcgaggtggcagttctggctgg 1396 
C8A A.A  V  E  D  I  I  S  R  V  R  G  G  S  S  G  W    435 
C8A seq  ggcggtggcttgacgcaaaacggcagcatcattacataccgtgcc 1441 
C8A A.A  G  G  G  L  T  Q  N  G  S  I  I  T  Y  R  A    450 
C8A seq  tgggggaggtcattaaagtataatcctgctgttattgattttgag 1486 
C8A A.A  W  G  R  S  L  K  Y  N  P  A  V  I  D  F  E    465 
 




C8A seq  atgaagcccatttacgagatactgcgccacacaaacctggggccc 1531 
C8A A.A  M  K  P  I  Y  E  I  L  R  H  T  N  L  G  P    480 
C8A seq  ctggaggccaagcgccagaacctgcgacgggccttggatcagtac 1576 
C8A A.A  L  E  A  K  R  Q  N  L  R  R  A  L  D  Q  Y    495 
C8A seq  ctgatggaattcaacgcctgccgctgtgggccctgcttcaacaat 1621 
C8A A.A  L  M  E  F  N  A  C  R  C  G  P  C  F  N  N    510 
C8A seq  ggcgagcccatcctcgtgggtaccagctgccggtgtcagtgccct 1666 
C8A A.A  G  E  P  I  L  V  G  T  S  C  R  C  Q  C  P    525 
C8A seq  gtgggttgccagggccttgcctgtgagcaaatgaagtcagaggga 1711 
C8A A.A  V  G  C  Q  G  L  A  C  E  Q  M  K  S  E  G    540 
C8A seq  gccaaggctgatggtcgctggagctgctggagctcctggtctgct 1756 
C8A A.A  A  K  A  D  G  R  W  S  C  W  S  S  W  S  A    555 
C8A seq  tgcagattgggcacccaggaaaggaggagagagtgtaacaaccct 1801 
C8A A.A  C  R  L  G  T  Q  E  R  R  R  E  C  N  N  P    570 
C8A seq  gcaccccagaatggaggtgcctcgtgttcaggccacaaagtgcag 1846 
C8A A.A  A  P  Q  N  G  G  A  S  C  S  G  H  K  V  Q    585 
C8A seq  acccaggcatgctga 1861    
C8A A.A  T  Q  A  C  *    589 
 
C8A seq  gggcctctgggcacaggctggaacccacccagcagacgtcaccgc 1906 
C8A seq  cggcaccgaccactggatacagacctcactccgctgagagaagat 1951 
C8A seq  gccaatcaacgtggaccttttctctgtcctgccagcttccaggct 1996 
C8A seq  gaagactgggccatgccagctatacccaactgttctgttactcac 2041 
C8A seq  aaaactcagtcagtcacaactgggggttgagagttaactagtgtt 2086 
C8A seq  aactgcttgcaacactttggatcattaaagaaaagaaaagagaaa 2131 
C8A seq  aaaaaaaaaaaaaaa 2146 
 
Figure 42   (continued)  
 
 
C8B seq                   attccctgtgcaggttcttcatggatcc   28 
 
C8B seq  atgagcctcagtcagatctcctgtcgcatagaaaaaatgaagacc   73 
C8B A.A  M  S  L  S  Q  I  S  C  R  I  E  K  M  K  T     15 
C8B seq  tctgggacgtgggcttggaggatgccggcaaggctgtttcttctc  118 
C8B A.A  S  G  T  W  A  W  R  M  P  A  R  L  F  L  L     30 
 
Figure 43 Nucleotide and predicted protein sequence of the porcine C8B gene. 
Nucleotide and amino acids are enumberated on the right side. The 
numbering of the nucleotide sequence starts with the first base of Gen-
Bank acc. no AK232952 and ends with the last base of GenBank acc. 
no AK233291. The 5´flanking region contains 28 nucleotides (nt. 1-
28). The start codon (ATG) is in the first bold box (nt.  29-31). The 
porcine boundaries between exons are in bold and underline. Positions 
of polymorphism present in shade blocks with white bold font. Cys-
teine residues are in underline. The open reading frame is terminated 




C8B seq  tgtgctgccctggggtgtctcagtttacctggctccagaggtgag  163 
C8B A.A  C  A  A  L  G  C  L  S  L  P  G  S  R  G  E     45 
C8B seq  aggccacactctcttgagtcaaatgcagtcaacgagagccttggc  208 
C8B A.A  R  P  H  S  L  E  S  N  A  V  N  E  S  L  G     60 
C8B seq  aagagtagacagacgcggagtgtggatgtcaccttgacgcctatt  253 
C8B A.A  K  S  R  Q  T  R  S  V  D  V  T  L  T  P  I     75 
C8B seq  gattgtgaactgtccagctggtcctcctggaccacgtgtgatccc  198 
C8B A.A  D  C  E  L  S  S  W  S  S  W  T  T  C  D  P     90 
C8B seq  tgtcagaagaaaaggtacagacatgcctccttgctccggccctct  343 
C8B A.A  C  Q  K  K  R  Y  R  H  A  S  L  L  R  P  S    105 
C8B seq  cagttccatggggaaccgtgcaacttctctgacaaggaagttgaa  388 
C8B A.A  Q  F  H  G  E  P  C  N  F  S  D  K  E  V  E    120 
C8B seq  gactgtgtttccaacagaccatgccgaagtcaagtgcgatgtgaa  433 
C8B A.A  D  C  V  S  N  R  P  C  R  S  Q  V  R  C  E    135 
C8B seq  ggctttgtgtgtgcgcagacagggagatgcatcaaccgtagactt  478 
C8B A.A  G  F  V  C  A  Q  T  G  R  C  I  N  R  R  L    150 
C8B seq  ctttgcaatggtgacaatgactgtggagatcagtcggatgaggca  523 
C8B A.A  L  C  N  G  D  N  D  C  G  D  Q  S  D  E  A    165 
C8B seq  aactgtaaaaggatttataaaaagtgtcagcaggaaatggaccag  568 
C8B A.A  N  C  K  R  I  Y  K  K  C  Q  Q  E  M  D  Q    180 
C8B seq  tactgggccattggcagcctggccagtgggataaatttgttcacg  613 
C8B A.A  Y  W  A  I  G  S  L  A  S  G  I  N  L  F  T    195 
C8B seq  aacaacttggagggcccagttctcgatcacaggtattacgccggt  658 
C8B A.A  N  N  L  E  G  P  V  L  D  H  R  Y  Y  A  G    210 
C8B seq  gcatgctccccccattacatactcaacacgaggtttcggaaacca  703 
C8B A.A  A  C  S  P  H  Y  I  L  N  T  R  F  R  K  P    225 
C8B seq  tacaatgtggaaaacttcaacccacagacccaaggaaaatatgac  748 
C8B A.A  Y  N  V  E  N  F  N  P  Q  T  Q  G  K  Y  D    240 
C8B seq  tttgcactgacagaatacgaatcatactcagatttcgaacaaaat  793 
C8B A.A  F  A  L  T  E  Y  E  S  Y  S  D  F  E  Q  N    255 
C8B seq  gtcacaactgcagcaattagcaagtctagtttcagcttcggtttt  838 
C8B A.A  V  T  T  A  A  I  S  K  S  S  F  S  F  G  F    270 
C8B seq  aaaatatctggaatgtttgaatttggcatcagtagcacaagtgat  883 
C8B A.A  K  I  S  G  M  F  E  F  G  I  S  S  T  S  D    285 
C8B seq  aaaggcaaacgttttattagcagaaccaagcgattctctcacacg  928 
C8B A.A  K  G  K  R  F  I  S  R  T  K  R  F  S  H  T    300 
C8B seq  aaaagcacatttctgcacgcgcgctctgaccttgaggtagcgcgt  973 
C8B A.A  K  S  T  F  L  H  A  R  S  D  L  E  V  A  R    315 
C8B seq  tacaagctgaaatccagaaacctcatgctgcattacgagttcctt 1018 
C8B A.A  Y  K  L  K  S  R  N  L  M  L  H  Y  E  F  L    330 
C8B seq  cagagggtcaagcagctgcctctggagtacagctacggggagtac 1063 
C8B A.A  Q  R  V  K  Q  L  P  L  E  Y  S  Y  G  E  Y    345 
C8B seq  agagatctcttccgagattttgggacccactacatcacagaggcc 1108 
C8B A.A  R  D  L  F  R  D  F  G  T  H  Y  I  T  E  A    360 
C8B seq  gtgctcgggggtgtttatgagtacacactcatcatgaacaaagag 1153 
C8B A.A  V  L  G  G  V  Y  E  Y  T  L  I  M  N  K  E    375 
C8B seq  gccatggagagagcagattattctctaaaggatgtccatgcctgt 1198 
C8B A.A  A  M  E  R  A  D  Y  S  L  K  D  V  H  A  C    390 
C8B seq  gcccaacatggttttaaaattggtgtcgccatagaagaggtctac 1243 
C8B A.A  A  Q  H  G  F  K  I  G  V  A  I  E  E  V  Y    405 
C8B seq  gtcaagttgggggtgccggtgcacaagtgcaaggacattctcaat 1288 
C8B A.A  V  K  L  G  V  P  V  H  K  C  K  D  I  L  N    420 
 




C8B seq  gagataaaagacagaaacaagagaagcagcatggtgaatgacttg 1333 
C8B A.A  E  I  K  D  R  N  K  R  S  S  M  V  N  D  L    435 
C8B seq  gtggtccttgtgcggggaggtgcaagtgaacacatcactgccctg 1378 
C8B A.A  V  V  L  V  R  G  G  A  S  E  H  I  T  A  L    450 
C8B seq  gcatataaggatctgccaacagcggacctgatgcaggaatgggga 1423 
C8B A.A  A  Y  K  D  L  P  T  A  D  L  M  Q  E  W  G    465 
C8B seq  gatgcagtgcagtacaacccagacatcatcaaaattaaggcagag 1468 
C8B A.A  D  A  V  Q  Y  N  P  D  I  I  K  I  K  A  E    480 
C8B seq  cctctctatgaactggtgacagccgcggactttgcctattccagc 1513 
C8B A.A  P  L  Y  E  L  V  T  A  A  D  F  A  Y  S  S    495 
C8B seq  acagtgaagcagaacatgaagcgagccctggaggagttcgagaag 1558 
C8B A.A  T  V  K  Q  N  M  K  R  A  L  E  E  F  E  K    510 
C8B seq  gaaatcagctcctgccactgtgctccctgccaggggaatggagtc 1603 
C8B A.A  E  I  S  S  C  H  C  A  P  C  Q  G  N  G  V    525 
C8B seq  cctgtcctgaaagaatcacgctgtgactgcatctgtcctgctgga 1648 
C8B A.A  P  V  L  K  E  S  R  C  D  C  I  C  P  A  G    540 
C8B seq  ttccaaggctcagcctgtgaggtcaccaatcggaaaaatgtcccc 1693 
C8B A.A  F  Q  G  S  A  C  E  V  T  N  R  K  N  V  P    555 
C8B seq  attgatgggaagtggaattgctggtcagactggttctccgtgttt 1738 
C8B A.A  I  D  G  K  W  N  C  W  S  D  W  F  S  V  F    570 
C8B seq  ctggaggacgtaaaacaagacgaaggcagtgcaacaatccacctc 1783 
C8B A.A  L  E  D  V  K  Q  D  E  G  S  A  T  I  H  L    585 
C8B seq  ctcaaaatgggggtagcccctgcttgggtcctgcttcagaaacac 1828 
C8B A.A  L  K  M  G  V  A  P  A  W  V  L  L  Q  K  H    600 
C8B seq  ttaactgttaaggaagggagagcttctagcgggtga 1864    
C8B A.A  L  T  V  K  E  G  R  A  S  S  G  *    611 
 
C8B seq  tgctactgtgggctgcacacagtgagagctctgagcccttaggaa 1909 
C8B seq  ccaggccagctcatctccacaccagcttccacctgggcctggccc 1954 
C8B seq  aggggtgggaaggctgtgccattcagatttgaaataaagatggta 1999 
C8B seq  tttgtaaaatgcacatggatttgaacaaatagcaagttaaatact 2044 
C8B seq  cattatagtctcctgaagggcttaagcctcttagtaatattcact 2089 
C8B seq  ttgcttacctctccaattttatttctacttctctctggaggggca 2134 
C8B seq  cactgtctcattcagtgtccgtggtagttcatatttgttgaataa 2179 
C8B seq  ttagtacatgccagctacagtgttcagtgcatgaattcattccat 2224 
C8B seq  cctcatgacagtcttataaggtggatgctgtcttagccccatgaa 2269 
C8B seq  acagcaggggaaccagcttaggacagttaagtgacttgtccaagg 2314 
C8B seq  tgatgcaattagggagtgggggagcggggctgtgaacttgggcac 2359 
C8B seq  atggactccagagttttaaacgcttaattaggatactcccttcct 2404 
C8B seq  cttaataaatgggcacttgattaaaaaaaaaaaaaaaaaaaaaaa 2449 
C8B seq  aaaaaaaaaaaa 2461 
 
Figure 43 (continued) Interestingly, alignment of sequences of GenBank acc. 
no DQ333201 (in normal) and AK233291 (in intalic) in Genbank al-
lowed merging 474 bp longer (nt. 1988-2461) in 3´ flanking region 
of the porcine C8B cDNA sequence, which contains putative 
polyadenylation signal aataaa in bold and italic. The translation stop 





C8G seq                                        atcgtc   6 
C8G seq ctgctctctgtctccaccggtcctgtcgccgttgccgccgtggcc  51 
 
C8G seq atgctagtccccagggctgcacccctcttgacgctgctcctggcc  96 
C8G a.a M  L  V  P  R  A  A  P  L  L  T  L  L  L  A    15 
C8G seq acgggctccttgggccagagggctcagagaccccctcgacgccca 141 
C8G a.a T  G  S  L  G  Q  R  A  Q  R  P  P  R  R  P    30 
C8G seq tcccccatcagcaccatccagcccaaggccagctttgatgcccag 186 
C8G a.a S  P  I  S  T  I  Q  P  K  A  S  F  D  A  Q    54 
C8G seq cagtttgcagggacgtggctcctggtggccgtggcttcctcctgc 231 
C8G a.a Q  F  A  G  T  W  L  L  V  A  V  A  S  S  C    60 
C8G seq cgcttcctgcaagagcagggccaccgggctgaggccacttcactg 276 
C8G a.a R  F  L  Q  E  Q  G  H  R  A  E  A  T  S  L    75 
C8G seq cacgtggctcctcagggtgcagccatggccgtcagcaccttccga 321 
C8G a.a H  V  A  P  Q  G  A  A  M  A  V  S  T  F  R    90 
C8G seq aagctggatgggatctgctggcaggtgcggcagctcttcagagac 366 
C8G a.a K  L  D  G  I  C  W  Q  V  R  Q  L  F  R  D   105 
C8G seq acggggctcccaggtcgcttcctgctccaggcccgaggcgcccga 411 
C8G a.a T  G  L  P  G  R  F  L  L  Q  A  R  G  A  R   120 
C8G seq ggcgcggtggatgtggtcgttggggagacggactaccggagcttt 456 
C8G a.a G  A  V  D  V  V  V  G  E  T  D  Y  R  S  F   135 
C8G seq gccatcctgtacctggagagggcccggcagctgtcggtgaagctg 501 
C8G a.a A  I  L  Y  L  E  R  A  R  Q  L  S  V  K  L   150 
C8G seq tacgcccgctcgctccccgtgagcgaatcagccctgagtgtcttt 546 
C8G a.a Y  A  R  S  L  P  V  S  E  S  A  L  S  V  F   165 
C8G seq gagcagcgggtccagggggccaacctgaccgaggaccacatcctg 591 
C8G a.a E  Q  R  V  Q  G  A  N  L  T  E  D  H  I  L   180 
C8G seq ttcttccccaagtacggcttctgcgacgctgcagaccagttccac 636 
C8G a.a F  F  P  K  Y  G  F  C  D  A  A  D  Q  F  H   195 
C8G seq gtcctggacgaagcaaagcagtga 660 
C8G a.a V  L  D  E  A  K  Q  *   202 
 
Figure 44 Nucleotide and predicted protein sequence of the porcine C8G 
gene. Nucleotide and amino acids are enumberated on the right 
side. The numbering of the nucleotide sequence starts with the first 
base of GenBank acc. no BP139629.1 and ends with the last base 
of GenBank acc. no BP443148.1. The 5´flanking region contains 
51 nucleotides (nt.  1-51). The start codon (ATG) is in the first bold 
box (nt.  52-54). The porcine boundaries between exons are in bold 
and underline. Positions of polymorphism present in shade blocks 
with white bold font. Cysteine residues are in underline. The open 
reading frame is terminated by a TGA stop codon in the second 
bold box (nt.  568-660). The 3´UTR (nt.  661-840) contains the pu-
tative polyadenylation signal attaaa (nt.  792-797) in bold and italic. 




C8G seq ggccggggccttgccgccgagagagagccacaagctggaagtgtg 705 
C8G seq ggcacccgccactcctggccgagcgggggcctctcccatctgccc 750 
C8G seq tggatgctgccacccccccacgagctcggggcgccaccttcatta 795 
C8G seq aacactgtcggtctcaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 840 
 
Figure 44 (continued)  
 
 
C9 seq   aaaaacaattgtggtgccccagtccttggcagataaatgtcttc   44 
C9 seq  caggcactgactgccattccgctcggagctgcctcactagagcag   89 
 
C9 seq  atgcgggtccgccggaggttcacctttgcagtatgcattttagaa  134 
C9 A.A  M  R  V  R  R  R  F  T  F  A  V  C  I  L  E     15 
C9 seq  ataagcattctgagcgccgggcccacacccagttaccacccgaag  179 
C9 A.A  I  S  I  L  S  A  G  P  T  P  S  Y  H  P  K     30 
C9 seq  cccgtggactgcaatggcacaccatcgcccattgactgcaggatg  224 
C9 A.A  P  V  D  C  N  G  T  P  S  P  I  D  C  R  M     45 
C9 seq  agtccctggggcgaatggtcaagatgtgacccttgcctcaaacaa  269 
C9 A.A  S  P  W  G  E  W  S  R  C  D  P  C  L  K  Q     60 
C9 seq  atgtttcgctcaaggagcattgagacctttggacaatttaacggg  314 
C9 A.A  M  F  R  S  R  S  I  E  T  F  G  Q  F  N  G     75 
C9 seq  caaaagtgcgtggacgccgtgggggacaggcggcagtgcgtgccc  359 
C9 A.A  Q  K  C  V  D  A  V  G  D  R  R  Q  C  V  P     90 
C9 seq  acggagccttgcgaagaccttgaggaggactgtggaagtgacttt  404 
C9 A.A  T  E  P  C  E  D  L  E  E  D  C  G  S  D  F    105 
C9 seq  cagtgtggtacaggcagatgcataaagaggcgccttctgtgtaat  449 
C9 A.A  Q  C  G  T  G  R  C  I  K  R  R  L  L  C  N    120 
C9 seq  ggtgacaatgactgcggagacttttcagatgaggatgactgtgac  494 
C9 A.A  G  D  N  D  C  G  D  F  S  D  E  D  D  C  D    135 
C9 seq  agtgatccccgccccccctgccgtgagagagtggtggaagagtct  539 
C9 A.A  S  D  P  R  P  P  C  R  E  R  V  V  E  E  S    150 
C9 seq  gagctggcacggacagcaggctacgggatcaacatcttaggaatg  584 
C9 A.A  E  L  A  R  T  A  G  Y  G  I  N  I  L  G  M    165 
 
Figure 45 Nucleotide and predicted protein sequence of the porcine C9 gene. Nu-
cleotide and amino acids are enumberated on the right side. The number-
ing of the nucleotide sequence starts with the first base of GenBank acc. 
no BP139003.1 and ends with the last base of GenBank acc. no 
CF363669. The 5´flanking region contains 89 nucleotides (nt.  1-89). The 
start codon (ATG) is in the first bold box (nt.  90-92). The porcine 
boundaries between exons are in bold and underline. Positions of poly-
morphism present in shade blocks with white bold font. Cysteine residues 
are in underline. The open reading frame is terminated by a TGA stop 
codon in the second bold box (nt.  1719-1721). The 3´UTR (nt.  1722-
2536) contains the putative polyadenylation signal attaaa (nt.  2505-2510) 




C9 seq  gaccccctcaccaccccatttgacaacgagtactacaacggactc  629 
C9 A.A  D  P  L  T  T  P  F  D  N  E  Y  Y  N  G  L    180 
C9 seq  tgtgaccgagttcgggatggaaacaccttgacctactaccgcaaa  674 
C9 A.A  C  D  R  V  R  D  G  N  T  L  T  Y  Y  R  K    195 
C9 seq  ccctggaacgtggctgccttgatctatgaaaccaaagttgacaaa  719 
C9 A.A  P  W  N  V  A  A  L  I  Y  E  T  K  V  D  K    210 
C9 seq  aatttcagaactgaatatcatgaaagacagattcaagtactcaaa  764 
C9 A.A  N  F  R  T  E  Y  H  E  R  Q  I  Q  V  L  K    225 
C9 seq  actatcatcgaagagaagaaatcaaattttaatgcagatttaact  809 
C9 A.A  T  I  I  E  E  K  K  S  N  F  N  A  D  L  T    240 
C9 seq  ataaaattcacacctaccgaagcaattgaacagctgaaaagtaaa  854 
C9 A.A  I  K  F  T  P  T  E  A  I  E  Q  L  K  S  K    255 
C9 seq  aatgtagaacttgccaacgaagaaaactcaaatcctatgaataac  899 
C9 A.A  N  V  E  L  A  N  E  E  N  S  N  P  M  N  N    270 
C9 seq  aaggctcacttccgatttacatattccaaaacggaaacctacaaa  944 
C9 A.A  K  A  H  F  R  F  T  Y  S  K  T  E  T  Y  K    285 
C9 seq  ctgttgttgtcatattcttctaagaaggaaaaaatattcctgcat  989 
C9 A.A  L  L  L  S  Y  S  S  K  K  E  K  I  F  L  H    300 
C9 seq  gtcaaaggagtaattcacctgggaagatttgtgatgagaaagcgg 1034 
C9 A.A  V  K  G  V  I  H  L  G  R  F  V  M  R  K  R    315 
C9 seq  gatgtcatgctgacaaaaactttcttggatgatgtaaagtatctg 1079 
C9 A.A  D  V  M  L  T  K  T  F  L  D  D  V  K  Y  L    330 
C9 seq  ccaagtacctatgaaaagggagaatattttgcatttttggaaacc 1124 
C9 A.A  P  S  T  Y  E  K  G  E  Y  F  A  F  L  E  T    345 
C9 seq  tatggaacccactacagtagctctgggtctctgggaggactctat 1169 
C9 A.A  Y  G  T  H  Y  S  S  S  G  S  L  G  G  L  Y    360 
C9 seq  gaactaatatatgttctggataaagctaccatgactgagaaaggt 1214 
C9 A.A  E  L  I  Y  V  L  D  K  A  T  M  T  E  K  G    375 
C9 seq  attgaactacgggatgtacacagatgccttgggtttaatctggat 1259 
C9 A.A  I  E  L  R  D  V  H  R  C  L  G  F  N  L  D    390 
C9 seq  ttatctctgaattttggagttgaaatcaaaggaaagattgattca 1304 
C9 A.A  L  S  L  N  F  G  V  E  I  K  G  K  I  D  S    405 
C9 seq  gaaaattgcttaaagaggggtgacggtaaaactgaaaacatcatg 1349 
C9 A.A  E  N  C  L  K  R  G  D  G  K  T  E  N  I  M    420 
C9 seq  aatgacgacttcatagatgatgttatttcattcataagaggagga 1394 
C9 A.A  N  D  D  F  I  D  D  V  I  S  F  I  R  G  G    435 
C9 seq  accagaaaatacgcaactgaactgaaagagaagcttctcaaagga 1439 
C9 A.A  T  R  K  Y  A  T  E  L  K  E  K  L  L  K  G    450 
C9 seq  gccaaaatgattaacgtgactgactttgtaaactgggcctcttcc 1484 
C9 A.A  A  K  M  I  N  V  T  D  F  V  N  W  A  S  S    465 
C9 seq  ttaaatgatgctccggtgctcataaatcaaaaactgtctccgata 1529 
C9 A.A  L  N  D  A  P  V  L  I  N  Q  K  L  S  P  I    480 
C9 seq  tatgatctgattccagtgaaactaaatgatgcacatctaaagaga 1574 
C9 A.A  Y  D  L  I  P  V  K  L  N  D  A  H  L  K  R    495 
C9 seq  caaaatttggaaagagccattgaagactacatcaatgaattcaat 1619 
C9 A.A  Q  N  L  E  R  A  I  E  D  Y  I  N  E  F  N    510 
C9 seq  gtaagaaaaatgccaactgtgccagaatggagggacagtgattct 1664 
C9 A.A  V  R  K  M  P  T  V  P  E  W  R  D  S  D  S    525 
C9 seq  gctggatggacagtgtttgtgttcctgcccaaacaaatttcaggg 1709 
C9 A.A  A  G  W  T  V  F  V  F  L  P  K  Q  I  S  G    540 
C9 seq  aattgcttgtga 1721    
C9 A.A  N  C  L  *    543 
 




C9 seq  aatcccaaaatagaaaatctctgaaggattgccagccccccacca 1766 
C9 seq  aaaaaaaacaaaacaaaacaaaacactgagctgttggtttccctg 1811 
C9 seq  ggatcacatgggaagaaaaacaccaggactccaggactgtctaga 1856 
C9 seq  ggtagtccttgctgccgaatgaaaagcaacatgcttcatgaaaat 1901 
C9 seq  ccccccaacctctgaagtctcctctctcagatccacagagcttct 1946 
C9 seq  tctcttccttgaactcctatggtttccagttttttattactaatg 1991 
C9 seq  aggagagtcagcagtcaaatatgccaagactgctttctcccacag 2036 
C9 seq  gcaatgccaatctcttgctaacaaaacaaaattaaattaaaaaga 2081 
C9 seq  aagtgttggttaaaaagaccttaaagtcattgccaaaggtctttg 2126 
C9 seq  tatgacgaatacgttctgccaggtccatcaccacaagtctgtacc 2171 
C9 seq  atgcaatttcactcctgtttacatacttgtgtcatgttcggtcat 2216 
C9 seq  ttgtagatacgtgcatgccttcgttctgaaagtacaaacacccac 2261 
C9 seq  cacaagcacagcactctgctttttaagtcttagctctctggttta 2306 
C9 seq  actctatgtgtccaaggaggaaaatgtattgtatttgtaaccaaa 2351 
C9 seq  aactattagattcagtaatgtgaaattacctttattcagtcatag 2396 
C9 seq  tttaccaaaaaatgaaaacaaaacaaaaaacaaaacccagcaatt 2441 
C9 seq  ccatatggtccccttaatacctagtgttacgagttgtataaagtc 2486 
C9 seq  tacccatataagaagttaattaaaggagctggctgtacaattgca 2531 
C9 seq  aaaaa 2536 
 
Figure 45 (continued)  
 
S.scrofa           MDKH-SVLYFILLSGLIDKSQACFCDHYPWTQWSSCSKTCNSGTQTRQRQITINQYYLDN 59 
B.taurus           MARH-SVMYFILLSALIDKSQACFCDHYPWSQWSSCSKTCNSGTQTRQRRIVTDKYYFEN 59 
H.sapiens          MARR-SVLYFILLNALINKGQACFCDHYAWTQWTSCSKTCNSGTQSRHRQIVVDKYYQEN 59 
P.troglodytes      MARR-SVLYFILLNALINKGQACFCDHYAWTQWTSCSKTCNSGTQSRHRQIVVDKYYQEN 59 
P.pygmaeus         MARC-SVLYFILLSALINKGQACFCDHYPWTQWTSCSKTCNSGTQSRHRQIVVDKYYQEN 59 
C.familiaris       MAGQ-SILYFILLSALIDKCQPCFCDHYPWSQWSSCSKTCNFGTQSRQRKIVVDQYYLDN 59 
R.norvegicus       MTRH-LTLCFILLIILIDKSEACFCDHYPWTHWSSCSKSCNSGTQSRQRQIVVNDYYRDN 59 
M.domestica        MDQN-ILLYSIVLSALISGSQACYCERYPWTSWSSCSSSCNYGSQIRERHIVRDKYYEEN 59 
G.gallus           MEKT-VLIQLILLSLVVGSCQGCYCEHYPWGSWSSCSKTCNYGTQTRHRQIKMDEYYNQN 59 
X.tropicalis       MGSR-PCIIFLLIVSLAGGALSCFCDHYPWTSWSSCSKTCDHGTQSRSRTISYDDYYWKH 59 
O.mykiss           MDRTNSLLVLLHVLGSVTVSLGCFCDHYAWSSWSTCTRTCNYGTQERRRSIRYDDYYWKN 60 
                   *      :  : :         *:*::*.*  *::*: :*: *:* * * *  :.** .: 
 
Figure 46 Alignment of the C6 proteins among species according to the GenBank ac-
cession no. as given in table 5 using the ClustalW2 tool. The amino acids are 
enumerated above each line on the right side. The identical, similar and 
missing residues are indicated with asterisks (*), points (.), and dashes (-), 
respectively. Signal peptides in human C6 protein (DiScipio et al. 1989) and 
in pig C6 protein are in bold and italic. The amino termini of C6 mature pro-
tein starts just after the signal peptide. The cysteine residues are highlighted. 
The cysteine-rich functional protein domains like TSP1, LDLa, MACPF, 
EGF, CCP, and FIMAC are in continuous underline.  The glycosylation sites 
in human (Chakravarti et al. 1989, DiScipio et al. 1989) and in pig using the 
NetNGlyc 1.0 Server tool present in shade blocks with white bold font.  The 
human C6 cleavage site into two fragments C6a (a.a 22-631) and C6b (a.a 




     TSP1 domain (26-79)  TSP1 domain (84-134) 
S.scrofa           FCDRLCTKQETRECNWQTCPINCLLGDYGPWSDCDPCVEKQFKVRSILRPNQFGGQPCTE 119 
B.taurus           FCGQLCTKQESRECNWQTCPINCRLGDYGPWSDCDPCVQKRFKVRSILRPSQFGGQPCTE 119 
H.sapiens          FCEQICSKQETRECNWQRCPINCLLGDFGPWSDCDPCIEKQSKVRSVLRPSQFGGQPCTE 119 
P.troglodytes      FCEQICSKQETRECNWQRCPINCLLGDFGPWSDCDPCVEKQSKVRSVLRPSQFGGQPCTE 119 
P.pygmaeus         FCEQICSKQETRECNWQRCPINCLLGDFGPWSDCDPCVEKQSKVRSVLRPSQFGGQPCTE 119 
C.familiaris       FCDQLCTKSETRECNWQRCPINCLLGDYGPWSDCDPCVEKQFKVRSILRPSQFGGQPCTE 119 
R.norvegicus       SCDQLCTKQETRQCNVETCPINCVLGDYGTWSDCDPCIRKQVKVRSVLRPSQFGGQPCTE 119 
M.domestica        YCDQLCTKRESRACNQQMCPINCLMGDFEPWSECDPCVKKQFRMRSILRPSQFGGQPCTE 119 
G.gallus           FCDRLCTKQESRACNQQTCPINCQLGDFGPWSECDPCIEKQFRVRKLLRPSQFGGQACTE 119 
X.tropicalis       NCGGLCTMRETRSCNEQSCPINCKLGDFGSWSDCDPCLKKQFRTRSLERPSQFGGEGCTE 119 
O.mykiss           SCEQLCQKHESRACNVQACFIHCQLTDWANWSGCSPCAKKQLRTRSLLRPSQFGGVECDA 120 
                    *  :*   *:* ** : * *:* : *:  ** *.** .*: : *.: **.****  *   
         LDLa domain (139-175) 
S.scrofa           PLMTFRPCIPSKLCKIEEVDCKNKFRCDSGRCIASKLECNGENDCGDNSDERNCGRTKAV 179 
B.taurus           PLMTFQPCIPSKLCKIEEIDCKNKFRCDSGRCIASKLECNGENDCGDNSDERNCGRKKTV 179 
H.sapiens          PLVAFQPCIPSKLCKIEEADCKNKFRCDSGRCIARKLECNGENDCGDNSDERDCGRTKAV 179 
P.troglodytes      PLVAFQPCIPSKLCKIEEADCKNKFRCDSGRCIARKLECNGENDCGDNSDERDCGRTKAV 179 
P.pygmaeus         PLVAFQPCIPSKLCKIEEADCKNKFRCDSGRCIARKLECNGENDCGDNSDERDCGRTKAV 179 
C.familiaris       PLVTFQPCIPSKLCKIEEIDCKNKFRCDSGRCIANKLECNGENDCGDNSDERNCGRAKAV 179 
R.norvegicus       PLVTFQPCVPSELCKIEETDCKNKFLCDSGRCIPSKLKCNGENDCGDNSDERNCGRTKPV 179 
M.domestica        QLVTSQKCYSTKLCNIEDIDCKNKFKCDSGRCIAMNLLCNEENDCGDSSDEKNCDRKKKV 179 
G.gallus           TLVQSRPCFPAKLCNIVDVDCKNKFQCENGRCIAKKLECNGDNDCGDNSDERYCGRKKVV 179 
X.tropicalis       ALVESRICVPAKLCKIEQLDCSGKFQCVSGRCIPFNLKCNGDNDCGDNSDERVCRKREPQ 179 
O.mykiss           VLTEDRACYPSTECKMETLNCK-EFQCGNGRCISSKLTCNKQNDCGDNSDEKNCDEFKIV 179 
                    *   : * .:  *::   :*. :* * .****. :* ** :*****.***: * . :   
 
S.scrofa           CS--RKYNPIPSVQLMGAGFHILAGEPRGEVLGNSFTGGICKTVKSS---KASNPFRVPA 234 
B.taurus           CS--RSHNPIPGVQLMGMGFHFLAGEPRGEVLDNSFTGGVCRTVKSS---RASNPYRVPA 234 
H.sapiens          CT--RKYNPIPSVQLMGNGFHFLAGEPRGEVLDNSFTGGICKTVKSS---RTSNPYRVPA 234 
P.troglodytes      CT--RKYNPIPSVQLMGNGFHFLAGEPRGEVLDNSFTGGICKTVKSS---RTSNPYRVPA 234 
P.pygmaeus         CT--RKYDPIPSVQLMGSGFHFLAGEPRGEVLDNSFTGGICKTVKSS---RTSNPYRVPA 234 
C.familiaris       CPGKRQWNPIPSVQLMGAGFHFLAGEPRGEVLDNSFTGGICKTVKSS---KASNPYRVPA 236 
R.norvegicus       CS--RTYTPIPSVQLMGAGFHFLAGEPRGDVPDNSFTGGICKSVRSS---RTSNPHRVPA 234 
M.domestica        CN--RVYQPIPSVQLMGNGFHILAGEPRGEVLDNAFMGGKCRTVRSS---RTSNPYRVPA 234 
G.gallus           CS--RKFESIPGVHLIGSGFHILSGESRGEVLGNSFNGGECRTVRRN---ETRKSYRVPA 234 
X.tropicalis       RS----FEPIPGIQLMGNGFNYLSGESRGEVLDNSFFGGKMDKVYGNGTGQNRKLYRLSA 235 
O.mykiss           CP--VEKRVVPGADLIGNGFDAMAEAMRGAVLDNMFMGDTCNLNRSRGS-SYRLYYRVPA 236 
                            :*. .*:* **. ::   ** * .* * *.                .*:.* 
 
S.scrofa           NLENVNFEVQTKEDDFQT--DFYEDLIPLENSKDQQATGFGQE-KSSFHVPIFYSSKKSQ 291 
B.taurus           NLENVNFEVQTKEDDLEA--DFYDDLIPLEDNKDQEALGSGLA-TSSFRVPIFYSSKRSQ 291 
H.sapiens          NLENVGFEVQTAEDDLKT--DFYKDLTSLGHNENQQGSFSSQG-GSSFSVPIFYSSKRSE 291 
P.troglodytes      NLENVGFEVQTAEDDLKT--DFYKDLTSLGHNENQQGSFSSQG-GSSFSVPIFYSSKRSE 291 
P.pygmaeus         NLENVGFEVQTAEDDLKT--DFYKDLTSLGHNENQQGSFSSQG-GSSFSVPIFYSSKRSE 291 
C.familiaris       NLENVNFEVQTKEDDLET--DFYKDLISLTKNENQQGLFGGEE-QSSLYIPIFYSSKKTQ 293 
R.norvegicus       NLENVNFEVQTIEDDLKT--DFYKDLATIGKNKNEDRSLSGEK-KDSFYVPIFYSSKKSE 291 
M.domestica        NIESINFEVNNEEDDLQT--DFYSNLIPLGNDHVLHKSDNLQG-NSHSGIPLLWSTKRKE 291 
G.gallus           NLEAVSFQVIDEEDDVKS--DFYRDLTPLSDGDVGSSTSSHSS-QRRSGIPGLFSKKRKV 291 
X.tropicalis       NLDTFKFELRNEEDDAVP--TFYNSLIDFDKENSRTGSSQSSR-RGSAGIPLLFHRKSNT 292 
O.mykiss           NVESFEIKVEIPDDFKQEPQPVYSETVNLASPPVSTRSDSSSGDSSSIWVPIFFVGSRRH 296 
                   *:: . :::   :*       .* .   :                    :* ::  .    
           MACPF domain (312-516) 
S.scrofa           TSSHNSAFKQAIQASHKKDSSFIRIHKVIKVLNFTMKTKDLQLSDVFLKALNHLPLEYNA 351 
B.taurus           SSSHSSAFKQAIQASQKKASSFIRIHKVIKVLNFTMKTKDLQLSDVFLKALNHLPLEYNS 351 
H.sapiens          NINHNSAFKQAIQASHKKDSSFIRIHKVMKVLNFTTKAKDLHLSDVFLKALNHLPLEYNS 351 
P.troglodytes      NINHNSAFKQAIQASHKKDSSFIRIHKVMKVLNFTTKAKDLHLSDVFLKALNHLPLEYNS 351 
P.pygmaeus         NINHNSAFKQAIQASHKKDSSFIRIHKVMKVLNFTTKAKDLHLSDIFLKALNHLPLEYNS 351 
C.familiaris       STTHNSAFKQAIQASHKKDSSFTRIHKVIEVLNFTMKTKDLQLSDVFLKALNHLPLEYNF 353 
R.norvegicus       NFQRNSGFKNAIEASHKKDSSFVRIHKVIKVLNFTMKTTDLQLSDVFLKALIHLPLEYNF 351 
M.domestica        RITQQYSFKKAIQASHKKDSSFIRVHKVISVLNFTMKPTELQLSDVFLKALNHLPLQYNY 351 
G.gallus           QITSSSSFKKAIEASHEKNSNFIRIHKVISVANFTMKESNLQLSDVFLKALNQLPLEYNY 351 
X.tropicalis       RITSSSSFREAAQASRKQSSKFIRINKVISVSDFTMKKNNLWLSDVFLKALNNLPLEYNY 352 
O.mykiss           HQSNTDTFKQAISASKKTDSQFFRVHQVLPVSRFRVKDSDLYLTEPFLQFLTSLPLEYNY 356 







S.scrofa           ALYSRIFDDFGTHYFTSGSLGGVYDLLYQFSNEELKNSGLTQEEAKNCIRIETKKRYFIV 411 
B.taurus           ALYSRIFDDFGTHYFTSGSLGGVYDLLYQFSKEELKNSGLTQEEAKNCIRIETKKRFLFV 411 
H.sapiens          ALYSRIFDDFGTHYFTSGSLGGVYDLLYQFSSEELKNSGLTEEEAKHCVRIETKKRVLFA 411 
P.troglodytes      ALYSRIFDDFGTHYFTSGSLGGVYDLLYQFSSEELKNSGLTEEEAKHCVRIETKKRVLFV 411 
P.pygmaeus         ALYSRIFDDFGTHYFTSGSLGGVYDLLYQFSSEELKNSGLTEEEAKHCVRIETKKRVLFA 411 
C.familiaris       ALYSRIFDDFGTHYYTSGSLGGVYDLLYQYSAEELRTSGLTEKEIQNCVSTETKKSVLFF 413 
R.norvegicus       ALYSRIFDDFGTHYFTSGSLGGKYDLLYQFSRQELQNSGLTEEETRNCVRYETKKRFLFF 411 
M.domestica        ALYSRLFDDFGTHYFTSGSMGGTYDLLYQYSREELKNSGLTEEESQHCVRIETVKRRLVF 411 
G.gallus           ALYSRIFDDFGTHYYTSGKMGGSYDILYQYSSEELKNSGLSVDESMECIRTETTRRVFFR 411 
X.tropicalis       PLYSRIFDDFGTHYITAGSMGGSYDLLFQYSSENLKSSGLTNQESLECVRTEITYRVFFR 412 
O.mykiss           ALYREIFKHFGTHYFASGTLGGHYDLLYQYSRLELKNSGLTEEHTKGCLKSESSMFIIIY 416 
                   .** .:*..***** ::*.:** **:*:*:*  :*:.***: ..   *:  *     :.  
 
S.scrofa           TKTKVEHRCTTNRMSEKYEGSFLQGSEKSISLVKGGRSEYAAALAWEKGSSGPGEKTYSD 471 
B.taurus           KKTKVEHRCTTNKLSEKYEGSFMQGSEKSISLVQGGRSAYAAALAWEKGSPVPEERVFSD 471 
H.sapiens          KKTKVEHRCTTNKLSEKHEGSFIQGAEKSISLIRGGRSEYGAALAWEKGSSGLEEKTFSE 471 
P.troglodytes      KKTKVEHRCTTNKLSEKHEGSFIQGAEKSISLIRGGRSEYAAALAWEKGSSGLEEKTFSE 471 
P.pygmaeus         KKTKVEHRCTTNKLSEKHEGSFIEGAEKSISLIRGGRSEYAAALAWEKGSSGLEEKTFSE 471 
C.familiaris       SKKEVEHRCTTNKMSKKYEGSFLQGAEKSISLIQGGRSKYAAALAWEKGSSVPTEKEFSE 473 
R.norvegicus       TKTYKEDRCTTNRLSEKYKGSFLQGSEKSISLVQGGRSQQAAALAWEKGSSGPEANVFSE 471 
M.domestica        KKKKVENRCTTNKMLDRYEGSFLQGAEKSLSLVRGGRSEHAAALAWEKKGSSPEETVFTE 471 
G.gallus           KKKKVSTECITNKMTVKHDGSILESAERSVSLVKGGRSEYAAALAWEKKGAFPGNTIFTN 471 
X.tropicalis       KKRKVRESCTRNKMSERYEGSFVQASEKSISLIKGGRAEYAAKLAWQRQETLPENTVFEE 472 
O.mykiss           SQSSNVVRCSDNTMTQKHEGSFVQSSEKSFSMVRGGRTGEAAALAWEQKGAAPDSTTYKN 476 
                   .:      *  * :  ::.**:::.:*:*.*:::***:  .* ***::  .      : : 
 
S.scrofa           WLESVKENPAVIDFELAPITDLVRNIPCAVTRRNNLRRAFREYAAKFDPCQCAPCPNNGR 531 
B.taurus           WLESVKENPSVIDFALAPITDLVRNIPCAVTRRNNLRRAFREYAAKFDPCQCARCPNSGR 531 
H.sapiens          WLESVKENPAVIDFELAPIVDLVRNIPCAVTKRNNLRKALQEYAAKFDPCQCAPCPNNGR 531 
P.troglodytes      WLESVKENPAVIDFELAPIVDLVRNIPCAVTKRNNLRKALQEYAAKFDPCQCAPCPNNGR 531 
P.pygmaeus         WLESVKENPAVIDFELAPIVDLVRNIPCAVTKRNNLRKAFQEYAAKFDPCQCAPCPNNGR 531 
C.familiaris       WLESVKENPVVIDFELAPITDLVRNIPCAVTRRNNLRKAFREYAAKFDPCWCAPCPNNGR 533 
R.norvegicus       WLESVKENPAVVDYELAPIIDLVRNIPCAVTKRNNLRKALQEYAAKFDPCQCAPCPNNGR 531 
M.domestica        WLQSVKENPAVVDFELAPILDLVKNIPCAVTKRKNLKQALHEYAEKFDPCKCAHCPNNGK 531 
G.gallus           WLESTKDNPVVIDFEVSSIVDLVKNMPCAVTRRRNLRRALREYAGRFDPCQCAPCPNNGR 531 
X.tropicalis       WVKSTIDNPVVVDFELAPILDLITGIPCAVTKKRNLQKAFAKYLETFDPCICAPCPNNAR 532 
O.mykiss           WAKSLIDNPAVVEYELLPIINLVKGIPCAATKRRHLTRALVEYLEDFDSCKCAPCPNNAR 536 
                   * :*  :** *::: : .* :*: .:***.*::.:* :*: :*   **.* ** ***..: 
        EGF domain (521-570)  TSP1 (568-617) 
S.scrofa           PVLSGTECLCVCQSGTYGDNCERRAPDYKSNAVDGNWGCWSSWSTCDATYKRSRTRECNN 591 
B.taurus           PVLSGTECLCVCQSGTYGENCERRSPDYKSNAVDGNWGCWSSWSSCDATYRRSRTRECNN 591 
H.sapiens          PTLSGTECLCVCQSGTYGENCEKQSPDYKSNAVDGQWGCWSSWSTCDATYKRSRTRECNN 591 
P.troglodytes      PTLSGTECLCVCQSGTYGENCEKQSPDYKSNAVDGHWGCWSSWSTCDATYKRSRTRECNN 591 
P.pygmaeus         PTLSGTECLCVCQSGTYGENCERRSPDYKSNAVDGHWGCWSSWSTCDATYKRSRTRECNN 591 
C.familiaris       PTLSGTECLCVCHSGTYGDNCERRSPDYKSNAVDGNWSCWSSWSTCDATYKRSRTRECNN 593 
R.norvegicus       PRLSGTECLCVCQSGTYGENCEKRSPDYKSNAVDGNWGCWSSWSACNAAYRRSRSRECNN 591 
M.domestica        PTLSGTECLCVCQSGTYGENCEIRAPDYTSNEVDGAWSCWSSWSPCAASYKRQRTRECNN 591 
G.gallus           PVLSGTECLCLCQAGTYGTNCEIRAPGYESVAVDGRWSCWSEWSSCDASFKRRRTRECNN 591 
X.tropicalis       VVLSGTECLCICQPGTYGDNCEKRTPDYTSVVVDGAWGCWKAWSSCDGAFTRRRTRECNN 592 
O.mykiss           AVLSGTDCQCICQTGTYGPNCEQRAQDYTSEAVDGYWSCWGTWSACDASMKRHRTRECNN 596 
                     ****:* *:*:.**** *** :: .* *  *** *.**  **.* .:  * *:***** 
 
S.scrofa           PAPRQGGKPCDGERRQEEHCTFSIMQNTGQPCIGDDEDMKEIDLPEIES-DSGCPQPVPP 650 
B.taurus           PAPQQGGKRCEGERRQEEHCTFSIMQNDGQPCISDDEDMKETDLPELES-DSGCPQPVPP 650 
H.sapiens          PAPQRGGKRCEGEKRQEEDCTFSIMENNGQPCINDDEEMKEVDLPEIEA-DSGCPQPVPP 650 
P.troglodytes      PVPQRGGKRCEGEKRQEEDCTFSIMENNGQPCINDDEEMKEVDLPEIEA-DSGCPQPVPP 650 
P.pygmaeus         PAPQRGGKHCEGEKRQEEDCTFSIMENNGQPCINDDEEMKEIDLPEIEA-DSGCPQPIPP 650 
C.familiaris       PAPQQGGKPCEGEQRQEEDCTFSVMENNGQACISDDEEVKEIDLPEIES-DSGCPRPVSP 652 
R.norvegicus       PEPQRGGQRCEGKHWQEEDCTFSIMEKVGQPCISDDEEIKEVDLAEPEA-DSGCPQPPLP 650 
M.domestica        PAPQNGGKPCVGEQEQEEDCSFSIFENRGDLCINDEEAEKEVDIDETNP-ESGCVKPIPP 650 
G.gallus           PSPINGGKPCKGEREEEEDCYVSVFMDNGAPCINDDEAKSELDIVVGVL-ETGCSRPDPP 650 
X.tropicalis       PYPRNGGKPCEGEATQEEDCNISLFEDTGALCINEGD-KKETDRVQPEH-DTGCPKPDLL 650 
O.mykiss           PAPLRGGKLCQGPARQEEGCFISIFQEQ-NVCVNDEDFATEGRAEGLPPGVEGCPRPKRP 655 






   CCP domain (644-699) 
S.scrofa           ENGFIRNEKTLYSVGEDVEIVCLTGFKTVGYQYFRCLPDRTWRRGDVECQRTDCLLPVVP 710 
B.taurus           ENGFIRNEKKQYSVGEEVEILCFTGFKAVGYQYFRCLPDRSWRQGDVECQRTECLKPIVP 710 
H.sapiens          ENGFIRNEKQLYLVGEDVEISCLTGFETVGYQYFRCLPDGTWRQGDVECQRTECIKPVVQ 710 
P.troglodytes      ENGFIRNEKQLYSVGEDVEISCLTGFETVGYQYFRCLPDGTWRQGDVECQRRECIKPVVQ 710 
P.pygmaeus         ENGFIRNEKKLYSVGEDVEILCLTGFETVGYQYFRCLPDGTWRQGDVECQRTECIKPVVQ 710 
C.familiaris       ENGFIRNEKKLYSVGEEVEILCFTGFKTVGYQYFRCLPDRTWRRGDVECRKTQCLKPVVQ 712 
R.norvegicus       ENAFVWNEKKLYSVGEEVEISCLTGFKAVGYQYFRCLPDRTWRQGDVECQRTECLKPVVQ 710 
M.domestica        ENGFLRNEKRLYSVGEEAEVACMMGFNLVGYPYLRCLPDQTWRQEGVECQRVGCIKPFVQ 710 
G.gallus           ENGFIRNEKNQYAVGEEAEIACVSGHVLIGYQFLRCLPDQTWTQQPVECQPSLCLRPPTS 710 
X.tropicalis       GIAFLTNEKNWYDVAEQIEIACVSGYELSGYPFLRCLPDGTWKQEDVECVKTTCPRPKAS 710 
O.mykiss           ANSHLRKDKRYYEFGDMEEFLCFTGFEMEGYQFINCRPDGTWTPPTGMCIRKVCSPPAVP 715 
                     ..: ::*  * ..:  *. *. *.   ** ::.* ** :*      *    *  * .  
    CCP domain (704-761) 
S.scrofa           EVLKLSPFQRLYKIGDSIELSCPK-GFVIAGPSRYTCSGD-SWTPPISSSLTCEQDFLTR 768 
B.taurus           EGLTLSPFQTLYKIGDSIELTCPR-GLVVNGPSRYTCSGD-SWTPPISDSLSCEKDVLTG 768 
H.sapiens          EVLTITPFQRLYRIGESIELTCPK-GFVVAGPSRYTCQGN-SWTPPISNSLTCEKDTLTK 768 
P.troglodytes      EVLTITPFQRLYRIGESIELTCPK-GFVVAGPSRYTCQGN-SWTPPISNSLTCEKDTLTK 768 
P.pygmaeus         EVLTITPFQRLYRIGESIELTCPK-GFVVAGPSRYTCQGN-SWTPPISNSLTCEKDTLIK 768 
C.familiaris       EVLTISPFQRLYRIGESIELTCPK-GFVVAGPSRYTCSED-SWTPPISNSLTCEKDVLTK 770 
R.norvegicus       DVLTISPFQSVYKIGESIELTCPR-GFVVAGPSRYTCKGD-SWTPPIPNSLSCEKDILTK 768 
M.domestica        EGISITPYQSVYDIGNTIKLTCPY-GFAITGPPNYLCGKQ-SWEPAIPSSLTCRQDILP- 767 
G.gallus           DSVEISPFKLHYNIGETVKLSCRA-GFVVTGQTQYTCGKDLSWFPSILRSITCEKDEQAK 769 
X.tropicalis       EDITIYHYKTDYKVGESIHVSCPR-DFVVVGSARYTCGRDLEWNPPILRQLTCGKETQKV 769 
O.mykiss           EGMTLYPSKKEYKVDHSVGLECTERGMVPSEQGFYTCAKSLTWEPPLPKDLHCKIDKPFV 775 
                  * *.:  .: *  :       : : :   :  * :..:: : *   .:.      * *  . 
    FIMAC domain (767-839) 
S.scrofa           LKGHCQPGQKQLGSECVCLSPEEDCSHHSEDLCVLDTDSNHYFTSSACKFLAEKCLNNQQ 828 
B.taurus           LRGHCQPGQKQLGSECVCMSPEEDCGHYSEEICVLDTTSSDYFTSSACKLLAEKCLNNQQ 828 
H.sapiens          LKGHCQLGQKQSGSECICMSPEEDCSHHSEDLCVFDTDSNDYFTSPACKFLAEKCLNNQQ 828 
P.troglodytes      LRGHCQLGQKQSGSECICMSPEEDCSHHSEDLCVFDTDSNDYFTSPACKFLAEKCLNNQQ 828 
P.pygmaeus         LKGHCQPGQKQSGSECICMYPEEDCSHYSEDLCVFDTDSNDYFTSPACKFLAEKCLNNQQ 828 
C.familiaris       LKGHCQPGQKQLGSECICMSPEEDCSHYSEDLCVFDTDTSHYFTLSACKFLAEKCLNNQQ 830 
R.norvegicus       SKGLCQPGQKQSGSECVCMSPEEDCSSYSEDLCIFDEGSSQYFTSSACKFLAEKCLNSNQ 828 
M.domestica        FPENCGPGHKLVESKCVCMSPEEDCSHYSEDLCVFNSESNHYFTKPSCKFLAEKCANAQK 827 
G.gallus           IRGVCNPGQKQVGSECVCMNPEEDCGHYSEDICVLHALSEQHVTKPSCQFSAEKCLGEQS 829 
X.tropicalis       IQGNCKPGQKQMGSDCICMSPETDCGHFTEDLCTFDAVSQNPVTISRCKFLAENCLGHKK 829 
O.mykiss           PDNQCGRGERHVGSKCICVARET-CLPYKTEFCIFNAEVGSGVMMSYCGFHSGRCHG-DQ 833 
                       *  *.:   *.*:*:  *  *  .. ::* :.      .  . * : : .* . .. 
 
S.scrofa           LQFLHIGSC-QDGPQLEWGLERIKLSSSSTKNESCGYDTCYSWEKCSATTSKCICLLPFQ 887 
B.taurus           LHFVHIGSC-EEGPQLKWGLERIKLSSSSTKNESCGYDTCYNWEKCSATTSKCVCLLPSQ 887 
H.sapiens          LHFLHIGSC-QDGRQLEWGLERTRLSSNSTKKESCGYDTCYDWEKCSASTSKCVCLLPPQ 887 
P.troglodytes      LHFLHIGSC-QDGHQLEWGLERTRLSSNSTKKESCGYDTCYDWEKCSASTSKCVCLLPPQ 887 
P.pygmaeus         LHFLHIGSC-QDGRQLEWGLERARFSSNSTKKESCGYDTCYDWEKCSASTSKCVCLLPPQ 887 
C.familiaris       LHFLHIGSC-QDGPQLEWGLERRILSSNSTKKEPCGYDTCYDWEKCSASVSKCVCLLPPQ 889 
R.norvegicus       FHFVHAGSC-QEGPQLEWGLERLKLAMKSTKRVPCGYDTCYDWEKCSAHTSNCVCLLPPQ 887 
M.domestica        LHFLSAGAC-QDGPQLERAIERIKLSYNSTKKEPCGYDTCYDWESCSASTSTCFCLMPYQ 886 
G.gallus           FHFLHAGPC-HSTSSVHWAIERAKLSANSLKKVPCGYDTCYDWEECPESQMQCSCLMPYQ 888 
X.tropicalis       LQFLDNGPC-KRD-QLDWYRTRVSLAVSSTKKEPCGYDFCYDWEQCSG--SECFCLLPPQ 885 
O.mykiss           LFFMNVGPCDEDVVSLDWAKFRVSMAAKSSVQEPCDSDTCYEWESCTES-KQCLCKVPRD 892 
                   : *:  *.* .   .:.    *  :: .*  . .*. * **.**.*.     * * :* : 
   FIMAC domain (861-934) 
S.scrofa           CLKGGYQHYCVKMGSSTTTRTMNICEVGAIRCALRKMEILYPGRCRSN- 935 
B.taurus           CTKGGDQLFCVQIGSSANGKTMNICEVGAVKCAKREMEILHSGRC---- 932 
H.sapiens          CFKGGNQLYCVKMGSSTSEKTLNICEVGTIRCANRKMEILHPGKCLA-- 934 
P.troglodytes      CFKGGNQLYCVKMGSSTSEKTLNICEVGTIRCANRKMEILHPGKCLA-- 934 
P.pygmaeus         CFKGGNQLYCVKMGSSTSEKTLNICEVGAIRCANRKMEILHPGKCLA-- 934 
C.familiaris       CFKGGSQLYCVKMGSSLSEKTVNICEVGAIRCANRKVDILYPGRCSA-- 936 
R.norvegicus       CPKDENQLHCVKMGSSMRGKTVNICTLGAVRCANRKVEILNPGRCLD-- 934 
M.domestica        CPKNGSQVYCIRTGSSKTEKTMNICALGTLYCAQKKVEIVHHGQCIA-- 933 
G.gallus           CPREESQLHCIRMESTGRRKRVSHCVLAAMKCAGIGLEVLEEGSCLG-- 935 
X.tropicalis       CPPNSEVQYCAKVGSAGKQRTISLCSLGAIKCASIKVEVLYDGACSTTN 934 
O.mykiss           CPKEGEHMFCVKLLKTQSKRSVNLCFMAAIKCRKMEFEILNEGLCEEST 941 
                   *       .* :  .:   : :. * :.:: *    .:::  * *     
 






M.musculus        MQVTSLLILVCFIAAFQV----------FSRASSPVNCKWDSYGPWSECNGCTKTQTRRR 50 
R.norvegicus      MKATSLLILVGFMTEFQI----------FSRASSPVNCEWDSYGPWSECNGCTKTQTRRR 50 
S.scrofa          MKAMSLVFLVGLIGEFQV----------FSSASSPVNCQWDSYAPWSECNGCTKTQTRRR 50 
B.taurus          MKAITLLFLVGFIGEFQV----------FSSASSPINCQWGSYAPWSECNGCTKTQTRRR 50 
H.sapiens         MKVISLFILVGFIGEFQS----------FSSASSPVNCQWDFYAPWSECNGCTKTQTRRR 50 
D.rerio           MKCVFLHGVFLLSLLSSAPITHAGSLRSIRSASEPVHCLWGSWSSWSACDRCSKTQTQIR 60 
O.mykiss          MKDRLSVSLICLSWLFFG-------MFSPINCVEPVHCQWGSYGDWSECDGCTKTQSRAR 53 
P.olivaceus       MKLSLAVCSSLLLILLSP-----------VCCQQSVNCRWGPYGEWSECDGCTSTEARTR 49 
                  *:         :                   . ..::* *. :. ** *: *:.*::: * 
 
   TSP1 domain (30-80)  LDLa domain (84-120) 
M.musculus        SVAVYGQYGGYPCEGSAFETQSCKPERGCPTEEGCGDRFRCFSGQCISKSLVCNGDPDCE 110 
R.norvegicus      SIAVYGQYGGHRCVGSAFETQSCNPERGCPTEEGCGDRFRCFSGQCISKSLVCNGDSDCE 110 
S.scrofa          PVAVYGQYGGHPCVGSTFETQSCEPTRGCPTEEGCGERFRCFSGQCISKSLVCNGDSDCE 110 
B.taurus          SIAVYGQYGGHSCVGSAFETQPCQPTRGCPTEDGCGERFRCFSGQCISKSLVCNGDSDCE 110 
H.sapiens         SVAVYGQYGGQPCVGNAFETQSCEPTRGCPTEEGCGERFRCFSGQCISKSLVCNGDSDCD 110 
D.rerio           FVAVFSQFGGQPCTGSSTRTQTCISTQVCPLEEGCGGRFRCQSGKCISLSLVCNSDQDCE 120 
O.mykiss          AMVVYAQFGGSPCSGGATQTQPCVTARGCPLKEGCGGRFRCRSGKCISQSMVCNGDQDCE 113 
P.olivaceus       HVEVYAQFGGAACSGEATQTQPCVPQKRCPLETGCGDRFRCTSGQCISRTLLCNGDFDCN 109 
                   : *:.*:**  * * : .**.* . : ** : *** **** **:*** :::**.* **: 
 
M.musculus        EDGADEDKCENVAN-PSCNID---KPPPNIELTGYGYNVVTGQGKKRVINTKSFGGQCRK 166 
R.norvegicus      EDGADEDRCEGAESRPSCDTV---KPPPNIELTGNGYNALTGQFRNRVINTKSFGGQCRK 167 
S.scrofa          EDSADEDRCEDSESRPSCDLS---KPPPNIELTGNGYNALTGQFRNRVLNTKSFGGQCRK 167 
B.taurus          EDGADEDRCEDAESRPACDKD---KPPPNIELTGRGYNALTGQFRNQVLNTKSFGGQCRK 167 
H.sapiens         EDSADEDRCEDSERRPSCDID---KPPPNIELTGNGYNELTGQFRNRVINTKSFGGQCRK 167 
D.rerio           -DGSDEQRCDSKPICKISENTNLQKPPPNVEITGQGFDAAKREARGTVINTKSFGGLCQK 179 
O.mykiss          EDNQDELKCGPDKTFPVCNND---KPPPNVEQLGLGFDAVTGKQRGSVINTKSYGGQCRT 170 
P.olivaceus       -DGLDERGCPQDDQQFSCDLD---KTPPNADFTGRGYDVLTGKLRAGVINTQSFGGQCGK 165 
                   *. **  *        .:     *.*** :  * *::  . : :  *:**:*:** * . 
 
M.musculus        VFSGDGKDFYRLSGNILSYTFQVKVDNDFNYEFYNSSWSYIKHTSTEQNTFYS-WKGLFS 225 
R.norvegicus      VFSGDGRDFYRLSGNILSYTFQVKIDNDFNYEFYNSSWSYVKHTSTDYTSSSSNRFLFFS 227 
S.scrofa          VFSGDGRDFYRLSGNVLSYTFQVKVNNDFNYEFYNSTWSYAKHTSTEHTSSSKGRVFIFS 227 
B.taurus          VYSGDGRDFYRLSGNILSYTFQVKINNDFNNEFYNSTWAYVKETSTEHSSSSKGRFLFFS 227 
H.sapiens         VFSGDGKDFYRLSGNVLSYTFQVKINNDFNYEFYNSTWSYVKHTSTEHTSSSRKRSFFRS 227 
D.rerio           TFSGDHKDFYRLPQSVLSYSFQVTAKNDFTDESFASSWHYLHHYEKHEK---------TT 230 
O.mykiss          VLSGDNKVIYRLPQSTLRYNFEVKVQNDFSDEFYTSSWSYAKDIVKRET---------TT 221 
P.olivaceus       VFSGDHKVYYRLPQSVLRYNFEVKVDNEDTDESYESSWSYTQHIQAN------------- 212 
                  . *** :  ***. . * *.*:*. .*: . * : *:* * :.                  
 
Figure 47 Alignment of the C7 proteins among species according to the GenBank ac-
cession no. as given in table 7 using the ClustalW2 tool. The amino acids are 
enumerated above each line on the right side. The identical, similar and 
missing residues are indicated with asterisks (*), points (.), and dashes (-), 
respectively. Signal peptides in human C7 protein (DiScipio et al. 1988) and 
in pig C7 protein are in bold and italic. The amino termini of C7 mature pro-
tein starts just after the signal peptide. The cysteine residues are highlighted. 
The cysteine-rich functional protein domains like TSP1, LDLa, MACPF, 
CCP, and FIMAC are in continuous underline.  The glycosylation sites in 
human (DiScipio et al. 1988) and in pig (Agah et al. 2000) present in shade 
blocks with white bold font. Fragment of amino- (a.a 23-575) and carboxyl- 
terminus (a.a 576-843) is in bold and double underline (DiScipio et al.1988). 
Continuously italic sequence in CCP domain is the internal peptide obtained 





M.musculus        HSRNTYGHGSAKEEIDTKMKSYKLLVVQNTVEVAQFTNNNPEFLQVAEPFWKELSHLPTL 285 
R.norvegicus      SSSNRHTQSSSTKEIYMK-KSYKLLVVQNTVEVAQFINNNPEFLQLAEPFWRELSHLPTL 286 
S.scrofa          SSSSSSSYYAKTYEILKK-KSYQLLVVQNTVEVAQFINNNPEFLQLAESFWKELSYLPPL 286 
B.taurus          SSSSSHGYSSNTNILTKK-KSYQLLVLQNTVEVAQFINNNPEFLQLAESFWKELSYLPSL 286 
H.sapiens         SSSSSRSYTSHTNEIHKG-KSYQLLVVENTVEVAQFINNNPEFLQLAEPFWKELSHLPSL 286 
D.rerio           GTDYGHDDYVFHDELSQS-KSKNLMIIKSDVEVGQFKNKDPEYLPLSEDFWKALVALPVV 289 
O.mykiss          GTTTGFNNYDLHQTEEKN-RNNHLLVVKNNVEVAQFQNQAPGYLSLSEEFWKVLATLPTV 280 
P.olivaceus       -ALFGHDRRTFHKDLTEN-KASRLIILKNKVELAQFQNSAPQYLTLSEGFWKALSSLPFT 270 
                   :                 :  .*::::. **:.** *. * :* ::* **: *  **   
    MACPF domain (249-450) 
M.musculus        YDYSAYRRLIDQYGTHYLQSGSLGGEYRVLFYVDSGSAKETGFQSDQDNACSSADFQFLF 345 
R.norvegicus      YDYSAYRRLIDQYGTHYLQSGSLGGEYRVLFYVDSGDVKHRGFGSVQEKACSSSDFKFIF 346 
S.scrofa          YDYSAYRRLIDQYGTHYLQSGSLGGEYKVLFYVDSEKVAESDLGSEDKKKCASSHISFLF 346 
B.taurus          YDYSAYRRLIDQYGTHYLQSGSLGGEYKVIFHMDSEKVKKFDFHSEDKRKCASSHFQFLF 346 
H.sapiens         YDYSAYRRLIDQYGTHYLQSGSLGGEYRVLFYVDSEKLKQNDFNSVEEKKCKSSGWHFVV 346 
D.rerio           YDYAAYRNVLERFGTHYISEGSLGGHFKLYLMASEDVISKLKSEKRDYEDCVVTSHSVMF 349 
O.mykiss          YDYATYRMVVERFGTHYLSEGTLGGYFQALLSIDQETATQMAKVTWKYNECTKTKHRILF 340 
P.olivaceus       YDYSAYRQLLQTYGTHYLSEGSLGGEYQGLLELDRQAFTSTSTTDTEYKRCWKKVKRRFF 330 
                  ***::** ::: :****:..*:*** ::  :  .            . . *       .. 
 
M.musculus        TS-SADQRCMKQLETEKSTSGNKGRLLR--GKPLVRGGDSGFVADLSFLDLDNPAGNKQR 402 
R.norvegicus      VS-SANQRCKELENIFKSNSGNQGRVLR--GEPSVIGGGPGFVADLSFLDLDNPAGNRQR 403 
S.scrofa          KS-SK-HKCKAMEEALKSASGTQSNVLR--GVPFVRGGRPGFVSGLSYLELDNPDGNKQR 402 
B.taurus          TS-SK-QKCTTMEEVLKSVSENEGNLLR--GVPFVRGGHSGFLAGLSYLDLNNPAGNKRR 402 
H.sapiens         KF-SS-HGCKELENALKAASGTQNNVLR--GEPFIRGGGAGFISGLSYLELDNPAGNKRR 402 
D.rerio           FIRWSTKTCKTDTIDETKTFYKSIPESD--MKTDIIGGDPGFIAKLSMFYKYDVKENART 407 
O.mykiss          VS-WTTEKCRKDEKEYTLPNPPSISRSDTVKKVDVEGGATAHIAALKALDLNTPGRNWDM 399 
P.olivaceus       RK-KVKITCETFMNSISSRDGHNVNKMP--IKVNVFGGDPSFIGALSVLDLEKPETNGEI 387 
                          *       .     .           : ** ...:. *. :       *    
 
M.musculus        YSSWAGSVTRLPQVIKEKLAPLYELVKEVPCASVKRLYLKRAIEEYFDEFDPCHCRPCQN 462 
R.norvegicus      YSSWASSVTSLPQVIKQRLTPLYELVKEVPCASVKRLYLKRALEEYLDEFDPCHCRPCQN 463 
S.scrofa          YSSWAGSVTDLPQVIKQKLTPLYELVKEVPCASVKRLYLKRALEEYLDEFDSCHCQPCQN 462 
B.taurus          YSQWAGSVPDLPEVIKQKLTPLYELVKEVPCASVKKLYLKRAIEEYLDEFDPCHCRPCHN 462 
H.sapiens         YSAWAESVTNLPQVIKQKLTPLYELVKEVPCASVKKLYLKWALEEYLDEFDPCHCRPCQN 462 
D.rerio           FSQWSGSLKYYPRIIKSKLRSLHELVKEVPCAGLKRFLLKRAIETYLTEKHSCQCRECQN 467 
O.mykiss          YKNWAESVRTFPAVIKRKMRPLYELVKEVQCAGMKRFHLKRAIEQYLNERHPCRCQPCRN 459 
P.olivaceus       YDNWASSVKDFPNIIDQKLRPLHELVKEVQCAGLKKLHLERATEEYLSEEHPCHCRPCQN 447 
                  :. *: *:   * :*. :: .*:****** **.:*:: *: * * *: * ..*:*: *:* 
 
M.musculus        GGLAIVVETQCQCLCKPYTFGSACEQGVLVGDQAGGVDGGWNCWSSWSPCVQGKRTRSRE 522 
R.norvegicus      GGIASVVGTQCQCHCKPYTYGMACEQGVLVGDQAGGVDGGWSCWSSWSPCVQGKKSRSRE 523 
S.scrofa          GGMASVEGTQCQCHCKPNTFGVACEQGVLVGDHAGGIDGGWSCWSSWGPCAQGKKTRSRK 522 
B.taurus          GGMATVQGSQCQCYCKPKTSGVACEQGVLLGDQAGGVDGGWNCWSSWGPCVQGKKTRSRQ 522 
H.sapiens         GGLATVEGTHCLCHCKPYTFGAACEQGVLVGNQAGGVDGGWSCWSSWSPCVQGKKTRSRE 522 
D.rerio           NGLRVLDGNVCKCVCKPGTSGQACEYGTAYDEQPGVIHGDWACWSSWSSCSGGQKSRRRS 527 
O.mykiss          NGLVVMAGDKCSCICKPGTDGLACEKGKEVEGQEGVIHGSWSCWSGWNSCSGGQRSRTRA 519 
P.olivaceus       NGQPLLSGSVCRCVCRPGTSGPACQTGAVIGEQPGLIHGGWSCWSSWGSCSGGRMSRTRS 507 
                  .*   :    * * *:* * * **: *     : * :.*.* ***.*..*  *: :* *  
       TPS1 domain (503-551) 
M.musculus        CNNPPPRDDGKSCLGETTESKQCEDQD-LEKLRLLEPHCFHSSLAPKEFCLSPPALKDGF 581 
R.norvegicus      CNNPPPRAGGKACIGETTESRQCEDQD-LENLRLLEPHCFHLSLVPKGFCPSPPALKDGF 582 
S.scrofa          CNNPPPSGGGKSCIGETSESRQCEDED-LEHLRLLEPHCFPLSLVPTEFCPSPPALKDGF 581 
B.taurus          CNNPSPSAGGKSCIGETSETRQCEDEE-LEHLRLLEPHCFPLSLVPTKFCSSPPALKDGF 581 
H.sapiens         CNNPPPSGGGRSCVGETTESTQCEDEE-LEHLRLLEPHCFPLSLVPTEFCPSPPALKDGF 581 
D.rerio           CTRPAPS-GGRDCIGNTEERTACEDEEELNHLRSMEPHCFDDSIKPRESCKTPPFVPNGF 586 
O.mykiss          CSNPAPQRGGHHCNGEVRETTGCDDDQDLQYLQTMEPQCFDLTVPPKETCRSPPPLPNGY 579 
P.olivaceus       CNNPAPSRGGQHCTGLRAEQKPCEDPQ-IQYLQTMEPQCFSLSVTPPKTCGPPPNLRNGF 566 
                  *..*.*  .*: * *   *   *:* : :: *: :**:**  :: *   * .** : :*: 
   CCP domain (571-626) 
M.musculus        VQGEGTMVPVGQSVVYACDEGYSLIGDPVARCGEDLQWLVGEMHCQKLACVLPGEMNGMQ 641 
R.norvegicus      VQSEGTMFPIGKNIVYACNEGYSLVGDPVARCGEDLQWLVGEMHCQKIACFLPGGMNGMR 642 
S.scrofa          VQNEETTFPVGKNIVYSCNEGYSLVGDPVARCGEDLQWTVGKMHCQKIACVLPTLMRGLQ 641 
B.taurus          VQDEGATFPVGKNIMYTCKEGYSLVGDPVARCGEDLQWLVGNMHCQKIACVLPALMDGIQ 641 
H.sapiens         VQDEGTMFPVGKNVVYTCNEGYSLIGNPVARCGEDLRWLVGEMHCQKIACVLPVLMDGIQ 641 
D.rerio           VLYPKDVYPVGSKIEYTCIEGYHLIGNAIAKCQEDLNWLQYPVECKKTQCDPPQLPPDVT 646 
O.mykiss          VLDPKDVYLVGSKIEYTCIEGYHLIGIRIAECTVALTWSTPSKECKSSRCHVPSLLNDVT 639 
P.olivaceus       IQNPRDFYVVGNTVEFSCTEGHYLSGDAVTRCTENQTWTPRTTVCKSTTCGIPQLGAEVM 626 






   CCP domain (631-688) 
M.musculus        SHPQKPFYMVGEKVTLSCVGGMSLEGPS-TLLCGSSLKWSPELKDAKCVQKENPATSTPP 700 
R.norvegicus      SDPQKPFYMVGEKVTLSCAGGMSLEGPS-TFLCGSSLKWSPELKSAQCVQKEN----TLT 697 
S.scrofa          SHPQKPFYTVGEKVTFSCSSGMSLEGPS-TFLCGSSLKWSPEMKNVQCVRKEAP----LA 696 
B.taurus          SHPHKPFYTIGEKVTISCSGGRSLEGPS-TFLCSSSLKWSPEVKDVQCVQREAP----LT 696 
H.sapiens         SHPQKPFYTVGEKVTVSCSGGMSLEGPS-AFLCGSSLKWSPEMKNARCVQKENP----LT 696 
D.rerio           ANPWKLNYNIGEAIALSCPEGKVKEGLD-EIQCNAGLSWSPQPKNTKCLTAVLKPT-VVP 704 
O.mykiss          GSPWQPTYDIGERIPLSCPKGRHIVGDK-EIICDSSLHWSPDPNTITCSQAPKTLD-HLD 697 
P.olivaceus       ATPTKAAYQIGDGVSLSCPAGSLLDGEVSEVICSPSLQWSPSPAGARCKAAPTAPP-PPS 685 
                  . * :  * :*: :..**  *    *    . *...* ***.     *             
   FIMAC domain(696-765) 
M.musculus        PAAPACQPWEKLQNSKCICKMPYECGSSLDVCARDESRNKILSLTICKMHVVHCHKRNYT 760 
R.norvegicus      PAAPACQPWEKLKNSKCVCKMPYECGSSLDVCARDERSNRILPLTICKMHVLQCQGRNYA 757 
S.scrofa          KKVPECQLWEKLQNSKCVCKMPYECGSSLDVCARDERSKRILRLTVCKMHVLQCQGRNYT 756 
B.taurus          PKVPKCQPWEKLQNSRCVCKMPYECGSSLGVCARDERSKRILPLTVCKMHVLQCQGRNYT 756 
H.sapiens         QAVPKCQRWEKLQNSRCVCKMPYECGPSLDVCAQDERSKRILPLTVCKMHVLHCQGRNYT 756 
D.rerio           ---VKCQPWENLAKDKCVCKVPHQCKSSLEVCVTDEKRGRTQRLSVCKVQAMRCLGHQYS 761 
O.mykiss          GPAGQCKPWEKLAKDKCICKMPYECTSSLQVCANNLENGRTNRLSVCKMHTLNCLGRSYN 757 
P.olivaceus       G--LKCKPWETAGKNKCVCKMPFQCSASLLLCAR--LGSAPKLLSTCQLGALQCLGRSFS 741 
                       *: **.  :.:*:**:*.:* .** :*.          *: *:: .:.*  :.:  
     FIMAC domain (772-840) 
M.musculus        LVGKESCTLPSPAEKVCGACPIWSKCDAQNGKCICREASECQTAGYRICVEVN----GKE 816 
R.norvegicus      LVGKNSCTLPASTEKACGACPIWSKCDAQNSKCVCREASECQKAGYRICVEVN----GKE 813 
S.scrofa          LSVGETCTLPGSAEKACGACPLWEKCDAQSSKCVCRAASECEEAGFRVCVEVN----GRE 812 
B.taurus          VAGRESCTLPASAEKACGVCPLWEKCDAEGSECVCRAASECEEAGFSVCVEVN----GRE 812 
H.sapiens         LTGRDSCTLPASAEKACGACPLWGKCDAESSKCVCREASECEEEGFSICVEVN----GKE 812 
D.rerio           LAEDSACQWTQPSTNNCTRCTLGETCDEQTNSCRCKTSEDCSSPDTWIHVCVKQDKASAP 821 
O.mykiss          LAEDSACEWPTNTTSPCTDCQLWETCDGQTNQCRCKDWAECSDPGLSVCVRMGDDANSAT 817 
P.olivaceus       LTSDADCQWPEG-----------AFCQESVRECPTDSAPLCVS-------------SGVV 777 
                  :     *  .               *: .  .*       *                .   
 
M.musculus        ETMSECEAGILRCRGQSISITAIKPCAEEAAQ 848 
R.norvegicus      ETMSECEAGILRCRGQSISITAIKPCAQEVQ- 844 
S.scrofa          QTMTECEAGVLRCLGLSITVTSIRPCAPEAP- 843 
B.taurus          QTMTECEAGVLRCRGLSISVTGIRPCVAEAA- 843 
H.sapiens         QTMSECEAGALRCRGQSISVTSIRPCAAETQ- 843 
D.rerio           VTMTECEVAMRKCRGETVHIVSIQACQS---- 849 
O.mykiss          QTLSECEAGLRRCKGEKVSVVSILPCSA---- 845 
P.olivaceus       TTMTECEVGARRCGGELMNVIGIDACPE---- 805 
                   *::***..  :* *  : : .* .*       
 
Figure 47 (continued) 
 
 
S.scrofa           -------------------MLAVAFFILSLMTCQP-----------GVTIPEKVNRRVSR 30 
B.taurus           -------------------MFAAAFFLLFLMTYQP-----------GVTIQEKVNWRVSR 30 
C.familiaris       -------------------MFAAAFFILSLMICQP-----------GVTIQEKVNRRVSR 30 
H.sapiens          -------------------MFAVVFFILSLMTCQP-----------GVTAQEKVNQRVRR 30 
P.troglodytes      -------------------MFAVVFFILSLMTCQP-----------GVTAQEKVNQRVRR 30 
M.mulatta          -------------------MFAVVFFILSLMTCQP-----------GVTAQEKVNQRVRR 30 
O.cuniculus        -------------------MLVAAFFTLFLVTCQP-----------AVTAQEKVNQRVNR 30 
M.musculus         -------------------MFVVAFFGLSLVAWHP-----------GVTAQEKVNQRVTR 30 
R.norvegicus       -------------------MFTVAFFGLSLMAWHS-----------GVTAQEKVNQRVTR 30 
G.gallus           ---------------MWWSLCQVSPLILTICSLSITARWATAAA-CGEPAAVPAQRRSSR 44 
X.tropicalis       -------------------MIVMLYHALALWGYTA--------------SIGNMDLLLFR 27 
O.mykiss           MSSFSSRSSFISNMNRLICVLLGSYILLLVLNKSPTVDATEYSWNMAETRTGQSAIRRVR 60 
                                      :       * :                             * 
 
Figure 48 Alignment of the C8A proteins among species according to the GenBank 
accession no. as given in table 9 using the ClustalW2 tool. The amino acids 
are enumerated above each line on the right side. The identical, similar and 
missing residues are indicated with asterisks (*), points (.), and dashes (-), 
respectively. Signal peptides in human C8A protein (Rao et al. 1987) and in 




             TSP1 (44-94) 
S.scrofa           AVLSSTPTAVSCQLSNWAEWTECFPCQDKKYRYRSLLQPNKFGGAICSGNVWDQASCHSP 90 
B.taurus           AVQSFTPTAVSCQLDNWAEWTDCFPCQDKKYRYRSLLQPNKFGGTICSGNVWDQASCHSP 90 
C.familiaris       AVQSAPITAVPCQLSNWSEWTDCFPCQDKKYRYRSLLQPDKFGGTICSGDVWDQASCHSP 90 
H.sapiens          AAT---PAAVTCQLSNWSEWTDCFPCQDKKYRHRSLLQPNKFGGTICSGDIWDQASCSSS 87 
P.troglodytes      AAT---PAAVTCQLSNWSEWTDCFPCQDKKYRHRSLLQPNKFGGTICSGDIWDQASCSSS 87 
M.mulatta          AAT---PAAVTCQLSNWSEWTDCFPCQDKRYRYRSLLQPNKFGGTICSGDVWDQASCSSS 87 
O.cuniculus        AAT---PRAFDCQLSSWSEWTDCFPCQDTKYRHRSLLQPNKFGGTICSGDIWDRASCYSP 87 
M.musculus         AVT---PQAVSCQLSDWYKWTDCFPCQDKKYRYRSLLQPSKFGGTICSGDIWDEASCDSP 87 
R.norvegicus       AVT---PGAVACQLSDWSEWTDCFPCQNEKYRYRSLLQPSKFGGTICSGDIWDKANCDSP 87 
G.gallus           DISS--PPPVDCQLSQWSEWTDCFPCQGRKHRHRTLLQPAMFGGQRCKGPLWDEQSCSAW 102 
X.tropicalis       SIAA--PQPEDCQLDQWSQWTSCFPCQQKKYRYRKLLQPAKYEGRPCVGSLWASMACQTA 85 
O.mykiss           SVN--KPAPINCKMKMWSSWSPCDSCTDKKFRFRYMEKASQFGGRQCLDSQWEELACPTA 118 
                           .  *::. * .*: * .*   :.*.* : :.  : *  * .  *    * :  
 
LDLa (98-135) 
S.scrofa           TE-CLRQAQCGQDFQCKETGRCLKRHLVCNGDRDCLDGSDEDDCEDVRIFEDDCSQYDPI 149 
B.taurus           TA-CLSQAQCGQDFQCKETGRCLKRHLVCNGDKDCLDGSDEDDCEDVRILENDCSQYDPI 149 
C.familiaris       TA-CLHQAQCGQDFQCKETGRCLKRHLVCNGDKDCLDGSDEDDCEDVRVAENDCSQYEPI 149 
H.sapiens          TT-CVRQAQCGQDFQCKETGRCLKRHLVCNGDQDCLDGSDEDDCEDVRAIDEDCSQYEPI 146 
P.troglodytes      TT-CVRQAQCGQDFQCKETDRCLKRHLVCNGDQDCLDGSDEDDCEDVRAIDEDCSQYEPI 146 
M.mulatta          TP-CIRQARCGQDFQCKETGRCLKRHLVCNGDQDCLDGSDEDDCEDVRAIDEDCSQYEPI 146 
O.cuniculus        TA-CLRPAQCGQDFQCKETGRCLKRHLVCNGENDCLDGSDEDNCEDIRATESDCAQYDPI 146 
M.musculus         TP-CLRQAQCGQDFQCRETGRCLKRHLVCNGDNDCLDGSDESDCEDVRVTEDDCHQYEPI 146 
R.norvegicus       TP-CLRQAQCGQDFQCRETGRCLKRHLVCNGDQDCLDGSDEDNCDDARVIEDDCRQYEPI 146 
G.gallus           ES-CARAPSCGNDFQCKESGRCIKQHLVCNGNTDCRDGSDENDCEHE-EIEHPCDNLFPI 160 
X.tropicalis       QK-CVPENNCGNDFQCRDSGRCIKRRLVCNGDLDCRDSSDEEDCDAP-EHETFCKTLFPI 143 
O.mykiss           QAVCWEPDICGERFTCNATGRCVSQALRCNGEVDCDDESDETDCEQVDDRQDKCSTLLPI 178 
                      *     **: * *. :.**:.: * ***: ** * *** :*:     :  *    ** 
         
S.scrofa           PGSERATLGYNILTQEETQSVYDARYYGGQCETVYNGEWRELRYDSACERLYYGDDEKYF 209 
B.taurus           PGSEKAALGYNILTQEEAQHVYDARYYGGQCETVYNGEWRELQYDPACERLYYGDDDKYF 209 
C.familiaris       PGSESAALGYNILTQKEAQHVYDPRYYGGQCETVYNGEWREIRYDPTCERLYYGEDEKYF 209 
H.sapiens          PGSQKAALGYNILTQEDAQSVYDASYYGGQCETVYNGEWRELRYDSTCERLYYGDDEKYF 206 
P.troglodytes      PGSQKAALGYNILTQEDAQSVYDASYYGGQCETVYNGEWRELRYDSTCERLYYGDDEKYF 206 
M.mulatta          PGSQKAALGYNILTQEDAQSVYDATYYGGQCETVYNGEWRELRYDPTCERLYYGDDEKYF 206 
O.cuniculus        PGSEKAALGYNILTQEEAQSVYDARYYGGRCETVYNGEWRHVRYDPVCERLHHGEDDKYF 206 
M.musculus         PGSERAALGYNILTQEEAQSVYDAKYYGGQCETVYNGDWRKLRYDPTCERLYYGEDEKYF 206 
R.norvegicus       PGSERAALGYNILTQEEGQSVYDAKYYGGQCETVYNGDWRRLQYDPTCERLYYGEDEKYF 206 
G.gallus           PGSEKAARGYNILTQEAKRYIYDPKFLGSHCESVYNGEWRALRYDAACERLYYGDDEKYL 220 
X.tropicalis       PGAEKSVRGINILTHEDTRNVIDHNYFGGQCEYIYNGEWRELRYEPVCEQMYYSDEEKYF 203 
O.mykiss           PGAGRGTQGFNILTGEFVDHVLDPQYYGGQCEYVYNGEWRKLIYDPFCENLHYNEDEKNY 238 
                   **:  .. * **** :    : *  : *.:** :***:** : *:. **.:::.:::*   
 
 
Figure 48 (continued) Position starts for amino terminus sequence of the mature por-
cine C8A protein in bold and double underline (Nakajima et al. 1998). The 
cysteine residues are highlighted. The cysteine-rich functional protein do-
mains like TSP1, LDLa, and MACPF are in continuous underline. The gly-
cosylation sites in human (Rao et al. 1987) and in pig (Nakajima et al. 1998) 
present in shade blocks with white bold font. Different amino acid sites in 
our protein and Nakajima et al ´s (1998) are in bold and double underlined. 
Position of sequence forming the disulfide bond to C8G is continuously bold 
underlined in italic (Plumb and Sodetz 2000). The proposed candidate site 
for CD59 recognition is performed in continuously bold in MACPF domain 




S.scrofa           RNPYNFLKYHFEALADSKFSSESYDDANDLLKKVKNEKSVSAGVTVGIGPTGSPFTANVG 269 
B.taurus           RKPYNFLKYHFEAQADTKISSEIYNDANDLLTKVKNDKSVSSGLTIGVGIRGVPVTVTAG 269 
C.familiaris       RKPYNFLKYHFEALADTRFSSELYDDAHDLLSKVKNNNFVSTGVTVGVSFTGSSVTVDVG 269 
H.sapiens          RKPYNFLKYHFEALADTGISSEFYDNANDLLSKVKKDKSDSFGVTIGIGPAGSPLLVGVG 266 
P.troglodytes      RKPYNFLKYHFEALADTGISSEFYDNANDLLSKVKKDKSDSFGVTIGIGPAGSPLLVGVG 266 
M.mulatta          RKPYNFLKYHFEALADTGISSELYDNANDLLSKVRKDKSDSFGVTIGIGPAGSPLMVGVG 266 
O.cuniculus        RKPYNFLKYHFEARADTGISFELYVDGNDLFSKVKNDKSHSAGVTISAGLTGSPLLGTVG 266 
M.musculus         RKPYNFLKYHFEALADTSISSEFYDDANDLFFHIKNGKSHSAGVTVGVAPVKSPVSIEVT 266 
R.norvegicus       RKPYNFLKYHFEALADTLISSEFYDDANDLFSKIQRDKSQSNSVTFGISPAKSPITLDAS 266 
G.gallus           LKPYNFHVYQFLAHADSGFSSEFYDDSKDLIDALKSSKSEGGGFTIGIGPKKIDFKLNLG 280 
X.tropicalis       RKPYNFHIYQFLARADTKMSIEIYEDSKDVVNAVKRDFSFNIGLTFGISVPEAPVGLELG 263 
O.mykiss           RKPYNFHTYRFMAQATSEGSSEYYEDMATLLKARKTEDSFNLGVTVGIR------YVEFG 292 
                    :****  *:* * * :  * * * :   :.   :     . ..*..              
 
S.scrofa           LSGSRESAFLNKLSTYNEKKYSFIRIFTKVQTASFMMRRDNIMLDEVMLQSLMELP-EQY 328 
B.taurus           VSMSQDAAFLKKLSKYHEKKYSFMRIFTKVQTAHFKMRRENIVLDEGMLQSLMELP-ERY 328 
C.familiaris       VSSSQNSSSLDELKKYNKKKYSFLRVFTKVQTAHFKMRRGNIVLDEGMLQSLMELP-EQY 328 
H.sapiens          VSHSQDTSFLNELNKYNEKKFIFTRIFTKVQTAHFKMRKDDIMLDEGMLQSLMELP-DQY 325 
P.troglodytes      VSHSQDTSFLNELNKYNEKKFIFTRIFTKVQTAHFKMRKDDIMLDEGMLQSLMELP-DQY 325 
M.mulatta          VSKSEDASFLKELNKYNEKKFIFMRIFTKVQTAHFKMRRDNIMLDEGMLQSLMELP-DQY 325 
O.cuniculus        VSGSEDASFLNKLSQYNEKKYNFMRIFTKVQTAHFKMRRDDIVLDEGMLQALVELP-EQY 325 
M.musculus         GSGSKASSFLNKLNKYNEKRYGFMRVSTKIQTAQFKMRRNNIVLDEGMLQSLMELP-EQF 325 
R.norvegicus       VSWSDESSFMKELSKYNEKKYSFMRVSTKVQTAHFKMRRHNIVLDEGMMESLMELP-EQF 325 
G.gallus           FTLSRGKGSLKNFTEYTAKNLGFIRIATKVQTARFKMRRNNIVLDEDMLISLRELP-DTY 339 
X.tropicalis       LNYGLKTSFLKKITSFNQKNLEFVRMVTKIQTARFKMRRNLLTLDEDAMQSLMELP-DEY 322 
O.mykiss           VSGNVESALLTNLTKYTNQELGFIRLQSKVQTAQFKMRSEGLMLHEDMYLSLMELPEEKY 352 
                    . .   . : ::. :  :.  * *: :*:*** * **   : *.*    :* *** : : 
    MACPF domain (291-497) 
S.scrofa           NYGMYAKFIDDYGTHYITSGSMGGVYEYILVLNKENMTKSGVTSDDVTSCFGGSFGIDYD 388 
B.taurus           HYGMYAKFINDYGTHYITSGSMGGVYEYILVLNREKMETAGVTSAEIQKCFGVSLGIEYE 388 
C.familiaris       NYGMYAKFINDYGTHYITSGSMGGIYEHILVLNKEEMESQRITSRDIEKCFGISVGIEYD 388 
H.sapiens          NYGMYAKFINDYGTHYITSGSMGGIYEYILVIDKAKMESLGITSRDITTCFGGSLGIQYE 385 
P.troglodytes      NYGMYAKFINDYGTHYITSGSMGGIYEYILVIDKAKMESLGITSRDITTCFGGSLGIQYE 385 
M.mulatta          NYGMYAKFINDYGTHYITSGSMGGTYEYILVIDKAKMESLGITSRDIMTCFGGSLGIQYE 385 
O.cuniculus        NYGMYSKFINDYGTHYITSGSMGGTYEYILVLNTEKMESLGVTSEDISSCFGGFGEIQYE 385 
M.musculus         NYGMYAKFINDYGTHYITSGTMGGIYEYVMVLDKEKMKTEGTTVDEVQKCIGGGIGIGIK 385 
R.norvegicus       NYGMYSKFINDYGTHYITSGTMGGIYEYVLVLDKEKMRIHGITVEDVKKCIGGGVGLQFG 385 
G.gallus           NYGMYAKFINDYGTHFMTSGTMGGDLEYILVVNKEEMRRKDISYEEVTTCFGLSLGVSAK 399 
X.tropicalis       NYGLYAQFINDFGTHYTTSGTMGGLVENIVVLDKEIMKKQEITASMVSHCFGASVRLSVQ 382 
O.mykiss           DFGLYSRFLNTYGTHYVTQGIMGGTLEYVAVVNTTAMKTSKIDAEQLKGCLGGSIGISSP 412 
                   .:*:*::*:: :***: *.* ***  * : *::   *         :  *:*    :    
 
S.scrofa           YTD--NLQITGSLSGKHCKK----LGGGHREDEESNMAVEDIISRVRGGSSGWGGGLTQN 442 
B.taurus           YSE--AIQIKGSSSLGPCKK----SGDGKLTENEKAMGVEDFISRVRGDSSGWGGSLTQD 442 
C.familiaris       YAN--WMKIGGSLGGKGCEN----IGGGDSKGHRLTTAVEDIISLVRGGSSGWGAGLAEK 442 
H.sapiens          D----KINVGGGLSGDHCKK----FGGGKTERARKAMAVEDIISRVRGGSSGWSGGLAQN 437 
P.troglodytes      D----KINVGGGLSGDHCKK----FGGGKTETARKAMAVEDIISRVRGGSSGWSGGLAQN 437 
M.mulatta          G----GINVDGSLSGDHCKK----FGDGKTERARKAMAVEDIISRVRGGSSGWSGGLAQN 437 
O.cuniculus        KG---KINAQGILSGKHCKK----SGSGDKEADKMGQAVKDIISRVRGGSSGWGGGLSQN 438 
M.musculus         DS----TIEGVGISGEFCEN----SGDGDRDIRKKITGVEDIISRVQGGSSVWGSVLTHN 437 
R.norvegicus       EK----IIGEGDLSGESCVM----TGDGNQDKRKKDLAVEDIISRVQGGSSRWSTGLAHN 437 
G.gallus           KL---MLHWEASVSLSVCAEKQLLNAVDFSDAGSNSPVMEDIIVRIKGGDTSYSARPISS 456 
X.tropicalis       TEFE-EIIPSLKLSGDFCTK----FERENQDNSSSSRAIKDVITYVIGGDSGSAGGILNV 437 
O.mykiss           IGKTKQVEVGGKLEVKGCKG----TGSYEKEMYGSSSLIKDIVTLVKGGSTGGSGGLLAI 468 
                                    *                    ::*.:  : *..:  .       
 
S.scrofa           GSIITYRAWGRSLKYNPAVIDFEMKPIYEILRHTNLG-PLEAKRQNLRRALDQYLMEFNA 501 
B.taurus           SSLVTYRSWGRSLKYNPAVIDFEMKPIHEILQHTNLG-SLETKRQNLRRALDKYLMEFNA 501 
C.familiaris       RSTITYRSWGRSLKYNPVVIDFEMQPIHEVLRHTTLG-PLETKRQNLHRALDQYLMEFNA 501 
H.sapiens          RSTITYRSWGRSLKYNPVVIDFEMQPIHEVLRHTSLG-PLEAKRQNLRRALDQYLMEFNA 496 
P.troglodytes      RSTITYRSWGRSLKYNPVVIDFEMQPIHEVLRHTSLG-PLEAKRQNLRRALDQYLMEFNA 496 
M.mulatta          RSTITYRSWGRSLKYNPVVIDFEMQPIHEVLRHTSLG-PLEAKRQNLRHALDQYLTEFNA 496 
O.cuniculus        GSATTYRFWGRSLKYNPVVIDFEMQPIHEVLLHTNLG-HVEAKRQNLRRALDQYLMEFNA 497 
M.musculus         SSAITYQSWGRSLKYNPVVIDFEMQPIYQLLRHTNLG-PLETKRQNLRRALDQYLMEFNA 496 
R.norvegicus       SSAITYRSWGRSLKYNPVVIDFEMQPIYQLLQHTNLG-PLETKRRNLRRALDQYLMEFNA 496 
G.gallus           WDSNTYRRWGRSLKYNPAIIDFELQPIHEILPRSDAG-NMETKRQHLKQALDEYLLEFNA 515 
X.tropicalis       FDGRMYRYWGRSLKYNPAVIDFEIQPIYEGLQQTGLS-GIEAKRQNLKRAYNEYLSEFDP 496 
O.mykiss           KDPDTYRKWGLSLKYNPNLIEFETLPIFELVRLSTAGDHVGARPAHLRRAWEEYLLQFNS 528 
                    .   *: ** ****** :*:**  **.: :  :  .  : ::  :*::* ::** :*:. 
 




S.scrofa           CRCGPCFNNGEPILVGTSCRCQCPVGCQGLACEQMKSE---GAKADGRWSCWSSWSACRL 558 
B.taurus           CRCGPCFNNGEPILEGTSCKCQCPVGHQGLACEQMQSE---GAQADGRWSCWSSWSACRS 558 
C.familiaris       CRCGPCFNNGKPILEGTSCKCQCPLGRKGLSCEQMEQK---GAKADGHWSCWSSWSACRA 558 
H.sapiens          CRCGPCFNNGVPILEGTSCRCQCRLGSLGAACEQTQTE---GAKADGSWSCWSSWSVCRA 553 
P.troglodytes      CRCGPCFNNGVPILEGTSCRCQCRLGSLGAACEQTQTE---GAKADGSWSCWSSWSVCRA 553 
M.mulatta          CRCGPCFNNGVPILEGTSCRCQCRLGRLGPACEQIQTE---GAKADGSWSCWSSWSVCRT 553 
O.cuniculus        CRCGPCFNNGKPILEGTSCRCQCSLGLQGPACEQTEQQ---GAKADGHWSCWGSWSPCTA 554 
M.musculus         CRCGPCFNNGEPILDGTNCRCQCSMGRQGLACERTVIEGLKDFKAAGHWSCWSSWSECRG 556 
R.norvegicus       CRCGPCFNNGVPILEGTSCSCQCSMGRQGPACESMVLEAMEGAKADGRWSCWSSWSECRG 556 
G.gallus           CRCGPCQNNGEPVLVGDECSCQCPSGYSGPACERSEHQ---GTEVDGRWSCWSSWTPCQS 572 
X.tropicalis       CRCGPCHNNGMPMLENNVCTCLCAAGFNGPSCENTLRK---DVKADGRWSCWSPWTQCQS 553 
O.mykiss           CRCAPCRHDGIPVLSQTSCHCICKQGFRGEACEETLRK---DSTTDGAWSCWGAWSSCQS 585 
                   ***.** ::* *:*    * * *  *  * :**    :   .  . * ****..*: *   
     TSP1 domain (547-586) 
S.scrofa           GTQERRRECNNPAPQNGGASCSGHKVQTQAC 589 
B.taurus           GTQERRRECNNPAPQNGGASCPGHRVQTQAC 589 
C.familiaris       GTQERRRECNNPTPQNGGASCPGWKAQTQAC 589 
H.sapiens          GIQERRRECDNPAPQNGGASCPGRKVQTQAC 584 
P.troglodytes      GIQERRRECDNPAPQNGGASCPGRKVQTQSC 584 
M.mulatta          GTQERRRECDNPAPQNGGASCPGRKVQTQAC 584 
O.cuniculus        GTRERRRECNNPAPQNGGAPCPGWRVQTQAC 585 
M.musculus         GSQERRRQCNNPPPKNGGTPCLGRNLQTQAC 587 
R.norvegicus       GSRERRRQCNNPAPQNGGAPCLGKSLQTQAC 587 
G.gallus           GSRRRSRQCTNPAPQHGGAPCMGRDVQSSSC 603 
X.tropicalis       GKRQRTRECNNPAPKNGGAWCLGKSLQSEPC 584 
O.mykiss           GSKTRRRSCDNPQP-DGGAACLGSSSQNQRC 615 
                   * : * *.* ** * .**: * *   *.. * 
 
 




O.mykiss          ----------------------MNHKLKP--TVGLGYCLLCAALCLLLLRD--------- 27 
P.olivaceus       ----------------------MFRVAIPRSALNLHSCLLHVTLSLVLISK--------- 29 
D.rerio           -------------------------------------------MHSFLRVN--------- 8 
H.sapiens         ----------------------MKNSRTWAWRAPVELFLLCAALGCLSLPGSRGER---- 34 
M.mulatta         ----------------------MKNSRTSAWRALVELFLLCAALGCLSLPGSRGER---- 34 
O.cuniculus       ----------------------MKKSWTWTWRVPAELLLLCAALGCLCVPGSRSER---- 34 
C.familiaris      ----------------------MKTSRPQGWRALAELILLCAALGCLSLPGSRSER---- 34 
S.scrofa          ----------MSLSQISCRIEKMKTSGTWAWRMPARLFLLCAALGCLSLPGSRGER---- 46 
R.norvegicus      ----------------------MKTG-AQVWRALAKSCLLCAALGCLHLPGARGEK---- 33 
G.gallus          ----------------------MTVAWMAFTLCPIKLLLLCAALCFLDVHCFSSG----- 33 
M.domestica       MFWVQNWKGSSSRDSETWQNGDWPKRTVRGLMDYVRAMLFTSSWRNLSNVDTVSLYNTDD 60 
                                                               .              
 
Figure 49 Alignment of the C8B proteins among species according to the GenBank 
accession no. as given in table 11 using the ClustalW2 tool. The amino ac-
ids are enumerated above each line on the right side. The identical, similar 
and missing residues are indicated with asterisks (*), points (.), and dashes 
(-), respectively. Signal peptides in human (Howard et al. 1987) and in pig 
C8B protein are in bold and italic. The amino termini of C8B mature pro-
tein starts just after the signal peptide. The cysteine residues are high-
lighted. The functional protein domains TSP1, LDLa, MACPF, and EGF 
are in continuous underline. The glycosylation site in human (Howard et 
al. 1987) and in pig using the NetNGlyc 1.0 Server tool present in shade 




O.mykiss          ----------------VAIAGSGEEPSGVREARSVGTQVAVQPVDCVQSEWSSWTRCDVC 71 
P.olivaceus       ----------------AAITTAGNEDSDVREARSVSDQQVVHPVDCVISDWSAWSRCDTC 73 
D.rerio           ----------------SAILCLGILCSSLSSADPAPKD----PVDCSLSEWSSWTRCDAC 48 
H.sapiens         ---------------PHSFGSNAVNKSFAKSRQMRSVDVTLMPIDCELSSWSSWTTCDPC 79 
M.mulatta         ---------------LHSFESNAVNKSFAKSRQTRNVDVTLMPIDCELSSWSSWTTCDPC 79 
O.cuniculus       ---------------PRSLEPTVVNRSLAKSRHSRSVDATPMPIDCELSSWSSWTMCDPC 79 
C.familiaris      ---------------PQSLESNAVNESLAKSRQTRSVDVTLMPIDCELSSWSSWTMCDPC 79 
S.scrofa          ---------------PHSLESNAVNESLGKSRQTRSVDVTLTPIDCELSSWSSWTTCDPC 91 
R.norvegicus      ---------------PDFFETNAVNGSLVRSRPVRSVDVTPAPTDCQLSTWSSWTACDPC 78 
G.gallus          --------------------TESLGPISTSSRQARSVRNPPQPRDCVLSTWSSWSKCDPC 73 
M.domestica       PRFPPWTFFCDLGCERKLFEDLIIKRNFTNGRRVHNQLGTPKPIDCLVSSWSQWSLCDPC 120 
                                                            * **  * ** *: ** * 
   TSP1 domain (79-129) 
O.mykiss          RKKRYRYAKLVQPSQFGGEPCHVQGKEVEPCSPPSRYDCTHDETPLCEGFLCTYTGRCVP 131 
P.olivaceus       QKKRYRYAKLDQPSQFGGEPCHFHDMEDEACDVPDRYTC--DSIPLCEGFLCTQTGRCIH 131 
D.rerio           LKKRFRYATLIQPSEFGGEPCQNNGREEESCTPPARFSCQ-KSFAICQGFRCTVTGRCVL 107 
H.sapiens         QKKRYRYAYLLQPSQFHGEPCNFSDKEVEDCVTNR--PCR--SQVRCEGFVCAQTGRCVN 135 
M.mulatta         QKKRYRYAYLLRPSQFHGEPCNFSDKEVEDCVTNR--PCR--TQVRCEGFVCAQTGRCVN 135 
O.cuniculus       QKKRYRHAYLLRPSQFNGEPCNFSDKEVEDCATSR--PCR--SQVRCEGFVCAQTGRCVN 135 
C.familiaris      QKKRYRHASLLRPSQFYGEPCNFSDKEVEDCVTSR--PCR--SQVRCEGFVCAQTGRCVN 135 
S.scrofa          QKKRYRHASLLRPSQFHGEPCNFSDKEVEDCVSNR--PCR--SQVRCEGFVCAQTGRCIN 147 
R.norvegicus      QKKRYRHTYLLRPSQFYGELCDFSDKEVEDCVTNR--ACR--SQVRCEGFVCAQTGRCVN 134 
G.gallus          QKKRYRFARLEQPSQFNGEPCDYSDNESEDCVTNN--PCR--NKVRCEGFACAVTGRCIA 129 
M.domestica       EKKRYRFVKVLRPSQFNGKACGLID-DSEPCSNMT--SCI-IPEVPCQGFNCNLTGRCIP 176 
                   ***:*.. : :**:* *: *   . : * *       *       *:** *  ****:  
  LDLa domain (133-169) 
O.mykiss          IDLRCNGDDDCGDWSAEKGSPKVPKACKQEAQEYHGIENLAKGINILHSHLEGSVIDNRY 191 
P.olivaceus       RTLQCNGEDDCGDMSDEVGCKKVPKPCRQEAEEYWGIENLAKGINILNSNLEGLVLDNRY 191 
D.rerio           ENLRCNGDDDCGDGSDEQDCKKVYKACNQPTEEYYGIENLAKGFNILNGKMEAVVLDNRY 167 
H.sapiens         RRLLCNGDNDCGDQSDEANCRRIYKKCQHEMDQYWGIGSLASGINLFTNSFEGPVLDHRY 195 
M.mulatta         RRLLCNGDNDCGDQSDEANCRRIYKKCQHEMDQYWGIGSLASGINLFTNSLEGSVLDHRY 195 
O.cuniculus       RRLLCNGDNDCGDQSDEANCRKIYKKCHHEMEQYWAIGSLASGINLFTNSLEGPVLDHRY 195 
C.familiaris      RRLLCNGDNDCGDQSDEANCRRIYKKCQHEMEQYWAIGRLASGVNLFTNSFEGPVLDHRY 195 
S.scrofa          RRLLCNGDNDCGDQSDEANCKRIYKKCQQEMDQYWAIGSLASGINLFTNNLEGPVLDHRY 207 
R.norvegicus      RRLLCNGDNDCGDQSDEANCRRIYKKCSQDMEQYWAIGNLASGINLFTNTFEGPVLDHRY 194 
G.gallus          RRLLCNGDDDCGDQSDEKNCKKVFKKCDQKMEQYWGIENLAKGLNIITKNLEGLVLDHRY 189 
M.domestica       LSQVCNGDNDCGDGADENDCKEVTKLCQGSKNQYWGTGSLASGINIFTNALEGVVFDNNY 236 
                      ***::**** : * .. .: * *    ::* .   **.*.*::   :*. *:*:.* 
 
O.mykiss          YAGSCLPHYIQDVRFRKPYNLQQYTLETKGTYDFKLQSFESYSEFVHYTMTERSSKTTVS 251 
P.olivaceus       YAGSCLPQYIQDVRFRKPHNLQQYTLETKGSYDFNVQSFESYSDYMDYSMRERMTQTIVS 251 
D.rerio           YAGGCLPHFIQDVRFRKPFNLQQYTIETKGSYDFNMKEYDSYSEYFKSESHSTLSKTSVS 227 
H.sapiens         YAGGCSPHYILNTRFRKPYNVESYTPQTQGKYEFILKEYESYSDFERNVTEKMASKSGFS 255 
M.mulatta         YAGGCSPHYILNTRFRKPYNVESYTPQTQGKYEFTLKEYESYSDFEHNVIEKAASSSGFS 255 
O.cuniculus       YAGGCNPHYILDMRFRKPYNVESYTPQTQGKYKFALAEYESYSDFERNVMEKTYSKSTFN 255 
C.familiaris      YAGGCSPHYILNTRFRKPYNVESYTPQTQGKYKFALTAYESYSDFEHNITKTERSTSSFS 255 
S.scrofa          YAGACSPHYILNTRFRKPYNVENFNPQTQGKYDFALTEYESYSDFEQNVTTAAISKSSFS 267 
R.norvegicus      YAGACSPHYILNTNFRKPYNVESYTPQTQGKYEFALTEYESYFDFEHNVTEKATSKSSFK 254 
G.gallus          YAGGCSPHYIADTRFRKPYNVESYTPETKGKYEFTMTEYDSYSNYESSVLKAEAAQSSFS 249 
M.domestica       YGGNCNAFVIDQDKYRLPSNLERYSIEVRGYYEFVYKEYESYAAFERSVIREGMKDKKMG 296 
                  *.* * .  * : .:* * *:: :. :.:* *.*    ::**  :           . .  
 
O.mykiss          IGFALPGVAEFGFNYADSKYSKSEKKIRRASRKENSFVQAKAELQLARYILKSEDLMLHP 311 
P.olivaceus       IGFAIPGIAEFGFNYNNAKVTRSIQKIRRASSKINSFVSAKAELELAQYMLRSDDLMLHP 311 
D.rerio           IGIAYPNAFDFSFAYNDHKYKRSVKKMRTYSGTKNKFIRAHSELEVARYALKPQNLMLHP 287 
H.sapiens         FGFKIPGIFELGISSQSDRGKHYIRRTKRFSHTKSVFLHARSDLEVAHYKLKPRSLMLHY 315 
M.mulatta         FGFKIPGIFELGISRQSDRGKHYIRRTKQFSHTKSVFLHARSDLEVAHYKLKPRSLMLHY 315 
O.cuniculus       LGFKIPSIFEFGINTESDQLMNYISRTKRFSHTKSKFLHARSALEVAHYKLKPRNLMLHY 315 
C.familiaris      FGFKIPEIFEFGISMASDNGKHFISRIKRFSHTKSTFLHARSDLEVAHYKLKPRSLMLHY 315 
S.scrofa          FGFKISGMFEFGISSTSDKGKRFISRTKRFSHTKSTFLHARSDLEVARYKLKSRNLMLHY 327 
R.norvegicus      FGFKLDGLVEFGVRKESNEGRHYISRTKRFSHTKSKFLHARSVLEVAHYKLKSRQLMLHY 314 
G.gallus          IGISIPSLFEIGYSNNDNRFRKFIQRMKRFSSTSSKFLHARSDLTVAVYKLKTRALMLHY 309 
M.domestica       PDLHILNWIDIGYNFESQSLRRFLSKIRRATQSKSKILHVQCTIDIGRYKMKSKLLMFDY 356 
                   .:      ::.    .    .   : :  : . . :: .:. : :. * ::.  **:.  
 
 




O.mykiss          EFFLRLRALPQSYNYGEYRQIYRDYGTHYITEATLGGDYEYTVILDKEKLEKTGYSLEAY 371 
P.olivaceus       EFLQRLRSLPQAYVYGEYRQIYRDYGTHYITEAALGGEYEHTIILDKEKLAKTDYSLEDY 371 
D.rerio           EFVSRLNALPLEYSYGEYRQIYQDYGTHFIKEATLGGEFEYTVILNDEKFEKSGYSLDET 347 
H.sapiens         EFLQRVKRLPLEYSYGEYRDLFRDFGTHYITEAVLGGIYEYTLVMNKEAMERGDYTLNNV 375 
M.mulatta         EFLQRVKRLPLEYSYGEYRDLFRDFGTHYITEAVLGGIYEYTLVMNKEAMERGDYTLNNV 375 
O.cuniculus       DFLQRVQRVPLEYSYGEYRDLFRDFGHHFITEAVLGGIYEYTLIMNKEAMERADYSLNDV 375 
C.familiaris      EFLQRVKLLPLEYSYGEYRDLFRDFGTHYITEAVLGGIYEYTLIMNKEAMERADYSLKAI 375 
S.scrofa          EFLQRVKQLPLEYSYGEYRDLFRDFGTHYITEAVLGGVYEYTLIMNKEAMERADYSLKDV 387 
R.norvegicus      EFLQRVKSLPLEYSYGEYRDLLRDFGTHFITEAVLGGIYEYTLIMNKDAMERGDYTLDHV 374 
G.gallus          EFLQRLHQLPLEYSYGEYRELYRDYGTHYITEATVGGIYEYTLVLNSNELQKAGFSMSDV 369 
M.domestica       EFLMRVGRLPSDYSYGEYRDFIRAYGTHIISDAIIGGVYEYALILNPDGMDSEGYTFDDI 416 
                  :*. *:  :*  * *****:: : :* * *.:* :** :*:::::: : :   .:::.   
   MACPF domain (303-510) 
O.mykiss          KNCEQIVLKVGANIKGVYVTVGLEGGGCDGLLNEMGEDTVKGS---MVEDYVAVVSGGDS 428 
P.olivaceus       KSCTQAGLKIGANIYGVYVSAGIEGGSCNGLLNEMGEDTAIGS---SVEDFVAVVRGGSS 428 
D.rerio           KNCVQVGLKVGVQVKKIYVGLGLSGGSCEGLLKEIGDSTKERD---MVEDVFIVVKGGDS 404 
H.sapiens         HACAKNDFKIGGAIEEVYVSLGVSVGKCRGILNEIKDRNKRDT---MVEDLVVLVRGGAS 432 
M.mulatta         HACAKNDFKIGGAIEEVYVKLGVSIGKCRGILNEIKDRNKRDT---MVEDLVVMVRGGAS 432 
O.cuniculus       QACAKNDFKLGAAIEEVYVSLGVSTSKCRGILNEIKDRNKRDT---MVQDLVVLVRGGAS 432 
C.familiaris      QTCAQNDFKIGAAIKKIYVNLGVSVDTCEHILREIGDRNKRNT---MVEDLVVLVRGGAS 432 
S.scrofa          HACAQHGFKIGVAIEEVYVKLGVPVHKCKDILNEIKDRNKRSS---MVNDLVVLVRGGAS 444 
R.norvegicus      SACAGGGFQIGGNVYKVYLKLGVSEKKCSDILNEIKDRNKRRT---MVEDLVVLVRGGTS 431 
G.gallus          QKCAQHGFKIGGTIKAVSLILGVNVEGCKSLLKEIGDSTSKKQ---YVEDFIALVRGGAS 426 
M.domestica       KSCTQEAYHSSDITNRDFVGMRMDQR-CHVLLDQIANLGKTEEDVPIVEDLAVFLRGGTI 475 
                    *     : .       :   :    *  :* :: :          *:*   .: **   
    
O.mykiss          ESITWLAAKNLPTPPLMRLWGEAVHYNLDFIRSVTRPLYELVTARDFSSANSLKKNLRRA 488 
P.olivaceus       ESITGLVSKKLPTPQLMRLWGEGVRFNPDFIRKTTRPLYELVTSKDFSHDATLKRNLKRA 488 
D.rerio           ETVSRLAAKQLPTPDIMQMWGEAVFYNPEFISKKIEPIYELVPPRE-ANANILKKNLKRA 463 
H.sapiens         EHITTLAYQELPTADLMQEWGDAVQYNPAIIKVKVEPLYELVTATDFAYSSTVRQNMKQA 492 
M.mulatta         EHITTLAYQELPTADLMQEWGDAVQYNPAIIKIKVEPLYELVTATDFAYSSTVKQNMKQA 492 
O.cuniculus       EHITALAYSDLPTADLMQEWGDAVQYNPAIIKIKVEPLYELVTATDVAYSSTVKQNMRQA 492 
C.familiaris      EHITTLAYKELPTADLMQEWGDAVQYNPDIIKIKAEPLYELVTATDFAYSSTVRQNMKRA 492 
S.scrofa          EHITALAYKDLPTADLMQEWGDAVQYNPDIIKIKAEPLYELVTAADFAYSSTVKQNMKRA 504 
R.norvegicus      EYITSLAYKDLPTAELMKEWGDAVQYNPAIIKLKAEPLYELVTATDFAYSSTVKQNMKKA 491 
G.gallus          EHITALANKGLPTAALMQEWGDAVQYNPEIIKLKVQPLYQLVTPADFANAMTIKENLRRA 486 
M.domestica       PSITSLAYKRLPNKELMEKWGDAAKLFPEVLKIKVIPMHEMWTGQNFINRLHLKNNMRSA 535 
                    :: *. . **.  :*. **:..     .:     *:::: .  :      ::.*:: * 
 
    EGF domain (519-547) 
O.mykiss          LAEYLEESSSCRCAPCRNNGLAVLKGTRCECVCPSGYSGLGCEITQRP-DIGIDGSWSCW 547 
P.olivaceus       LSEYLAESSSCRCAPCHNNGVAVLRGTRCDCVCPTGYTGRGCEITQRKKQIATDGSWSCW 548 
D.rerio           LSEYLSESSACRCSPCLNNGLAVLKGMRCTCICPAGVKGVSCEITQRK-GLAIDGNWSCW 522 
H.sapiens         LEEFQKEVSSCHCAPCQGNGVPVLKGSRCDCICPVGSQGLACEVSYRK-NTPIDGKWNCW 551 
M.mulatta         LEEFQKEVSSCHCAPCQGNGVPVLKGSRCDCICPVGSQGLACEVSYRK-NIPTDGKWNCW 551 
O.cuniculus       LEEFQGEVSPCRCAPCQGNGVPVQKGSRCDCICPVGFQGSACEITSRK-NVPIDGRWSCW 551 
C.familiaris      LEEFQKEVSSCRCAPCQGNGVPVLKESRCDCICPIGSRGPACEVTYEK-NVAIDGRWNCW 551 
S.scrofa          LEEFEKEISSCHCAPCQGNGVPVLKESRCDCICPAGFQGSACEVTNRK-NVPIDGKWNCW 563 
R.norvegicus      LEEFQMEVSSCRCAPCRNNGVPILKESRCECICPAGFQGVACEVTNRK-DIPIDGKWSCW 550 
G.gallus          LDEFQLETSSCRCAPCQGNGIPVLKGTHCECICPLSRRGTACETPSRT-DAAINGNWGCW 545 
M.domestica       VKEYYEETHVCHCAPCLGNGFPIIRDSYCECLCGMGTCGISCELGTSE--GDATGSWSCW 593 
                  : *:  *   *:*:** .**..: :   * *:*  .  * .**           * *.** 
 
O.mykiss          GSWSPCR-GRSKTRSRQCNNPAPSSGGIACRGLQMETTDCF------- 587 
P.olivaceus       GAWSSCS-GRKMSRSRQCNNPVPSDGGLACRGLQQESTDCF------- 588 
D.rerio           SSWSSCS-GKIQHRTRQCNNPAPHNGGVACAGAQEESADCV------- 562 
H.sapiens         SNWSSCS-GRRKTRQRQCNNPPPQNGGSPCSGPASETLDCS------- 591 
M.mulatta         SSWSSCS-GGRKTRQRQCNNPPPQNGGSPCSGPASETLDCS------- 591 
O.cuniculus       SRWSSCS-GGQKTRRRQCNNPAPQDGGSPCSGPASETLAC-------- 590 
C.familiaris      SNWSPCS-GGHKTRQRQCNNPPPQNEGSPCLGPASETLNC-------- 590 
S.scrofa          SDWFSVFLEDVKQDEGSATIHLLKMGVAPAWVLLQKHLTVKEGRASSG 611 
R.norvegicus      SDWSPCS-GGRKTRQRQCNNPAPQRGGSPCSGPASETLD--------- 588 
G.gallus          ASWSPCS-GGQRTRRRQCNNPTPQNGGSSCSGPDAETVTC-------- 584 
M.domestica       TSWTECIEAKQK-RERLCNSPIPG-SIKTCPGRQKEETSC-------- 631 
                    *              ..         ..     :             
 








S.scrofa          -----------------------MLVPRAAPLLTLLLATGSLGQRAQRPPRRPSP----- 32 
C.familiaris      -----------------------MLTPWTALLLTLLLAGGSVSQRARRPPRPASR----- 32 
H.sapiens         -----------------------MLPPGTATLLTLLLAAGSLGQKPQRPRRPASP----- 32 
O.cuniculus       -----------------------MVLRGRAVLLAVLLAAGSLGRWAQKPRGAPSA----- 32 
M.musculus        -----------------------MLSPGAVLFFTLLLTASSLGQRTRKPIGSTSP----- 32 
R.norvegicus      -----------------------MLSPGAVLFFTLILMASSLGQRTRKPYGSTSP----- 32 
G.gallus          MNPVARPAGARPAPLPGTGLRCAMAAPRALMLLSRAPRRAAGDGNSGRP-LPTAL----- 54 
D.rerio           --------------MIRFWLYL-FFVLACLSFWEPVETRR-ARYKPEPPK-PKKTETQKA 43 
O.mykiss          --------------MTGVWQCVTMLMVVCVCLWGSAEAIGGAKSRPRPQRRPPKKPKVNP 46 
                                         :       :             .               
 
S.scrofa          ISTIQPKASFDAQQFAGTWLLVAVASSCRFLQEQGHRAEATSLHVA-PQGAA--MAVSTF 89 
C.familiaris      ISTIQPQVNFDAHQFAGTWLLVAVASSCRFLQEQGHRAEATLLHVA-PQGAD--MAVSTF 89 
H.sapiens         ISTIQPKANFDAQQFAGTWLLVAVGSACRFLQEQGHRAEATTLHVA-PQGTA--MAVSTF 89 
O.cuniculus       ISAIQPKANFDAQQFAGTWLLAAVGSACHFLQEQGHRAEATALHVA-PQGAA--MAVSTF 89 
M.musculus        ISTIQAQVNFSAQKFAGTWLLVAVGSSCRFLQEQGHRAEATTLHAA-PQGAA--MAVSTF 89 
R.norvegicus      ISTIQAQANFNAQQFAGTWLLVAVGSACRFLQEQGHRAEATTLHIA-PQGAA--MAASTF 89 
G.gallus          LRKVVTEGNLSLGELVGRWFLVGVASRCSYLAENSHRLEATAMTVAVPDGQS--LAISTF 112 
D.rerio           IDTLAPGQNINIDQMSGKWHLLTVASRCKNLLESGFKTESTSLTWNITAD---TVTVGTV 100 
O.mykiss          IDDTPPAQNIDIQQMGGPWYLVNAASKCNFLMKNGLKVEATVMTLTSPSSQNPTLSVSTT 106 
                  :    .  .:.  :: * * *  ..* *  * :.. : *:* :    . .    :: .*  
    Lipocalin domain (48-184) 
S.scrofa          RKLDGICWQVRQLFRDTGLPGRFLLQARGARGAVDVVVGETDYRSFAILYLERARQLSVK 149 
C.familiaris      QKLDGICWQVRQLYRDGEVLGRFLLQARGARGAVNMVVGETDYQGFAILYLEQKRQLSVK 149 
H.sapiens         RKLDGICWQVRQLYGDTGVLGRFLLQARGARGAVNVVVAETDYQSFAVLYLERAGQLSVK 149 
O.cuniculus       RKLDGICWQVSQRYGATGVPGRFLLPARGPRGAVHVVAAETDYHSFAVLYLERARQLSVK 149 
M.musculus        RKLDGICWQVRQLFENTGVPGRFLFQVSRARGPVHMVVAETDYQSFAILYLEQGRKLSVK 149 
R.norvegicus      RKLDGICWQVRQLYGITGVPGRFLLQAPRARGPVHVVVAETDYQSFAILYLEQARRLSVK 149 
G.gallus          RKLDGQCWEIRQRYVPEGAHRRFSVRGRGYNSKMEVVVGEADPRSYAIIYYQDSQGLSVK 172 
D.rerio           RKLNFVCWEIKQNYMKTKTPGQLFLKGKRPSDNVDIMVLETDYSTYAMLVFKRAEKITMK 160 
O.mykiss          TRLNHQCWEILQAYTITPTPGRLVLNGSRPLLNTDIVIGESDYSSYAVFYYQKQGQLTMK 166 
                   :*:  **:: * :       :: .         .::  *:*   :*::  :    :::* 
 
S.scrofa          LYARSLP-VSESALSVFEQRVQGANLTEDHILFFPKYGFCDAADQFHVLDEAKQ- 202 
C.familiaris      LYARSLP-PSDSALSAFEQRIQRVNLTEDHVLFFPKYGFCEAADQFHVLDEAGR- 202 
H.sapiens         LYARSLP-VSDSVLSGFEQRVQEAHLTEDQIFYFPKYGFCEAADQFHVLDEVRR- 202 
O.cuniculus       LYVRSLP-VSDSVLGAFEQRVAQANLTQDQVLFFPTYGFCEAADQFHILDEVRR- 202 
M.musculus        LYVRSLP-VNDSVLDVFERRVREANLTEDQILFFPKYGFCETADQLHILNEVPR- 202 
R.norvegicus      LYTRTLP-VSDSALNAFEERVRGANLTEDQIFFFPKYGFCETADQFHILNEMPK- 202 
G.gallus          LYGRSSQ-LSNAIVDKFEQRARAVGLSEDVTHYFPTYGFCDSADDFHILDETEL- 225 
D.rerio           LYGRSGE-VPDNIVDKFEDRAKTFNLGLDVVFQFPDYGFCESAEK--VLDLT--- 209 
O.mykiss          LYGRSKDTLSEAILDKFEDLAEKKGLGLAYVFAFPNYSHCESVDKDHVINCVPTC 221 
                  ** *:     :  :. **       *       ** *..*::.:.  :::      
 
 
Figure 50 Alignment of the C8G proteins among species according to the GenBank 
accession no. as given in table 13 using the ClustalW2 tool. The amino acids 
are enumerated above each line on the right side. The identical, similar and 
missing residues are indicated with asterisks (*), points (.), and dashes (-), 
respectively. Signal peptide in pig C8G protein is in bold and italic. The 
amino termini of C8G mature protein starts just after the signal peptide. The 
cysteine residues are highlighted. The lipocalin functional protein domain is 
in continuous underline. The glycosylation site presents in shade blocks with 





R.norvegicus      MLLRTPGLPRRSGMASGVTITLAIAIFALEINAQAPEPTPREEPSAD--ALLPIDCRMST 58 
M.musculus        MLCKPPGLPRRSSMASGMAITLALAIFALGVNAQMPIPVSREEQEQH--YPIPIDCRMSP 58 
S.scrofa          -------------MRVRRRFTFAVCILEISILSAGPTPSYHPKPVDCNGTPSPIDCRMSP 47 
B.taurus          -------------MSAGQRFAFAICILEISLLRAGPTPSYD--PAERQGTPLPIDCRMSS 45 
M.mulatta         -------------MSACWSFAAAICILEISVLTAEYTPSYDPQPTESRGSASHIDCRMSP 47 
H.sapiens         -------------MSACRSFAVAICILEISILTAQYTTSYDPELTESSGSASHIDCRMSP 47 
E.caballus        -------------MSAGRTFAFAICILEVSVLTAGPTPNYAPEPEQQSGTPLPIDCRMSS 47 
O.cuniculus       -------------MAASHSFAFVVCVLEIGALTAGPTPSYVHEPIQRSDPLQPIDCRMSP 47 
M.domestica       -----------------------MSLSETALN----------RPRREIETPAPIDCKLTS 27 
                                         :.:                           ***:::. 
   TSP1 domain (45-95) 
R.norvegicus      WSQWSQCDPCLKQRFRSRSMEVFGQFQGKSCADALGDRQHCEPTQECEEVQENCG-NDFQ 117 
M.musculus        WSNWSECDPCLKQRFRSRSILAFGQFNGKSCVDVLGDRQGCEPTQECEEIQENCG-NDFQ 117 
S.scrofa          WGEWSRCDPCLKQMFRSRSIETFGQFNGQKCVDAVGDRRQCVPTEPCEDLEEDCG-SDFQ 106 
B.taurus          WSEWSKCDPCLKQMFRSRSIEIFGQFNGRKCVDAVGDRQQCVPTEACEDPEEGCG-NDFQ 104 
M.mulatta         WSEWSQCDPCLRQMFRSRSIEVFGQFNGKSCTDAVGDRRQCVPTEPCEDAEDDCG-NDFQ 106 
H.sapiens         WSEWSQCDPCLRQMFRSRSIEVFGQFNGKRCTDAVGDRRQCVPTEPCEDAEDDCG-NDFQ 106 
E.caballus        WSEWSECDPCLRQMFRSRSIEVFGQFNGQRCVDAVGDRRQCVPTEACEEVEDDCG-NDFQ 106 
O.cuniculus       WSEWSHCDPCLRQMFRSRSIEVFGQFHGKSCVDALGDRRACIPTEACEDAEEDCEKDEFH 107 
M.domestica       WSEWSSCEPCQKEMYRSRTIEAFGQFGGKRCLHSLGDRRSCEPFRACDDEEYDCE-NDFK 86 
                  *.:** *:** :: :***::  **** *: * . :***: * * . *:: : .*  .:*: 
 
    LDLa domain (100-136) 
R.norvegicus      CETGRCIKRKLLCNGDNDCGDFSDESDCESDPRLPCRDRVVEESELGRTAGYGINILGMD 177 
M.musculus        CETGRCIKRRLLCNGDNDCGDYSDENDCDDDPRTPCRDRVAEESELGLTAGYGINILGME 177 
S.scrofa          CGTGRCIKRRLLCNGDNDCGDFSDEDDCDSDPRPPCRERVVEESELARTAGYGINILGMD 166 
B.taurus          CGTGRCIKNRLLCNEDNDCGDYSDEDNCEQDPRPPCRNRVVEESELARTAGFGINILGMD 164 
M.mulatta         CGTGRCIKRRLLCNGDNDCGDFSDEDDCEGDPRPPCRDRVVEESELARTAGYGINILGMD 166 
H.sapiens         CSTGRCIKMRLRCNGDNDCGDFSDEDDCESEPRPPCRDRVVEESELARTAGYGINILGMD 166 
E.caballus        CGTGRCIKKRLLCNGDNDCGDFSDEDDCENDPRPPCRERVVEESELARTAGYGINILGMD 166 
O.cuniculus       CGTGRCIKRRLLCNGDNDCGDFSDEDDCETEPRLTCRNREVQESELARTAGYGINILGMD 167 
M.domestica       CETGRCIKKRLLCNVDNDCGDFSDEDNCEKDPRSPCHTD-VEMSELGRTAGYGMNILGMD 145 
                  * ****** :* ** ******:***.:*: :** .*:   .: ***. ***:*:*****: 
 
R.norvegicus      PLGTPFDNEFYNGLCDRVRDGNTLTYYRKPWNVAFLAYETKADKNFRTENYEEQFEMFKT 237 
M.musculus        PLRTPFDNEFYNGLCDRVRDEK--TYYRKPWNVVSLIYETKADKSFRTENYDEHLEVFKA 235 
S.scrofa          PLTTPFDNEYYNGLCDRVRDGNTLTYYRKPWNVAALIYETKVDKNFRTEYHERQIQVLKT 226 
B.taurus          PLSTPFDNQYYNGLCDRVWDGNTLTYYRRPWNVASLTYDTKADKNFRTENHEESIQILRT 224 
M.mulatta         PLSTPFDNEFYNGLCNRDRDGNTLTYYRRPWNVASLIYETKGEKNLRTEHYEEQIEAFKS 226 
H.sapiens         PLSTPFDNEFYNGLCNRDRDGNTLTYYRRPWNVASLIYETKGEKNFRTEHYEEQIEAFKS 226 
E.caballus        PLSTPFDNEYYNGLCDRVRDGNTLTYYRKPWNLASLAYETKADKNFRIEHYEQQIQAFRS 226 
O.cuniculus       PLATPFDNEYYHGLCDRVWDGNTLTHYRKPWNVAVLAYETKIDKNFRTEYYEEQMQAFKS 227 
M.domestica       PLDTPFDNEYFHGLCERVRDGNTGTYYRKPWNVATLNYDTKAEKRLRTENYEEHVLQITD 205 
                  ** *****::::***:*  * :  *:**:***:. * *:** :* :* * ::. .  :   
 
Figure 51  Alignment of the C9 proteins among species according to the GenBank ac-
cession no. as given in table 4 using the ClustalW2 tool. The amino acids are 
enumerated above each line on the right side. The identical, similar and 
missing residues are indicated with asterisks (*), points (.), and dashes (-), 
respectively. Signal peptides in human C9 protein (DiScipio et al. 1984) and 
in pig C9 protein are in bold and italic. The amino termini of C9 mature pro-
tein starts just after the signal peptide. The cysteine residues are highlighted. 
The cysteine-rich functional protein domains TSP1 followed by LDLa, and 
MACPF are in continuous underline. The glycosylation sites in human (DiS-
cipio et al. 1984) and in pig present in shade blocks with white bold font. 
The human C9 cleavage site into C9a and C9b by α-thrombin is in bold and 




R.norvegicus      IVRDRTTSFNANLALKFTITEAPIKK-VGVDEVSPE--KNSSKPKDSSVDFQFSYFKKEN 294 
M.musculus        INREKTSNFNADFALKFSATEVPEK---GAGEVSPA--EHSSKPTNISAKFKFSYFMGKN 290 
S.scrofa          IIEEKKSNFNADLTIKFTPTEAIEQLKSKNVELANE-ENSNP--MNNKAHFRFTYSKTET 283 
B.taurus          IIEEKKLNFNAGLSVKYTPVEAIEKNKCVDLEHSDKGSTSSPSKLAAEAKFRFTYSKDDI 284 
M.mulatta         IVQEKTSNFNADISLKFIPTEANK----VKTEKSSE-KQASSNSLRGQGSFRFSYSKNET 281 
H.sapiens         IIQEKTSNFNAAISLKFTPTETN------KAEQCCE-ETASSISLHGKGSFRFSYSKNET 279 
E.caballus        VIEERRSHFNADFTLKFTPTEAK------KCKQEPE-ESCNGTDSSENRIFRFAYSKNET 279 
O.cuniculus       IIEEETSNFNANLALKFTPTEAKAS---KAEEASPKNKSLDDNDKGFSSKFQFSYSKNET 284 
M.domestica       TFRERQKNFGFDISLKLTSTEAPEG---GTPKRKPD---PKRNQQDAGLTFRFRYSKNES 259 
                    .:.   *.  :::*   .*.         :        .         *:* *   .  
 
R.norvegicus      FQRLSSYLSQTKKMFLHVRGMIQLGRFVMRNRGVMLTTTFLDDVKALPVSYEKGEYFGFL 354 
M.musculus        FRRLSSYFSQSKKMFVHLRGVVQLGRFVMRNRDVVLRSTFLDDVKALPTSYEKGEYFGFL 350 
S.scrofa          YKLLLSYSSKKEKIFLHVKGVIHLGRFVMRKRDVMLTKTFLDDVKYLPSTYEKGEYFAFL 343 
B.taurus          YRLLSSYSAKQEKMFLHVKGKVHLGRFVMRSRDVMLQTTFLDSINTLPTTYEKGEYFAFL 344 
M.mulatta         YQLFLSYSSKKEKMFLHVKGEIHLGRFMMRNRDVVLTTTFVDDIKALPTTYEKGEYFAFL 341 
H.sapiens         YQLFLSYSSKKEKMFLHVKGEIHLGRFVMRNRDVVLTTTFVDDIKALPTTYEKGEYFAFL 339 
E.caballus        YQLFLSYSSKKEKMFLHVKGVIQLGKFVMRSRDVVLTTTFLDDIKALPTAYEKGEYIAFL 339 
O.cuniculus       YQLFLSYSSQKEKMFLLVKGIIQLGRFVMKNRGVMLTNTFLDDIKSLPTTYEKGEYFAFL 344 
M.domestica       LHLIKYYASDKTKMFLQVKGEIQLGRFHMRNREFMLKSTFLDDLKALPTSYEKGEYFGFL 319 
                   : :  * :.  *:*: ::* ::**:* *:.* .:* .**:*.:: ** :******:.** 
 
R.norvegicus      ETYGTHYSSSGSLGGLYELIYVLDKASMKEKGVELSDVKRCLGFNLDVSLYTPLQTALEG 414 
M.musculus        ETYGTHYSTSGSLGGQYEIVYVLDKASMKEKGVDLNDVKHCLGFNMD--LRIPLQDDLKD 408 
S.scrofa          ETYGTHYSSSGSLGGLYELIYVLDKATMTEKGIELRDVHRCLGFNLDLSLN-------FG 396 
B.taurus          ETYGTHYSSSGSLGGLYELIYVLDKKSMEQKDIELRDVQRCLGFDLDLSLK-------VG 397 
M.mulatta         ETYGTHYSSSGSLGGLYELIYVLDKASMNRKGVELKDVKRCLGYHLDVSLDF------SK 395 
H.sapiens         ETYGTHYSSSGSLGGLYELIYVLDKASMKRKGVELKDIKRCLGYHLDVSLAF------SE 393 
E.caballus        ETYGTHYSSSGSLGGLYELIYVLDKASMDQKGVELRDIQRCLGFNLDLSLK-------DK 392 
O.cuniculus       ETYGTHYSSSGSLGGRYELIYVLDKASMKEKGIELNDIKKCLGFDLDLSLNIPGK--SAG 402 
M.domestica       ETYGTHYSSSGNIGGKYELIYVLDKEEMQRKGLEIQDVRKCLGLDLDLSYQS-------A 372 
                  ********:**.:** **::*****  * .*.::: *:::*** .:*              
 
    MACPF domain (297-507) 
R.norvegicus      PSLTANVNHSDCLKTGDGKVVNISRDHIIDDVISFIRGGTRKQAVLLKEKLLRGAKTIDV 474 
M.musculus        ASVTASVNADGCIKTDNGKTVNITRDNIIDDVISFIRGGTREQAILLKEKILRGDKTFDK 468 
S.scrofa          VEIKGKIDSENCLKRGDGKTENIMNDDFIDDVISFIRGGTRKYATELKEKLLKGAKMINV 456 
B.taurus          VEVTGNFDSKLCSKKGMGQTETNPEADLFDDVITFIRGGTRKYATELKEKLLRGARMINV 457 
M.mulatta         ISAGAKADKDDCVKRGEGRAVNITSDHLIDDVISLIRGGTRQYAFELKEKLLRG-TMIDV 454 
H.sapiens         ISVGAEFNKDDCVKRGEGRAVNITSENLIDDVVSLIRGGTRKYAFELKEKLLRG-TVIDV 452 
E.caballus        YEVTAKIDKNDCLKRNEKEIVNIMDGSLIDDVISLIRGGTRKYAFELKEKLLKGAKTVNV 452 
O.cuniculus       LSLTGQANKNNCLKSGHGNAVNITRANLIDDVISLIRGGTQKFAFELKEKLLTKAKMVDV 462 
M.domestica       VNFEANIKGSDCSSVN--WKHDNERKHIIDDVISLIEGGTREYATNLKEKLLRGPKVVDV 430 
                   .  .. . . * . .           ::***:::*.***:: *  ****:*     .:  
 
R.norvegicus      NDFINWASSLDDAPALISQKLSPIYNLIPLTMKDAYAKKQNMEKAIEDYVNEFSARKCYP 534 
M.musculus        TDFANWASSLANAPALISQRMSPIYNLIPLKIKDAYIKKQNLEKAVEDYIDEFSTKRCYP 528 
S.scrofa          TDFVNWASSLNDAPVLINQKLSPIYDLIPVKLNDAHLKRQNLERAIEDYINEFNVRKMPT 516 
B.taurus          TDFVNWAASLNHAPVLISQKLVPIYDLIPVKMKDAHLKKQNLERAIEDYINEFSVRKCQP 517 
M.mulatta         TDFVNWASSINDAPVLISQKLSPIYNLVPVKMKNAHLKKQNLERAIEDYINEFSVRKCHS 514 
H.sapiens         TDFVNWASSINDAPVLISQKLSPIYNLVPVKMKNAHLKKQNLERAIEDYINEFSVRKCHT 512 
E.caballus        TDFVNWASSLNDAPVLISQRLSPIYNLIPVKMKDAHQKKQNLERAIEDYINEFSVRKCHP 512 
O.cuniculus       TDFINWASSLSDAPVLINQKLSPIYNLIPVKIKDAHQKRQNLERGIEDYINEFSTKKCSP 522 
M.domestica       TDFLNWSASLDNAPVLINQKLLPIGNLVPVRMENAHEKKQNLEQAINDYVDQFNSHKCQP 490 
                  .** **::*: .**.**.*:: ** :*:*: :::*: *:**:*:.::**:::*. ::  . 
 
R.norvegicus      CQNGGTAILLDGQCMCSCTIKFKGIACEISKQR-------------- 567 
M.musculus        CLNGGTIILLDGQCLCSCPMMFRGMACEIHQKI-------------- 561 
S.scrofa          VPEWRDSDSAGWTVFVFLPKQISGNCL-------------------- 543 
B.taurus          CQNGGTVVLLDGECVCSCPKEFKGVACEIKK---------------- 548 
M.mulatta         CQNGGTAILMDGKCLCTCPFKFEGIACEISKQKVSEGLPALDFPREK 561 
H.sapiens         CQNGGTVILMDGKCLCACPFKFEGIACEISKQKISEGLPALEFPNEK 559 
E.caballus        CQNGGTVIQIDGQCLCSCPIAFEGIACETGKKKIS------------ 547 
O.cuniculus       CQNGGTALLMDGQCLCTCPFMFEGIACEISKRKLA------------ 557 
M.domestica       CQNEGTTMLLDGECICACKTGFQGVACQISPVV-------------- 523 
                    :       .   .      : * .                      
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